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 Abstract 
 Ventricular arrhythmias are an important cause of morbidity and mortality and come 
in a variety of forms, from single premature ventricular complexes to sustained ven-
tricular tachycardia and fibrillation. Rapid developments have taken place over the 
past decade in our understanding of these arrhythmias and in our ability to diagnose 
and treat them. The field of catheter ablation has progressed with the development 
of new methods and tools, and with the publication of large clinical trials. Therefore, 
global cardiac electrophysiology professional societies undertook to outline recom-
mendations and best practices for these procedures in a document that will update 
and replace the 2009  EHRA / HRS  Expert Consensus on Catheter Ablation of Ventricular 
Arrhythmias . An expert writing group, after reviewing and discussing the literature, in-
cluding a systematic review and meta- analysis published in conjunction with this docu-
ment, and drawing on their own experience, drafted and voted on recommendations 
and summarized current knowledge and practice in the field. Each recommendation 
is presented in knowledge byte format and is accompanied by supportive text and 
references. Further sections provide a practical synopsis of the various techniques and 
of the specific ventricular arrhythmia sites and substrates encountered in the electro-
physiology lab. The purpose of this document is to help electrophysiologists around 
the world to appropriately select patients for catheter ablation, to perform procedures 
in a safe and efficacious manner, and to provide follow- up and adjunctive care in order 
to obtain the best possible outcomes for patients with ventricular arrhythmias. 
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  1    |   INTRODUC TION 
 1.1  |  Document scope and rationale 
 The field of electrophysiology has undergone rapid progress in the 
last decade, with advances both in our understanding of the gen-
esis of ventricular arrhythmias (VAs) and in the technology used to 
treat them. In 2009, a joint task force of the European Heart Rhythm 
Association (EHRA) and the Heart Rhythm Society (HRS), in col-
laboration with the American College of Cardiology (ACC) and the 
American Heart Association (AHA), produced an expert consensus 
document that outlined the state of the field and defined the indi-
cations, techniques, and outcome measures of VA ablation (S1.1.1). 
In light of advances in the treatment of VAs in the interim, and the 
growth in the number of VA ablations performed in many countries 
and regions (S1.1.2, S1.1.3), an updated document is needed. This 
effort represents a worldwide partnership between transnational 
cardiac electrophysiology societies, namely, HRS, EHRA, the Asia 
Pacific Heart Rhythm Society (APHRS), and the Latin American 
Heart Rhythm Society (LAHRS), and collaboration with ACC, AHA, 
the Japanese Heart Rhythm Society (JHRS), the Brazilian Society of 
Cardiac Arrhythmias (Sociedade Brasileira de Arritmias Cardíacas 
[SOBRAC]), and the Pediatric and Congenital Electrophysiology 
Society (PACES). The consensus statement was also endorsed by the 
Canadian Heart Rhythm Society (CHRS). 
 This clinical document is intended to supplement, not replace, 
the  2017 AHA/ACC/HRS Guideline for Management of Patients with 
Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death 
(S1.1.4) and the  2015 ESC Guidelines for the Management of Patients 
with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death 
(S1.1.5). The scope of the current document relates to ablation ther-
apy for VAs, from premature ventricular complexes (PVCs) to mono-
morphic and polymorphic ventricular tachycardia (VT) and triggers of 
ventricular fibrillation (VF). Due to its narrower scope, the consensus 
statement delves into greater detail with regard to indications and 
technical aspects of VA ablation than the above- mentioned guidelines. 
 Where possible, the recommendations in this document are 
evidence based. It is intended to set reasonable standards that can 
be applicable worldwide, while recognizing the different resources, 
technological availability, disease prevalence, and health care deliv-
ery logistics in various parts of the world. In addition, parts of this 
document, particularly Section  9 , present a practical guide on how 
to accomplish the procedures described in a manner that reflects the 
current standard of care, while recognizing that some procedures 
are better performed, and some disease states better managed, in 
settings in which there is specific expertise. 
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Force for the Management of Patients with Ventricular 
Arrhythmias and the Prevention of Sudden Cardiac Death of 
the European Society of Cardiology (ESC). 2015 ESC guide-
lines for the management of patients with ventricular ar-
rhythmias and the prevention of sudden cardiac death: the 
Task Force for the Management of Patients with Ventricular 
Arrhythmias and the Prevention of Sudden Cardiac Death 
of the European Society of Cardiology (ESC).  Europace . 
2015;17:1601–87. 
 1.2  |  Methods 
 The writing group was selected according to each society ' s procedures, 
including content and methodology experts representing the following 
organizations: HRS, EHRA, APHRS, LAHRS, ACC, AHA, JHRS, PACES, 
and SOBRAC. Each partner society nominated a chair and co- chair, 
who did not have relevant relationships with industry and other enti-
ties (RWIs). In accordance with HRS policies, disclosure of any RWIs 
was required from the writing committee members (Appendix  1 ) and 
from all peer reviewers (Appendix  2 ). Of the 38 committee members, 
17 (45%) had no relevant RWIs. Recommendations were drafted by 
the members who did not have relevant RWIs. Members of the writ-
ing group conducted comprehensive literature searches of electronic 
databases, including Medline (via PubMed), Embase, and the Cochrane 
Library. Evidence tables were constructed to summarize the retrieved 
studies, with nonrandomized observational designs representing the 
predominant form of evidence (Appendix  S3 ). Case reports were not 
used to support recommendations. Supportive text was drafted in the 
“knowledge byte” format for each recommendation. The writing com-
mittee discussed all recommendations and the evidence that informed 
them before voting. Initial failure to reach consensus was resolved by 
subsequent discussions, revisions as needed, and re- voting. Although 
the consensus threshold was set at 67%, all recommendations were 
approved by at least 80% of the writing committee members. The 
mean consensus over all recommendations was 95%. A quorum of 
two- thirds of the writing committee was met for all votes (S1.2.1). 
 Each recommendation in this document was assigned a Class of 
Recommendation (COR) and a Level of Evidence (LOE) according to 
the system developed by ACC and AHA (Table  1 ) (S1.2.2). The COR 
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denotes the strength of the recommendation based on a careful as-
sessment of the estimated benefits and risks; COR I indicates that the 
benefit of an intervention far exceeds its risk; COR IIa indicates that 
the benefit of the intervention moderately exceeds the risk; COR IIb 
indicates that the benefit may not exceed the risk; and COR III indi-
cates that the benefit is equivalent to or is exceeded by the risk. The 
LOE reflects the quality of the evidence that supports the recommen-
dation. LOE A is derived from high- quality randomized controlled trials 
(RCTs); LOE B- R is derived from moderate- quality RCTs; LOE B- NR 
is derived from well- designed nonrandomized studies; LOE C- LD is 
derived from randomized or nonrandomized studies with limitations of 
design or execution; and LOE C- EO indicates that a recommendation 
was based on expert opinion (S1.2.2). 
 Unique to this consensus statement is the systematic review com-
missioned specifically for this document as part of HRS ' s efforts to 
adopt the rigorous methodology required for guideline development. 
 TA B L E  1     ACC/AHA recommendation system: Applying class of recommendation and level of evidence to clinical strategies, 
interventions, treatments, and diagnostic testing in patient care* 
 
 
 Reproduced with permission of the American College of Cardiology (ACC) and the American Heart Association (AHA) (S1.2.2). 
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The systematic review was performed by an experienced evidence- 
based practice committee based at the University of Connecticut, which 
examined the question of VT ablation vs control in patients with VT and 
ischemic heart disease (IHD) (S1.2.3). The question, in PICOT format, 
was as follows: In adults with history of sustained VT and IHD, what 
is the effectiveness and what are the detriments of catheter ablation 
compared with other interventions? Components of the PICOT were 
as follows: P = adults with history of sustained VT and IHD; I = cath-
eter ablation; C = control (no therapy or antiarrhythmic drug [AAD]); 
O = outcomes of interest, which included (a) appropriate implantable 
cardioverter defibrillator (ICD) therapies (ICD shock or antitachycardia 
pacing [ATP]), (b) appropriate ICD shocks, (c) VT storm (defined as three 
shocks within 24 hours), (d) recurrent VT/VF, (e) cardiac hospitaliza-
tions, and (f) all- cause mortality; and T = no time restrictions. 
 An industry forum was conducted to achieve a structured dialogue 
to address technical questions and to gain a better understanding of 
future directions and challenges. Because of the potential for actual or 
perceived bias, HRS imposes strict parameters on information sharing 
to ensure that industry participates only in an advisory capacity and 
has no role in either the writing of the document or its review. 
 The draft document underwent review by the HRS Scientific 
and Clinical Documents Committee and was approved by the writ-
ing committee. Recommendations were subject to a period of public 
comment, and the entire document underwent rigorous peer review 
by each of the participating societies and revision by the Chairs, be-
fore endorsement. 
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 2    |   BACKGROUND 
 2.1  |  History of ventricular arrhythmia ablation 
 In 1959, Couch (S2.1.1) reported the elimination of VT with the re-
section of a postinfarction left ventricular (LV) aneurysm. In the 
early to mid- 1970s, standard LV aneurysmectomy was performed 
for patients with preoperative VT episodes in the setting of prior 
infarction. Unfortunately, the operative mortality rates were high 
and VT recurrences were frequent (S2.1.2). Endocardial encircling 
ventriculotomy, introduced by Guiraudon et al. (S2.1.3), was de-
signed to isolate the arrhythmogenic tissue from the remainder 
of the ventricle by creating a nearly transmural incision through 
the edge of the border zone, sparing only the epicardium. This 
operation was associated with marked postoperative LV dysfunc-
tion, likely due to interference with coronary arterial blood sup-
ply. Guiraudon et al. (S2.1.4) also attempted to disarticulate the 
right ventricular (RV) free wall from the rest of the ventricles in 
patients with arrhythmogenic right ventricular cardiomyopathy 
(ARVC). Although the surgery was successful in isolating the ar-
rhythmogenic RV free wall and in producing interesting 12- lead 
electrocardiogram (ECG) recordings of sinus rhythm simultaneous 
with persistent sustained VT in the same patient, most patients ul-
timately did poorly because of progressive RV failure. In the late 
1970s, Josephson et al. (S2.1.5) developed the technique of map- 
guided subendocardial resection. This procedure was based on the 
observation that diastolic or presystolic electrical activation could 
be recorded during VT on the endocardium near or within the bor-
der between the densely scarred aneurysm or infarct and more 
normal muscle (S2.1.6–S2.1.8). The surgical procedure thus tar-
geted areas specified by mapping. As originally practiced, subendo-
cardial resection removed segments of endocardium approximately 
3 mm thick and 5 cm 2  (S2.1.5). These areas were almost always 
within regions of visibly scarred endocardium, extending from the 
edge of a densely scarred aneurysm. As the procedure evolved, a 
more extensive area of resection was typically performed because 
of the ease of defining a single plane of resection with the goal 
of eliminating other arrhythmogenic areas within the visual scar. 
Adjunctive cryoablation was applied to locations that were not eas-
ily resected, such as the papillary muscles or the deep myocardial 
layers beneath the removed subendocardium when VT was local-
ized to these regions. Cryoablation targeting an isthmus of surviv-
ing myocardium between a more densely scarred inferior infarction 
and the mitral annulus improved the outcome of VT ablation asso-
ciated with this substrate (S2.1.9). More extensive cryoablation of 
the entire visually scarred endocardial surface was also used with 
some success (S2.1.10). Although success rates approached 90% 
with surgery in terms of VT elimination, a mortality rate of 5%- 15% 
limited the procedure to a few select patients (S2.1.11). 
 In 1983, endocardial catheter ablation of VT using direct current 
energy electrical shock delivered via the distal electrode of a stan-
dard quadripolar endocardial catheter positioned in the area to be 
modified was first described by Hartzler (S2.1.12). One of the largest 
early studies was by Fontaine et al. (S2.1.13), who referred to direct 
current shock ablation as fulguration and reported their results in 43 
patients. One to 8 R- wave- synchronous shocks of preselected en-
ergy ranging from 160 to 320 J were delivered per session, with 23 
patients undergoing at least one repeat procedure. Of note, a success 
rate of 87% in preventing VT recurrence was achieved, and no deaths 
were thought to be related to the endocardial shock itself. Strategies 
for analyzing the 12- lead ECG during VT and pace mapping to mimic 
the QRS of VT were first described in the early 1980s to help to re-
gionalize areas of interest for more detailed activation mapping for 
surgical or early catheter- based VT ablation (S2.1.14–S2.1.16). 
 Concern about barotrauma and the need for general anesthesia 
with direct current shock ablation led to the use of radiofrequency 
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(RF) energy for catheter ablation for all arrhythmias, including VT, by 
the end of the 1980s (S2.1.17, S2.1.18). The safety and short- term 
effectiveness of RF catheter ablation for VT occurring either in the 
absence or presence of structural heart disease (SHD) was first re-
ported in observational reports by Klein et al (S2.1.19) and Morady 
et al (S2.1.20), respectively. Activation mapping to identify diastolic 
activation coupled with entrainment mapping techniques to identify 
critical components of the VT circuit ultimately proved most useful 
to define a critical isthmus through which a VT circuit must pass. This 
isthmus identification allowed for successful targeted ablation using 
RF ablation techniques for hemodynamically tolerated VT (S2.1.21–
S2.1.25). Using both computer simulations and catheter mapping of 
stable VT in humans, Stevenson et al (S2.1.22) elucidated a schematic 
model of the postinfarction VT circuit that endures. 
 Unfortunately, detailed activation and entrainment mapping is not 
always feasible when VT is hemodynamically poorly tolerated (S2.1.26, 
S2.1.27). A successful substrate- based ablation strategy that did not 
require detailed mapping of VT was first described by Marchlinski et al. 
(S2.1.28, S2.1.29). Linear ablation created by sequential point lesions 
transected the border zone, extending into the region of dense infarc-
tion defined by detailed bipolar voltage mapping with a color- coded 
display on a three- dimensional (3D) mapping system. The mapping sys-
tem facilitated the ability to track lesion deployment. The location of 
the ablation line was guided by analyzing the 12- lead QRS of VT and by 
pace mapping to mimic the QRS complex. Subsequent substrate- based 
VT targets, which were reported to be effective surrogates of the VT 
circuit, included (a) late potentials (LPs); (b) channels defined by high 
voltage surrounded by lower voltage or by areas of pace capture sur-
rounded by myocardium that could not be captured at 10 mA pacing 
output; (c) local abnormal ventricular activity (LAVA) that could demon-
strate more abnormality with pacing; (d) paced map QRS morphologies 
that matched VT and demonstrated a long stimulus to QRS duration; 
and (e) regions in which pace mapping demonstrates abrupt transi-
tion in paced QRS morphologies (S2.1.30–S2.1.41). More recently, 
isolation of abnormal myocardium demonstrating critical components 
of the VT circuit or extensive direct ablation of all low- voltage areas 
have been reported as successful techniques for possibly improving 
substrate- based ablation outcome (S2.1.42, S2.1.43). The integration 
of anatomical imaging of ventricular myocardial scar by computed 
tomography (CT) or cardiac magnetic resonance imaging (CMR) with 
electroanatomical mapping (EAM) has further contributed to the ability 
to recognize and eliminate disrupted and potentially slowly conducting 
regions of myocardium that are critical to the maintenance of VT. 
 The documentation of basal, perivalvular, low- voltage scar 
serving as the substrate for VT in nonischemic LV and RV cardio-
myopathy focused attention on these regions for VT localization 
(S2.1.44–S2.1.46). The basal involvement frequently included the 
septum, and not uncommonly the substrate was intramurally located 
in the septum or midmyocardial with epicardial extension if located 
in the free wall (S2.1.47–S2.1.49). 
 The percutaneous technique for accessing the pericardial 
space to allow mapping of the epicardium as described by Sosa 
et al (S2.1.50) provided the opportunity to define the epicardial 
substrate in patients with SHD. Epicardial mapping and ablation 
proved particularly valuable in patients with nonischemic RV and LV 
cardiomyopathy, where the predominant substrate and VT circuits 
are frequently located (S2.1.51–S2.1.56). Endocardial unipolar volt-
age mapping helped to identify the probable epicardial substrate 
when normal endocardial bipolar voltage was demonstrated in pa-
tients with VT and nonischemic cardiomyopathy (NICM) (S2.1.57, 
S2.1.58). The value of epicardial mapping and ablation in select pa-
tients with postinfarction and idiopathic VT has also been demon-
strated (S2.1.59–S2.1.61). 
 In an attempt to overcome the biophysical limitations of lesion for-
mation in scar, irrigated ablation for VT was introduced with closed- 
loop, internal irrigation in the late 1990s (S2.1.62). This was followed 
by reports of even more extensive experience with open irrigated 
catheter ablation (S2.1.63, S2.1.64). More recently, techniques have 
been described to further enhance lesion formation in scar and/or 
deep to the endocardium, including alcohol infusion in the coronary 
arteries or coronary veins; bipolar and simultaneous unipolar ablation 
at both endocardial and epicardial sites; ablation with near freezing 
saline; half normal saline as the irrigant; and needle electrode ablation 
(S2.1.65–S2.1.70). Simultaneously, small, multipolar electrode record-
ing techniques have been proven to further enhance the accuracy of 
activation and entrainment mapping (S2.1.71–S2.1.73). 
 Idiopathic VT ablation with RF ablation also evolved from the ini-
tial catheter ablation experience. The most common anatomical sites 
of origin of frequent PVCs and VF triggers were described (S2.1.74). 
Twelve- lead ECG QRS assessment provided reasonably precise char-
acterization of origin for these focal arrhythmias occurring in the ab-
sence of SHD, with an emphasis on clues to identify left versus RV 
outflow tract (RVOT) origin and epicardial origin (S2.1.75). New tech-
niques to overcome the challenges of idiopathic VT ablation associ-
ated with the sinuses of Valsalva (SV), the coronary venous system, 
the LV summit, and papillary muscle arrhythmias have been described 
(S2.1.76–S2.1.79). The importance of PVC- induced cardiomyopathy 
has been recognized, and the potential for improvement in LV func-
tion with ablation has been demonstrated (S2.1.80, S2.1.81). 
 Of note, this brief historical summary of VT ablation provides 
only an overview. There have been many important contributions 
related to VT ablation, the details of which will be further highlighted 
elsewhere in this document. 
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 2.2  |  Mechanisms of ventricular arrhythmia 
 2.2.1  |  Mechanisms and basis for catheter 
ablation of ventricular tachycardia 
 Catheter ablation has an important role in reducing or preventing 
VAs both in patients with heart disease and in those with idio-
pathic VTs not associated with SHD. The approach to ablation and 
the efficacy are determined by the characteristics of the arrhyth-
mia and the anatomy and location of the arrhythmia substrate, 
which can often be anticipated from the ECG of the VT and the 
nature of any underlying heart disease. Focal VTs are susceptible 
to ablation with discrete RF lesions (S2.2.4.1–S2.2.4.8). Relatively 
large scar substrates requiring more extensive ablation are com-
mon in VT associated with SHD; however, VT origin can appear 
focal if the reentry circuit is small, or if it is due to a focal en-
docardial breakthrough from an epicardial or intramural reentry 
circuit. Automatic VTs can also occur in some patients with SHD 
and ventricular scars. 
 Focal VT has a point source of earliest ventricular activation with 
a spread of activation away in all directions from that site. The mech-
anism can be automaticity, triggered activity, or microreentry. Focal 
origin arrhythmias should be particularly suspected in patients with-
out SHD who have repetitive monomorphic and nonsustained VTs 
and PVCs or who have sustained VT from the outflow tract (OT) and 
other more stereotypical sites of origin (S2.2.4.6–S2.2.4.8). A focal 
origin is confirmed by mapping that shows spread of activation away 
in all directions from the site of earliest activation relative to the QRS 
onset. Unipolar unfiltered (or minimally high pass filtered at 0.5 Hz) 
electrograms typically display a QS configuration at the site of ori-
gin (SOO) (S2.2.4.9, S2.2.4.10). Pacing at the origin will replicate the 
VT/PVC QRS morphology if the origin is on the surface; however, 
matching pace maps are frequently found within 1 cm of the site of 
earliest activation. Pace mapping is particularly unreliable for VTs 
originating from the aortic sinuses (S2.2.4.11). 
 2.2.2  |  Triggered activity and automaticity 
 Triggered activity arises from oscillations in membrane potential dur-
ing (early afterdepolarizations) or following (delayed afterdepolariza-
tions) an action potential and can give rise to focal VA. Experimental 
evidence implicates early afterdepolarizations in the initiation of pol-
ymorphic tachycardias in long QT syndromes (S2.2.4.12). However, 
the mechanism of the premature ventricular beats targeted for abla-
tion in these syndromes is unknown (S2.2.4.13). 
 Delayed afterdepolarizations can be caused by intracellular cal-
cium overload, which activates the Na + /Ca 2+  exchanger, resulting 
in the transient inward current  I ti (S2.2.4.14). Factors that increase 
intracellular calcium include increases in heart rate, beta- adrenergic 
stimulation, and digitalis. Beta- adrenergic effects are mediated 
through a cyclic adenosine monophosphate (cAMP)- induced in-
crease in intracellular calcium and are antagonized by adenosine, 
which effects a decrease in cAMP. Termination of idiopathic RVOT 
tachycardias by an intravenous bolus of adenosine, by infusion of 
calcium channel blockers, or by vagotonic maneuvers is consistent 
with triggered activity as the likely mechanism for some of these 
tachycardias (S2.2.4.3). These tachycardias can be difficult to induce 
at electrophysiology testing; rapid burst pacing and/or isoproterenol 
infusion is often required. Aminophylline, calcium infusion, and atro-
pine can also be useful (S2.2.4.2). 
 Less commonly, focal VT can be due to automaticity provoked 
by adrenergic stimulation that is not triggered (S2.2.4.2, S2.2.4.14). 
This type of VT can become incessant under stress or during iso-
proterenol administration, and it cannot be initiated or terminated 
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by programmed electrical stimulation (PES); however, it can some-
times be suppressed by calcium channel blockers or beta blockers. 
In contrast to its effects on triggered RVOT tachycardia, adenos-
ine transiently suppresses, but does not terminate, the arrhythmia. 
Automaticity from damaged Purkinje fibers has been suggested as 
a mechanism for some catecholamine- sensitive, focal origin VTs 
(S2.2.4.15, S2.2.4.16). Whether these VTs are due to abnormal au-
tomaticity, originating from partially depolarized myocytes, as has 
been shown for VTs during the early phase of myocardial infarction 
(MI), is not clear (S2.2.4.17). 
 Although automaticity is frequently considered as a mechanism 
of VT in the absence of overt SHD, disease processes that diminish 
cell- to- cell coupling are likely to facilitate automaticity (S2.2.4.18). 
Automatic VTs can occur in SHD, and automatic premature beats 
can initiate reentrant VTs. 
 2.2.3  |  Scar- related reentry 
 Scar- related reentry is the most common cause of sustained mono-
morphic VT in the presence of SHD (S2.2.4.19). Evidence supporting 
reentry includes initiation and termination by programmed stimula-
tion (although this does not exclude triggered activity), demonstrable 
entrainment or resetting with fusion, and continuous electrical ac-
tivity that cannot be dissociated from VT by extrastimuli (S2.2.4.20, 
S2.2.4.21). Prior MI is the most common cause of the substrate, but 
scar- related VT also occurs in other myocardial diseases, including 
ARVC, sarcoidosis, Chagas disease (ChD), dilated cardiomyopathy 
(DCM) including laminopathies, and after cardiac surgery for con-
genital heart disease (CHD) (particularly, tetralogy of Fallot) or valve 
replacement (S2.2.4.22–S2.2.4.28). 
 Regions of fibrosis with surviving myocyte bundles create fixed 
and/or functional conduction block and disrupted or slow conduc-
tion that are the substrate for reentry. Stable circuits can be modeled 
as having an isthmus or channel comprised of a small mass of tissue 
that does not contribute to the surface ECG. QRS onset occurs when 
the excitation wave front emerges from an exit along the border of 
the scar and spreads across the ventricles (S2.2.4.29, S2.2.4.30). 
Scars associated with VT are often close to a valve annulus and to-
gether can form the borders of the isthmus of a VT circuit (S2.2.4.31, 
S2.2.4.32). The 3D structure of the reentry circuit and substrate can 
be subendocardial, intramural, or subepicardial, or it can span the 
width of the entire ventricular wall (S2.2.4.33, S2.2.4.34). The entire 
circuit or only a portion of it might be accessible to ablation. 
 The substrate supporting scar- related reentry is characterized 
by (1) regions of slow conduction; (2) unidirectional conduction 
block at some point in the reentry path that allows initiation of 
reentry; and (3) areas of conduction block that often define parts 
of the reentry path. Some of the substrate might exhibit functional 
rather than fixed conduction block (S2.2.4.35–S2.2.4.37). VT after 
MI has been extensively studied in canine models and in humans 
(S2.2.4.35, S2.2.4.38). Reentry occurs through surviving muscle 
bundles, commonly located in the subendocardium; however, this 
can also occur in the midmyocardium and epicardium. Evidence 
has shown ongoing ion channel remodeling within scar, at least 
early after MI, resulting in regional reductions in ionized sodium 
and ionized calcium currents (S2.2.4.39), although action poten-
tial characteristics of surviving myocytes late after infarction can 
be normal or near normal (S2.2.4.38). Coupling between myocyte 
bundles and myocytes is reduced by increased collagen and con-
nective tissue, diminished gap junction density, and alterations in 
gap junction distribution, composition, and function (S2.2.4.40). 
Surviving fibers can be connected by side to side connections in 
regions where the collagenous sheaths are interrupted, resulting 
in a “zig- zag” pattern of transverse conduction along a pathway 
lengthened by branching and merging bundles of surviving myo-
cytes (S2.2.4.41). The fibrosis pattern might be important in de-
termining the degree of conduction delay; patchy fibrosis between 
strands of surviving muscle produces greater delay than diffuse 
fibrosis (S2.2.4.36). These aspects of scar remodeling contribute 
to the formation of channels and regions in which conduction time 
is prolonged, facilitating reentry (S2.2.4.42). 
 Unidirectional conduction block can occur after a properly timed 
PVC and is often functional (S2.2.4.35, S2.2.4.43, S2.2.4.44); it can 
present only during tachycardia, when the refractory period of the 
tissue exceeds the tachycardia cycle length (CL) or is maintained by 
collision of excitation waves. Regions of conduction block can also 
be anatomically fixed such that they are present during tachycardia 
and sinus rhythm; dense, nonexcitable fibrosis, calcifications, surgi-
cal scars, or valve annuli create these types of anatomical boundaries 
for reentry (S2.2.4.31, S2.2.4.32, S2.2.4.45). Multiple VTs with var-
ious QRS morphologies can be due to multiple exits from the same 
region of scar, or to changes in activation remote from the circuit 
due to functional regions of block. Ablation at one region can abolish 
more than one VT. Multiple reentry circuits from widely separated 
areas also occur. 
 It is possible that other reentry mechanisms cause some VTs. 
Spiral wave reentry can be induced in excitable tissue in the ab-
sence of tissue discontinuities and could cause VF or polymorphic 
VT (S2.2.4.46); anchoring to a discontinuity or to a region of slow 
conduction could theoretically cause monomorphic VT (S2.2.4.47). 
 2.2.4  |  Reentry in the Purkinje system and 
ventricular fibrillation 
 Reentry within the Purkinje fibers and the specialized conduc-
tion system is a particular form of reentry and is covered in detail in 
Section  9.4 . Other nonreentrant arrhythmias involving the Purkinje 
system can also occur, including VF and automatic rhythms (S2.2.4.16, 
S2.2.4.48–S2.2.4.50). PVCs initiating VF most often originate from 
the Purkinje fiber system. Structural abnormalities in the vicinity of 
the Purkinje fibers are frequently present and facilitate the anchor-
ing of reentry (S2.2.4.51). However, even in the absence of detectable 
structural alterations, VF can be initiated by PVCs from the Purkinje 
fiber system (S2.2.4.52) and can be maintained in the complex fiber 
interaction between Purkinje and myocardial fibers located in the pap-
illary muscles (S2.2.4.53). The latter situation can be operative in some 
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patients who have idiopathic VF, in whom no structural abnormalities 
can be detected with current technology. Some structural abnor-
malities, however, have also recently been described in patients with 
idiopathic VF, when high- density mapping is performed during sinus 
rhythm revealing abnormal electrograms in a confined area located in 
the epicardium (S2.2.4.54). This potential substrate, although not usu-
ally detected by imaging, was reported to colocalize with areas where 
VF drivers were identified by mapping. Interestingly, in most of these 
patients with idiopathic VF, VF was still triggered by PVCs originating 
from the Purkinje fiber system (S2.2.4.54). 
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 2.3  |  Definitions 
 The previous EHRA/HRS expert consensus on catheter ablation of VA 
in 2009 proposed several definitions to standardize nomenclature in 
the field (S2.3.1). The current consensus statement repeats the majority 
of these recommendations for VT ablation. In the last 10 years, knowl-
edge and experience of PVC ablations have significantly increased. In 
the current report, new proposals are made to facilitate understand-
ing of clinical characteristics and reporting of the ablation outcomes 
of these arrhythmias (Table  2 ). Note that different cutoff rates for VT 
and (accelerated) idioventricular rhythm could be appropriate for chil-
dren, who have a higher resting sinus rate than adults: the mechanism, 
symptoms, and clinical setting of the VA are more important than the 
rate (S2.3.2). 
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 2.4  |  Standard anatomical terminology 
 The following are the suggested anatomical terminology for use in the 
description of catheter ablation of VA (Table  3 ). While these generally 
represent the most commonly used terms, the writing committee rec-
ognizes that several variants or alternatives are in use and may also be 
valid. 
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 TA B L E  2     Definitions 
 Clinical characteristics 
 Clinical ventricular tachycardia (VT) : VT that has occurred spontaneously based on analysis of 12- lead ECG QRS morphology. 
 Hemodynamically unstable VT : causes hemodynamic compromise requiring prompt termination. 
 Idiopathic VT : used to indicate VT that is known to occur in the absence of clinically apparent SHD. 
 Idioventricular rhythm : three or more consecutive beats at a rate of up to 100 per minute that originate from the ventricles independent of atrial or 
atrioventricular (AV) nodal conduction. Although various arbitrary rates have been used to distinguish it from VT, the mechanism of ventricular 
rhythm is more important than the rate. Idioventricular rhythm can be qualified as “accelerated” when the rate exceeds 40 bpm. 
 Incessant VT : continuous sustained VT that recurs promptly despite repeated intervention for termination over several hours. 
 Nonclinical VT : VT induced by PES that has not been documented previously. 
 Nonsustained VT : terminates spontaneously within 30 s. 
 PVC : premature ventricular complex; it is an early ventricular depolarization with or without mechanical contraction. We recommend avoiding the 
use of the terms “ventricular premature depolarization” and “premature ventricular contraction” to standardize the literature and acknowledge 
that early electrical activity does not necessarily lead to mechanical contraction. 
 Presumptive clinical VT : similar to a spontaneous VT based on rate, limited ECG, or electrogram data available from ICD interrogation, but without 
the 12- lead ECG documentation of spontaneous VT. 
 PVC burden : the amount of ventricular extrasystoles, preferably reported as the % of beats of ventricular origin of the total amount of beats over a 
24- hour recording period. 
 Repetitive monomorphic VT : continuously repeating episodes of self- terminating nonsustained VT. 
 Sustained VT : continuous VT for 30 s, or which requires an intervention for termination (such as cardioversion). 
 VT : a tachycardia (rate >100 bpm) with 3 or more consecutive beats that originates from the ventricles independent of atrial or AV nodal 
conduction. 
 VT storm : three or more separate episodes of sustained VT within 24 h, each requiring termination by an intervention. 
 VT Morphologies 
 Monomorphic VT : a similar QRS configuration from beat to beat (Figure  1 A). Some variability in QRS morphology at initiation is not uncommon, fol-
lowed by stabilization of the QRS morphology. 
 Monomorphic VT with indeterminate QRS morphology : preferred over  ventricular flutter ; it is a term that has been applied to rapid VT that has a sinu-
soidal QRS configuration that prevents identification of the QRS morphology. 
 Multiple monomorphic VTs : more than one morphologically distinct monomorphic VT, occurring as different episodes or induced at different times. 
 Pleomorphic VT : has more than one morphologically distinct QRS complex occurring during the same episode of VT, but the QRS is not continuously 
changing (Figure  1 B). 
 Polymorphic VT : has a continuously changing QRS configuration from beat to beat, indicating a changing ventricular activation sequence (Figure  1 C). 
 Right bundle branch block (RBBB)- and left bundle branch block (LBBB)-like VT configurations : terms used to describe the dominant deflection in V1, with a 
dominant R wave described as “RBBB- like” and a dominant S wave with a negative final component in V1 described as “LBBB- like” configurations. 
 Torsades de pointes : a form of polymorphic VT with continually varying QRS complexes that appear to spiral around the baseline of the ECG lead in a 
sinusoidal pattern. It is associated with QT prolongation. 
 Unmappable VT : does not allow interrogation of multiple sites to define the activation sequence or perform entrainment mapping; this could be due 
to hemodynamic intolerance that necessitates immediate VT termination, spontaneous or pacing- induced transition to other morphologies of VT, or 
repeated termination during mapping. 
 Ventricular fibrillation (VF) : a chaotic rhythm defined on the surface ECG by undulations that are irregular in both timing and morphology, without 
discrete QRS complexes. 
 PVC Morphologies 
 Monomorphic PVC : PVCs felt reasonably to arise from the same focus. Slight changes in QRS morphology due to different exit sites from the same 
focus can be present. 
 Multiple morphologies of PVC : PVCs originating from several different focal locations. 
 Predominant PVC morphology : the one or more monomorphic PVC morphologies occurring most frequently and serving as the target for ablation. 
 Mechanisms 
 Focal VT : a point source of earliest ventricular activation with a spread of activation away in all directions from that site. The mechanism can be 
automaticity, triggered activity, or microreentry. 
 Scar-related reentry : arrhythmias that have characteristics of reentry that originate from an area of myocardial scar identified from electrogram char-
acteristics or myocardial imaging. Large reentry circuits that can be defined over several centimeters are commonly referred to as “macroreentry.” 
 Abbreviations: AV, atrioventricular; ECG, electrocardiogram; ICD, implantable cardioverter defibrillator; LBBB, left bundle branch block; PES, programmed 
electrical stimulation; PVC, premature ventricular complex; RBBB, right bundle branch block; SHD, structural heart disease; VT, ventricular tachycardia. 
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 F I G U R E  1     Monomorphic (A), 
pleomorphic (B), and polymorphic (C)  VT . 
Reproduced with permission of the Heart 
Rhythm Society (S2.3.1).  VT = ventricular 
tachycardia 
 3    |   CLINIC AL E VALUATION 
 3.1  |  Clinical presentation 
 Recommendation for clinical evaluation of patients with VAs 
 COR  LOE  Recommendation 
 I  C- EO  1 A careful clinical evaluation including history, physical examination, review of available cardiac rhythm data, 
prior imaging, and relevant laboratory workup should be performed in patients presenting with VAs 
 Recommendation- specific supportive text 
 History should identify the onset, duration, frequency, and trig-
ger of any symptoms and should include medication use as well as 
comorbidities and family history. Available cardiac rhythm data in-
clude interrogation of cardiovascular implantable electronic devices 
(CIEDs) to assess arrhythmia burden, morphologies, and duration as 
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 TA B L E  3     Anatomical terminology 
 Term  Definition 
 RV inflow  The part of the RV containing the tricuspid valve, chordae, and proximal RV 
 RV outflow tract 
(RVOT) 
 The conus or infundibulum of the RV, derived from the bulbus cordis. It is bounded by the supraventricular crest and the 
pulmonic valve 
 Tricuspid annulus  Area immediately adjacent to the tricuspid valve, including septal, free wall, and para- Hisian regions 
 Moderator band  A muscular band in the RV, typically located in the mid to apical RV, connecting the interventricular septum to the RV 
free wall, supporting the anterior papillary muscle. It typically contains a subdivision of the right bundle branch (RBB) 
 RV papillary muscles  Three muscles connecting the RV myocardium to the tricuspid valve via the tricuspid chordae tendineae, usually desig-
nated as septal, posterior, and anterior papillary muscles. The septal papillary muscle is closely associated with parts of 
the RBB 
 Supraventricular 
crest 
 Muscular ridge in the RV between the tricuspid and pulmonic valves, representing the boundary between the conus 
arteriosus and the rest of the RV. The exact components and terminology are controversial; however, some character-
ize it as being composed of a parietal band that extends from the anterior RV free wall to meet the septal band, which 
extends from the septal papillary muscle to meet it 
 Pulmonary valves  The pulmonic valve includes three cusps and associated sinus, variously named right, left, and anterior; or anterolateral 
right, anterolateral left, and posterior sinuses. The posterior- right anterolateral commissure adjoins the aorta (junction 
of the right and left aortic sinuses). Muscle is present in each of the sinuses, and VA can originate from muscle fibers 
located within or extending beyond the pulmonary valve apparatus 
 Sinuses of Valsalva, 
aortic cusps, aortic 
commissures 
 The right (R), left (L), and noncoronary aortic valve cusps are attached to the respective SV. The left sinus of Valsalva (LSV) 
is posterior and leftward on the aortic root. The noncoronary sinus of Valsalva (NCSV) is typically the most inferior and 
posterior SV, located posterior and rightward, superior to the His bundle, and anterior and superior to the paraseptal region 
of the atria near the superior AV junctions, typically adjacent to atrial myocardium. The right sinus of Valsalva (RSV) is the 
most anterior cusp and may be posterior to the RVOT infundibulum. VAs can also arise from muscle fibers at the commis-
sures (connections) of the cusps, or from myocardium accessible to mapping and ablation from this location, especially from 
the RSV/LSV junction 
 LV outflow tract 
(LVOT) 
 The aortic vestibule, composed of an infra- valvular part, bounded by the anterior mitral valve leaflet, but otherwise not 
clearly distinguishable from the rest of the LV; the aortic valve; and a supra- valvular part 
 LV ostium  The opening at the base of the LV to which the mitral and aortic valves attach 
 Aortomitral con-
tinuity (AMC); 
aortomitral curtain, 
or mitral- aortic in-
tervalvular fibrosa 
 Continuation of the anteromedial aspect of the mitral annulus to the aortic valve; a curtain of fibrous tissue extending 
from the anterior mitral valve leaflet to the left and noncoronary aortic cusps. The AMC is connected by the left and 
right fibrous trigones to ventricular myocardium, the right fibrous trigone to the membranous ventricular septum 
 Mitral valve annulus  Area immediately adjacent to the mitral valve. This can be approached endocardially, or epicardially, either through the 
coronary venous system or percutaneously 
 LV papillary muscles  Muscles connecting the mitral valve chordae tendineae to the LV, typically with posteromedial and anterolateral papil-
lary muscles. Papillary muscle anatomy is variable and can have single or multiple heads 
 LV false tendon (or 
LV moderator band) 
 A fibrous or fibromuscular chord- like band that crosses the LV cavity, attaching to the septum, papillary muscles, tra-
beculations, or free wall of the LV. They may contain conduction tissue and may impede catheter manipulation in the LV 
 Posterior- superior 
process 
 The posterior- superior process of the LV is the most inferior and posterior aspect of the basal LV, posterior to the plane 
of the tricuspid valve. VAs originating from the posterior- superior process of the LV can be accessed from the right 
atrium, the LV endocardium, and the coronary venous system 
 Endocardium  Inner lining of the heart 
 Purkinje network  The specialized conduction system of the ventricles, which includes the His bundle, RBB and left bundle branches (LBB), 
and the ramifications of these, found in the subendocardium. The Purkinje system can generate focal or reentrant VTs, 
typically manifesting Purkinje potentials preceding QRS onset 
 Interventricular 
septum 
 Muscular wall between the LV and RV 
 Membranous ven-
tricular septum 
 The ventricular septum beneath the RSV and NCSV, through which the penetrating His bundle reaches the ventricular 
myocardium 
 LV summit  Triangular region of the most superior part of the LV epicardial surface bounded by the left circumflex coronary artery, 
the left anterior descending artery, and an approximate line from the first septal coronary artery laterally to the left AV 
groove. The great cardiac vein (GCV) bisects the triangle. An area superior to the GCV is considered to be inaccessible 
to catheter ablation due to proximity of the coronary arteries and overlying epicardial fat 
(Continues)
     |  341CRONIN  ET AL .
well as treatment. Electrogram storage may be programmed to include 
far- and near- field electrograms to allow superior assessment of VA 
morphologies. The laboratory workup should be individualized to the 
patient ' s presentation and may include electrolytes, troponin, brain 
natriuretic peptide, genetic testing, or drug screening as appropriate. 
 Synopsis 
 The clinical presentations of patients with VAs encompass a wide 
spectrum, ranging from asymptomatic to VT/VF storm or sudden 
cardiac death (S3.1.1). 
 Presenting symptoms can be classified into five groups: due to 
the VA itself (eg, PVCs, VT or VF); due to a secondary disease caused 
by the VAs (eg, PVC- induced cardiomyopathy); due to an underlying 
pathology associated with the VAs (eg, ischemia); due to ICD ther-
apy; and a combination of these causes. 
 Idiopathic VA is frequently asymptomatic, especially when present-
ing as PVCs or nonsustained VT. In those cases, VAs are commonly de-
tected coincidentally during routine exams. If symptomatic, symptoms 
can often be secondary to post- PVC augmentation of contractility or a 
post- PVC compensatory pause, and commonly consist of palpitations, 
dizziness, shortness of breath, fatigue, or chest discomfort. With in-
creasing duration or VA rate (eg, VT or VF), hemodynamic compromise 
can result in more severe symptoms, such as pre- syncope, syncope, or 
even sudden cardiac death (S3.1.1, S3.1.2). 
 Secondary diseases caused by VA include PVC- induced cardio-
myopathy, which can present with typical symptoms of heart failure 
and reduced ejection fraction (EF) (S3.1.3, S3.1.4). If PVCs are as-
ymptomatic, the diagnosis is commonly made by a routine physical 
exam and is confirmed by a 12- lead ECG. 
 Underlying pathologies resulting in VA are numerous and include 
ischemia (S3.1.5); cardiomyopathy (S3.1.6); genetic diseases (eg, in-
herited arrhythmia syndromes) (S3.1.7); hypertrophic cardiomyopathy 
(HCM) (S3.1.8); ARVC (S3.1.9); CHD (S3.1.10); infiltrative, inflamma-
tory, or infectious diseases (S3.1.11); and correctible causes, such 
as electrolyte abnormalities or medication adverse effects (S3.1.12). 
If VAs themselves are asymptomatic, the presenting symptoms will 
mostly depend on the underlying pathology and might include chest 
pain, heart failure, dizziness, syncope, and sudden cardiac death. A 
careful history and physical exam with a review of the family history, 
ECG, imaging, and laboratory data (S3.1.13) will direct diagnosis and 
specific treatment (eg, immunosuppression in cardiac sarcoidosis) 
(S3.1.11). If inherited arrhythmia syndromes are suspected (eg, long 
QT syndrome), genetic testing should be considered (S3.1.7). 
 ICD therapy including shocks is an increasingly common presenta-
tion of VAs in patients with CIEDs, and appropriate ICD therapy occurs 
 Term  Definition 
 Crux of the heart 
(crux cordis) 
 Epicardial area formed by the junction of the AV groove and posterior interventricular groove, at the base of the heart, 
approximately at the junction of the middle cardiac vein and coronary sinus (CS) and near the origin of the posterior 
descending coronary artery 
 Epicardium  The outer layer of the heart—the visceral layer of the serous pericardium 
 Epicardial fat  Adipose tissue variably present over the epicardial surface around coronary arteries, LV apex, RV free wall, left atrial 
appendage, right atrial appendage, and AV and interventricular grooves 
 Pericardial space or 
cavity 
 The potential space between the parietal and visceral layers of serous pericardium, which normally contains a small 
amount of serous fluid. This space can be accessed for epicardial procedures 
 Parietal pericardium  The layer of the serous pericardium that is attached to the inner surface of the fibrous pericardium and is normally ap-
posed to the visceral pericardium, separated by a thin layer of pericardial fluid 
 Fibrous pericardium  Thick membrane that forms the outer layer of the pericardium 
 Subxiphoid area  Area inferior to the xiphoid process; typical site for percutaneous epicardial access 
 Phrenic nerve  The right phrenic nerve lays along the right atrium and does not usually pass over ventricular tissue. The course of the left 
phrenic nerve on the fibrous pericardium can be quite variable and may run along the lateral margin of the LV near the left 
obtuse marginal artery and vein; inferior, at the base of the heart; or anterior over the sternocostal surface over the L main 
stem coronary artery or left anterior descending artery 
 Coronary sinus (CS) 
and branches 
 The CS and its branches comprise the coronary venous system with the ostium of the CS opening into the right atrium. 
Tributaries of the CS, which runs along the left AV groove, may be used for mapping. These include the anterior 
interventricular vein (AIV), which arises at the apex and runs along the anterior interventricular septum, connecting to 
the GCV that continues in the AV groove to the CS; the communicating vein located between aortic and pulmonary 
annulus; various posterior and lateral marginal branches or perforator veins; and the middle cardiac vein that typically 
runs along the posterior interventricular septum from the apex to join the CS or empty separately into the right atrium. 
The junction of the GCV and the CS is at the vein or ligament of Marshall (or persistent left superior vena cava, when 
present), and the valve of Vieussens (where present) 
 Anatomical terminology (S2.4.1–S2.4.9). See also Figures  3 ,  4 ,  7 , and  8 . 
 Abbreviations: AIV, anterior interventricular vein; AMC, aortomitral continuity; AV, atrioventricular; CS, coronary sinus; GCV, great cardiac vein; LBB, 
left bundle branch; LSV, left sinus of Valsalva; LV, left ventricle; LVOT, left ventricular outflow tract; NCSV, noncoronary sinus of Valsalva; RBB, right 
bundle branch; RSV, right sinus of Valsalva; RV, right ventricle; RVOT, right ventricular outflow tract; SV, sinus of Valsalva; VA, ventricular arrhythmia; 
VT, ventricular tachycardia. 
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in the first year in >50% of patients with secondary and approximately 
5% of patients with primary prevention ICDs (S3.1.14, S3.1.15). 
 Combined presentations of those scenarios are common, such 
as worsening heart failure status with increased arrhythmias burden 
(S3.1.3, S3.1.4) or acute MI presenting with sudden cardiac death as 
a manifestation of the VAs (S3.1.5). 
 Given that presenting symptoms of VA vary widely, careful documen-
tation and correlation of the specific arrhythmia (ECG, telemetry, Holter or 
event monitor, electrograms) with the presenting symptoms is important 
to guide further workup and therapy. Symptoms commonly attributed to 
VA (eg, palpitations, dizziness, chest pain, syncope) are nonspecific and 
can either be due to other arrhythmias (S3.1.16) (eg, supraventricular 
tachycardia [SVT] or bradycardia), other cardiac diseases, noncardiac con-
ditions, anxiety, or have no clear identifiable cause (S3.1.17). 
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 3.2  |  Diagnostic evaluation 
 3.2.1  |  Resting 12- lead electrocardiogram 
 Recommendations for resting 12- lead ECG 
 COR  LOE  Recommendations  References 
 I  B- NR  1. In patients with wide complex tachycardia, a 12- lead ECG during tachycardia 
should be obtained whenever possible. 
 S3.2.1.1–S3.2.1.15 
 I  B- NR  2. In patients with suspected or documented VA, a 12- lead ECG should be ob-
tained in sinus rhythm to look for evidence of underlying heart disease. 
 S3.2.1.16 
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 Recommendation- specific supportive text 
 1 A 12-lead ECG during tachycardia is the first diagnostic test that 
should be performed for any patient with a stable, wide, QRS 
complex tachycardia to differentiate VT from SVT prior to attempts 
to terminate the tachycardia. Criteria that support a diagnosis 
of VT include AV dissociation, a QRS complex >0.14 seconds, 
monophasic R wave in aVR, positively or negatively concordant 
QRS complexes in the precordial leads, the absence of an RS 
complex in all precordial leads, and an RS interval >100 ms in 
at least 1 precordial lead (S3.2.1.1–S3.2.1.3). For patients with 
preexisting bundle branch block, comparison of the QRS mor-
phology during sinus rhythm with QRS morphology during wide 
complex tachycardia is important. Various QRS morphologies (eg, 
bundle branch block pattern) strongly support the diagnosis of 
VT. An identical QRS complex during sinus rhythm and broad 
QRS tachycardia, however, does not rule out the presence of 
bundle branch reentry (BBR) tachycardia. Patients without SHD 
can present with idiopathic VT (eg, fascicular VT) that can be 
easily recognized by 12-lead ECG (S3.2.1.4). For nonsustained 
VAs (PVCs or nonsustained VT), the 12-lead QRS morphology 
is critical to allow for identification of the SOO. Idiopathic VAs 
(eg, right and left OT VAs, PVCs from the aortic SV, papillary 
muscle VAs) can be recognized, given they exhibit characteristic 
ECG patterns (see Section  5.2 ) (S3.2.1.5–S3.2.1.10). 
 2 A 12-lead ECG during sinus rhythm is helpful to evaluate the pres-
ence of underlying heart disease and might be a clue for scar lo-
cation and origins of related VAs, such as inferior wall or anterior 
wall Q waves. An inherited arrhythmia disorder can also be identi-
fied, such as ARVC (epsilon waves and/or inverted T waves in right 
precordial leads), long QT syndrome, Brugada syndrome (coved-
type ST-segment elevation in the right precordial leads), and ChD 
(right bundle branch block [RBBB] and/or left anterior hemiblock) 
(S3.2.1.17). In patients with SHD, QRS duration and the presence 
of conduction abnormalities might provide additional prognostic 
information (S3.2.1.18–S3.2.1.23). 
 References 
 S3.2.1.1.   Brugada P, Brugada J, Mont L, Smeets J, Andries EW. A new 
approach to the differential diagnosis of a regular tachycardia 
with a wide QRS complex.  Circulation. 1991;83:1649–59. 
 S3.2.1.2.   Wellens HJ, Bar FW, Lie KI. The value of the electrocardio-
gram in the differential diagnosis of a tachycardia with a wid-
ened QRS complex.  Am J Med . 1978;64:27–33. 
 S3.2.1.3.   Vereckei A, Duray G, Szenasi G, Altemose GT, Miller JM. New 
algorithm using only lead aVR for differential diagnosis of wide 
QRS complex tachycardia.  Heart Rhythm. 2008;5:89–98. 
 S3.2.1.4.   Ohe T, Shimomura K, Aihara N, et al. Idiopathic sustained left 
ventricular tachycardia: clinical and electrophysiologic char-
acteristics.  Circulation. 1988;77:560–68. 
 S3.2.1.5.   Dixit S, Gerstenfeld EP, Callans DJ,Marchlinski FE. 
Electrocardiographic patterns of superior right ventricular 
outflow tract tachycardias: distinguishing septal and free- wall 
sites of origin.  J Cardiovasc Electrophysiol. 2003;14:1–7. 
 S3.2.1.6.   Callans DJ, Menz V, Schwartzman D, Gottlieb CD, Marchlinski 
FE. Repetitive monomorphic tachycardia from the left ventricular 
outflow tract: electrocardiographic patterns consistent with a left 
ventricular site of origin.  J Am Coll Cardiol. 1997;29:1023–27. 
 S3.2.1.7.   Kanagaratnam L, Tomassoni G, Schweikert R, et al. Ventricular 
tachycardias arising from the aortic sinus of valsalva: an 
under- recognized variant of left outflow tract ventricular 
tachycardia.  J Am Coll Cardiol. 2001; 37:1408–14. 
 S3.2.1.8.   Crawford T,Mueller G, Good E, et al. Ventricular arrhythmias 
originating from papillary muscles in the right ventricle.  Heart 
Rhythm. 2010; 7:725–30. 
 S3.2.1.9.   Yamada T, McElderry HT, Okada T, et al. Idiopathic focal ventric-
ular arrhythmias originating from the anterior papillary muscle in 
the left ventricle.  J Cardiovasc Electrophysiol. 2009;20:866–72. 
 S3.2.1.10.   Li S, Wang Z, Shan Z, et al. Surface electrocardiography char-
acteristics and radiofrequency catheter ablation of idiopathic 
ventricular arrhythmias originating from the left infero- septal 
papillary muscles: differences from those originating from the 
left posterior fascicle.  Europace . 2018; 20:1028–34. 
 S3.2.1.11.   Berruezo A, Mont L, Nava S, Chueca E, Bartholomay E, Brugada 
J. Electrocardiographic recognition of the epicardial origin of 
ventricular tachycardias.  Circulation. 2004;109:1842–47. 
 S3.2.1.12.   Daniels DV, Lu YY, Morton JB, et al. Idiopathic epicardial left 
ventricular tachycardia originating remote from the sinus of 
Valsalva: electrophysiological characteristics, catheter ablation, 
and identification from the 12- lead electrocardiogram.  Circulation. 
2006;113:1659–66. 
 S3.2.1.13.   Bazan V, Gerstenfeld EP, Garcia FC, et al. Site- specific twelve- 
lead ECG features to identify an epicardial origin for left ven-
tricular tachycardia in the absence of myocardial infarction. 
 Heart Rhythm. 2007;4:1403–10. 
 S3.2.1.14.   Valles E, Bazan V, Marchlinski FE. ECG Criteria to identify epi-
cardial ventricular tachycardia in nonischemic cardiomyopa-
thy.  Circ Arrhythm Electrophysiol. 2010;3:63–71. 
 S3.2.1.15.   Bazan V, Bala R, Garcia FC, et al. Twelve- lead ECG features 
to identify ventricular tachycardia arising from the epicardial 
right ventricle.  Heart Rhythm. 2006;3:1132–1139. 
 S3.2.1.16.   Perez- Rodon J, Martinez- Alday J, Baron- Esquivias G, et al. 
Prognostic value of the electrocardiogram in patients with 
syncope: data from the group for syncope study in the emer-
gency room (GESINUR).  Heart Rhythm. 2014;11:2035–44. 
 S3.2.1.17.   Marcus FI, McKenna WJ, Sherrill D, et al. Diagnosis of arrhythmo-
genic right ventricular cardiomyopathy/dysplasia: proposed mod-
ification of the task force criteria.  Circulation. 2010;121:1533–41. 
 S3.2.1.18.   Baldasseroni S, Opasich C, Gorini M, et al. Left bundle- branch 
block is associated with increased 1- year sudden and total 
mortality rate in 5517 outpatients with congestive heart fail-
ure: a report from the Italian network on congestive heart 
failure.  Am Heart J. 2002;143:398–405. 
 S3.2.1.19.   Desai AD, Yaw TS, Yamazaki T, Kaykha A, Chun S, Froelicher 
VF. Prognostic significance of quantitative QRS duration.  Am 
J Med . 2006;119:600–606. 
 S3.2.1.20.   Dhar R, Alsheikh- Ali AA, Estes NA 3rd, et al. Association of 
prolonged QRS duration with ventricular tachyarrhythmias and 
sudden cardiac death in the Multicenter Automatic Defibrillator 
Implantation Trial II (MADITII).  Heart Rhythm. 2008;5:807–13. 
 S3.2.1.21.   Freedman RA, Alderman EL, Sheffield LT, Saporito M, Fisher 
LD. Bundle branch block in patients with chronic coronary 
artery disease: angiographic correlates and prognostic signif-
icance.  J Am Coll Cardiol. 1987;10:73–80. 
 S3.2.1.22.   Iuliano S, Fisher SG, Karasik PE, Fletcher RD, Singh SN. QRS 
duration and mortality in patients with congestive heart fail-
ure.  Am Heart J. 2002; 143:1085–91. 
 S3.2.1.23.   Zimetbaum PJ, Buxton AE, Batsford W, et al. 
Electrocardiographic predictors of arrhythmic death and total 
mortality in the multicenter unsustained tachycardia trial. 
 Circulation. 2004;110:766–69. 
344  |     CRONIN  ET AL .
 3.2.2  |  Assessment of structural heart disease and myocardial ischemia 
 Recommendations for assessment of SHD and myocardial ischemia
 COR  LOE  Recommendations  References 
 I  B- NR  1. In patients with known or suspected VA, echocardiography is recommended for evaluation 
of cardiac structure and function. 
 S3.2.2.3–S3.2.2.4 
 IIa  B- NR  2. In patients presenting with VA who are suspected of having SHD, even after normal echo-
cardiographic evaluation, advanced cardiac imaging can be useful to detect and characterize 
underlying SHD. 
 S3.2.2.5–S3.2.2.7 
 IIa  C- EO  3. In patients with VA in whom myocardial ischemia is suspected, stress testing and/or 
coronary angiography and subsequent revascularization can be beneficial before catheter 
ablation to avoid significant ischemia during induced VT. 
 
 III: No 
Benefit 
 B- NR  4. In patients presenting with monomorphic VT, revascularization alone is not effective to 
prevent VT recurrence. 
 S3.2.2.8–S3.2.2.10 
 Recommendation- specific supportive text 
 1 Assessment of global and regional myocardial function, valvu-
lar structure and function, along with testing for adult CHD 
is required in patients with or at high risk for VA or sudden 
cardiac death. Echocardiography is the most readily available and 
commonly used imaging technique (S3.2.2.1, S3.2.2.2). Accurate 
assessment of LV ejection fraction (LVEF) using CMR is hindered 
by the presence of frequent PVCs (S3.2.2.11). In these patients, 
echocardiographic evaluation of LVEF may be superior to CMR. 
 2 Advanced cardiac imaging, such as cardiac CT, CMR, and fluoro-
deoxyglucose positron emission tomography (PET), is useful for 
the evaluation of SHD and assessment of LV and RV function 
(S3.2.2.3–S3.2.2.7). CMR with assessment of late gadolinium en-
hancement (LGE) is the gold standard technique for determination 
of location and the extent of scarring. This information has implica-
tions for planning the ablation strategy (see Section  5.4 ) (S3.2.2.7, 
S3.2.2.12). The use of this imaging technique is limited in some 
patients with CIEDs (S3.2.2.13) (see Section  5.4 ). Additional myo-
cardial inflammation or infiltrative diseases can be detected with 
CMR or fluorodeoxyglucose PET (S3.2.2.14). 
 3 Transient myocardial ischemia is a known cause of polymorphic 
rather than monomorphic sustained VT. Monomorphic VT in the 
setting of prior MI is typically due to scar-related reentry and not 
due to acute ischemia. For patients suspected to have myocardial 
ischemia, stress testing and/or coronary angiography and sub-
sequent revascularization should be performed when possible 
before catheter ablation to avoid significant ischemia during VT 
induction, mapping, and ablation. 
 4 Revascularization alone is unlikely to reduce the recurrence of 
monomorphic VT (S3.2.2.8–S3.2.2.10). However, revascularization 
might be beneficial in patients with IHD and VF, polymorphic VT, or 
exercise-induced arrhythmias associated with ischemia (S3.2.2.15). 
Revascularization for prognostic indications may also be indicated. 
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 3.2.3  |  Risk stratification in the setting of frequent premature ventricular complexes 
 Recommendations for CMR in patients with frequent PVCs and for PES in patients with SHD and frequent PVCs
 COR  LOE  Recommendations  References 
 IIa  B- NR  1. CMR can be useful for risk stratification for sudden cardiac death in patients with 
frequent PVCs. 
 S3.2.3.1, S3.2.3.2 
 IIa  C- LD  2. PES can be useful for risk stratification for sudden cardiac death in patients with SHD 
undergoing ablation of frequent PVCs. 
 S3.2.3.2 
 Recommendation- specific supportive text 
 1 CMR has been reported to identify patients at increased risk for 
adverse outcomes in the presence of frequent PVCs (S3.2.3.1, 
S3.2.3.2). One study assessed the value of CMR in an Italian patient 
population with frequent LBBB PVCs (S3.2.3.1). Patients without RV 
CMR abnormalities had better outcomes than patients with CMR 
abnormalities. Another study assessed the benefit of CMR for risk 
stratification in patients with frequent PVCs undergoing ablation 
procedures for PVCs (S3.2.3.2). Except for 1 patient who had in-
ducible idiopathic VT, 14 of 15 patients with inducible, sustained, 
monomorphic VT had scarring identified by CMR. All patients with 
inducible VT except the patient with idiopathic VT underwent ICD 
implantation, and 50% had appropriate ICD therapy during follow-up. 
 2 Programmed stimulation has been reported to identify patients at 
increased risk for adverse outcomes in the presence of frequent 
PVCs (the PVC burden was 20 ± 13% in the cited study), but with-
out prior documented VT, and who are undergoing PVC ablation 
procedures (S3.2.3.2). All but one patient with inducible VT had 
SHD prompting ICD implantation, and 50% of the patients had ap-
propriate ICD therapy during follow-up (S3.2.3.2). 
 Synopsis 
 LVEF continues to be the main prognostic clinical variable for VA. The 
presence and extent of myocardial fibrosis, assessed by CMR- LGE, 
predict ventricular tachyarrhythmias in patients with ischemic and 
nonischemic LV dysfunction (S3.2.3.3–S3.2.3.8). In a meta- analysis 
including 2850 patients with IHD and nonischemic heart disease 
from 19 studies, the composite arrhythmic endpoint was significantly 
higher in the patients with LGE (annualized event rate of 8.6%) than in 
the patients without LGE (annualized event rate of 1.7%;  P  <  0.0001) 
(S3.2.3.8). In a larger meta- analysis including 7882 patients from 36 
studies (both ischemic cardiomyopathy [ICM] and NICM), LGE was 
associated with an increase in all- cause mortality (hazard ratio [HR] 
2.96; 95% CI 2.37- 3.70;  P  <  0.001), cardiovascular mortality (HR 3.27; 
95% CI 2.05- 5.22;  P  <  0.001), VA and sudden cardiac death (HR 3.76; 
95% CI 3.14- 4.52;  P  <  0.001), and major adverse cardiovascular events 
(HR 3.24; 95% CI 2.32- 4.52;  P  <  0.001) (S3.2.3.6). In both studies, the 
predictive value of LGE was independent of LVEF and whether the 
cardiomyopathy was of ischemic or nonischemic etiology. 
 Patients with PVC- induced cardiomyopathy show improvement 
(even normalization) of LVEF after effective PVC treatment. As op-
posed to patients with NICM, the absence of LGE is a common finding 
in these patients; thus, absence of LGE could be used to identify pa-
tients with greater chance of LVEF recovery (S3.2.3.9). Patients with 
frequent PVCs in the presence of LGE still have a possibility of LVEF 
improvement (S3.2.3.10) post ablation, although the LVEF might not 
completely normalize (S3.2.3.11). An RBBB morphology of the PVC 
has been associated with an increased prevalence of LGE- defined 
fibrosis (S3.2.3.12). This finding has prognostic implications. CMR 
has been reported to identify patients at increased risk for adverse 
outcomes in the presence of frequent PVCs (S3.2.3.1, S3.2.3.2). In 
addition, CMR provides important information about the underlying 
fibrotic substrate and facilitates ablation procedure planning. Inducible 
VT can have prognostic implications in patients with frequent PVCs 
and LGE- CMR. Over 80% of the writing committee members perform 
programmed stimulation to induce VT at the time of PVC or VT abla-
tion in patients without known SHD. 
 The arrhythmogenic substrate can also be recognized by volt-
age mapping at the time of the procedure. Low- voltage areas have 
been correlated with scar tissue identified as LGE- CMR (S3.2.3.13, 
S3.2.3.14). Although OT PVCs typically occur in patients with normal 
heart, identification of low- voltage areas and transitional zones could 
provide helpful information at the time of ablation (S3.2.3.15). Two- 
thirds of the writing committee members perform voltage mapping of 
the relevant ventricle at the time of PVC or VT ablation in patients 
without known SHD. 
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 3.2.4  |  Longitudinal follow- up in the setting of frequent premature ventricular complexes 
 Recommendation for longitudinal follow- up of patients with frequent PVCs 
 COR  LOE  Recommendation  Reference 
 IIa  B- NR  1 Periodic monitoring of PVC burden and LV function and dimensions can be useful in pa-
tients with frequent, asymptomatic PVCs and normal LV function and dimensions. 
 S3.2.4.1 
 Recommendation- specific supportive text 
 1 Frequent PVCs can be associated with the development of cardio-
myopathy in susceptible individuals. Despite extensive study, the 
predictors of future deterioration of LV function are unclear. In 
one study of 249 patients, all of whom were followed for at least 
4 years, none developed overt congestive heart failure, but the 
LVEF decreased in 20% of patients with very frequent PVCs (>20 000 
per 24 hours) (S3.2.4.1). Therefore, until the development of PVC-
induced cardiomyopathy can be predicted with more precision, 
periodic measurement of LVEF and LV end-diastolic dimensions, 
along with quantification of PVC burden, may be useful for patients 
with a high PVC burden [approximately 10% or higher (S3.2.4.2)] 
to identify deteriorating LV function before symptoms appear. 
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 4    |   I N D I C ATI O N S FO R C ATH E TER 
A B L ATI O N 
 Following are the consensus recommendations for catheter abla-
tion of VAs organized by underlying diagnosis and substrate. These 
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recommendations are each assigned a COR and an LOE according 
to the current recommendation classification system (S4.1). In draft-
ing each of these recommendations, the writing committee took into 
account the published literature in the specific area, including the 
methodological quality and size of each study, as well as the col-
lective clinical experience of the writing group when published data 
were not available. Implicit in each recommendation are several 
points: (a) the procedure is being performed by an electrophysiolo-
gist with appropriate training and experience in the procedure and 
in a facility with appropriate resources; (b) patient and procedural 
complexity vary widely, and some patients or situations merit a more 
experienced operator or a center with more capabilities than others, 
even within the same recommendation (eg, when an epicardial pro-
cedure is indicated and the operator or institution has limited experi-
ence with this procedure, it might be preferable to refer the patient 
to an operator or institution with adequate experience in performing 
epicardial procedures); (c) the patient is an appropriate candidate for 
the procedure (as outlined in Section  5.1 ), recognizing that the level 
of patient suitability for a procedure will vary widely with the clini-
cal scenario; and (d) the patient ' s (or designee ' s) informed consent, 
values, and overall clinical trajectory are fundamental to a decision 
to proceed (or not) with any procedure. Therefore, in some clinical 
scenarios, initiation or continuation of medical therapy instead of an 
ablation procedure may be the most appropriate option, even when 
a class 1 recommendation for ablation is present. There may also be 
scenarios not explicitly covered in this document, and on which lit-
tle or no published literature is available, in which the physician and 
patient must rely solely on their own judgment. 
 In drafting these recommendations, the writing committee also 
referenced several other relevant clinical documents, including 
the  2017 AHA/ACC/HRS Guideline for Management of Patients with 
Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death 
(S4.2), among others. The exclusive focus of the current document on 
VA ablation led to the opportunity to develop more detailed and nu-
anced recommendations. 
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 4.1  |  Idiopathic outflow tract ventricular arrhythmia 
 Recommendations for catheter ablation of idiopathic OT VA 
 COR  LOE  Recommendations  References 
 I  B- R  1. In patients with frequent and symptomatic PVCs originating from the RVOT in an otherwise 
normal heart, catheter ablation is recommended in preference to metoprolol or propafenone. 
 S4.1.1 
 I  B- NR  2. In patients with symptomatic VAs from the RVOT in an otherwise normal heart for whom 
antiarrhythmic medications are ineffective, not tolerated, or not the patient ’ s preference, 
catheter ablation is useful. 
 S4.1.2–S4.1.12 
 I  B- NR  3. In patients with symptomatic idiopathic sustained monomorphic VT, catheter ablation is 
useful. 
 S4.1.13–S4.1.17 
 IIa  B- NR  4. In patients with symptomatic VAs from the endocardial LVOT, including the SV, in an other-
wise normal heart for whom antiarrhythmic medications are ineffective, not tolerated, or not 
the patient ’ s preference, catheter ablation can be useful. 
 S4.1.18–S4.1.27 
 IIa  B- NR  5. In patients with symptomatic VAs from the epicardial OT or LV summit in an otherwise 
normal heart for whom antiarrhythmic medications are ineffective, not tolerated, or not the 
patient ’ s preference, catheter ablation can be useful. 
 S4.1.28–S4.1.32 
 Recommendation- specific supportive text 
 1  In symptomatic patients with frequent PVCs from the RVOT, 
catheter ablation had a higher rate of efficacy than pharmaco-
therapy with either metoprolol or propafenone in an RCT (S4.1.1). 
Ablation success rates are reported at 80%-95%, with low 
complication rates (S4.1.1, S4.1.12, S4.1.21, S4.1.33–S4.1.35). 
Catheter ablation can be considered as a preferred therapy in 
suitable, symptomatic patients. However, some patients with 
minimal or tolerable symptoms might prefer medical therapy 
or no therapy. 
 2  RVOT and LVOT are the most common SOOs for idiopathic VA 
in patients without SHD. VAs arising from these locations mostly 
present with a unique pattern on 12-lead surface ECG. The most 
common underlying pathophysiological mechanism is triggered 
activity, and RF catheter ablation is highly effective and has low 
complication rates (S4.1.2–S4.1.12). Multiple studies have shown 
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that for RVOT VAs, catheter ablation is effective for prevention 
of arrhythmia recurrences. 
 3  In patients with symptomatic, idiopathic, sustained monomorphic 
VT, catheter ablation might be preferable to medical therapy. It is 
a more definitive treatment option, given its high success and low 
recurrence rates (S4.1.13–S4.1.17). 
 4 LVOT VA is reported to account for 12%-45% of all idiopathic 
VAs (S4.1.18–S4.1.22). Compared with VAs originating from the 
RVOT, ablation of LVOT VAs is more complex (S4.1.18–S4.1.22). 
Rarely, LVOT VA sites require epicardial ablation via the GCV/
AIV or subxiphoid puncture. Clinically, ablation of LVOT VA can 
involve greater procedural complexity as well as periprocedural 
risk (stroke or coronary artery injury) compared with RVOT VA. 
However, many studies report good results pertaining to the 
safety, feasibility, and potential curative ability of RF catheter ab-
lation (S4.1.18–S4.1.22). 
 5  Although most idiopathic VAs originate from the RVOT or 
LVOT, in some cases, RF catheter ablation cannot successfully 
be performed from either site. In such cases, the VAs might 
originate from the LV summit (see Section  2 for definition). 
VAs originating from this area can present challenges for suc-
cessful RF catheter ablation, and the failure rate is high due to 
epicardial fat and the proximity of coronary arteries if a subxi-
phoid epicardial access is used (S4.1.14–S4.1.16). Appropriate 
patient selection for this approach is key, and the initial ap-
proach should focus on the endocardium and adjacent struc-
tures, including the coronary venous system, the aortic cusps, 
and the RVOT. 
 References 
 S4.1.1.   Ling Z, Liu Z, Su L, et al. Radiofrequency ablation versus 
antiarrhythmic medication for treatment of ventricular 
premature beats from the right ventricular outflow tract: 
prospective randomized study.  Circ Arrhythm Electrophysiol. 
2014;7:237–43. 
 S4.1.2.   Zhang F, Yang B, Chen H, Ju W, Kojodjojo P, Cao K, Chen M. 
Magnetic versus manual catheter navigation for mapping 
and ablation of right ventricular outflow tract ventricular 
arrhythmias: a randomized controlled study.  Heart Rhythm. 
2013;10:1178–83. 
 S4.1.3.   Krittayaphong R, Sriratanasathavorn C, Dumavibhat C, et al. 
Electrocardiographic predictors of long term outcomes after 
radiofrequency ablation in patients with right- ventricular out-
flow tract tachycardia.  Europace . 2006; 8:601–6. 
 S4.1.4.   Vestal M, Wen MS, Yeh SJ, Wang CC, Lin FC, Wu D. 
Electrocardiographic predictors of failure and recurrence in 
patients with idiopathic right ventricular outflow tract tachy-
cardia and ectopy who underwent radiofrequency catheter 
ablation.  J Electrocardiol . 2003;36:327–32. 
 S4.1.5.   Miyazawa K, Ueda M, Kondo Y, Hayashi T, Nakano M, Ishimura 
M, Nakano M, Kobayashi Y. Rapid mapping and differentia-
tion in ventricular outflow tract arrhythmia using non- contact 
mapping.  J Interv Card Electrophysiol. 2017;49:41–9. 
 S4.1.6.   Akdeniz C, Gul EE, Celik N, Karacan M, Tuzcu V. Catheter 
ablation of idiopathic right ventricular arrhythmias in chil-
dren with limited fluoroscopy.  J Interv Card Electrophysiol. 
2016;46:355–60. 
 S4.1.7.   Morady F, Kadish AH, DiCarlo L, Kou WH, Winston S, deBuit-
lier M, Calkins H, Rosenheck S, Sousa J. Long- term results of 
catheter ablation of idiopathic right ventricular tachycardia. 
 Circulation. 1990;82:2093–99. 
 S4.1.8.   Liao Z, Zhan X, Wu S, et al. Idiopathic ventricular arrhythmias 
originating from the pulmonary sinus cusp: prevalence, elec-
trocardiographic/electrophysiological characteristics, and 
catheter ablation.  J Am Coll Cardiol. 2015;66:2633–644. 
 S4.1.9.   Bogun F, Crawford T, Reich S, Koelling TM, Armstrong W, 
Good E, et al. Radiofrequency ablation of frequent, idiopathic 
premature ventricular complexes: comparison with a control 
group without intervention.  Heart Rhythm. 2007; 4:863–67. 
 S4.1.10.   Chen H, Shehata M, Swerdlow C, et al. Intramural outflow 
tract ventricular tachycardia: anatomy, mapping, and ablation. 
 Circ Arrhythm Electrophysiol. 2014;7:978–81. 
 S4.1.11.   Teh AW, Reddy VY, Koruth JS, et al. Bipolar radiofrequency 
catheter ablation for refractory ventricular outflow tract ar-
rhythmias.  J Cardiovasc Electrophysiol. 2014;25:1093–99. 
 S4.1.12.   Lamba J, Redfearn DP, Michael KA, Simpson CS, Abdollah 
H, Baranchuk A. Radiofrequency catheter ablation for the 
treatment of idiopathic premature ventricular contractions 
originating from the right ventricular outflow tract: a sys-
tematic review and meta- analysis.  Pacing Clin Electrophysiol. 
2014;37:73–8. 
 S4.1.13.   Calkins H, Kalbfleisch J, El- Atassi R, Langberg J, Morady F. 
Relation between efficacy of radiofrequency catheter abla-
tion and site of origin of idiopathic ventricular tachycardia.  Am 
J Cardiol. 1993;71:827–33. 
 S4.1.14.   Rodriguez LM, Smeets JL, Timmermans C, Wellens HJ. 
Predictors for successful ablation of right- and left- 
sided idiopathic ventricular tachycardia.  Am J Cardiol. 
1997;79:309–14. 
 S4.1.15.   Coggins DL, Lee RJ, Sweeney J, et al. Radiofrequency 
catheter ablation as a cure for idiopathic tachycardia of 
both left and right ventricular origin.  J Am Coll Cardiol. 
1994;23:1333–41. 
 S4.1.16.   Wen MS, Yeh SJ, Wang CC, Lin FC, Chen IC,Wu D. 
Radiofrequency ablation therapy in idiopathic left ventric-
ular tachycardia with no obvious structural heart disease. 
 Circulation. 1994;89:1690–96. 
 S4.1.17.   Movsowitz C, Schwartzman D, Callans DJ, et al. Idiopathic 
right ventricular outflow tract tachycardia: narrowing 
the anatomic location for successful ablation.  Am Heart J. 
1996;131:930–36. 
 S4.1.18.   Frey B, Kreiner G, Fritsch S, Veit F, Gossinger HD. Successful 
treatment of idiopathic left ventricular outflow tract tachy-
cardia by catheter ablation or minimally invasive surgical 
cryoablation.  Pacing Clin Electrophysiol. 2000;23:870–6. 
 S4.1.19.   Krebs ME, Krause PC, Engelstein ED, Zipes DP, Miles WM. 
Ventricular tachycardiasmimicking those arising from the 
right ventricular outflow tract.  J Cardiovasc Electrophysiol. 
2000;11:45–51. 
 S4.1.20.   Kumagai K, Fukuda K, Wakayama Y, et al. Electrocardiographic 
characteristics of the variants of idiopathic left ventricu-
lar outflow tract ventricular tachyarrhythmias.  J Cardiovasc 
Electrophysiol. 2008;19:495–501. 
 S4.1.21.   Latchamsetty R, Yokokawa M, Morady F, et al. Multicenter 
outcomes for catheter ablation of idiopathic premature ven-
tricular complexes.  JACC Clin Electrophysiol. 2015;1:116–23. 
 S4.1.22.   Kamakura S, Shimizu W, Matsuo K, et al. Localization of op-
timal ablation site of idiopathic ventricular tachycardia from 
right and left ventricular outflow tract by body surface ECG. 
 Circulation. 1998;98:1525–33. 
 S4.1.23.   Yamada T, Yoshida N, Murakami Y, et al. Electrocardiographic 
characteristics of ventricular arrhythmias originating from the 
     |  349CRONIN  ET AL .
junction of the left and right coronary sinuses of Valsalva in 
the aorta: the activation pattern as a rationale for the electro-
cardiographic characteristics.  Heart Rhythm. 2008;5:184–192. 
 S4.1.24.   Tada H, Naito S, Ito S, et al. Significance of two potentials for 
predicting successful catheter ablation from the left sinus of 
Valsalva for left ventricular epicardial tachycardia.  Pacing Clin 
Electrophysiol. 2004;27:1053–59. 
 S4.1.25.   Ouyang F, Fotuhi P, Ho SY, et al. Repetitive monomorphic 
ventricular tachycardia originating from the aortic sinus cusp: 
electrocardiographic characterization for guiding catheter 
ablation.  J Am Coll Cardiol. 2002; 39:500–8. 
 S4.1.26.   Callans DJ, Menz V, Schwartzman D, Gottlieb CD, Marchlinski 
FE. Repetitive monomorphic tachycardia from the left ven-
tricular outflow tract: electrocardiographic patterns con-
sistent with a left ventricular site of origin.  J Am Coll Cardiol. 
1997;29:1023–27. 
 S4.1.27.   Bala R, Garcia FC, Hutchinson MD, et al. Electrocardiographic 
and electrophysiologic features of ventricular arrhythmias 
originating from the right/left coronary cusp commissure. 
 Heart Rhythm. 2010;7:312–22. 
 S4.1.28.  Tada H, Nogami A, Naito S, et al. Left ventricular epicardial 
outflow tract tachycardia: a new distinct subgroup of outflow 
tract tachycardia.  Jpn Circ J . 2001;65:723–30. 
 S4.1.29.   Baman TS, Ilg KJ, Gupta SK, et al. Mapping and ablation 
of epicardial idiopathic ventricular arrhythmias from within 
the coronary venous system.  Circ Arrhythm Electrophysiol. 
2010;3:274–79. 
 S4.1.30.   Carrigan T, Patel S, YokokawaM, et al. Anatomic relationships 
between the coronary venous system, surrounding struc-
tures, and the site of origin of epicardial ventricular arrhyth-
mias.  J Cardiovasc Electrophysiol. 2014; 25:1336–42. 
 S4.1.31.   Santangeli P, Marchlinski FE, Zado ES, et al. Percutaneous 
epicardial ablation of ventricular arrhythmias arising from 
the left ventricular summit: outcomes and electrocardio-
gram correlates of success.  Circ Arrhythm Electrophysiol. 
2015;8:337–43. 
 S4.1.32.   Nagashima K, Choi EK, Lin KY, et al. Ventricular arrhythmias 
near the distal great cardiac vein: challenging arrhythmia for 
ablation.  Circ Arrhythm Electrophysiol. 2014;7:906–12. 
 S4.1.33.   Yamada T, Murakami Y, Yoshida N, et al. Efficacy of elec-
troanatomic mapping in the catheter ablation of premature 
ventricular contractions originating from the right ventricular 
outflow tract.  J Interv Card Electrophysiol. 2007;19:187–94. 
 S4.1.34.   Wang Z, Zhang H, Peng H, et al. Voltage combined with 
pace mapping is simple and effective for ablation of non-
inducible premature ventricular contractions originat-
ing from the right ventricular outflow tract.  Clin Cardiol . 
2016;39:733–8. 
 S4.1.35.   Zhong L, Lee YH, Huang XM, et al. Relative efficacy of cath-
eter ablation vs antiarrhythmic drugs in treating premature 
ventricular contractions: a singlecenter retrospective study. 
 Heart Rhythm. 2014;11:187–93. 
 4.2  |  Idiopathic nonoutflow tract ventricular arrhythmia 
 Recommendations for catheter ablation of nonoutflow tract VAs in the absence of SHD 
 COR  LOE  Recommendations  References 
 I  B- NR  1. In patients with symptomatic VAs from the RV at sites other than the OTs (tricuspid annulus, 
moderator band, parietal band, or papillary muscles) in an otherwise normal heart for whom an-
tiarrhythmic medications are ineffective, not tolerated, or not the patient ’ s preference, catheter 
ablation is useful. 
 S4.2.1–S4.2.14 
 I  B- NR  2. In patients with symptomatic VAs from the LV at sites other than the OTs (mitral annulus, papil-
lary muscles, or AMC) in an otherwise normal heart for whom antiarrhythmic medications are 
ineffective, not tolerated, or not the patient ’ s preference, catheter ablation is useful. 
 S4.2.15–S4.2.31 
 IIa  B- NR  3. In patients with symptomatic VAs from the epicardial coronary venous system in an otherwise 
normal heart for whom antiarrhythmic medications are ineffective, not tolerated, or not the 
patient ’ s preference, catheter ablation can be useful. 
 S4.2.32–S4.2.43 
 IIa  B- NR  4. In patients with symptomatic VAs from para- Hisian sites in an otherwise normal heart for 
whom antiarrhythmic medications are ineffective, not tolerated, or not the patient ’ s preference, 
catheter ablation can be useful. 
 S4.2.7, S4.2.13, 
S4.2.14, 
S4.2.44–S4.2.49 
 IIa  C- LD  5. In patients with symptomatic VAs from the posterior- superior process of the LV in an otherwise 
normal heart for whom antiarrhythmic medications are ineffective, not tolerated, or not the pa-
tient ’ s preference, catheter ablation from the LV endocardium, right atrium, or CS, can be useful. 
 S4.2.50–S4.2.52 
 Recommendation- specific supportive text 
 1. Among idiopathic RV arrhythmias presenting for catheter abla-
tion, approximately 10%- 15% arise at sites other than the RVOT 
(S4.2.1). Sites that can be ablated with a high level of success 
include any of the three RV papillary muscles (S4.2.3, S4.2.6), 
the parietal band (S4.2.7, S4.2.9–S4.2.11), the tricuspid annulus 
(S4.2.5, S4.2.8, S4.2.12, S4.2.13), and the moderator band (S4.2.2, 
S4.2.14). Although frequent PVCs, nonsustained VT, and sustained 
monomorphic VT are the most common idiopathic VAs at these 
sites of origin, VF triggered by PVCs arising from the moderator 
band (S4.2.2) can occasionally occur. Successful catheter ablation 
is achieved in over 90% of patients with RV VAs arising outside 
the RVOT, with a low risk of complications. The recurrence rate 
and need for repeat procedures are higher for VAs arising from the 
moderator, septal, and parietal bands than from other sites (S4.2.2, 
S4.2.7). In addition, the probability of successful ablation is higher 
for tricuspid annular VAs arising from the free wall than the septal 
regions, which are closer to the conduction system (S4.2.5). 
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 2. Idiopathic VAs arising from the LV papillary muscles account for 
approximately 15% of idiopathic LV arrhythmias referred for 
catheter ablation and are characterized by frequent PVCs or re-
current monomorphic VT with a catecholamine- sensitive focal 
mechanism. VT can arise from either the posteromedial papillary 
muscles or the anterolateral papillary muscles (S4.2.15–S4.2.23). 
These arrhythmias often require several RF applications for suc-
cessful ablation. A change in QRS morphology of the VA after 
ablative applications to either side of the involved papillary mus-
cle is common. Due to the thickness of the papillary muscles and 
their vigorous contraction, catheter stability can be challenging 
and might be improved by the use of intracardiac ultrasound and 
possibly cryoablation (S4.2.18, S4.2.22). The recurrence risk after 
initial successful ablation of papillary muscle VAs is higher than 
for many other idiopathic VA sites, and repeat procedures are re-
quired in approximately 30% of patients (S4.2.16, S4.2.18). 
 The mitral annulus is the SOO for approximately 20% of idiopathic 
LV arrhythmias, with the majority being PVCs or nonsustained 
VT rather than sustained VT (S4.2.24, S4.2.25). Mitral annular 
VAs are based on a focal, catecholamine- sensitive mechanism. A 
superior- anterior mitral annular origin is more common than an 
inferior- posterior origin (S4.2.23–S4.2.26). Successful ablation is 
achieved in approximately 90% of mitral annular VAs, with a very 
low risk of complications (S4.2.23–S4.2.29). The AMC is a com-
mon location of mitral annular VAs at the base of the LV ostium. 
Most patients with VA from the AMC have frequent PVCs rather 
than sustained VT (S4.2.30). Endocardial mapping demonstrates 
a prepotential in the majority of VAs originating in this location, 
with successful ablation in over 90% of patients with a low risk of 
complications (S4.2.30, S4.2.31). 
 VAs that can be mapped and ablated within the GCV or AIV are 
relatively common SOOs near or within the LV summit (S4.2.32–
S4.2.36). Proximity to the coronary arteries needs to be assessed 
(see Sections  9.3 and  11.1 ) prior to ablation. If the SOO is too 
close (<5- 10 mm) to a coronary artery, ablation from the adjacent 
endocardium might be successful when within 1 cm of the SOO 
(S4.2.37). These arrhythmias from the superior portion of the 
coronary venous system are usually based on a focal mechanism 
and typically require an irrigated- tip ablation catheter due to high 
impedance within the coronary vein. Mapping and ablation from 
the LSV or LV endocardium might also be successful, even if the 
local ECG in the coronary venous system is earlier (S4.2.38). For 
VAs with an intramural location, ablation within the perforator 
veins from within the LV septum (S4.2.39), simultaneous bipolar 
or simultaneous unipolar RF energy from the coronary venous 
system and the LV endocardium might be required to achieve 
successful ablation. 
 Sustained monomorphic VT arising from the crux of the heart 
is typically very rapid, based on a focal catecholamine- sensitive 
mechanism, and often produces syncope (S4.2.40–S4.2.43). 
The QRS morphology is characterized by an abrupt transition 
from negative in lead V1, to positive in lead V2, to more nega-
tive in lead V3 (S4.2.40). Ablation can be achieved within the 
coronary venous system, including the middle cardiac vein 
(S4.2.40, S4.2.41, S4.2.43) and the adjacent endocardium, or 
might require epicardial access (S4.2.40–S4.2.42). The proximity 
of the coronary venous system to the posterior descending coro-
nary artery requires imaging to prevent arterial injury. 
 3. VAs arising from the RV septum near the His bundle can be 
successfully ablated in approximately 70%- 90% of patients, 
with several series reporting a higher likelihood of abandoning 
attempts at ablation due to concerns about inducing AV block 
(S4.2.7, S4.2.13, S4.2.14, S4.2.44–S4.2.49). The appearance of an 
accelerated junctional rhythm is common during RF application 
in this region, though AV block is not (S4.2.7). Catheter stability 
and the need to prevent injury to the AV node are issues that are 
carefully considered for these VAs (S4.2.49). Pacing maneuvers 
may be beneficial to prevent damage to the AV node (S4.2.53). 
The careful use of cryoablation can help to prevent damage to the 
conduction system if ablative therapy is delivered in close prox-
imity to the conduction system. 
 4. The posterior- superior process of the LV is the most inferior and 
posterior aspect of the basal LV, posterior to the plane of the 
tricuspid valve (S4.2.50). Ablation of VAs in this region can be 
accomplished from the LV endocardium (S4.2.51). However, VAs 
arising from this region can also be successfully ablated from the 
inferior septal surface of the right atrium, where a small atrial sig-
nal and a larger ventricular signal, earlier than the earliest site in 
the LV endocardium, can be recorded (S4.2.50). Reports also de-
scribe ablation from within the CS (S4.2.52). Successful ablation 
can be achieved with either RF or cryoablation energies. The risk 
of complications appears to be low, although data are limited, and 
caution is required due to the proximity to the AV node and the 
AV nodal artery (S4.2.50). 
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 4.3  |  Premature ventricular complexes with or without left ventricular dysfunction 
 Recommendations for catheter ablation of PVCs in patients with or without LV dysfunction 
 COR  LOE  Recommendations  References 
 I  B- NR  1. In patients with cardiomyopathy suspected to be caused by frequent and predominately 
monomorphic PVCs and for whom AADs are ineffective, not tolerated, or not preferred for 
long- term therapy, catheter ablation is recommended. 
 S4.3.1–S4.3.10 
 IIa  B- NR  2. In patients with SHD in whom frequent PVCs are suspected to be contributing to a cardio-
myopathy and for whom AADs are ineffective, not tolerated, or not preferred for long- term 
therapy, catheter ablation can be useful. 
 S4.3.3, S4.3.11, 
S4.3.12 
 IIa  B- NR  3. In patients with focally triggered VF refractory to AADs and triggered by a similar PVC, cath-
eter ablation can be useful. 
 S4.3.13–S4.3.17 
 IIa  C- LD  4. In nonresponders to cardiac resynchronization therapy (CRT) with very frequent unifocal 
PVCs limiting optimal biventricular pacing despite pharmacological therapy, catheter ablation 
can be useful. 
 S4.3.18 
 Recommendation- specific supportive text 
 1 In patients with a suspected PVC-induced cardiomyopathy, 
catheter ablation can be considered an alternative to long-
term AAD therapy, particularly for patients with monomor-
phic PVCs, or PVCs of an RVOT origin (S4.3.1). PVC-induced 
cardiomyopathy should be suspected when cardiomyopathy 
and frequent PVCs are present and a comprehensive car-
diac evaluation fails to identify alternate etiologies. Several 
studies have confirmed a correlation between a higher PVC 
burden and development of cardiomyopathy, although no pre-
cise burden of PVCs consistently predicts the development 
of a cardiomyopathy. Several studies have demonstrated a 
higher incidence of cardiomyopathy with PVC burdens >15%-
25% (S4.3.3, S4.3.5, S4.3.8, S4.3.19); however, patients with 
similarly high PVC burdens can also maintain normal cardiac 
function. Reversible PVC-induced cardiomyopathy has also 
been reported in patients with PVC burdens as low as 4%–5% 
(S4.3.9, S4.3.20). When PVC-induced cardiomyopathy is sus-
pected in these patients with relatively low PVC burdens, 
other etiologies for cardiomyopathy should be thoroughly 
investigated and addressed, and the persistence of the PVC 
burden established. Other risk factors for the development of 
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a PVC-induced cardiomyopathy to consider include epicardial 
origin of PVCs, PVCs with a longer QRS duration, longer 
exposure to PVCs, asymptomatic PVCs, interpolated PVCs, 
and male sex (S4.3.1, S4.3.5, S4.3.21, S4.3.22). In patients 
with PVC-induced cardiomyopathy, PVC ablation has an overall 
reported success rate of 65%-90%, with a low complication 
rate (S4.3.1, S4.3.3–S4.3.7, S4.3.9, S4.3.10). Predictors of 
ablation success include an RVOT PVC origin and a uniform 
PVC morphology. Following successful ablation, the major-
ity of patients with PVC-induced cardiomyopathy experience 
significant improvement and, possibly, normalization of their 
LVEF. Based on a review of current data, routine catheter 
ablation of frequent PVCs in asymptomatic patients without 
evidence of LV dysfunction is not presently recommended. 
In some asymptomatic patients with very frequent PVCs and 
preserved cardiac function who express a strong preference 
for ablation, approximately half of the writing committee 
members agreed that an ablation can be considered after 
adequate counseling on the risks, benefits, and alternatives 
to ablation, whereas half would not offer ablation. Additional 
clinical features that may portend worsening LV function that 
should be considered include LV dilation or a relative decrease 
in EF that may still be considered in the normal range. 
 2 In patients with underlying SHD, the presence of frequent PVCs 
can contribute to a cardiomyopathy, and successful PVC elimi-
nation by ablation can improve cardiac function (S4.3.3, S4.3.11, 
S4.3.12). Detailed cardiac imaging (such as CMR to quantify 
scarring) in conjunction with a comprehensive cardiac history, 
including the time course of cardiomyopathy development and 
onset of PVCs, can help to estimate the contribution of the PVCs 
to the cardiomyopathy and guide treatment decisions targeting 
the PVCs. 
 3  In patients with recurrent VF refractory to antiarrhythmic 
medications and triggered by PVCs from a potentially iden-
tifiable site, successful ablation of the PVC can lead to VF 
suppression (S4.3.13–S4.3.15). The triggering PVC is often 
located in the Purkinje system and can exhibit slight varia-
tions in morphology. It is important to recognize that despite 
an initially successful ablation, PVC and VF recurrences are 
possible, and recurrent PVCs can arise from an alternate focus 
(S4.3.14). Successful ablation, therefore, often does not elimi-
nate the need for an ICD. 
 4 In patients who are clinical nonresponders to CRT, with limited bi-
ventricular pacing due to frequent PVCs despite pharmacological 
therapy, successful PVC ablation has demonstrated an improve-
ment in heart failure class and a modest improvement in LVEF. In 
one prospective multicenter study in which CRT nonresponders 
with frequent and primarily monomorphic PVCs were ablated, 
the improvements in LV function and New York Heart Association 
(NYHA) class were proportional to the preprocedural PVC burden, 
and the greatest improvement was noted in patients with a preab-
lation PVC burden >22% (S4.3.16). 
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 4.4  |  Ventricular arrhythmia in ischemic heart disease 
 Recommendations for catheter ablation of VAs in patients with IHD
 COR  LOE  Recommendations  References 
 I  B- R  1. In patients with IHD who experience recurrent monomorphic VT despite chronic amiodarone 
therapy, catheter ablation is recommended in preference to escalating AAD therapy. 
 S4.4.1 
 I  B- NR  2. In patients with IHD and recurrent symptomatic monomorphic VT despite AAD therapy, or 
when AAD therapy is contraindicated or not tolerated, catheter ablation is recommended to 
reduce recurrent VT. 
 S4.4.2–S4.4.4 
 I  B- NR  3. In patients with IHD and VT storm refractory to AAD therapy, catheter ablation is 
recommended. 
 S4.4.5–S4.4.9 
 IIa  C- EO  4. In patients with IHD and recurrent monomorphic VT, in whom AADs are not desired, catheter 
ablation can be useful. 
 
 IIb  A  5. In patients with IHD and an ICD who experience a first episode of monomorphic VT, cath-
eter ablation may be considered to reduce the risk of recurrent VT or ICD therapies. 
 S4.4.10–S4.4.14 
 IIb  C- LD  6. In patients with prior MI and recurrent episodes of symptomatic sustained VT for whom 
prior endocardial catheter ablation has not been successful and who have ECG, endocardial 
mapping, or imaging evidence of a subepicardial VT substrate, epicardial ablation may be 
considered. 
 S4.4.15–S4.4.19 
 Recommendation- specific supportive text 
 1  For patients presenting with VT despite AAD therapy, which 
often results in ICD therapies (shocks or ATP), therapeutic 
options include escalating AAD therapy by increasing the dose, 
changing the drug, adding a new drug, and catheter ablation. 
The VANISH trial (S4.4.1) compared the strategies of escalat-
ing AAD therapy according to a predefined protocol versus 
catheter ablation in 259 patients and followed them for a 
mean (± standard deviation [SD]) of 27.9 ± 17.1 months. The 
composite primary endpoint of death, VT storm, or appropriate 
ICD shock was reduced by catheter ablation. Benefit was ob-
served in the subgroup on amiodarone at baseline, for whom 
escalated drug therapy was an increase in amiodarone or an 
addition of mexiletine (HR 0.55; 95% CI 0.38-0.80;  P = 0 .001), 
but not in the subgroup of patients who were on sotalol at 
baseline, for whom escalation of drug therapy was initiation 
of amiodarone (HR 1.14; 95% CI 0.65-2.02;  P = 0 .64) (S4.4.1). 
Further analysis found that catheter ablation was markedly 
superior to the addition of mexiletine in a small subgroup 
of patients with VT refractory to high dose (≥300 mg daily) 
amiodarone (S4.4.20). There were no procedure-related deaths. 
 2 In addition to the VANISH trial described above (S4.4.1), 3 large, 
prospective, multicenter cohort studies have examined the role 
of catheter ablation in reducing recurrent VT in patients with 
IHD, most of whom had recurrent VT despite AAD therapy 
(S4.4.2–S4.4.4). In these trials, the patient served as his/her 
own control, and VT episodes were reported for the 6 months 
before and the 6 months after ablation. In each study, a consist-
ent reduction in VT episodes was observed post ablation. In the 
Euro-VT study, VT recurrence occurred in 49% of the patients 
(S4.4.3). A reduction in device therapies (ATP and shocks) was 
observed in 79% of these patients, with the mean number of 
therapies falling from 60 ± 70 in the 6 months prior to ablation 
to 14 ± 15 in the same period of time after ablation ( P =  0.02). In 
the Multicenter Thermocool VT Ablation Trial, and the similarly 
designed Post-Approval THERMOCOOL VT Trial, the number 
of VT episodes in the 6 months before and after ablation was 
reduced from a median of 11.5 to 0 episodes ( P  <  0.0001), and 
from 13 to 0 episodes ( P  <  0.0001), respectively (S4.4.2, S4.4.4). 
 3 There are limited comparative data on catheter ablation vs other 
therapies in the management of VT storm. AAD therapy is almost 
universally used as first-line therapy for these patients; however, 
catheter ablation is a particularly important therapy when VA re-
curs. Two small, single-center, nonrandomized studies found that 
patients treated with ablation had a lower risk of recurrence than 
those treated medically (S4.4.21), or they had a similar risk of re-
currence but lower mortality (S4.4.22); however, these studies 
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were limited by their retrospective study design and the small 
number of patients. Several other large series (S4.4.5–S4.4.8) and 
a systematic review and meta-analysis (S4.4.9) have shown a re-
duction in ICD therapies after catheter ablation and reasonable 
success in controlling arrhythmia, with a nonetheless significant 
mortality. A common finding is that unsuccessful ablation (persis-
tent VT inducibility) is associated with poor outcomes. 
 4 Patients who do not tolerate or are unsuitable for AAD therapy 
have not generally been included in RCTs. However, the writing 
committee felt it was reasonable to recommend catheter ablation 
in such patients over no therapy, in view of the reduction in re-
current VT demonstrated in multiple clinical trials. Examples of 
contraindications to AAD therapy include significant renal dys-
function or QT prolongation in the case of sotalol, and severe pul-
monary disease, which might be worsened by amiodarone. 
 5 Four RCTs have examined the role of catheter ablation in patients 
who have experienced their first episode of VT (S4.4.10–S4.4.14). 
In these studies, an ICD has been a mandatory part of the pro-
tocol. Two of these trials have shown a reduction in the primary 
endpoint with catheter ablation (S4.4.10, S4.4.11). The CALYPSO 
pilot study found an increased time to first VT recurrence with 
ablation versus AADs (S4.4.12). The Substrate Modification Study 
(SMS) failed to meet its primary endpoint of time to first VT/VF re-
currence; however, catheter ablation reduced the total number of 
ICD interventions (S4.4.13). A meta-analysis of these trials, com-
missioned to guide recommendations in this consensus document, 
showed a reduction in the risk of appropriate ICD therapies with 
catheter ablation (S4.4.14). However, in drafting this recommenda-
tion, the writing committee also considered that only the CALYPSO 
pilot study randomized patients to either catheter ablation or AAD 
therapy (S4.4.12). The other trials (S4.4.10, S4.4.11, S4.4.13) com-
pared catheter ablation without specifying antiarrhythmic therapy 
in the control group. Prospective trials have not shown that catheter 
ablation reduces mortality, and the risks of the procedure must be 
carefully weighed against the benefits in this population. In a large 
study using the US National Inpatient Sample database, the over-
all rate of any in-hospital complication was 11.2% in patients with 
prior MI undergoing catheter ablation, and in-hospital mortality was 
1.6%, without changes over a decade (S4.4.23). The VANISH2 trial 
is currently comparing these two strategies in patients with prior MI 
and VT while not on AAD therapy (S4.4.24). There are limited data 
exploring the feasibility of managing VT with catheter ablation with-
out an ICD in selected patients with IHD and relatively preserved LV 
function (S4.4.25–S4.4.27). Of 302 patients with IHD who under-
went a catheter ablation procedure sufficiently successful to make 
ICD implantation unnecessary, approximately 3% experienced sud-
den death during 3-4 years of follow-up (S4.4.25–S4.4.27). The 
writing group did not feel there was sufficient evidence to make a 
recommendation regarding ablation as a stand-alone therapy with-
out an ICD for patients with IHD and sustained VT. 
 6 It has long been recognized that the epicardial surface can con-
tain critical elements of VT circuits in patients with IHD (S4.4.15, 
S4.4.16). However, the VT substrate can be accessed from the 
endocardium in most cases, and endocardial mapping and abla-
tion have been the mainstay of therapy. A number of studies have 
shed light on the incidence of epicardial substrate in IHD. In the 
initial description of epicardial mapping and ablation in patients 
with inferior wall MI, an epicardial circuit was found in 7 of 30 VTs 
(S4.4.16). In another series of 11 patients with 1-4 prior unsuc-
cessful endocardial ablation procedures, epicardial access was suc-
cessful in 10, and 7 required epicardial ablation, which abolished 
the clinical VT in all patients. However, 40% had recurrence dur-
ing follow-up, and there was one periprocedural death (S4.4.17). 
Two larger, single-center observational studies have reported simi-
lar or improved VT-free survival in patients with IHD undergoing 
combined endocardial and epicardial ablation (S4.4.28, S4.4.29). 
A prospective study of patients undergoing catheter ablation for 
electrical storm, in which epicardial access was obtained in all pa-
tients in one arm being treated with a scar homogenization tech-
nique (n = 43), found that ablation was performed in one-third. 
However, whether the epicardial substrate participated in clinical 
or inducible VT was not assessed (S4.4.18). There are limited data 
on the use of combined endocardial and epicardial ablation as a 
first-line approach in patients with IHD and VT (S4.4.19); an RCT is 
currently examining this question (S4.4.30). Preprocedural imaging 
can be useful to determine the presence of epicardial substrate, 
and therefore the likelihood of requiring epicardial access for com-
plete substrate ablation (S4.4.31). 
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 4.5  |  Nonischemic cardiomyopathy 
 Recommendations for catheter ablation of VT in NICM 
 COR  LOE  Recommendations  References 
 I  B- NR  1. In patients with NICM and recurrent sustained monomorphic VT for whom antiarrhythmic 
medications are ineffective, contraindicated, or not tolerated, catheter ablation is useful for 
reducing recurrent VT and ICD shocks. 
 S4.5.1–S4.5.6 
 I  B- NR  2. In patients with NICM and electrical storm refractory to AAD therapy, catheter ablation 
is useful for reducing recurrent VT and ICD shocks. 
 S4.5.7–S4.5.9 
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 COR  LOE  Recommendations  References 
 IIa  B- NR  3. In patients with NICM, epicardial catheter ablation of VT can be useful after failure of 
endocardial ablation or as the initial ablation approach when there is a suspicion of an 
epicardial substrate or circuit. 
 S4.5.4, S4.5.10–S4.5.13 
 IIa  B- NR  4. In patients with cardiac sarcoidosis and recurrent VT despite medical therapy, catheter 
ablation can be useful to reduce the risk of VT recurrence and ICD shocks. 
 S4.5.14–S4.5.18 
 IIa  C- EO  5. In patients with NICM and recurrent sustained monomorphic VT for whom antiarrhythmic 
medications are not desired, catheter ablation can be useful for reducing recurrent VT and ICD 
shocks. 
 
 IIb  B- NR  6. In patients with NICM related to lamin A/C ( LMNA ) mutations and recurrent VT, catheter 
ablation may be considered as a palliative strategy for short- term arrhythmia control. 
 S4.5.19 
 Recommendation- specific supportive text 
 1  Patients with NICM represent a heterogeneous population with 
diverse etiologies, including undifferentiated dilated NICM and 
valvular, hypertensive, hypertrophic, toxic, genetic, inflammatory, 
tachycardia-induced, peripartum, and infiltrative cardiomyopa-
thy. Several retrospective and prospective cohort studies have 
shown VT-free survival of 40.5%-70% at 1 year post ablation 
(S4.5.1–S4.5.6). VTs in the context of NICM are more often 
pleomorphic and polymorphic; they are less hemodynamically 
tolerated, are more difficult to induce, and are faster com-
pared with postinfarction VT (S4.5.20, S4.5.21). Differences in 
the results of VT catheter ablation between NICM and ICM 
could be due to a substrate that is less favorable to ablation 
with NICM (S4.5.22). The substrate is often intramurally located 
and can involve the epicardium; it is typically located at the 
basal perivalvular regions and at the interventricular septum. 
The intramural substrate makes the arrhythmogenic substrate 
less accessible for identification of optimal ablation target sites 
based on pace mapping and identification of abnormal electro-
grams. Although sustained VT occurs in only 5% of patients 
with NICM, it is an important cause of sudden cardiac death 
(S4.5.23). Recurrent VT is associated with significantly increased 
mortality in NICM (S4.5.24). 
 2 Electrical storm with recurrent VT/VF episodes in patients with 
NICM and ICD can adversely affect hospitalization rates and long-
term survival (S4.5.24, S4.5.25). Catheter ablation of patients with 
NICM and electrical storm refractory to, or intolerant of, AADs 
eliminates recurrent VT in most cases (S4.5.7–S4.5.9). Whether 
ablation reduces mortality in this population is unclear at present. 
 3  In multicenter registries, 30% of epicardial VT catheter abla-
tions were performed on patients with NICM (S4.5.12, S4.5.13). 
Epicardial mapping and catheter ablation can significantly reduce 
VT recurrence in patients with NICM (S4.5.3, S4.5.4) and long-
term success rates reach 55% to 70% after epicardial ablation 
(S4.5.11, S4.5.13). However, due to an increased risk of compli-
cations or late adhesions preventing future pericardial accesses, 
epicardial ablation may be reserved to first-line endocardial ap-
proach failures (S4.5.1), except when ECG or imaging suggests a 
predominant epicardial substrate (S4.5.1). Consideration should 
be given to the ability to proceed to epicardial access during the 
initial procedure. 
 4 Cardiac sarcoidosis is associated with a poor prognosis. VT is 
frequently resistant to AADs and immunosuppression, requiring 
ICDs. Recurrent VT is common in cardiac sarcoidosis and is associ-
ated with a poorer prognosis. Catheter ablation decreases VT re-
currence and ICD shocks in cardiac sarcoidosis (S4.5.14–S4.5.18). 
 5 AADs are not as effective as the ICD at decreasing mortality in 
patients with SHD and sustained VAs. Even if successful at acutely 
terminating VT or VF, ICD shocks have been associated with in-
creased heart failure and mortality in NICM (S4.5.26, S4.5.27). 
To date, there has been no RCT comparing catheter ablation with 
AADs for preventing VT recurrences in NICM. Indirect comparisons 
have found similar reductions in VT recurrences with catheter ab-
lation or amiodarone in patients with SHD (S4.5.28). Amiodarone 
might increase mortality in patients with cardiomyopathy (S4.5.28, 
S4.5.29) and can cause serious long-term adverse effects. Catheter 
ablation of VT appears to be safe and effective in NICM, achiev-
ing long-term arrhythmia control in 50%-70% (S4.5.1, S4.5.6, 
S4.5.23, S4.5.30) (with AADs in one-third), with a survival rate of 
70% (S4.5.1, S4.5.6). Retrospective series show that acute success 
of catheter ablation and freedom from recurrent VT after catheter 
ablation are associated with a significant reduction in mortality and 
heart transplantation in NICM (S4.5.1, S4.5.6, S4.5.31, S4.5.32). 
 6 Mutations in the lamin A/C ( LMNA ) gene are an important cause 
of NICM, with a disease course more aggressive than other forms 
of idiopathic NICM in terms of progression to end-stage heart 
failure or the tendency toward malignant VAs (S4.5.33, S4.5.34). 
Catheter ablation can be beneficial as a palliative strategy to allow 
transient arrhythmia control in patients with NICM related to 
 LMNA mutations before aggressive heart failure management is 
proposed (S4.5.19). However, acute and chronic success are low, 
due to frequent intramural substrate, and complication rates are 
high in the published literature (S4.5.19). Disease progression to 
end-stage heart failure requiring mechanical support or transplant 
is also common, and VT ablation might be best targeted toward 
those with relatively earlier stage disease, rather than being a 
means to delay progression in those approaching end-stage heart 
failure. 
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 4.6  |  Ventricular arrhythmia involving the His- Purkinje system, bundle branch reentrant ventricular 
tachycardia, and fascicular ventricular tachycardia 
 Recommendations for catheter ablation of bundle branch reentrant VT and for catheter ablation of fascicular VT 
 COR  LOE  Recommendations  References 
 I  B- NR  1. In patients with bundle branch reentrant VT, catheter ablation is useful for reducing 
the risk of recurrent VT. 
 S4.6.1–S4.6.9 
 I  B- NR  2. In patients with idiopathic left fascicular reentrant VT for whom medications are 
ineffective, not tolerated, or not the patient ’ s preference, catheter ablation is useful. 
 S4.6.10–S4.6.22 
 I  B- NR  3. In larger pediatric patients (≥15 kg) with idiopathic left fascicular reentrant VT in 
whom medical treatment is ineffective or not tolerated, catheter ablation is useful. 
 S4.6.23–S4.6.26 
 I  B- NR  4. In patients with focal fascicular VT with or without SHD, catheter ablation is useful.  S4.6.11, S4.6.27–S4.6.29 
 I  B- NR  5. In patients with postinfarction reentrant Purkinje fiber- mediated VT, catheter abla-
tion is useful. 
 S4.6.30–S4.6.32 
 Recommendation- specific supportive text 
 1  Bundle branch reentrant VT (BBRVT) is curable by catheter ab-
lation, which is successful in almost all patients (S4.6.1–S4.6.4). 
However, for patients with SHD or conduction system disease, 
long-term outcome depends on the type of underlying cardiac 
disease. Despite successful BBRVT ablation, many patients re-
main at risk of sudden death due to concomitant scar-related 
VTs and/or LV dysfunction. An ICD with or without cardiac 
resynchronization should be considered (S4.6.4–S4.6.6). On the 
other hand, for patients with BBRVT who have unacceptably 
frequent shocks from their ICD, catheter ablation can be helpful 
in preventing or reducing the shocks (S4.6.3). Even for patients 
with terminal heart failure and incessant BBRVT, catheter abla-
tion can function as a bridge to cardiac transplantation (S4.6.3). 
BBRVT can be cured by catheter ablation for patients with nor-
mal heart structure and function (S4.6.3–S4.6.5, S4.6.7, S4.6.8). 
Although data are limited, some reports suggest that patients 
with preserved LV systolic function and no other inducible VT 
might not further benefit from ICD insertion after successful 
ablation. This subgroup had excellent long-term outcomes for 
VT-free survival without deterioration of conduction properties 
during follow-up. However, further study is required before a 
specific recommendation can be formulated (S4.6.4). For pa-
tients with BBRVT who have a normal HV interval, catheter 
ablation is also a curative approach. Approximately 22%-46% 
of patients with BBRVT had a normal baseline HV interval, and 
significant prolongation of the HV interval only developed during 
tachycardia. This result suggests that either a functional or fixed 
conduction block in the His-Purkinje system could be sufficient 
to maintain a BBRVT mechanism. Long-term outcome depends 
on the underlying cardiac disease (S4.6.4, S4.6.6). Patients with 
normal LV systolic function and HV interval have excellent long-
term outcomes after ablation (S4.6.4). Myocardial VT is the 
most common type of inducible sustained monomorphic VT 
in patients with valvular heart disease. The majority of these 
patients have underlying coronary artery disease and significant 
LV dysfunction. However, in almost one-third of the patients, 
sustained BBRVT is the only type of inducible VT. This type 
of VT is facilitated by the valve procedure occurring within 
4 weeks after surgery in most patients. In these patients, LV 
function is relatively well preserved, and the RBBB-type of BBRVT 
is frequently induced. Because a curative intervention can be 
offered to these patients (eg, bundle branch ablation), BBRVT 
should be seriously considered as the VT mechanism in patients 
with valvular heart disease, particularly if the arrhythmia occurs 
soon after valve surgery (S4.6.5). Catheter ablation of the RBB 
or LBB interrupts the circuit and is usually curative. However, 
severely impaired antegrade conduction in the remaining bundle 
is often present, requiring permanent pacing, which can have 
hemodynamic consequences. Consideration should be given to 
future CIED requirements when selecting the ablation target. In 
patients with baseline complete or incomplete LBBB, anterograde 
slow conduction over the LBB is present, and ablation of the 
LBB might leave adequate residual anterograde conduction over 
the right bundle. Ablation targeting the portion of the distal LBB 
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(left posterior or anterior fascicle) that has slow conduction can 
potentially preserve the residual AV conduction. Close follow-up 
for recurrent arrhythmias, progressive conduction deterioration, 
or LBBB-induced ventricular dysfunction is important (S4.6.9). 
 2 In the published literature, the overall success rate of ablation for 
idiopathic left fascicular reentrant VT is >95%. Although compli-
cations related to left heart catheterization might be encountered, 
no serious complications were reported. Left posterior hemiblock 
was observed when a line of RF lesions was applied through the 
posterior septal region (S4.6.10–S4.6.22). Left upper septal fas-
cicular VT often presents as narrow QRS complex tachycardia, 
but some left upper septal fascicular VTs occur after catheter ab-
lation targeting left posterior fascicular VT. Such VTs can be man-
aged successfully by focal ablation at the left upper septum with 
some risk of fascicular injury (S4.6.22). 
 3  In pediatric patients with fascicular reentrant VT (age 10.0 ± 5.1 years, 
62% males), nondihydropyridine calcium channel blockers were ef-
fective at terminating and preventing VT in 80% of the patients; 
however, 21% of the patients experienced recurrence during chronic 
oral therapy. Catheter ablation was successful in 71% of fascicular 
VTs. After a follow-up period of 2 years (1 day to 15 years), 72% of 
all patients with fascicular VT were off medications, with no tachy-
cardia recurrence (S4.6.23). Two small series reported an acute suc-
cess rate for catheter ablation for fascicular VT of 100%. However, 
the overall recurrence rate was 0%-50% over 2-3 years’ follow-up. 
Major complications included 1 case of complete AV block and 1 
case of LBBB (S4.6.24, S4.6.25). In smaller patients (less than 15 kg) 
with fascicular reentrant VT that either is controlled medically or is 
hemodynamically well tolerated without ventricular dysfunction, 
ablation is generally not pursued (S4.6.26, S4.6.33). As with many 
other forms of arrhythmia, infants with this VT frequently experi-
ence resolution of the VT with time; such resolution is much less 
common in older children and adolescents. Idiopathic VAs are often 
well tolerated, minimally symptomatic, and are not associated with a 
risk of sudden death (S4.6.33). A case series of two patients showed 
that oral verapamil suppressed VTs in newborns. Following discon-
tinuation of verapamil at 1 year of age, both children remained free 
of tachycardia recurrence at 3 and 4 years of age (S4.6.34). 
 4  Among idiopathic VT cases referred for ablation, 2.8% were focal 
nonreentrant fascicular tachycardia, which had distinct clini-
cal characteristics and usually originated from the left posterior 
fascicle (LPF), and less commonly from the left anterior fascicle 
(LAF) and RV Purkinje network. Catheter ablation guided by ac-
tivation mapping is effective, whereas a pace map–guided ap-
proach is less effective. VT recurrence was observed in 27% of 
patients, and among them, pace mapping was used to target VT 
during the initial ablation attempt (S4.6.27). Another small series 
reported two focal Purkinje VT cases with IHD in whom com-
plete AV block occurred after the successful ablation of the VT. 
This outcome suggests that ablation often is not sufficient as the 
sole therapy due to other induced VTs and conduction abnor-
malities, requiring pacemaker and/or defibrillator implantation 
for these VT patients with SHD (S4.6.28). 
 5 The Purkinje system might be part of the reentry circuit in pa-
tients with postinfarction monomorphic VT, resulting in a type of 
VT with a relatively narrow QRS complex that mimics fascicular 
VT. Catheter ablation is effective (S4.6.31, S4.6.33). 
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 4.7  |  Congenital heart disease 
 Recommendations for catheter ablation of VA in patients with CHD 
 COR  LOE  Recommendations  References 
 I  B- NR  1. In patients with CHD presenting with sustained VAs, evaluation for potential residual anatomi-
cal or coronary abnormalities should be performed. 
 S4.7.1–S4.7.6 
 I  B- NR  2. In patients with CHD presenting with sustained VT in the presence of important 
hemodynamic lesions, treatment of hemodynamic abnormalities as feasible should be 
performed in conjunction with consideration for ablation. 
 S4.7.2, S4.7.7–S4.7.16 
 I  B- NR  3. In patients with repaired tetralogy of Fallot and sustained monomorphic VT or recurrent 
appropriate ICD therapy for VAs, catheter ablation is effective. 
 S4.7.17–S4.7.24 
 IIa  B- NR  4. In select patients with CHD and clinical episodes of sustained VT who are undergoing 
surgical repair of residual hemodynamic abnormalities, surgical ablation of VT guided by 
preoperative or intraoperative EAM can be beneficial. 
 S4.7.2, S4.7.8, S4.7.9, 
S4.7.11, S4.7.25 
 Recommendation- specific supportive text 
 1 The substrate for VAs in patients with repaired CHD is typically 
reentry related to ventricular hypertrophy and areas of scar from 
prior incisions, patches, and conduit placement. The development 
of VAs in patients with CHD can be a manifestation of hemody-
namic abnormalities, including valvar obstruction or regurgitation, 
ventricular dysfunction, or coronary abnormalities. Identification of 
the underlying abnormality contributing to ischemia, ventricular 
dysfunction, and VAs is important to therapeutic planning, given 
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that interventions for the substrate may reduce the frequency 
of recurrent VAs and/or improve the hemodynamic status. 
 2 Most data regarding reoperation for patients with CHD and sus-
tained VAs are from patients with tetralogy of Fallot. Treatment of 
underlying hemodynamic abnormalities may reduce the incidence 
of recurrent VAs and allow for ventricular remodeling or improve-
ment in ventricular function. In studies of patients with tetralogy 
of Fallot and sustained VT undergoing reoperation for hemody-
namic abnormalities without specific arrhythmia intervention, 
late postoperative VT was reduced to 11%-33% during mid-term 
follow-up (S4.7.2, S4.7.7–S4.7.9, S4.7.13). Given the incomplete 
protection from recurrent VA, consideration should also be given 
to catheter and surgical ablation and/or ICD therapy as indicated 
(Figure  2 ). 
 3 The majority of reports of successful VT ablation in adults with 
repaired CHD include patients with tetralogy of Fallot, with small 
numbers of patients with transposition of the great arteries, ven-
tricular septal defects (VSDs), and other lesions (S4.7.17, S4.7.18, 
S4.7.26, S4.7.27). VT circuits tend to be multiple and related to prior 
ventriculotomies and VSD patches in patients with complex CHD 
(S4.7.19–S4.7.22, S4.7.24, S4.7.26, S4.7.28). In patients with te-
tralogy of Fallot, anatomical isthmuses (AIs) critical to the reentrant 
circuit have been identified between the septal defect patch or 
ventriculotomy and the pulmonary valve, and between the tricuspid 
annulus and the OT patch or septal defect patch (S4.7.19, S4.7.22, 
S4.7.24). EAM to identify and ablate reentrant channels, with veri-
fication of conduction block and occasionally ablation from the left 
side of the ventricular septum, have procedural success rates of 
approximately 80% (S4.7.21, S4.7.24, S4.7.28). Patients with pro-
cedural success from catheter ablation and with preserved biven-
tricular ventricular function have not experienced recurrent VT or 
sudden cardiac death in up to 10-year follow-up (S4.7.22, S4.7.28). 
 4 Several small studies have demonstrated the effectiveness of 
map-guided surgical ablation of VT during concomitant repair 
of SHD, with recurrent VT reported in 15%-20% of patients 
(S4.7.2, S4.7.8, S4.7.9, S4.7.11). To date, in patients with tetral-
ogy of Fallot empiric surgical cryoablation lesions for sustained 
VT without electrophysiological mapping of the tachycardia cir-
cuit have shown recurrent VT in 18%–45% of patients (S4.7.25, 
S4.7.29). The role of prophylactic empiric cryoablation of the OT 
in selected high-risk patients with tetralogy of Fallot is evolving 
(S4.7.16, S4.7.25). 
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 F I G U R E  2     Congenital heart disease and sustained  VT . For 
further discussion of  ICD candidacy, please see  PACES / HRS 
Expert Consensus Statement on the Recognition and Management 
of Arrhythmias in Adult Congenital Heart Disease (S4.7.14) and 
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 4.8  |  Inherited arrhythmia syndromes 
 Recommendations for catheter ablation of VA in inherited primary arrhythmia disorders 
 COR  LOE  Recommendations  References 
 I  B- NR  1. In patients with ARVC who experience recurrent sustained VT or frequent appropri-
ate ICD interventions for VT in whom AAD therapy is ineffective or not tolerated, 
catheter ablation, at a center with specific expertise, is recommended. 
 S4.8.1–S4.8.11 
 I  B- NR  2. In patients with ARVC who have failed one or more attempts of endocardial VT cath-
eter ablation, an epicardial approach for VT ablation is recommended. 
 S4.8.3–S4.8.7, S4.8.12, 
S4.8.13 
 IIa  B- NR  3. In patients with ARVC who experience recurrent sustained VT or frequent appropri-
ate ICD interventions for VT in whom AAD therapy is not desired or preferred, catheter 
ablation, at a center with specific expertise, is reasonable. 
 S4.8.1, S4.8.3–S4.8.6, 
S4.8.8 
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 COR  LOE  Recommendations  References 
 IIa  B- NR  4. In patients with Brugada syndrome who experience recurrent sustained VAs or fre-
quent appropriate ICD interventions, catheter ablation can be useful. 
 S4.8.14–S4.8.17 
 IIa  C- LD  5. In patients with ARVC, a first- line combined endocardial/epicardial approach for VT 
ablation is reasonable. 
 S4.8.1, S4.8.6, S4.8.12, 
S4.8.18 
 Recommendation- specific supportive text 
 1 In patients with ARVC, recurrent VT or frequent appropriate 
ICD interventions for VT can be seen despite the use of 
multiple AAD therapies, including amiodarone and sotalol. 
Catheter ablation has demonstrated an acceptable acute suc-
cess rate and over time with development of different tech-
niques (substrate vs. conventional mapping) and approaches 
(endocardial, epicardial, or combined endo-epicardial) has 
reduced recurrence rates and appropriate ICD interventions 
(S4.8.1–S4.8.11). The writing committee felt that earlier con-
sideration could be given to ablation, as opposed to further 
AAD therapy, in centers with specific expertise in VA ablation 
in ARVC, including epicardial access. Reference should also 
be made to the  2019 HRS Expert Consensus Statement on 
Evaluation, Risk Stratification, and Management of Arrhythmogenic 
Cardiomyopathy (S4.8.19). 
 2 In patients with ARVC, scar location is heterogeneous based on the 
chamber (mainly RV dominant but can involve the LV), the num-
ber of foci, and depth (epicardial and/or endocardial) (S4.8.7). Over 
time, the need for repeat catheter ablation is common and due to 
the scar location, and an epicardial approach is often necessary. 
Long-term freedom from VA is achieved in approximately one-third 
of patients with an endocardial approach (S4.8.4). An endocardial 
followed by an epicardial ablation approach if the patient remains 
inducible for VT may avoid unnecessary epicardial access and as-
sociated procedural risk. However, strong consideration should be 
given to performing the procedure in a setting where it is possible 
to proceed to epicardial ablation during the same procedure, if en-
docardial ablation fails to terminate the clinical VA, or if the patient 
remains inducible. 
 3 In patients with ARVC, recurrent VT or frequent appropri-
ate ICD interventions for VT can be seen despite the use of 
multiple AAD therapies (S4.8.20). The majority of patients 
undergoing catheter ablation are on antiarrhythmic therapy, 
including beta blockade before and after ablation. However, 
some patients in the published series were not on AAD ther-
apy at the time of ablation (S4.8.1, S4.8.3–S4.8.6, S4.8.8). The 
overall acute success rates are acceptable, especially when an 
epicardial approach is used, and indeed are superior to that 
reported for other substrates like NICM (S4.8.2). Patients are 
often younger and might not be on other medications, which 
could influence the choice between AAD therapy and ablation. 
Two studies have assessed whether the substrate underly-
ing VAs in ARVC progressed over time. In the first, scar pro-
gression, as assessed by bipolar voltage mapping in patients 
undergoing repeat ablation, was observed in 2 of 11 patients 
over a mean follow-up of approximately 6 years (S4.8.21). In 
the second, similar progression occurred in 2 of 7 patients 
over a 30-month follow-up, and recurrent VTs were ablated 
within the previously documented scar, suggesting incom-
plete ablation at the index procedure (S4.8.22). This outcome 
suggests that with a comprehensive initial procedure that 
achieves noninducibility, substrate progression and recurrent 
VA are not inevitable, at least over the medium term. Strong 
consideration should be given to performing such a procedure 
in a center that can proceed to an epicardial ablation during 
the same procedure should an endocardial ablation be insuf-
ficient to eliminate VT. However, to achieve long-term free-
dom from AADs, patients might require repeated ablation 
procedures and rely on ICD interventions for treatment of 
hemodynamically unstable VT. The writing committee felt that 
stronger consideration could be given to catheter ablation as 
a first-line approach without preceding AAD therapy by ex-
perienced operators and centers, and with fully informed pa-
tients. Reference should also be made to the  2019 HRS Expert 
Consensus Statement on Evaluation, Risk Stratification, and 
Management of Arrhythmogenic Cardiomyopathy (S4.8.19). The 
role of catheter ablation in new-onset single morphology VT 
without ICD therapy prior to or after ablation was examined 
only in a small number of patients (S4.8.20). Catheter ablation 
has not been shown to reduce sudden cardiac death in patients 
with ARVC; thus, ICD therapy remains the mainstay for sudden 
cardiac death prevention (S4.8.20, S4.8.23–S4.8.25). 
 4 Patients with Brugada syndrome and a type I Brugada ECG pat-
tern (spontaneous or drug induced) have an arrhythmogenic 
substrate located in the anterior epicardial RVOT that can be 
further unmasked with provocative drug testing (S4.8.16). 
Targeted catheter ablation can normalize the electrographic 
abnormalities and reduce VA inducibility during programmed 
stimulation (S4.8.14–S4.8.17). Use of ablation with substrate 
modification in the most symptomatic patients (recurrent VF/
VT, VF storm, or frequent ICD interventions) with Brugada syn-
drome and a type I Brugada ECG pattern (spontaneous or drug 
induced) has demonstrated a reduction in arrhythmic events 
(S4.8.14–S4.8.17). Long-term follow-up has been limited, and 
generalizability is unknown, given that procedures have been 
performed at highly specialized centers with expertise in 
Brugada syndrome and epicardial ablations (S4.8.14–S4.8.17). 
Drug therapy with quinidine should be considered as a first-line 
alternative (S4.8.26). 
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 5 In patients with ARVC, combined endocardial and epicardial sub-
strate catheter ablation has improved acute success and lowered 
recurrence rates compared with endocardial-only catheter ab-
lation. A combined endocardial-epicardial approach might be a 
reasonable first-line approach, although not all patients require 
epicardial catheter ablation for elimination of VT. Risks associ-
ated with epicardial access and ablation should be considered, 
and these procedures should be performed at centers with ex-
pertise (S4.8.27, S4.8.28). 
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 4.9  |  Ventricular arrhythmia in hypertrophic cardiomyopathy 
 Recommendation for VA ablation in HCM 
 COR  LOE  Recommendation  References 
 IIa  B- NR  1. In patients with HCM and recurrent monomorphic VT in whom AAD therapy is 
ineffective or not tolerated, catheter ablation can be useful. 
 S4.9.1–S4.9.5 
 Recommendation- specific supportive text 
 1 Although a less common arrhythmia in HCM, the reported 
ablation experience is largely limited to monomorphic VT 
(S4.9.1–S4.9.5). Most patients in these series had already 
failed AAD therapy. Ablation can be challenging due to the 
thickness of the myocardium, and epicardial access has been 
required in the majority of patients (S4.9.1–S4.9.4), along 
with adjunctive techniques such as intracoronary ethanol 
ablation and surgical epicardial cryoablation (S4.9.3, S4.9.4). 
Satisfactory results have been reported, although multiple 
procedures were required in some patients (S4.9.1–S4.9.5). 
VAs associated with apical aneurysms are mostly ablated from 
the LV endocardium. 
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 5    |   PROCEDUR AL PL ANNING 
 5.1  |  Patient selection and preprocedural risk 
assessment 
 RF catheter ablation is an important therapeutic option in patients 
with different forms of VA. Over the last decade, significant im-
provements in the techniques and technologies available for cath-
eter ablation have been paralleled by an increasing number of 
procedures performed for high- risk and complex patient subsets 
(S5.1.3.1–S5.1.3.4). In these cases, the competing risks associated 
with the concomitant presence of advanced heart failure syn-
dromes and high burden of associated comorbidities pose substan-
tial periprocedural and postprocedural management challenges. A 
proper preprocedural risk stratification is crucial to minimize the risk 
of adverse periprocedural outcomes such as acute hemodynamic 
decompensation (AHD), which can have devastating consequences 
(S5.1.3.2, S5.1.3.5, S5.1.3.6). 
 5.1.1  |  The PAAINESD Risk Score 
 The PAAINESD risk score (chronic obstructive Pulmonary disease 
[5 points], Age >60 years [3 points], General anesthesia [4 points], 
Ischemic cardiomyopathy [6 points], New York Heart Association class 
III or IV [6 points], Ejection fraction <25% [3 points], presentation with 
VT Storm [5 points], Diabetes mellitus [3 points]) has been demon-
strated to be helpful to identify patients undergoing scar- related VT 
ablation who are at increased risk of adverse periprocedural outcomes, 
and represents the most studied risk stratification tool in this context 
(Table  4 ) (S5.1.3.2, S5.1.3.3, S5.1.3.5–S5.1.3.8). In a single center, the 
risk of acute hemodynamic deterioration increased across tertiles 
of the score, with values ≥ 17 (or ≥ 15 when “general anesthesia” is 
excluded) being associated with a risk of 24%. Another single- center 
report found that, when excluding general anesthesia, a score be-
tween 9 and 14 points was associated with a 6% risk of acute hemo-
dynamic collapse, and that risk increased to 24% in patients with a 
score ≥ 15 (S5.1.3.6). A multicenter cohort found the score (excluding 
general anesthesia) was higher in those who died early post procedure 
versus those who survived to the end of follow- up (16 ± 7 vs 9 ± 6; 
 P  <  0.001), although chronic obstructive pulmonary disease was not 
included in the calculation (S5.1.3.3). These findings were mirrored in 
another single- center cohort, which found a higher score (excluding 
general anesthesia) in those who died early post ablation (17.4 ± 6.3 vs 
11.6 ± 7.6;  P =  0.012) and in patients who experienced complications 
(16.4 ± 6.7 vs 11.6 ± 7.6;  P < 0.001) (S5.1.3.7). Of note, intraprocedural 
mechanical hemodynamic support (HS) was commonly used in two of 
these series, which could limit the generalizability of these findings 
(S5.1.3.6, S5.1.3.7). 
 The cumulative evidence arising from published studies sug-
gests that a PAAINESD score ≥ 15- 17 (depending on whether the 
variable “general anesthesia” is included in the risk score calculation 
or not) identifies patients with SHD and VT at particularly high risk 
of adverse periprocedural and postprocedural outcomes (S5.1.3.2, 
S5.1.3.3, S5.1.3.6, S5.1.3.8). Careful consideration of the optimal 
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sedation or anesthesia strategy could further help to prevent AHD 
in patients with multiple other risk factors. 
 5.1.2  |  The Seattle Heart Failure Model 
 Another potentially useful risk stratification tool is the Seattle Heart 
Failure Model (SHFM), given its established role in predicting mortal-
ity in patients with heart failure. The major limitation of the SHFM is 
that it has been developed from cohorts of patients with heart failure 
without recurrent VAs, and it remains a complex risk score to calcu-
late due to the number of variables included. Evidence from a single 
observational study has shown that the SHFM may help to identify 
patients with scar- related VT undergoing catheter ablation at high 
risk of midterm (ie, 6 months) postprocedural mortality (S5.1.3.9). 
Other institutional risk assessment protocols combining variables in-
cluded in the PAAINESD and SHFM with other risk features, such as 
hemodynamic status during recurrent VT episodes, have also been 
proposed to determine which patients are best managed in the set-
ting of dedicated intensive care units or with the aid of HS devices, 
and whether prolonged postablation surveillance may be helpful 
(S5.1.3.1, S5.1.3.10). 
 5.1.3  |  Multidisciplinary involvement 
 The optimal management of high- risk patients extends well beyond 
the treatment of recurrent VAs and typically involves shared treatment 
plans and close collaboration between multiple disciplines, including 
interventional electrophysiologists, cardiologists, heart failure special-
ists, cardiac anesthesiologists, cardiothoracic surgeons, and pediatric 
electrophysiologists or those with expertise in CHD (especially in young 
patients <16 years of age or those with moderate/complex CHD) as ap-
propriate. As such, it is preferable that high- risk patients with recurrent 
VAs for whom a catheter ablation procedure is planned are managed 
in centers with proficiency in these procedures, and that they receive 
prompt access to advanced therapies, including percutaneous HS de-
vices, permanent ventricular assist devices (VADs), and/or heart trans-
plantation. Ongoing heart failure management is a critical component 
of the management of such patients both immediately after VA ablation 
and in the longer term. 
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 TA B L E  4     The PAAINESD Score, developed to predict the risk of periprocedural hemodynamic decompensation 
 Variable  Points 
 P ulmonary disease (COPD)  5 
 A ge  >  60  3 
 General  a nesthesia  4 
 I schemic cardiomyopathy  6 
 N YHA class III/IV  6 
 E F  <  25%  3 
 VT  s torm  5 
 D iabetes mellitus  3 
 The PAAINESD Score, developed to predict the risk of periprocedural hemodynamic decompensation, has values that range from 0 to 35 points (or 0 
to 31 [PAINESD] when the modifiable intraprocedural variable “general anesthesia” is excluded) (S5.1.3.2). 
 Abbreviations: COPD, chronic obstructive pulmonary disease; EF, ejection fraction; NYHA, New York Heart Association; VT, ventricular tachycardia. 
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 5.2  |  12- lead electrocardiogram and body surface 
mapping before ventricular tachycardia ablation 
 5.2.1  |  Standard 12- lead electrocardiogram 
 The standard 12- lead ECG has been shown to be a valuable tool 
in planning catheter ablation procedures for treatment of VAs, in-
cluding VT and PVC, and in the case of hemodynamically toler-
ated VAs, every effort should be taken to record the 12- lead ECG. 
In cases of focal VA in the absence of SHD, the 12- lead ECG is 
a relatively accurate indicator of the source location, whereas in 
the presence of myocardial scarring from whatever cause (in which 
reentry is the predominant mechanism of arrhythmia), the ECG re-
flects the exit site from the reentrant circuit, rather than the di-
astolic corridor that typically represents the best ablation target. 
In some cases, the distance between these two locations can be 
several centimeters. 
 5.2.2  |  Ventricular tachycardia and premature 
ventricular complex in the absence of structural 
heart disease 
 Features of the 12- lead ECG during VT or PVC occurring in the 
absence of SHD have been reported, which suggest endocardial 
catheter- accessible origins in the RV vs LV outflow regions (includ-
ing the aortic SV), idiopathic fascicular (verapamil- sensitive) VT 
related to the LV Purkinje system, and other LV sources, including 
anterior and posterior papillary muscle VT, para- Hisian VT, mitral an-
nular VT, AMC VT, and GCV/AIV VT; and other RV sources, including 
tricuspid annular VT, moderator band VT, and papillary muscle VT. 
Certain ECG patterns can indicate these regions of origin. An LBBB 
inferior axis morphology with late transition (>lead V3) indicates an 
origin in the RVOT. Lead I indicates whether the origin is anteri-
orly (negative) or posteriorly (positive) located (S5.2.8.1). Notching 
in the inferior leads indicates a lateral (free wall) position in the OT 
(S5.2.8.1). A Q wave in lead V1, combined with an R wave in lead aVL 
and an R wave in lead I, together with smaller R waves in the inferior 
leads, has been found for VAs originating from close to the conduc-
tion system (S5.2.8.2). An early transition (≤lead V3) in the presence 
of an LBBB pattern could indicate a left- sided origin (S5.2.8.3), and 
a broader and taller R wave in V1 or V2 could indicate an origin from 
the SV (S5.2.8.4). 
 Epicardial origins from the LVOT, in addition to displaying a broad 
QRS complex with a pseudodelta wave (see below), often have a Q 
wave in lead I. An epicardial origin close to the AIV, however, can 
closely resemble the ECG pattern of an origin from the RVOT. An RBBB 
and inferior axis pattern with positive concordance is the hallmark for 
VAs originating from the anterior mitral annulus (S5.2.8.5). A transition 
to a precordial rS pattern, usually in lead V3–V4, has been observed 
for origins from the papillary muscles with a leftward axis, indicating 
an origin from the posteromedial, or with a rightward axis, indicating 
an origin from the anterolateral papillary muscle (S5.2.8.6). Papillary 
muscle sources often produce a small Q wave in lead V1 (S5.2.8.7, 
S5.2.8.8). In contradistinction to papillary muscle origins, a fascicular 
origin has a much narrower QRS complex (S5.2.8.6). 
 Despite the range of heart positions in the chest and body hab-
itus, and variations of ECG lead positions, these ECG features can 
be remarkably accurate at indicating the SOO to within a 1- to 2- cm 
radius. Refinement of the exact site of impulse formation using ac-
tivation or pace mapping is still needed prior to ablation (S5.2.8.9–
S5.2.8.13). Examples of PVC morphologies from several common 
SOOs in the RV and LV are shown in Figures  3 and  4 . 
 5.2.3  |  Postinfarction ventricular tachycardia 
 Several algorithms have been devised to predict the exit site in post-
 MI VT. As noted above, these all have the important limitation that 
(to the degree they can reveal localizing information about the ar-
rhythmia) they indicate the exit site of the circuit, not the location 
of the midportion of the diastolic corridor (S5.2.8.14–S5.2.8.17). 
Although the distance from the exit site to a vulnerable portion of 
the diastolic corridor can be 1 cm or less, it could be more. In addi-
tion, the existing algorithms are not applicable in all cases, and in 
those cases in which they are, only approximately 75% of VTs can be 
regionalized to a 2- to 5- cm 2  area. In general, correlation of exit sites 
with VT morphology conforms to rather intuitive principles:
 1 The majority of post-MI VT exit sites are LV endocardial. 
 2 LBBB VTs tend to have exit sites on, or within 1 cm of, the intra-
ventricular septum. 
 3 Patients with inferior infarctions often have Q waves in the infe-
rior leads, indicating inferior wall scarring and an inferior wall exit 
site, which tend to be located on the inferobasal septum or the 
inferolateral free wall, with a common diastolic corridor on the 
inferobasal free wall along the mitral annulus. 
 4  VTs with a predominant inferior axis tend to have exit sites on the 
anterior wall (cranial half of the LV). 
 5 VTs with a predominant superior axis tend to have exit sites on 
the inferior half of the LV. 
 6 VTs with a leftward axis tend to have exit sites on or within 1 cm 
of the septum. 
 7  VTs with concordant positive precordial QRS complexes tend to 
have basal exit sites. 
 8 VTs with concordant negative precordial QRS complexes tend to 
have apical exit sites. 
 There can sometimes be disagreement among observers about spe-
cific features of ECGs, such as whether an axis is leftward or rightward 
(ie, discordance between vector of leads I and aVL/lateral precordial 
leads). Automated algorithms can remove some of the subjectivity of 
VT ECG analysis (S5.2.8.18–S5.2.8.20). 
 5.2.4  |  Epicardial sources 
 Several ECG criteria have been proposed that indicate an epicardial 
source of VT in patients without SHD or with NICM. These include 
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several interval measurements that reflect slow, muscle- to- muscle 
propagation at the beginning of the QRS complex, the maximum de-
flection index in precordial leads, and presence of Q waves where 
they would not ordinarily be expected (indicating propagation away 
from the epicardial surface of the ventricular wall recorded by that 
chest lead) (S5.2.8.21–S5.2.8.24). Of these, the raw interval meas-
urements are subject to false- positive errors in that they can be 
nonspecifically prolonged by sodium- channel blocking effects of 
AADs or hyperkalemia as well as by CL (less accurate with faster VTs) 
(S5.2.8.25). The maximum deflection index (time to earliest peak in 
any precordial lead divided by the total QRS duration (S5.2.8.26), at 
least in principle, prevents this problem by indexing the intrinsicoid 
deflection to the total QRS duration, which will be subject to the 
same effects. 
 FIGURE 4   Examples of 12- lead  ECG s of premature ventricular 
complexes from different right ventricular sites, as corroborated 
by successful focal ablation. All leads are displayed at the same 
amplification and sweep speed. A, shows the 12- lead  ECG pattern 
of common origins of right ventricular arrhythmias in patients 
without  SHD [1- 6]. The locations are detailed in a 3D reconstruction 
of the computed tomography using the  MUSIC software that was 
developed at the University of Bordeaux. The reconstruction shown 
in (B) illustrates the septal view of the right ventricle. Indicated are 
the pulmonary artery, the tricuspid valve annulus, and the right 
ventricular apex.  ECG s = electrocardiograms;  PA = pulmonary artery; 
 RVOT = right ventricular outflow tract;  SHD = structural heart 
disease;  TVA = tricuspid valve annulus 
 F I G U R E  3     Examples of 12- lead  ECG s of premature ventricular 
complexes from different  LV sites, as corroborated by successful 
focal ablation. A, shows 12- lead  ECG patterns of common 
ventricular arrhythmia origins in patients without  SHD [1- 9] from 
the left ventricle. All leads are displayed at the same amplification 
and sweep speed. These locations are illustrated in (B) based on 3D 
reconstruction of a cardiac computed tomography using the  MUSIC 
software that was developed at the University of Bordeaux. The 
reconstruction shows an anterolateral view of the left ventricle, 
aorta, and left atrium. Also shown are the coronary arteries (red), 
the coronary venous system (blue), and the phrenic nerve (green). 
 AIV = anterior interventricular vein;  AL  PAP = anterolateral papillary 
muscle;  AMC = aortomitral continuity;  GCV = great cardiac vein; 
ant.  MA = anterior mitral valve annulus;  PM  PAP = posteromedial 
papillary muscle; R/L = right- left;  SHD = structural heart disease; 
SoV = sinus of Valsalva. 
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 5.2.5  |  Ventricular tachycardia in nonischemic 
cardiomyopathy 
 The 12- lead ECG of a VT could be less helpful in NICM to direct abla-
tion; however, target areas can be estimated in a fashion comparable 
to post- MI VT. In many cases of NICM, successful ablation sites are 
on the epicardial surface; however, NICM VTs originating from an-
teroseptal scar typically have an LBBB inferior axis morphology, and 
these patients (who might also present with AV conduction distur-
bances due to septal scarring in the region of the bundle branches) 
might not benefit from an epicardial approach for ablation (S5.2.8.27). 
 5.2.6  |  Bundle branch reentrant ventricular 
tachycardia 
 Patients with BBRVT typically have some form of SHD (nonischemic 
more than ICM), with an LBBB pattern in the baseline conducted 
rhythm (sinus or atrial fibrillation [AF]), although RBBB or nonspecific 
interventricular conduction delay can also occur. During BBRVT, the 
QRS generally closely resembles the baseline QRS, with character-
istically rapid initial forces (in contrast to the delayed upstrokes in 
most other myocardial VTs). This is an important entity to recognize 
because of its prevalence as well as its curability with a rather simple 
ablation procedure (targeting RBBs or LBBs). 
 Many patients with SHD have an ICD in place that terminates 
the majority of VT episodes with pacing or shock, thus precluding 
recording of a full 12- lead ECG of the arrhythmia. Only when the 
device is disabled, or when the VT rate or episode duration is below 
the device ' s programmed detection levels, is it possible to record 
the ECG during VT. In patients with SHD, having the 12- lead ECG of 
all spontaneously occurring VTs is especially important during pro-
cedures in which multiple morphologies of VT are induced and the 
operator must decide which morphology (or morphologies) are most 
important to target for ablation. In the absence of a 12- lead ECG, 
ICD electrograms of the recorded VT episodes have been particu-
larly helpful to identify the clinical VT when multiple VTs are induced 
during an ablation procedure (S5.2.8.28). 
 5.2.7  |  Body surface mapping 
 Body surface mapping has been used for many years as a predictor of 
VA exit site, starting with skin surface potential minima and more re-
cently as electrocardiographic imaging (ECGI). The latter integrates un-
ipolar electrograms obtained during the arrhythmia while the patient is 
wearing a 256- electrode vest, with ventricular anatomy derived from 
a CT or CMR scan with the vest in place. An activation map during the 
arrhythmia is then mathematically derived using the inverse solution 
and is plotted on the epicardial surface as designated by the CT or 
CMR scan. Although experience with this modality in VAs is limited, 
ECGI maps have shown good correlations with endo- and epicardial 
mapping results in a variety of settings, in patients with and without 
SHD (S5.2.8.29–S5.2.8.32). Correlations appear to be very good for 
OT arrhythmias (right vs left) and for those with epicardial sources, and 
poorer for reentrant VTs (many of which have septal diastolic corridors 
with variable epicardial breakthrough sites that can be detected by 
ECGI), and with origin from sites close to scar (S5.2.8.33). 
 5.2.8  |  Summary 
 In most settings, ECG tracings provide important insights regarding 
location of either the source of focal arrhythmias or the exit site for 
reentrant VTs; when possible, a 12- lead ECG should be obtained of 
the target VA(s) (PVC or VT) and be used as a guide for where to con-
centrate mapping efforts based on published algorithms. However, no 
matter how specific the ECG algorithm or ECGI map is, it remains as 
a guide to where mapping efforts should begin or focus, rather than 
pinpointing an actual site at which ablation will be certain to eliminate 
the arrhythmia. Careful mapping is still needed in all situations. 
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 5.3  |  Facilities for the procedure 
 5.3.1  |  Facilities 
 VT ablation can be a complex electrophysiological procedure, espe-
cially in patients suffering from deterioration of LV function or from 
cardiogenic shock. In addition, many patients with scar- related VT have 
comorbidities that impact on procedural planning. Adequate preproc-
edural planning and standardization of procedural steps are crucial in 
this population with advanced heart disease. Preprocedural planning 
should involve communication with other subspecialties, including car-
diothoracic surgeons and physicians with expertise in heart failure man-
agement, to optimize patient safety. In general, VT ablation in patients 
with advanced heart disease should only be performed by experienced 
operators in centers with expertise for complex electrophysiological 
procedures with onsite cardiosurgical backup and expertise in HS. 
 All personnel and equipment should meet institutional require-
ments and training requirements for treating patients with complex 
cardiac pathologies. Integrity and functionality of the equipment 
should be regularly maintained as required by institutional standards. 
 5.3.2  |  Laboratory equipment 
 The electrophysiology laboratory for VT ablation should meet stand-
ard requirements for any type of catheter ablation procedure, with 
availability of emergent echocardiography to rule out cardiac tam-
ponade. Laboratory specifications include a dedicated work space 
and fluoroscopy system (mono- or biplane, capability of cinefluor-
oscopy or angiography), a programmed stimulator, an electrophysi-
ology recording system with EAM ability, as well as the possibility 
to perform cardiac catheterization procedures with hemodynamic 
monitoring capabilities. Institutional and societal requirements for 
electrophysiology laboratories should be met, and regular mainte-
nance is imperative (S5.3.4.1). The electrophysiology lab should be 
equipped with a biphasic defibrillator and an ECG monitor, and a 
backup defibrillator should be immediately accessible. Continuous 
connection of the defibrillator to the patient (eg, using attached de-
fibrillator pads) is used in many labs for fast and easy defibrillation. A 
code cart with standard advanced cardiac life support medications is 
mandatory. For surgical access, such as epicardial surgical windows, 
institutional hygienic standards should be maintained. 
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 Programming devices for the patient ' s specific ICDs should be avail-
able in the electrophysiology lab to allow pre- and intraprocedural pro-
gramming and device interrogation as well as emergency internal shock 
delivery if required. For patients with implanted left or right VADs, the 
appropriate equipment and personnel should be available as required. 
 Epicardial access for mapping and ablation might be needed in a sub-
group of patients with VT. Epicardial instrumentation is a complex part 
of VT ablation and requires high expertise and experience with epicar-
dial puncture or surgical access. Continuous availability of an ICD pro-
grammer and the capability of delivering internal shocks can be crucial 
to terminate VAs in case of external defibrillation failure due to pericar-
dial fluid and/or air and in cases of suboptimal defibrillator pad location. 
 Patient monitoring is crucial for safety during ablation of VT, in-
dependent of the underlying cardiac disease. A physiological recorder 
capable of monitoring pulse oximetry, noninvasive and invasive arte-
rial blood pressure, and ECG is recommended. Vital signs in addition 
to oxygen saturation should be displayed for the operator and assist-
ing staff throughout the procedure. For longer procedures involving 
patients with SHD, invasive intra- arterial blood pressure monitor-
ing might be superior to noninvasive noncontinuous measurement. 
Noninvasive monitoring of cerebral tissue oxygen saturation has been 
used to reflect end organ perfusion when longer episodes of VT were 
required, to allow for adequate mapping (S5.3.4.2, S5.3.4.3). 
 5.3.3  |  Personnel 
 Credentialing of personnel involved in VT ablation procedures is 
specific to institutions and can vary by country. The personnel in the 
electrophysiology lab typically consist of a nurse and a technician 
involved in patient care and monitoring; possibly a person handling 
the ICD programmer (approximately 15% of the writing committee 
have a representative from the device company assisting with in-
traprocedural management of the ICD) during the ablation; an ex-
pert operator for manipulation and placement of catheters; and one 
or two operators managing the electrophysiology recording system, 
the stimulator, and the mapping system. When a 3D EAM system is 
used, as is the case in most VA ablation procedures, a highly trained 
professional (eg, a manufacturer ' s representative, a technician, or a 
physician) is usually present to operate this system and assist with 
acquisition, editing, and interpretation of data. With respect to seda-
tion, different requirements exist in different countries and societies. 
An anesthesiologist, a nurse anesthetist, or an equivalent person ex-
perienced with sedation and intubation should be present if deeper 
sedation is required. In this regard, sedation during VT ablation by 
trained cardiologists has been shown to be safe (S5.3.4.4–S5.3.4.6). 
 Personnel involved in VT ablations should be trained for complex 
electrophysiology maneuvers and mapping maneuvers for monitoring 
severely impaired patients under sedation and administration of anti-
arrhythmic as well as inotropic drugs (S5.3.4.4–S5.3.4.6). Recognizing 
any potential complication or prolonged hemodynamic compromise 
is a key feature to patient safety. Personnel involved in VT ablation 
should be proficient in using cardiac defibrillators and in performing 
advanced life support and cardiopulmonary resuscitation. 
 Operators performing VT ablation procedures should be certi-
fied interventional electrophysiologists with expertise for RV and LV 
mapping and ablation. Coronary angiography by the operator him- or 
herself or by another physician might be needed during epicardial or 
aortic SV ablation procedures to delineate anatomy of the coronary 
arteries. In addition, physicians capable of inserting percutaneous HS 
devices should be available in case of prolonged hemodynamic com-
promise. A cardiac surgeon should be available in case cardiopulmo-
nary bypass, surgical HS, or sternotomy is required. 
 Epicardial VT procedures can be more complex than endocar-
dial VT ablation procedures; these are discussed in more detail in 
Section  6.3 . For adequate treatment of possible complications and 
also for surgical epicardial access, cardiac surgical backup is warranted. 
 5.3.4  |  Patient safety 
 Due to procedural complexity and risks, catheter ablation for VAs 
should have appropriate patient safety and pertinent laboratory pro-
tocols in place. Electrophysiology laboratory equipment should un-
dergo routine maintenance by a biomedical engineering department 
to ensure appropriate functionality and should be available for trou-
bleshooting. In particular, routine assessment for external defibrillator 
functionality should be performed according to regulatory, manufac-
turer, and institutional policies. Radiation exposure should be mini-
mized to the operator and patient with the use of digital- pulsed, low 
pulse rate fluoroscopy if feasible, and implementation of ALARA (as 
low as reasonably achievable) principles. Safety protocols should be 
in place for management of emergent complications, with a focus on 
those pertaining to higher- risk VA ablation (eg, epicardial access with 
surgical backup, hemodynamically unstable VAs requiring HS, acute 
coronary injury requiring coronary intervention). 
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 5.4  |  Preprocedural imaging 
 Recommendations for preprocedural imaging for VA catheter ablation 
 COR  LOE  Recommendations  References 
 I  B- NR  1. In patients with LV dysfunction undergoing catheter ablation of VA, preprocedural or intraproce-
dural imaging is recommended to rule out cardiac thrombi. 
 S5.4.1–S5.4.6 
 IIa  B- NR  2. In patients with NICM or ICM undergoing catheter ablation of VT, preprocedural CMR can be 
useful to reduce VT recurrence. 
 S5.4.7–S5.4.9 
 IIa  B- NR  3. In patients with NICM or ICM undergoing catheter ablation of VA, preprocedural imaging can be 
useful for procedural planning. 
 S5.4.10–S5.4.26 
 IIa  C- EO  4. In patients with NICM, CMR can be useful prior to ICD implantation to allow imaging without 
device- related artifact for diagnostic purposes and identification of potential arrhythmogenic 
substrate. 
 
 IIb  C- EO  5. In patients with ICM, CMR may be considered prior to ICD implantation to allow imaging without 
device- related artifact for identification of the potential arrhythmogenic substrate. 
 
 Recommendation- specific supportive text 
 1 In patients with LV dysfunction, recent preprocedural imaging 
should be performed if LV catheter manipulation is anticipated 
to assess for LV thrombi to prevent thromboembolic events. 
Typically, a transthoracic echocardiogram is performed to as-
sess for intracardiac thrombi (S5.4.27, S5.4.28), and contrast 
echocardiography has further been shown to improve the yield 
of echocardiography to detect cardiac thrombi, especially in 
high-risk patients (S5.4.4, S5.4.29) and in patients with poor 
echocardiographic windows. CMR has been shown to be su-
perior to transthoracic echocardiography for the detection of 
intracardiac thrombi (S5.4.5, S5.4.6, S5.4.30), especially in the 
presence of small and mural thrombi. To further minimize the 
possibility of thromboembolic events, for patients with concom-
itant AF, it might be prudent to also obtain a preprocedural 
transesophageal echocardiogram to rule out left atrial thrombi 
if defibrillation or cardioversion might be required during the 
ablation procedure (S5.4.27). An intracardiac echocardiogra-
phy (ICE) can alternatively be performed prior to LV catheter 
manipulation if no recent imaging is available to rule out LV 
thrombi. 
 2 Preprocedural imaging with CMR and use of CMR for targeting the 
arrhythmogenic substrate has resulted in reduced VT recurrence 
and reduced mortality in a few observational studies (S5.4.7–
S5.4.9). Patients with contraindications to CMR were excluded, 
and in one study, only patients with good image quality benefited 
from the preprocedural CMR (S5.4.9). CIEDs have long been con-
sidered as being contraindicated for magnetic resonance imaging 
(MRI). However, provided that appropriate precautions are taken, 
MRIs in patients with CIEDs have been demonstrated to be safe in 
multiple studies and registries (S5.4.31–S5.4.33), and a recent HRS 
expert consensus statement details specific recommendations for 
MRIs in patients with CIEDs (S5.4.34). 
 3 By demonstrating location (S5.4.12, S5.4.25, S5.4.26) and extent 
(S5.4.26) of delayed enhancement, CMR helps to identify the loca-
tion of the arrhythmogenic substrate and therefore is beneficial in 
periprocedural planning regarding the need for obtaining epicardial 
access. Other imaging modalities, such as CT and nuclear imaging, 
have been correlated with electroanatomical voltage mapping data 
to identify scarring by detecting areas of delayed enhancement 
(S5.4.10–S5.4.17, S5.4.19), wall thinning (S5.4.21), hypoperfu-
sion (S5.4.20), and lack of metabolic activity (S5.4.24). Contrary to 
CMR, CT and nuclear imaging do not provide specific information 
about the precise extent of scarring within the myocardial wall; 
these imaging techniques might be preferable for preprocedural 
imaging in case of contraindications to CMR. 
 4  Prior to implantation of a cardioverter defibrillator, performing a 
CMR might be beneficial in patients with NICM and ICM. Especially 
for patients with NICM, the writing committee felt that in addition to 
localizing scar in the event of future VT development, a CMR will be 
beneficial for diagnostic reasons to clarify the etiology of NICM. In 
the  2013 ACC/AHA Guideline for Management of Heart Failure , CMR is 
considered a class IIa recommendation to assess for infiltrative dis-
orders (S5.4.35). In general, it was felt that the higher the odds that 
patients might have recurrent VTs, the stronger the indication for a 
CMR prior to ICD implantation (for example, in patients with a sec-
ondary prevention indication for ICD implantation). Concerns about 
cost implications were the main reason why the writing committee 
issued a class IIb recommendation for patients with ICM. 
 Synopsis 
 Although randomized studies that demonstrate that the use of im-
aging results in improved procedural outcomes are lacking, pre- , 
intra- and postprocedural imaging is routinely used for VA ablation 
procedures. 
 Advances in imaging technology, image integration, and image 
analysis have paved the way for CMR and CT to take the lead as im-
aging modalities to define the presence and extent of SHD as well as 
to refine the characteristics of the arrhythmogenic substrate. 
 Due to the high spatial resolution of ex vivo MRI, myocardial 
scarring can be characterized with an almost histological precision 
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(S5.4.36, S5.4.37). Therefore, LGE- CMR is often referred to as the 
gold standard for scar assessment. Unfortunately, a clinical CMR 
study obtained for a patient has a much lower spatial resolution due 
to the motion of the beating heart compared with an ex vivo MRI. 
Several studies have reported on the accuracy of CMR- defined scar 
by correlating CMR- defined scar with areas of low voltage from EAM 
data (S5.4.10–S5.4.17). Although differences exist between these 
studies, there is general agreement between imaging defined scar 
and the abnormal substrate defined by EAM. Important limitations of 
the EAM- defined substrate, however, need to be kept in mind, and 
there is mounting evidence for improved procedural outcomes with 
an imaging- guided ablation compared with an EAM- guided ablation 
approach (S5.4.7–S5.4.9). EAM- derived data reflect the 3D surface of 
the myocardium and lack information about the 3D anatomical and 
pathological integrity of the heart. Hence, CMR offers a more com-
prehensive assessment of the entire heart, especially of the intramural 
and epicardial myocardium, which is difficult, if not impossible, to as-
sess with endocardial voltage mapping alone. Lack of adequate cath-
eter contact with the myocardium can further impact on accuracy of 
EAM. These limitations can be overcome by integrating the CMR data 
into the EAM. Accurate registration of the CMR with the electroana-
tomical map is of critical importance to have reliable information about 
location and extent of myocardial scarring. The information about scar 
location has been supplemented by further characterization of the tis-
sue heterogeneity within the scar that contains the surviving myofiber 
bundles as the arrhythmogenic substrate (S5.4.38–S5.4.40). 
 Two methods have been described to characterize tissue hetero-
geneity: the SD method, which uses the remote, unenhanced myo-
cardium as a reference, defining scar if the signal intensity is above 
normal myocardium (usually >2–3 SD) (S5.4.11, S5.4.12, S5.4.41); and 
the signal intensity method (full- width at half maximum technique), 
which uses >50% of the maximal signal intensity within a region of 
interest to define scar. Various cutoff values have been used to dis-
tinguish the border zone from the scar core and have been correlated 
with outcomes (S5.4.38–S5.4.40). Controversy exists, however, about 
which of the methods and which of the cutoff values is preferable for 
assessment of tissue heterogeneity. It is important to note that quanti-
fication of the border zone still awaits histologic validation. Limitations 
of LGE- CMR include the limited spatial resolution that is in the 1- to 
2- mm range, making it difficult to characterize tissue heterogeneity 
if the wall thickness is in this range. This, among others, is one of the 
reasons why the assessment for LGE in the thinner RV is challenging 
when using standard LGE- CMR techniques. In the past, CIEDs have 
been considered to be contraindications for CMR. This is no longer 
the case, and provided that certain precautions are followed, CMR 
has been shown to be safe in several studies (S5.4.33) and registries 
(S5.4.31, S5.4.32). However, in the presence of a CIED, artifacts from 
the device generator, especially from ICDs, can obscure the myocar-
dium and render a CMR study completely or partially nondiagnostic 
(S5.4.42). It is therefore recommended to perform CMRs prior to 
ICD implantation. The prevalence and extent of artifact can be min-
imized by wideband CMR sequences (S5.4.43). CMR in patients with 
NICM has been particularly helpful despite the presence of ICDs, and 
improved outcomes have been described in patients who underwent 
CMR prior to VT ablation procedures (S5.4.7–S5.4.9). 
 The advantage of multidetector cardiac CT (MDCT) over LGE- 
CMR is the higher spatial resolution that is in the submillimeter 
range. Various MDCT characteristics indicative of scarring have 
been described, including a degree of wall thinning with a cutoff 
wall thickness of <5 mm (S5.4.22), hypoattenuation (S5.4.20), and 
delayed enhancement (S5.4.19). More recently, thanks to the higher 
spatial resolution of MDCT, thicker ridges of tissue separating 
areas of thinning have been described within the myocardial scar 
harboring the majority of VT target sites in patients post infarction 
(S5.4.18). Hence, MDCT imaging has been found to be beneficial 
as an alternative to CMR to indicate the location of myocardial 
scarring, especially in the presence of contraindications for CMR. 
Although assessment of wall thickness in MDCT imaging has been 
used successfully in patients with prior infarctions, the ability to 
identify scarring based on wall thickness alone has been less suc-
cessful (S5.4.21, S5.4.44) in patients with NICM, and might require 
a different approach (S5.4.19). MDCT is the imaging technique of 
choice for preprocedural imaging of the coronary arteries, the coro-
nary veins, and the phrenic nerve. The ability to image the coronary 
arteries in conjunction with the ability to image epicardial fat thick-
ness has been especially valuable for epicardial ablation procedures 
to enhance safety and to quantify epicardial fat thickness covering 
potential epicardial VT target sites (S5.4.45, S5.4.46). 
 Nuclear imaging for the purpose of facilitating VT ablation 
procedures has been described for PET and single- photon emis-
sion computerized tomography (SPECT) scanning, using CT for 
image integration. Although there is a correlation between PET/
CT defined scar and EAM (S5.4.23, S5.4.24), the correlation 
of SPECT perfusion imaging with low- voltage areas on EAM is 
lower (S5.4.47). It is intriguing that metabolically active areas 
corresponding to critical VT sites have been identified; however, 
they might not correspond to areas of low voltage on the EAM 
(S5.4.23). Furthermore, sympathetic denervation can be imaged 
using tracers, such as 11C- meta- hydroxyepinephrine and iodine- 
123- metaiodobenzylguanidine. Regional sympathetic denerva-
tion has been recognized as an imaging marker for an increased 
risk of sudden cardiac death (S5.4.48). Viable but denervated 
myocardium has been shown to be particularly sensitive to de-
velopment of arrhythmias (S5.4.49, S5.4.50). Klein et al (S5.4.51) 
have demonstrated that critical VT ablation sites were located 
in denervated areas, some of which were located in areas with 
preserved bipolar voltage. 
 Finally, echocardiography is typically used to rule out the presence 
of cardiac thrombi (S5.4.27, S5.4.28) prior to an ablation in patients 
with SHD in whom catheter manipulation in the LV is anticipated. 
Although transthoracic echocardiography has been beneficial in iden-
tifying intracardiac thrombi (S5.4.1–S5.4.3), the use of contrast has 
been shown to further increase the yield of cardiac thrombi (S5.4.4, 
S5.4.29) and should be used if the LV endocardium is not well visual-
ized. Although ablation procedures might be safe in the presence of 
laminated thrombi (S5.4.52), it would be prudent in the absence of 
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an urgent indication for VT ablation, and especially in the presence 
of a mobile thrombus, to anticoagulate the patient for a period of 
time and reassess for LV thrombus prior to the ablation procedure. 
Not every patient has optimal echocardiographic windows that allow 
for comprehensive assessment of the entire endocardium to rule out 
LV thrombi, even if sonographic contrast is used. LGE- CMR and Cine- 
CMR are alternative imaging techniques that have a higher accuracy in 
identifying myocardial thrombi (S5.4.5, S5.4.6, S5.4.30), which should 
be kept in mind, particularly in patients for whom transthoracic echo-
cardiography is considered insufficient to rule out an LV thrombus. The 
sensitivity of ICE for detection of LV thrombus has not been system-
atically studied, but it can provide real- time assessment immediately 
before catheter placement. To minimize the risk of thromboembolic 
events for patients with concomitant AF, a preprocedural transesoph-
ageal echocardiogram will be helpful to exclude a left atrial thrombus 
if a cardioversion is required during the ablation procedure (S5.4.27). 
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 5.5  |  Patient preparation 
 Heart failure, electrolyte abnormalities, and myocardial ischemia should 
be adequately treated and controlled, if possible, before the patient is 
subjected to an invasive electrophysiology study. Similarly, associated 
SHDs should be clearly defined, given that patients with conditions 
such as severe LV systolic dysfunction, severe coronary artery disease, 
critical aortic stenosis, and advanced renal impairment might not toler-
ate induction of arrhythmia, prolonged procedures, or fluid overload 
resulting from the use of saline- irrigated catheters. Although some of 
these conditions can be optimized prior to an elective procedure, this 
is often not possible for more emergent procedures. In these cases, 
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a substrate- based ablation approach without repeated VT inductions 
might be preferable. 
 AADs, with the exception of amiodarone, should, if at all possible, 
be discontinued for at least 5 half- lives prior to the ablation procedure. 
This is almost mandatory for cases in which the primary strategy of 
mapping is not substrate- based, but it might not be possible for emer-
gency cases. Oral anticoagulants are generally discontinued prior to 
the ablation to achieve an international normalized ratio < 1.5 at the 
time of the study. Direct oral anticoagulants should be withheld for 
24- 48 hours before the procedure, depending on anticipated access, 
and bridging with heparin can be used for patients with mechanical 
heart valves or other features that place them at high risk of thrombo-
sis. The majority of the writing committee (60%) usually use bridging 
in patients with mechanical valves, where possible, but many distin-
guish between mechanical aortic valves, in which transseptal access 
with continued anticoagulation can be used, and mechanical mitral 
valves, in which retrograde access is used. For elective procedures, 
imaging with ultrasound can help to define the feasibility of an arte-
rial closure device, and therefore continued anticoagulation. Routine 
perioperative bridging in patients with AF who interrupted warfarin 
for procedures, including percutaneous transvascular procedures, was 
noninferior to no bridging in a large RCT with respect to the occurrence 
of thromboembolic events (S5.5.1). Approximately half of the writing 
committee do not use bridging in similar patients, and a further 20% 
do not use bridging in patients taking direct oral anticoagulants. 
 Informed consent needs to be obtained from the patient or his or 
her surrogate after discussing the risks and benefits involved in the 
procedure, as well as alternatives. The patient should fast overnight 
or for at least for 6 hours prior to the procedure (S5.5.2, S5.5.3). 
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 6    |   INTR APROCEDUR AL PATIENT C ARE 
 6.1  |  Anesthesia 
 Recommendations for anesthesia during catheter ablation of VA 
 COR  LOE  Recommendations  References 
 I  C- EO  1. Provision of variable depth of sedation, analgesia, and anesthesia during mapping and ablation of VA is 
recommended. 
 
 I  C- EO  2. In patients undergoing VA ablation, careful preprocedural assessment is indicated to define the ideal 
strategy for sedation and analgesia. 
 
 IIa  C- LD  3. It is reasonable to avoid general anesthesia and deeper levels of sedation in patients with idiopathic VA, 
particularly if the arrhythmia is suspected to be catecholamine- sensitive or was not inducible at a prior 
procedure. 
 S6.1.1 
 IIb  B- NR  4. Moderate to deep sedation under close hemodynamic and respiratory monitoring might be considered 
for VA ablation in stable patients with idiopathic or scar- related VAs expected to have a longer procedure 
or undergo a painful technique, such as epicardial access. 
 S6.1.1–
S6.1.3 
 Recommendation- specific supportive text 
 1. The American Society of Anesthesiologists defines levels of sedation 
in a continuum, varying from minimal sedation (anxiolysis), to mod-
erate sedation or analgesia (conscious sedation), to deep sedation 
or analgesia, to general anesthesia (S6.1.4). Careful preprocedural 
assessment is indicated to define the ideal strategy for sedation 
and analgesia based on age and comorbidities, targeted arrhythmia, 
planned procedure, risk for airway obstruction, and patient wishes. 
General anesthesia ensures patient comfort that facilitates vascular 
and especially epicardial access, and also ensures immobility during 
catheter manipulation for mapping and ablation, especially for pro-
cedures of long duration. However, a major disadvantage of general 
anesthesia is its potential suppression of VA. Elimination of mental 
stress and the related changes in the autonomic tone during general 
anesthesia or deep sedation can potentially decrease the spontane-
ous manifestation of catecholamine- sensitive VA and the induction/
maintenance of reentrant VT (S6.1.5–S6.1.8). Inhaled anesthetics 
that prolong action- potential duration and ventricular refractoriness 
(sevoflurane and isoflurane) and intravenous anesthetics that reduce 
sympathetic tone (dexmedetomidine) are commonly avoided for abla-
tion procedures (S6.1.5, S6.1.6). Additionally, most of the anesthetic 
agents used for sedation and analgesia reduce myocardial contractility 
and systemic vascular resistance, causing hypotension that could be 
exacerbated during VT, requiring pharmacological or mechanical HS. 
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Those cardiovascular effects are more intense at the anesthetic doses 
needed for general anesthesia, which additionally produce higher at-
tenuation of sympathetic tone. General anesthesia or the use of car-
diodepressive medications, such as propofol for anesthesia in patients 
with severely compromised LV function, can result in acute hemody-
namic compromise during the ablation procedure, and its use needs to 
be carefully considered for these patients. If general anesthesia is used 
during epicardial ablation procedures, the concomitant use of muscle 
relaxants could preclude identification of the phrenic nerve during 
epicardial ablation. Use of a short- acting muscle relaxant during induc-
tion of anesthesia is acceptable, without redosing; however, it could 
necessitate a deeper level of anesthesia with resultant exaggeration of 
the above- mentioned hypotensive effects. Nevertheless, the effects 
of propofol on cardiac electrophysiological proprieties are diverse and 
could include arrhythmia suppression. In fact, propofol has been as-
sociated with suppression of VT and VT storm (S6.1.7). 
 The need for sedation and analgesia varies throughout the proce-
dure, being higher during vascular and epicardial access and car-
dioversion or defibrillation. On the other hand, a more superficial 
level of sedation (or any) is desirable to prevent VA suppression 
and to assure VT induction and maintenance for mapping. Short- 
acting agents are considered more suitable to provide those rapid 
changes in the requirements of sedation level during mapping and 
ablation of VAs (S6.1.9). Intravenous boli of midazolam and fen-
tanyl at repeated doses as needed was reported by a single- center 
observational study as a feasible and safe strategy for minimal se-
dation in patients with idiopathic PVC or VT planned for shorter 
procedures (S6.1.1). However, even shorter- acting sedatives such 
as midazolam have the potential for suppressing idiopathic VA 
for prolonged periods of time and need to be used with caution 
during procedures targeting idiopathic VAs, such as frequent PVCs. 
A strategy to use shorter- acting sedatives such as propofol for al-
lowing temporary deeper sedation is frequently used initially, and 
if VAs are suppressed, sedation can be reduced or discontinued to 
allow for arrhythmias to reappear as necessary. For patients with 
scar- related VTs, sedatives such as midazolam, which has the ad-
ditional benefit of amnesia, do not impact on inducibility of VT 
and can be used in conjunction with analgesics and/or other sed-
atives such as propofol to achieve the desired level of sedation. 
Continuous infusion of propofol, alone or complemented with re-
peated boli of fentanyl (as needed), has been proposed for deep 
sedation of stable patients during ablation of idiopathic or scar- 
related VT that are expected to have a longer duration or that re-
quire more painful and challenging techniques, such as epicardial 
access. Two single- center observational studies reported that this 
strategy can be safely performed in this subset of patients under 
close hemodynamic monitoring (S6.1.1, S6.1.2). Propofol had to be 
discontinued (switched to midazolam) in 11.7% of the procedures, 
predominantly due to hypotension presenting in elderly patients 
and prolonged procedural duration (S6.1.2). Respiratory depression 
resulting in sustained oxygen saturation of <90% requiring reduc-
tion of propofol and transitory mechanical maneuvers to assist ven-
tilation was present in 1.5% of the patients in the same study. 
 2. The selection of sedation strategy for patients undergoing ablation 
of VAs requires a balance between the desire of assuring a comfort-
able and safe procedure and the need to induce the targeted ar-
rhythmia (S6.1.9). Proactive communication between the operator 
and the anesthesia team and with the patient about the patient ' s 
needs and desires, as well as the electrophysiological requirements, 
helps to select a sedation strategy that is in the best interest of the 
patient. 
 3. In the prospective arm of a large observational study, in which pa-
tients with sustained, monomorphic VT and SHD underwent noninva-
sive programmed stimulation (NIPS) under minimal sedation, followed 
by invasive programmed stimulation under general anesthesia using 
propofol or isoflurane, >90% remained inducible under general anes-
thesia, although in half, a different VT was induced (S6.1.10). General 
anesthesia was associated, however, with less hemodynamic stability 
and greater use of vasopressor support with phenylephrine, without 
an adverse effect on procedural outcomes. More aggressive stimula-
tion was often required with general anesthesia than with conscious 
sedation (S6.1.10). In another cohort of 25 patients referred for epicar-
dial ablation in the setting of NICM, a strategy of initial programmed 
stimulation under sedation with midazolam, fentanyl, or remifentanil 
led to induction of tolerated VT in 15 patients, and avoidance of epi-
cardial access (which was performed under general anesthesia) alto-
gether occurred in 10 (40%) (S6.1.3). 
 On the basis of the cited single- center observational studies 
(S6.1.1–S6.1.3, S6.1.5–S6.1.11) about the various sedative and 
analgesic strategies for ablation of VAs, it is reasonable to avoid 
general anesthesia and deeper levels of sedation in patients with 
idiopathic VAs (PVC or VT) planned for shorter procedures, par-
ticularly when the arrhythmia is suspected to be catecholamine- 
sensitive (typically, automatic and triggered arrhythmias) or was 
not inducible during a prior procedure. In these patients, a minimal 
sedation strategy with short- acting sedatives and analgesics, with 
repeated doses as needed, can be useful to ensure adequate seda-
tion without VA suppression. 
 4. Epicardial scar- related VT mapping and ablation under deep seda-
tion with sufentanil or remifentanil and intermittent boli of midaz-
olam was reported as a feasible and safe strategy in a single- center 
prospective series and a case report (S6.1.9, S6.1.11). Interestingly, 
no respiratory failure resulting in endotracheal intubation or pro-
longed periods of hypotension requiring HS were observed (except 
during periods of unstable VT) in these cases (combined 79 proce-
dures in 73 patients). Importantly, this strategy allowed epicardial 
access with comfort, preventing the need for general anesthesia 
and muscle relaxants (facilitating the identification of the phrenic 
nerve during epicardial ablation), and providing rapid recuperation 
of consciousness with no recall of punctures or cardioversions. 
Remifentanil is an opioid with an analgosedative effect that can 
have advantages for ablation of VAs, including a lack of negative 
inotropic effect, comparatively little effect on arrhythmogenicity, 
time- to- peak effect of approximately 90 seconds and a half- life of 
3- 4 minutes (S6.1.9). This agent is also associated with hypoten-
sion likely secondary to vasodilatation and bradycardia. 
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 Moderate to deep sedation with continuous infusion of propofol 
and repeated boli of fentanyl under close hemodynamic and re-
spiratory monitoring might be considered for stable patients with 
ablation of idiopathic or scar- related VA with no indication for 
general anesthesia who are expected to undergo a procedure of 
longer duration or for patients who require more painful tech-
niques, such as epicardial access. Another short- action anesthetic, 
such as remifentanil or sufentanil, could also be considered. Of 
note, patients with severe hemodynamic compromise, severe life- 
threatening comorbidities or acute illness, respiratory failure, high 
risk for airway obstruction, or who were intubated before the pro-
cedure for arrhythmia storm or cardiogenic shock were excluded in 
the cited studies and are also traditionally considered candidates 
for general anesthesia. Hospital and regulatory guidance varies 
widely on the training and specialization required for different lev-
els of sedation and administration of various drugs (see Section  11 ). 
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 6.2  |  Vascular access 
 Recommendation for vascular access during catheter ablation of VA 
 COR  LOE  Recommendation  References 
 I  B- NR  1 Ultrasound-guided femoral arterial and venous access is recommended to reduce the inci-
dence of vascular access complications during VA ablation. 
 S6.2.1–S6.2.5 
 Recommendation- specific supportive text 
 1. Significant vascular complications occur in approximately 2% of VT 
ablation procedures (S6.2.6), which are further detailed in Section  10 . 
Ultrasound- guided femoral arterial and venous access has been 
widely implemented in electrophysiological procedures in an effort 
to reduce vascular complications. Several observational studies of 
electrophysiological procedures, mostly examining AF ablation, one 
RCT, and a meta- analysis have shown an association of ultrasound 
guidance with a reduction in major and minor vascular access com-
plications and bleeding (S6.2.1–S6.2.4). One observational study re-
ported the rate of major complications in the subgroup undergoing 
VA ablation, which was 8.9% in the conventional group and 0% in 
the ultrasound- guided group (S6.2.1). In a single RCT in patients un-
dergoing AF ablation, ultrasound guidance reduced time, additional 
punctures, arterial puncture, and unsuccessful access. Although it 
increased first pass success, however, it was underpowered for the 
primary endpoint of major vascular access complications due to a 
lower than expected observed complication rate (S6.2.3). Similarly, 
a meta- analysis of nonrandomized controlled trials of ultrasound- vs 
fluoroscopy- or palpation- guided femoral arterial access found it was 
associated with a reduction in the number of attempts and vascular 
complications (S6.2.4). An RCT of ultrasound- vs fluoroscopic- guided 
retrograde femoral arterial access in patients undergoing angiogra-
phy or interventional procedures found that ultrasound guidance re-
duced the number of attempts, time to access, risk of venipuncture, 
and vascular complications (S6.2.5). 
 Synopsis 
 For VA ablation, standard percutaneous vascular access techniques 
are used. The choice of peripheral vascular access depends upon 
several factors, including the arrhythmia ' s SOO, the location of 
any substrate identified on pre- or intraprocedural imaging, the pa-
tient ' s anatomy, and the presence of peripheral vascular disease or 
venous occlusion or agenesis. LV access can be achieved through 
either retrograde transaortic or antegrade transseptal approaches, 
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depending on patient specifics and operator preference, the latter 
especially in the presence of mechanical aortic valve replacement 
or severe aortic or peripheral vascular disease. Although most areas 
of the endocardial LV can be accessed by either approach, the de-
gree of contact force can vary (eg, contact force was significantly 
higher transseptally in the mid- anteroseptum, mid- lateral, and api-
cal segments, and significantly higher with a retrograde approach in 
the basal- anteroseptum, basal- inferoseptum, basal- inferior, and the 
basal- lateral segments) (S6.2.7). If a retrograde access to the LV en-
docardium has been chosen, the use of long sheaths can be helpful 
in the presence of tortuosity of the iliac arteries or the distal aorta. 
Once vascular access has been obtained, heparin can be adminis-
tered to prevent clotting of the sheaths. 
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 6.3  |  Epicardial access 
 Recommendations for epicardial access for catheter ablation 
 COR  LOE  Recommendations 
 I  C- EO  1. In patients undergoing epicardial VT ablation, imaging of the epicardial coronary arteries by 
coronary arteriography or coronary CT angiogram prior to ablation is recommended to reduce 
the risk of arterial injury. 
 I  C- EO  2. In patients undergoing epicardial VT ablation via a percutaneous approach, provision for 
immediate echocardiography, blood transfusion, and onsite cardiothoracic surgical backup is 
recommended. 
 I  C- EO  3. In patients with prior cardiac surgery or pericardial adhesions for whom epicardial VT ablation 
via a percutaneous approach is considered, careful assessment of the risk/benefit ratio and 
alternative therapies such as surgical dissection are recommended. 
 I  C- EO  4. In patients undergoing epicardial VT ablation, pacing with high stimulus intensity from the 
ablation electrode to rule out diaphragmatic stimulation is recommended to avoid phrenic nerve 
injury. 
 Recommendation- specific supportive text 
 1 Inadvertent injury to an epicardial coronary artery can occur 
by puncture or laceration with a needle and is recognized by 
aspiration of arterial blood from the pericardial space. Arterial 
injury can require arterial stenting or surgical repair. In addi-
tion, application of RF current within 5 mm of an epicardial 
coronary artery can result in stenosis, spasm, or occlusion of 
the vessel (S6.3.4.1–S6.3.4.3). Because of the risk of arterial 
injury, imaging of the coronary arteries with arteriography is 
essential. The use of other coronary artery imaging techniques 
assumes that an adequate registration of imaging data has been 
accomplished. Hence, coronary angiography is the preferred 
technique. 
 2 Epicardial ablation requires considerable preparation prior to the 
procedure. Major complications occur in approximately 5% of epi-
cardial ablation procedures (S6.3.4.4). Unintended puncture of the 
RV can occur in up to 17% of cases (S6.3.4.4), although bleeding is 
usually self-limited provided that a sheath has not been introduced 
through the RV free wall. The patient ' s blood should be typed and 
cross-matched for immediate transfusion should significant bleed-
ing occur. Because bleeding within the pericardial space is common, 
intracardiac or transthoracic echocardiography should be immedi-
ately available. In addition, cardiothoracic surgical backup should 
be readily available. A potentially serious complication of percu-
taneous subxiphoid transpericardial puncture is laceration of the 
liver or intra-abdominal arteries. Thus, unexplained hypotension 
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should prompt imaging of these structures to evaluate possible 
intra-abdominal bleeding that could necessitate surgical repair. 
 3 The presence of pericardial adhesions can severely restrict the 
ability to maneuver a guidewire or catheter within the pericardial 
space. Thus, patients with prior cardiac surgery or a history of 
pericarditis can present significant challenges for epicardial abla-
tion. Although dissection of pericardial adhesions using a guide-
wire, deflectable catheter, or deflectable sheath can be useful to 
allow epicardial mapping (S6.3.4.5–S6.3.4.7), access to the entire 
epicardial surface might not be possible, and loculated pericar-
dial effusions that are challenging to drain percutaneously can 
occur in this setting. A planned surgical dissection of pericardial 
adhesions can allow dense adhesions to be safely lysed and allow 
epicardial ablation in selected cases (S6.3.4.8, S6.3.4.9). 
 4  Damage to the phrenic nerves can occur if the ablation electrode 
lies adjacent to these structures (S6.3.4.10) and can be minimized 
by pacing from the ablation electrode using high stimulus inten-
sity to identify phrenic nerve stimulation. If phrenic nerve stimu-
lation is observed during pacing, mechanical means to protect the 
phrenic nerve might be required, such as inflation of an intraperi-
cardial balloon (S6.3.4.11). 
 6.3.1  |  Background 
 VA can originate from the endocardium, the midmyocardium, or 
might involve the epicardium. The latter is particularly true for pa-
tients with NICMs, including idiopathic DCM (S6.3.4.12–S6.3.4.14), 
ARVC (S6.3.4.15–S6.3.4.19), myocarditis (S6.3.4.20), sarcoidosis 
(S6.3.4.21, S6.3.4.22), and ChD (S6.3.4.23–S6.3.4.26), as well as 
Brugada syndrome (S6.3.4.27–S6.3.4.30). Also, for patients with 
VT following MI, the arrhythmogenic substrate can be located 
in the midmyocardium or in the subepicardial region (S6.3.4.31–
S6.3.4.36). Finally, idiopathic VA can originate from the LV epi-
cardium (S6.3.4.37–S6.3.4.40). The percutaneous technique for 
epicardial mapping and ablation in patients with Chagas cardiomyo-
pathy (CCM) was described by Sosa et al in 1996 (S6.3.4.23). Since 
that initial description, epicardial ablation has become an important 
technique to effectively treat VA in a variety of diseases. Despite 
mapping data implicating an epicardial origin of postinfarction VT in 
up to one- third of cases (S6.3.4.31, S6.3.4.32, S6.3.4.41), epicardial 
ablation procedures are typically performed in only a small minority 
of patients post infarction. This is most likely due to the predominant 
endocardial involvement of postinfarction scarring and the three- 
dimensionality of reentry circuits that can include the endocardium. 
The anatomical distribution of post- MI epicardial VTs is highly as-
sociated with infarctions in the distribution of the left circumflex or 
right coronary arteries (S6.3.4.42). The prevalence of epicardial VT 
in patients with NICMs appears to be significantly higher than for 
VT following MI (S6.3.4.13, S6.3.4.43, S6.3.4.44). The site of scarring 
and slowed conduction supporting VT in NICM is most often located 
on the epicardial surface of the basal lateral LV (S6.3.4.43, S6.3.4.44). 
Thus, epicardial ablation is an important technique to address VT in a 
variety of SHDs, particularly in those with NICM. 
 6.3.2  |  Criteria suggesting epicardial substrate 
 Several factors suggest an epicardial substrate for VT, including 
the anatomical location of scar on CMR or CT imaging (S6.3.4.12, 
S6.3.4.45, S6.3.4.46), unipolar voltage mapping from the endocar-
dium (S6.3.4.14), and the lack of identifiable scarring or regions 
of slow conduction with endocardial mapping. The presence of a 
subepicardial or midmyocardial scar with contrast- enhanced CT or 
CMR is a valuable tool to identify potential epicardial substrates 
for VT and correlates with voltage mapping (S6.3.4.45, S6.3.4.46). 
Preprocedural imaging is therefore useful to select patients for 
epicardial mapping and ablation and to guide the operator to the 
regions of interest. The surface ECG (S6.3.4.47–S6.3.4.51) dur-
ing VT provides important clues to an epicardial origin, including 
the presence of a pseudo- delta wave (≥34 ms in duration) in the 
precordial leads, an intrinsicoid deflection to the peak of the R 
wave in lead V2 ≥ 85 ms, and an RS duration of ≥ 121 ms, although 
with limited specificity in patients with ICM (S6.3.4.47, S6.3.4.48). 
An ECG algorithm to identify epicardial VT in patients with NICM 
includes the absence of Q waves in the inferior leads with either 
pseudo- delta waves (≥75 ms), a maximum deflection index ≥ 0.59, 
or a Q wave in lead I (S6.3.4.51). The reported sensitivity and spec-
ificity of these criteria to predict successful epicardial ablation in 
NICM can exceed 90% (S6.3.4.51). ICE has also been shown to 
be useful for identifying epicardial scar as VT substrate with in-
creased echogenicity strongly correlating with the results of EAM 
(S6.3.4.52). Although the origin of epicardial VTs in patients with 
SHD depends on scar location, in patients without SHD, the SOO 
is often in close proximity to the mitral annulus and the LV sum-
mit. This area can be reached and mapped via the coronary ve-
nous system. Scar- related VTs are often beyond the reach of the 
coronary venous system and hence require different access to the 
pericardial space. 
 6.3.3  |  Epicardial access technique 
 Access to the epicardium is most often achieved with a subxiphoid, 
transpericardial puncture using either a 17–18- gauge, 6- inch Tuohy 
or similar needle with a beveled tip (S6.3.4.23), a thinner 21- gauge 
needle (S6.3.4.53), or a needle- in- needle technique (S6.3.4.53, 
S6.3.4.54). Three- quarters of the writing committee who perform 
epicardial access use a Tuohy needle, whereas the rest use the 
needle- in- needle technique. The latter approach uses a 7- cm, 18- 
gauge needle for support while puncturing the skin and subcuta-
neous tissues, while a longer (15–20- cm) 21- gauge micropuncture 
needle is inserted through the 18- gauge needle to puncture the pa-
rietal pericardium (S6.3.4.54). With either approach, small amounts 
of radiographic contrast are injected to confirm that the needle is 
within the pericardial space and that contrast moves freely within 
this space. A long guidewire is then advanced through the needle, 
with care taken to ensure that it moves freely to surround the car-
diac silhouette. The angle of entry into the pericardial space can be 
either anterior, in which case the guidewire travels superiorly over 
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the free wall of the RV, or posterior (inferior approach), in which the 
guidewire travels beneath the LV inferior wall before traveling su-
periorly toward the posterobasal LV. Transpericardial access should 
be guided by fluoroscopy, including a steep left anterior oblique or 
lateral view; the latter being useful for an anterior access. Once 
successful entry within the pericardial space is achieved, a sheath 
is advanced over the guidewire, allowing the mapping and ablation 
catheter to be moved across the epicardial surface. Percutaneous 
subxiphoid access to the pericardial space might not be feasible in 
patients with dense pericardial adhesions, including patients with 
prior cardiac surgery, previous pericarditis, or prior epicardial abla-
tion procedures (S6.3.4.5–S6.3.4.7). For these patients, a limited 
thoracotomy with a small subxiphoid or larger left lateral thora-
cotomy might be required that allows for manual lysis of adhesions 
and control of bleeding (S6.3.4.8, S6.3.4.9). Thus, a collaborative 
approach with a cardiothoracic surgeon and an electrophysiologist 
might be required for patients in whom a percutaneous approach 
is not feasible because of pericardial adhesions. The presence of 
less extensive pericardial adhesions can be approached percutane-
ously, using a deflectable catheter and sheath for adhesion lysis. 
Insufflation of carbon dioxide or contrast via intentional exit into 
the pericardial space from the right atrium (S6.3.4.55) or coronary 
venous system (S6.3.4.56) could have a role in determining the ex-
tent of adhesions in patients with prior cardiac surgery (S6.3.4.55) 
and can facilitate epicardial access; however, further study is 
required. 
 Catheter ablation on the epicardial surface is usually performed 
with irrigated RF current, though cryoablation has also been re-
ported (S6.3.4.57–S6.3.4.61). Use of a low irrigation flow rate 
(5- 7 mL/min) appears to result in a similar lesion size as the higher 
flows used in endocardial ablation while limiting intrapericardial fluid 
accumulation, which reduces lesion size (S6.3.4.58). Frequent aspi-
ration of irrigant is also important to prevent hemodynamic com-
promise. The use of contact force- sensing catheters can improve 
orientation of the ablation electrode so that current is directed to-
ward the epicardial surface rather than toward the parietal pericar-
dium (S6.3.4.62–S6.3.4.64). Epicardial fat >5 mm in thickness results 
in reduced electrogram voltage and increased stimulation thresh-
old, and could limit the depth of RF lesions (S6.3.4.41, S6.3.4.65–
S6.3.4.70). Epicardial fat is typically clustered along the course of 
epicardial coronary arteries, within the AV grooves, and along the 
free wall of the RV. 
 6.3.4  |  Epicardial access complications 
 The complications of epicardial ablation are important to consider. 
Major complications have been reported in approximately 5% of pa-
tients (S6.3.4.4, S6.3.4.44). The most common complication of epicar-
dial mapping and ablation is pericarditis, which can occur in over 20% 
of patients (S6.3.4.44). The use of systemic or intrapericardial steroids 
can decrease the risk and severity of pericarditis (see Section  10.1 ). 
Inadvertent puncture of the RV can occur in up to 17% of cases and 
usually results in self- limited bleeding of < 80 cc venous blood (S6.3.4.4). 
Avoidance of dual antiplatelet therapy can reduce periprocedural bleed-
ing during epicardial ablation. Inadvertent puncture of the RV can be 
recognized if a guidewire can be advanced into the pulmonary artery. 
This is managed by withdrawing the guidewire from the RV, withdraw-
ing the needle, and readvancing the wire until the pericardial space is 
accessed. If the needle enters and then exits the RV before pericardial 
access is obtained, a “through and through” puncture of the RV can re-
sult. In this case, hemodynamic collapse might occur only on removal 
of the sheath at the end of the procedure. This complication can be de-
tected when bleeding occurs after withdrawal of the pericardial sheath 
with the guide wire still in place. It is recommended to advance a guide 
wire into the pericardial space prior to sheath removal and to observe 
the puncture site for bleeding before removing the guide wire. Other 
complications of percutaneous, subxiphoid pericardial access include 
laceration or puncture of an epicardial coronary artery or vein (which 
could necessitate coronary stenting or surgical repair), RV pseudoaneu-
rysm, and coronary spasm (S6.3.4.71). RF current that is applied within 
5 mm of an epicardial coronary artery can produce occlusion, spasm, or 
stenosis of the artery (S6.3.4.1–S6.3.4.3). Because of this risk, imaging 
of the coronary arteries with arteriography or preprocedural CT angi-
ography is essential to accurately localize the ablation electrode rela-
tive to the position of the coronary arteries. The left phrenic nerve has 
a variable course and can be damaged by RF or cryoablation energy 
(S6.3.4.10, S6.3.4.11). Preprocedural imaging (see Section  5 ) has been 
particularly helpful to display the anatomical course of the coronary ar-
teries and the phrenic nerve, thereby preventing damage to these struc-
tures. Reliance on imaging only, however, might cause damage to these 
structures in case of imperfect image registration. Also, pacing from the 
ablation electrode with high stimulus intensity prior to ablation should 
be performed to exclude phrenic nerve stimulation. In some cases in 
which the ablation target is in close proximity to the phrenic nerve, a 
balloon or steerable catheter can be advanced into the pericardial space 
to shield the nerve from ablation- related injury (S6.3.4.10, S6.3.4.72); 
the use of air and fluid in the pericardial space has also been reported 
to reduce the risk of phrenic nerve damage (S6.3.4.11). Of note, the 
presence of air in the pericardial space can increase the defibrillation 
threshold, requiring emergent decompression or internal defibrillation if 
defibrillation is required (S6.3.4.73). 
 Esophageal injury can also occur if ablation is performed in the 
posterior LV (S6.3.4.74–S6.3.4.76). Although the exact mechanism 
and risk factors are unclear, esophageal temperature monitoring 
might be warranted before ablating near the esophagus. A significant 
complication of subxiphoid transpericardial access is bleeding within 
the abdomen from laceration of the liver or an intra- abdominal artery 
(S6.3.4.71). Unexplained hypotension during or after epicardial abla-
tion should lead to prompt investigation of possible intra- abdominal 
bleeding, which could require surgical repair. 
 Because of the many important complications that can occur 
with epicardial ablation, extensive experience with this procedure 
is required. Careful preprocedural planning is essential, including 
immediate access to echocardiography, imaging of the coronary ar-
teries, provision for immediate blood transfusion of cross- matched 
blood, and backup cardiothoracic and general surgical support. 
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 6.4  |  Intraprocedural hemodynamic support 
 Recommendations for catheter ablation of VA with mechanical HS 
 COR  LOE  Recommendations  References 
 I  C- EO  1. In select patients at risk of requiring HS, a decision to proceed 
with catheter ablation of VA should be made in collaboration 
with specialists in advanced heart failure management. 
 
 IIa  B- NR  2. In select patients, HS with a percutaneous VAD and extracor-
poreal membrane oxygenation during VT ablation can be useful 
to avoid acute hemodynamic deterioration. 
 S6.4.1–S6.4.7 
 IIb  B- NR  3. Mechanical HS may be considered in select cases to allow map-
ping and ablation of unstable VTs. 
 S6.4.1–S6.4.6 
 Recommendation- specific supportive text 
 1 In patients with VAs and severe comorbidities, incessant or 
recurrent VTs treated by multiple ICD shocks might cause end 
organ hypoperfusion and further deterioration in cardiac func-
tion (S6.4.8, S6.4.9). Planning for a VA ablation procedure, in 
which there is a significant risk that it will be complicated by 
hemodynamic deterioration, should involve specialists in heart 
failure. The patient ' s values regarding the various temporary and 
permanent HS options and their feasibility should be considered. 
 2 Data about strategies for HS during VT ablation are available 
from single and multicenter, nonrandomized, retrospective, 
and observational trials, which have demonstrated feasibility 
and safety (S6.4.1–S6.4.6). Mapping of nontolerated VTs can 
be performed for longer periods of time when HS with either 
percutaneous left ventricular assist device (pLVAD) (Tandem 
Heart, CardiacAssist, Pittsburgh, PA; and Impella, Abiomed, 
Danvers, MA) or extracorporeal membrane oxygenation is per-
formed as opposed to no support or intra-aortic balloon pump 
(IABP) (S6.4.1, S6.4.2). A large retrospective multicenter report, 
however, has demonstrated that the use of HS was associated 
with higher acute ablation failure rates, increased periproce-
dural complications, higher mortality, and a higher rate of VT 
recurrence (S6.4.6). It is possible that HS was used in patients 
with more severe disease in this study, and outcome data were 
similar between the HS and no HS groups compared with pa-
tients with severely compromised EF (≤20%) and advanced heart 
failure (NYHA class III and IV). Hence, the use of HS in these pa-
tients needs to be carefully considered. Of note, data supporting 
HS as a bailout strategy during or right after VT ablation are poor 
and do not demonstrate a benefit for procedural outcomes and 
survival (S6.4.3, S6.4.5, S6.4.7). 
 3 The benefit of HS to allow mapping of unstable VTs needs to be 
weighed against the potential detrimental effects of HS, depend-
ing on the type of support that is used, including vascular damage 
due to large-bore venous and arterial access sites, among others 
(S6.4.1). Prevention of hemodynamic deterioration during the ab-
lation procedure by cautious use of cardiodepressive medications 
such as propofol could obviate the necessity for HS; also, the use 
of general anesthesia has been identified as a factor associated 
with hemodynamic deterioration and needs to be carefully con-
sidered in patients with severely impaired myocardial function. 
Adequate patient selection using risk assessment algorithms (see 
Section  5 ) could help to identify patients for whom HS might be 
beneficial. 
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 6.5  |  Intraprocedural anticoagulation 
 Recommendations for intraprocedural anticoagulation 
 COR  LOE  Recommendations  References 
 I  B- NR  1. In patients undergoing endocardial LV catheter mapping and/or ablation, intraprocedural 
systemic anticoagulation with intravenous heparin is recommended. 
 S6.5.1–S6.5.6 
 I  C- EO  2. In patients undergoing RV endocardial mapping and/or ablation who are considered high risk 
for thromboembolism, intraprocedural systemic anticoagulation with intravenous heparin is 
recommended. 
 
 IIa  C- LD  3. In patients undergoing epicardial access after systemic heparinization, reversal of heparin with 
protamine is reasonable. 
 S6.5.7, S6.5.8 
 Recommendation- specific supportive text 
 1  Catheter ablation of VA can be associated with risk of thrombus 
formation and thromboembolism. Although the individual risk 
varies with type and site of ablation and patient factors, the 
risk of clinically apparent stroke or thromboembolism in patients 
with SHD undergoing VT ablation in RCTs has ranged from 
0% to 1.9% (S6.5.1–S6.5.5) and is lower in patients without 
SHD (S6.5.9). A small study with diffusion-weighted magnetic 
resonance brain imaging demonstrated the presence of a new 
brain lesion in 58% of patients undergoing LV endocardial ab-
lation (S6.5.10). These lesions were detected in the absence 
of clinically apparent stroke; no brain lesion was identified in 
patients undergoing RV ablation. Although systemic heparinization 
has been routine for LV endocardial ablation since the earliest 
large-scale investigations, few studies have compared different 
approaches to anticoagulation before, during, or after the VT 
ablation procedure (S6.5.6, S6.5.7) (Table 9). Systemic anticoag-
ulation with heparin is recommended for all procedures that last 
more than several minutes involving left heart catheterization. 
Intraprocedural anticoagulation schemes differ between centers. 
Unfractionated heparin is commonly administered after sheath 
insertion as an initial bolus (empirical dose 5000–10,000 IU or 
50–100 IU/kg) followed by intermittent boli and/or continuous 
infusion to maintain a target activated clotting time (ACT) longer 
than 250-350 seconds (S6.5.4, S6.5.6–S6.5.8, S6.5.10, S6.5.11). 
In a survey regarding intraprocedural anticoagulation among the 
writing committee members, for idiopathic VA, 48% of the re-
sponders use ACT levels longer than 250 seconds, 39% longer 
than 300 seconds, and 13% longer than 350 seconds. For patients 
with SHD, 25% of the committee members use an ACT target 
of 250 seconds, 58% use a target longer than 300 seconds, 
and 17% use a target longer than 350 seconds. The ACT level 
should be checked at 15-minute intervals until therapeutic anti-
coagulation is achieved, and then at 15- to 30-minute intervals 
for the duration of the procedure. Approximately 90% of the 
surveyed committee members routinely check for ACT during VT 
ablation procedures. Most members use either a Hemochron ACT 
(Instrumentation Laboratory, Bedford, MA) or an i-STAT (Abbott 
Point of Care Inc., Princeton, NJ) device for ACT monitoring. For 
transseptal access, heparin should be administered prior to or 
immediately following the transseptal puncture. More than 70% 
of the writing committee members surveyed routinely administer 
heparin before the transseptal puncture, and approximately 20% 
use a higher target ACT when a transseptal approach is used. 
Among the writing committee members, 85% use continuous 
flushing for sheaths, especially if a transseptal approach is used. 
     |  387CRONIN  ET AL .
Heparin infusion can be discontinued once all catheters are re-
moved from left sided chambers. In the event of significant 
persistent bleeding or cardiac tamponade, protamine should be 
administered to reverse heparin. In patients with a history of 
heparin-induced thrombocytopenia or allergy, a direct thrombin 
inhibitor, such as bivalirudin or argatroban, can be considered as 
an alternative for intraprocedural anticoagulation; however, limited 
experience exists in patients undergoing VA ablation (S6.5.11). 
 2 During RV endocardial mapping, systemic anticoagulation with 
heparin is not necessary unless other factors are present that in-
crease the thromboembolic risk. The use of heparin can, however, 
prevent deep venous thrombosis or pulmonary embolism, espe-
cially when a prolonged procedure with multiple venous catheters 
and extensive ablation is anticipated. Similarly, patients with a 
history of deep venous thrombosis, pulmonary embolism, hyper-
coagulable state (eg, factor V Leiden), right-to-left cardiac shunt, 
severe RV dilatation, and advanced heart failure should undergo 
systemic anticoagulation. Among the writing committee mem-
bers, 65% reported routine use of heparin for VT ablation proce-
dures even in the absence of risk factors for thromboembolism. 
 3 Anticoagulation is not required solely for epicardial mapping and/
or ablation. If LV mapping is planned, epicardial access can be ob-
tained prior to LV instrumentation and systemic anticoagulation 
(see Section  6.3 ). When epicardial access is required after thera-
peutic heparinization, reversal of heparin anticoagulation with 
protamine is typically performed (S6.5.12, S6.5.13). Two small 
studies reported epicardial access in fully anticoagulated patients 
without a major increase in risk of bleeding complications (S6.5.14, 
S6.5.15). When the writing committee was surveyed about epicar-
dial access after full heparinization, half of the writing committee 
would administer protamine for heparin reversal even when ex-
tensive endocardial ablation had been performed, 20% would ad-
minister protamine only after limited LV endocardial ablation, and 
another 20% of the writing committee members would terminate 
the procedure and schedule an epicardial ablation as a separate 
procedure. 
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 6.6  |  Antibiotic prophylaxis 
 Prophylactic antibiotics are not generally indicated for sterile 
procedures such as VA ablation (S6.6.1). However, patients with 
ICDs undergoing VA ablation, in which catheters might be in di-
rect contact with the intravascular leads, could present a special 
circumstance. No data exist to support this practice, nor is a spe-
cific antibiotic preferred over another. Approximately 40% of the 
writing committee members administer prophylactic antibiotics to 
patients with a pacemaker or ICD undergoing VA ablation, whereas 
a quarter never do, and the remaining do in select patients based 
on potential risk factors for device infection, such as a prosthetic 
valve or use of a Foley catheter. Thirty percent of the writing com-
mittee use antibiotic prophylaxis for patients undergoing epicardial 
access. 
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 6.7  |  Fluid balance 
 Careful monitoring of fluid balance is essential in patients undergo-
ing VA ablation, especially given that many have impaired ventricular 
function, putting them at risk of volume overload, and they might 
have renal impairment. Various irrigated catheters are currently in 
use, allowing for different flow rates, and hence, different volume 
loads. A urinary catheter might not be required for cases performed 
under sedation when the anticipated procedure duration is short, 
but for longer ablation procedures, it should be considered. This per-
mits more precise assessment of the fluid balance, which becomes 
particularly important for patients in whom irrigated- tip RF cath-
eters are used. However, urinary catheters can cause urinary tract 
infection and bleeding; thus, a sterile technique is essential during 
insertion and after- care. After measurement of volume infused and 
eliminated (“ins and outs”), an intravenous loop diuretic should be 
considered, especially with a large infused volume, a significantly 
positive procedural fluid balance, and impaired LV function. 
 7    |   ELEC TROPHYSIOLOGIC AL TESTING 
 PES is a key component of the VT ablation procedure, allowing for 
mapping of induced arrhythmias. In addition, a baseline assessment 
of arrhythmia induction can be useful by comparison for the even-
tual assessment of procedural outcome (see Section  9.17 ). Given the 
majority of idiopathic VAs are caused by cAMP- mediated delayed 
afterdepolarizations, they can be provoked with catecholamine infu-
sion and burst pacing (S7.1, S7.2). Although purely substrate- based 
ablation (without arrhythmia induction) can be performed, many 
laboratories perform programmed stimulation in select patients 
with reentrant scar- related VT for several reasons: 1) to perform ac-
tivation and entrainment mapping in tolerated VT; 2) to identify the 
clinical VT morphologies to better focus substrate- based ablation; 
and 3) to limit the extent of ablation delivery. Although “legacy” pro-
tocols for programmed stimulation have been proposed (S7.3, S7.4), 
most laboratories that perform programmed stimulation would hold 
to a minimal standard of at least 1 site and 2 drive CLs, with the 
delivery of 1- 4 ventricular extrastimuli at coupling intervals limited 
by local refractoriness or a minimum of 180- 200 ms. Given known 
site dependence for induction of reentrant VT, additional sites of 
stimulation (particularly the LV) can be useful. The use of long- short 
sequences during programmed stimulation has been particularly 
helpful to induce BBRVT that can easily be addressed with an abla-
tion procedure. 
 The most important objective of the ablation procedure is to 
identify and eliminate the clinical VT. Prior studies have demon-
strated that programmed stimulation results in VT induction in 
93%–95% of patients with healed MI and a history of sustained 
VT (S7.4, S7.5). Importantly, these studies were concerned with 
induction of any VT, but not necessarily the clinical VTs. Limited 
data are available to address the question of how reliable PES 
is in reproducing all clinically pertinent VT morphologies. Given 
that 12- lead ECGs of the clinical VT are frequently not avail-
able, ICD electrograms have been described to reliably identify 
the clinical VT when induced in the electrophysiology lab (S7.6). 
Unfortunately, the clinical VT is not always inducible: 7%- 24% 
of patients are completely noninducible (S7.7–S7.9), and the 
clinical VT cannot be induced in another 13%- 30% of patients 
(S7.6, S7.7, S7.10). Furthermore, induction of VTs that have not 
been previously documented occurs frequently, depending on 
whether the PES protocol is completed, until all extrastimuli 
are delivered from multiple sites and refractoriness has been 
reached. Elimination of all inducible VTs has been found to re-
sult in improved outcomes (S7.11, S7.12); hence, this is the ideal 
objective of the ablation procedure. Inducibility of nonclinical 
VTs post ablation has been found to be associated with a high 
VT recurrence rate (S7.13). Risks and benefits will need to be 
weighed, however, given it might take performance of longer 
procedures to reach this objective. A major concern about the 
reliability of PES is that VTs often recur even when patients 
have been rendered completely noninducible post ablation 
(S7.12). Edema formation in a critical area can render a targeted 
VT temporarily noninducible; however, incomplete lesions can 
also form a new or modified substrate, generating new VTs. The 
former can be addressed with NIPS a few days after the ablation 
procedure, which has been found to predict VT recurrence in 
patients who were noninducible at the conclusion of the abla-
tion procedure (S7.14). PES is typically performed at the onset 
of the procedure, but it might need to be deferred to the con-
clusion of the procedure if there is concern about the patient ' s 
hemodynamic status. 
 Despite there being less complete characterization of the effec-
tiveness of PES to guide ablation of VT in nonischemic substrates, 
noninducibility has also been demonstrated to result in superior out-
comes post ablation (S7.15). Only limited data and anecdotal reports 
exist on the use of other agents (aminophylline, epinephrine, cal-
cium, dobutamine, caffeine) to induce idiopathic arrhythmias when 
isoproterenol and burst pacing fail (S7.16). 
 A survey of the writing committee is summarized here to give 
some perspective. For induction of VT in SHD, all the members 
routinely stimulate from the RV apex, 66% from the RVOT and 
59% from the LV if LV access has already been obtained. Up to 3 
extrastimuli are routinely performed in 76%, and up to 4 in 24%. For 
induction of idiopathic arrhythmias, the majority of the committee 
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uses isoproterenol frequently (93%), followed by epinephrine (21%), 
phenylephrine (14%), atropine (11%), and calcium (7%). In addition, 
some members of the committee at least considered dobutamine 
and caffeine. 
 At this point, PES remains a key tool of the mapping and abla-
tion procedure. The use of PES, however, often needs to be comple-
mented by alternative strategies, given its many limitations. 
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 8    |   MAPPING AND IMAGING TECHNIQUES 
 8.1  |  Mapping catheters 
 8.1.1  |  Multielectrode mapping 
 The use of multielectrode mapping catheters has gained popularity 
over the past several years with the introduction of mapping sys-
tems capable of acquiring data from multiple sites for each beat. 
These catheters offer several advantages, particularly in respect to 
mapping density, resolution, and speed. The ability to record elec-
trograms from multiple sites at each beat increases the number of 
data points and can shorten the duration of mapping. 
 Multielectrode catheters often use small electrodes with 
short interelectrode spacing, thereby increasing mapping resolu-
tion, which can be advantageous for substrate mapping (S8.1.1.1–
S8.1.1.3), facilitating identification of surviving myocardial bundles 
within heterogeneous scar tissue that may escape detection when 
mapping with standard ablation catheters with larger electrodes 
and spacing is performed (S8.1.1.3–S8.1.1.5). Multielectrode cathe-
ters allow pacing from multiple electrodes positioned in and around 
areas of scar. The increased current density during pacing from 
smaller electrodes can achieve capture at relatively low pacing stim-
ulus strength (S8.1.1.1). In addition, pacing from one site while re-
cording from surrounding sites allows investigation of propagation 
in multiple directions that can identify anisotropy and areas prone to 
slow conduction and/or block (S8.1.1.6, S8.1.1.7). These catheters 
can also be useful for activation mapping during VT, given they allow 
rapid acquisition of multiple sites at high spatial resolution that can 
facilitate identification of a reentry isthmus or VT focus (S8.1.1.5). 
 Currently, several multielectrode catheters are available. The 
Pentaray catheter (Biosense Webster, Diamond Bar, CA) is shaped 
like a flower and has 5 splines, each with 4 electrodes (a total of 20 
electrodes), which can be used with the CARTO EAM system. This 
catheter frequently causes ectopic beats in areas of contracting myo-
cardium, and spatial sampling is nonuniform due to variable spread 
of the splines and limited contact with the myocardium. A linear 
catheter with 20 electrodes is also available for use with this map-
ping system. This catheter has uniform spatial spread of electrodes 
and a relatively large area of contact, although during endocardial 
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mapping the proximal electrodes are often not in contact. It is well 
suited for mapping of the epicardial surface. A duodecapolar cathe-
ter with tighter interelectrode spacing (Livewire, Abbott Laboratories, 
Abbott Park, IL) has been used to map endocardial and epicardial ven-
tricular surfaces in vivo and has been validated against histology in 
an animal model (S8.1.1.8, S8.1.1.9). The Advisor HD Grid catheter 
(Abbott Laboratories, Abbott Park, IL) is a novel 4- by- 4 unipolar elec-
trode array with 1- mm (diameter) electrodes, equidistantly spaced 3 
mm apart from each other, which can be used in conjunction with 
the EnSite Precision system (S8.1.1.10). A potential advantage is the 
uniform spatial sampling; however, collection of ventricular mapping 
data in humans in vivo is currently not available. The fourth catheter 
is a small basket catheter with 64 very small electrodes arranged on 
8 splines that can be used with the Rhythmia EAM system (Orion, 
Boston Scientific, Marlborough, MA) (S8.1.1.5, S8.1.1.11). This cath-
eter has a low noise level, facilitating recording of low amplitude sig-
nals. However, the basket is not well suited for mapping the papillary 
muscles, the RV, or the epicardium. 
 Common limitations of multielectrode mapping catheters include 
mechanical trauma with frequent ectopy, transient injury of the su-
perficial conduction bundles, limited maneuverability, lack of tissue 
contact information, and the potential for thrombus formation with 
the need for careful anticoagulation. In addition, the potential benefit 
of mapping with smaller electrodes in patients with NICM and high 
prevalence of intramyocardial substrate is unclear. Currently, ablation 
is performed with a second catheter, necessitating integration of the 
anatomy and physiology acquired with the multielectrode catheter in 
a mapping system that can also support data acquisition with an abla-
tion catheter. Newer catheter designs integrating very small electrodes 
positioned at the circumference of a standard ablation catheter could 
allow combining high- resolution mapping with ablation on a single 
catheter (S8.1.1.2). 
 References 
 S8.1.1.1.   Tschabrunn CM, Roujol S, Dorman NC, Nezafat R, Josephson 
ME, Anter E. High- resolution mapping of ventricular scar: 
comparison between single and multielectrode catheters. 
 Circ Arrhythm Electrophysiol. 2016;9:e003841. 
 S8.1.1.2.   Leshem E, Tschabrunn CM, Jang J, et al. High- resolution 
mapping of ventricular scar: evaluation of a novel integrated 
multielectrode mapping and ablation catheter.  JACC Clin 
Electrophysiol. 2017;3:220–31. 
 S8.1.1.3.   Berte B, Relan J, Sacher F, et al. Impact of electrode type 
on mapping of scar- related VT.  J Cardiovasc Electrophysiol. 
2015;26:1213–23. 
 S8.1.1.4.   Anter E, Tschabrunn CM, Josephson ME. High- resolution 
mapping of scar- related atrial arrhythmias using smaller 
electrodes with closer interelectrode spacing.  Circ Arrhythm 
Electrophysiol. 2015;8:537–45. 
 S8.1.1.5.   Anter E, Tschabrunn CM, Buxton AE, Josephson ME. High- 
resolution mapping of postinfarction reentrant ventricular 
tachycardia: electrophysiological characterization of the cir-
cuit.  Circulation. 2016;134:314–27. 
 S8.1.1.6.   Josephson ME, Anter E. Substrate mapping for ventricu-
lar tachycardia: assumptions and misconceptions.  JACC Clin 
Electrophysiol. 2015; 1:341–52. 
 S8.1.1.7.   Ciaccio EJ, Coromilas J, Wit AL, Peters NS, Garan H. 
Formation of reentrant circuits in the mid- myocardial infarct 
border zone. Comput Biol Med 2016;71:205–13. 
 S8.1.1.8.   Tung R, Nakahara S, Maccabelli G, et al. Ultra high- density 
multipolar mapping with double ventricular access: a novel 
technique for ablation of ventricular tachycardia.  J Cardiovasc 
Electrophysiol. 2011;22:49–56. 
 S8.1.1.9.   Tung R, Nakahara S, Ramirez R, et al. Accuracy of combined en-
docardial and epicardial electroanatomic mapping of a reperfused 
porcine infarct model: a comparison of electrofield and mag-
netic systems with histopathologic correlation.  Heart Rhythm. 
2011;8:439–47. 
 S8.1.1.10.   Magtibay K, Massé S, Asta J, et al. Physiological assessment 
of ventricular myocardial voltage using omnipolar electro-
grams.  J Am Heart Assoc. 2017;6:e006447. 
 S8.1.1.11.   Viswanathan K, Mantziari L, Butcher C, et al. Evaluation of a 
novel high- resolutionmapping system for catheter ablation of 
ventricular arrhythmias.  Heart Rhythm. 2017;14:176–83. 
 8.2  |  Activation mapping 
 Mapping of the electrical activation sequence during VT is a valuable 
mapping strategy for patients with hemodynamically stable mono-
morphic tachycardia (S8.2.1). It can localize the origin for focal tach-
ycardias and potentially reentry circuits, depending on their anatomy 
(S8.2.2). 
 Activation mapping is performed by recording of local electro-
grams from multiple sites during VT and is facilitated by the use of 3D 
mapping systems, allowing display of the position and relative timing 
on the EAM system. For focal VTs, the earliest site of activation iden-
tifies the SOO and is the target of ablation. At this site, the local bipo-
lar electrogram precedes the QRS onset, and the unipolar signal (with 
high- pass filter setting <1 Hz) demonstrates a QS configuration, con-
sistent with a centrifugal spread of activation away from the SOO. In 
intramural focal tachycardias, the bipolar electrogram often inscribes 
with or after the onset of the QRS and the unipolar electrogram 
demonstrates an rS configuration, consistent with an initial activation 
propagating toward the recording electrode. In a true intramyocardial 
origin, mapping from all opposing surfaces demonstrate relatively late 
bipolar activations with rS unipolar configurations. 
 The most common VT mechanism in patients with SHD is scar- 
related reentry with continuous excitation of the circuit throughout 
the tachycardia CL (S8.2.1). The QRS onset typically occurs when 
the impulse reaches the exit from the scar to activate the contractile 
myocardium (S8.2.3). In “exit sites,” electrograms can be fractionated 
and immediately precede the onset of the QRS complex. Ablation at 
exit sites can terminate the tachycardia; however, it can also result 
in a change of the tachycardia configuration and/or CL in which the 
diastolic pathway exits at different locations from the scar (S8.2.4). 
Ablation of the diastolic pathway “isthmus” is therefore a more desir-
able target, given it can eliminate the machinery required for reentry. 
Electrograms at isthmus sites occur earlier during diastole, are typ-
ically of very low- voltage amplitude (<0.5 mV), and can have multi-
ple potentials. Mapping of these circuits with multielectrode mapping 
catheters can be helpful for identifying low amplitude signals, for dif-
ferentiating near- field from far- field potentials, and for shortening the 
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time required for mapping (see Section 8.1 ). It should be noted that 
the mere presence of diastolic potentials does not suggest an isth-
mus location. These can also be recorded in dead- end pathways and 
adjacent bystanders unrelated to the circuit. It is therefore important 
to carefully review and interpret the activation map in order to under-
stand the location and complexity of the circuit. In principle, an activa-
tion map of a macroreentrant VT circuit should demonstrate distinct 
entrance, isthmus, and exit sites that all serve as obligatory parts of 
the circuit, such that it cannot continue without all of these elements. 
However, scar- related circuits (particularly in patients with a nonisch-
emic substrate) can have intramural component(s) that might not be 
recorded on the surface. These usually exhibit a “gap” in the activation 
sequence, such that part of the circuit is “concealed” from the surface 
map, residing deep in the myocardium or on the opposing surface. 
 Activation mapping of scar- related VTs can be highly valuable 
for identifying the isthmus. However, it is often limited to patients 
with hemodynamically stable VT. In patients with less tolerated VTs, 
limited activation mapping can be performed in conjunction with 
substrate, entrainment, and/or pace mapping. The utility of HS to 
allow extended mapping during VT can improve the acute proce-
dural end- point of noninducibility; however, it has limited impact on 
the long- term outcome (see Section  6.4 ) and has not reduced VT 
recurrence (S8.2.5, S8.2.6). 
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 8.3  |  Entrainment mapping 
 8.3.1  |  Entrainment mapping: overview 
 Entrainment is a pacing maneuver that helps to distinguish reentrant 
from nonreentrant arrhythmias and can be used as a mapping tool 
to target ablation to critical parts of the reentry circuit. Entrainment 
involves the continuous resetting of a reentry circuit during pac-
ing at sites that are either within or outside the reentry circuit. This 
technique is used to identify critical sites of the arrhythmia circuit, 
through the analysis of the QRS morphology, the measured inter-
vals, and the recorded electrograms (S8.3.2.1) (Figures  5 and  6 ):
 1 The QRS configuration during entrainment provides information 
about whether the pacing site is within or outside the pro-
tected zone of the reentry circuit. With the pacing site being 
located outside the reentry circuit, during entrainment, the 
stimulated wavefronts that propagate out from the pacing site 
collide with the orthodromically propagating wavefront of the 
reentry circuit and fuse; therefore, the QRS complex is due to 
the fusion of wavefronts propagating directly away from the 
pacing site with those emerging from the tachycardia circuit 
(classic entrainment). During pacing from within a protected 
region in or near the reentry circuit, pacing entrains VT with-
out changing the QRS configuration (concealed entrainment or 
entrainment with concealed fusion) (S8.3.2.2–S8.3.2.4). 
 2 The stimulus-QRS interval during entrainment with concealed fu-
sion: Entrainment with concealed fusion indicates that the pacing 
site is within a protected region of the reentry circuit, and can be 
located in the common pathway of the reentry circuit (also re-
ferred to as a critical isthmus or channel), or in a bystander site 
that communicates with a critical isthmus. If pacing is performed 
from a site in the circuit, the stimulus-QRS interval should be 
equal to the electrogram-QRS interval during VT. On the other 
hand, if stimulation is performed from a bystander site, the stimu-
lus-QRS interval is longer than the electrogram-QRS interval dur-
ing tachycardia (S8.3.2.5, S8.3.2.6). A difference in stimulus-QRS 
and electrogram-QRS up to 30 ms was superior to other criteria 
for distinguishing bystander sites from critical sites in one study 
(S8.3.2.7). The stimulus-QRS interval indicates the conduction 
time from the pacing site to the VT exit site (S8.3.2.8). Similarly, 
the stimulus-QRS/VT CL ratio is a reflection of the pacing site 
location within the critical zone of the reentry circuit. The exit site 
is defined as a stimulus-QRS/VT CL ratio <0.3, the common path-
way and entry sites have a stimulus-QRS/VT CL ratio 0.3-0.7, and 
the inner loop sites have a stimulus-QRS/VT CL ratio >0.7. There 
is, however, an important exception to keep in mind: a longer 
stimulus-QRS/VT CL ratio of >0.7 can occur at critical sites within 
the reentry circuit. Discrete potentials located in electrical systole 
rather than diastole that match with the stimulus-QRS interval are 
present in these situations and reflect that the catheter is within 
the VT entrance zone (S8.3.2.9). 
 3 The postpacing interval (PPI): The PPI is also an indication of the 
proximity of the pacing site to the reentry circuit (S8.3.2.6); the PPI 
measures the interval from the pacing stimulus to the following 
nonstimulated depolarization recorded at the pacing site. The PPI 
can be used during entrainment to verify whether the pacing site is 
within the circuit or is in a bystander area. At a site with concealed 
entrainment, a PPI that matches the VT CL (±30 ms) is consistent 
with a site where delivery of RF energy is likely to terminate VT; a 
PPI >30 ms is often an adjacent bystander (S8.3.2.1) when ablation 
fails to terminate VT. The PPI includes the conduction time for a 
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full revolution of the propagating wavefront through the reentry 
circuit. Several factors can impact PPI accuracy. A faster pacing 
rate can result in slower conduction and a prolongation of the PPI. 
The measurement of the PPI assumes that the recorded electro-
gram indicates a depolarization at the pacing site. Electrograms 
generated by remote tissue represent far-field electrograms and 
 F I G U R E  6     Pacing from the protected 
isthmus of a  VT circuit. Entrainment 
mapping during  VT . The  VT  CL is 620 ms, 
and pacing is performed at a  CL of 
580 ms. A low- voltage electrogram is 
located in diastole on the recordings of 
the ablation catheter (Map). The stimulus- 
 QRS interval is 230 ms and matches 
with the electrogram- QRS interval. The 
postpacing interval ( PPI ) is equal to the  VT 
 CL . The stimulus- QRS / VT  CL ratio is 0.37, 
indicating that the catheter is located in 
the common pathway.  CL = cycle length; 
 PPI = postpacing interval;  VT = ventricular 
tachycardia 
 F I G U R E  5     Entrainment responses from components of reentrant  VT circuit.  CL = cycle length;  PPI = postpacing interval;  VT = ventricular 
tachycardia 
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can result in erroneous measurements of the PPI. Distinction of 
local electrograms from far-field electrograms is hence key to ac-
curately measuring the PPI (S8.3.2.10). 
 Both the PPI and the comparison of the stimulus- QRS interval 
to the electrogram intervals are methods to differentiate bystander 
sites from critical ablation sites. The method using stimulus- QRS 
and electrogram- QRS interval assesses a smaller part of the reen-
try circuit (pacing site to exit site); thus, it could be less susceptible 
to error than the PPI that assesses a full revolution of the reentry 
circuit. 
 Entrainment mapping is most easily used to select ablation sites 
during mapping of hemodynamically tolerated VTs and is particularly 
useful in patients with incessant VTs (S8.3.2.4). Unfortunately, the 
majority of inducible VTs in patients with SHD are not hemodynam-
ically tolerated, and entrainment mapping can only be used for short 
time periods to confirm that a particular site is critical. 
 8.3.2  |  How to perform entrainment mapping 
 Ideally, the VT is hemodynamically tolerated in order to perform entrain-
ment mapping. Furthermore, the VT must have regular RR intervals to 
prevent erroneous PPI measurements. Pacing is performed at a CL faster 
than the VT, with care taken to ensure that all QRS complexes and elec-
trograms are accelerated to the pacing rate. Pacing at faster rates can fa-
cilitate detection of QRS fusion; however, it can further slow conduction 
in the circuit, resulting in termination of VT or resulting in acceleration 
to a different VT. A pacing interval 10–50 ms shorter than the VT CL is 
frequently used for pacing. Pacing can be performed either in a unipolar 
manner from the tip electrode or in a bipolar manner from the two dis-
tal electrodes. Theoretically, the optimal pacing output is slightly above 
threshold to limit capture to the tissue immediately beneath the distal 
electrode, which is also the source of the near- field signal. Determining 
threshold at each site is not practical, however, and some centers use 
an initial output of 10 mA and a pulse width of 2 ms, which can increase 
until capture is achieved or which can decrease if capture of a large area 
is suspected (S8.3.2.11). Pacing for a sufficient duration to be certain 
that reliable capture is achieved is important. 
 Limitations of entrainment mapping are as follows:
 1  Inducibility of sustained and stable VT is required if pacing 
maneuvers are to be attempted. 
 2 Pacing during VT can either interrupt, accelerate, or modify the 
ongoing VT. 
 3 AADs can decrease conduction velocity during pacing, increasing 
the postpacing and stimulus-QRS intervals (S8.3.2.5). 
 4  Electrograms indicating local depolarization need to be distin-
guished from far-field signals, and this is subject to error in re-
gions of fractionated, complex electrograms (S8.3.2.1, S8.3.2.2, 
S8.3.2.6, S8.3.2.12). 
 5 Incomplete ablation can create areas where conduction slows or 
blocks during pacing, creating misleading, increased postpacing 
and stimulus-QRS intervals. 
 The advantage of entrainment mapping over a substrate mapping ap-
proach is that individual VTs can be reliably and permanently elimi-
nated with few RF ablation lesions when reentry circuit targets are 
identified (S8.3.2.7, S8.3.2.13). An approach targeting only VT exit 
sites in the border zone based on QRS morphology and presystolic 
activity in VT, for example, can fail to eliminate VT if the exit site is 
deep to the endocardium. Entrainment mapping can potentially iden-
tify critical components of the reentry circuit other than the exit site 
that might be within the reach of the ablation catheter. Unfortunately, 
most patients with heart disease have multiple VTs that are not he-
modynamically tolerated; hence, entrainment mapping as the only 
mapping technique is insufficient to eliminate most of the VTs en-
countered in a given patient. In the modern era of VT ablation in the 
setting of complex VAs and multiple etiologies with different sub-
strates, in which 3D mapping is routinely adopted, entrainment map-
ping is only one component of the ablation strategy. Ablation guided 
by entrainment and activation mapping of hemodynamically tolerated 
VT has not been shown to be superior to substrate- based ablation 
(S8.3.2.14). Therefore, entrainment mapping is typically combined 
with substrate mapping in patients with VT associated with scars and 
SHD. 
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 8.4  |  Pace mapping 
 Pace mapping is a technique used to locate the origin of a PVC or 
VT by stimulating the myocardium to reproduce the clinical 12- 
lead morphology in the absence of VT; it is particularly useful if 
the targeted arrhythmia is difficult to induce or is hemodynami-
cally unstable. The optimal site should exactly match the tachycar-
dia QRS, including individual notches as well as major deflections. 
Comparison of the 12- lead ECG during pace mapping and VT is usu-
ally expressed with a scale from 0 to 12; however, computer- assisted 
comparison allows its quantification (S8.4.1). Manufacturer- specific 
algorithms (Labsystem Pro, Boston Scientific, Arden Hills, MN [for-
merly Bard]; PaSo CARTO module, Biosense Webster, Diamond 
Bar, CA; Rhythmia, Boston Scientific, Marlborough, MA; and EnSite 
Precision, Abbott Laboratories, Abbott Park, IL) exist that use 
template- matching algorithms to generate a correlation coefficient 
between VT morphology and pace maps (S8.4.2, S8.4.3). These algo-
rithms allow computational comparisons between pace maps; how-
ever, careful external validation is currently lacking. 
 Pace mapping indicates the location of the origin of focal VAs 
(S8.4.4), although activation sequence mapping is more accurate 
(S8.4.5). Furthermore, pace mapping is used to identify the exit of 
the VT in reentrant VTs (S8.4.6–S8.4.8). Critical sites of the reen-
try circuit and regions of slow conduction can be identified based 
on pace mapping and electrogram characteristics (S8.4.9). Pacing in 
noncritical areas adjacent to the exit can generate an adequate pace 
match that is similar in morphology to a pace map from the VT exit. 
On the other hand, pacing at sites close to the entrance of the reen-
try circuit during sinus rhythm often generates markedly different 
QRS complexes, given the stimulated wavefront propagates away 
from the pacing site via paths that are blocked during VT (S8.4.7, 
S8.4.10, S8.4.11). Thus, sites without matching pace maps could still 
be critical for the reentry circuit, and identification of a transition 
from an adequate to a poor matching pace map might indicate the 
isthmus orientation (S8.4.3). Importantly, the pacing rate has been 
reported to alter the QRS morphology; therefore, a pacing rate close 
to the VT rate should be used (S8.4.12). 
 Within scar, the spatial resolution of pace mapping is hetero-
geneous and can indicate a region of interest that measures up to 
18 cm 2  (S8.4.13). Even in patients without SHD, a perfect pace map 
can be observed at sites up to 2 cm away from the VT origin (S8.4.5, 
S8.4.14). Most electrophysiologists of the writing committee per-
form pacing in a bipolar manner, starting with an output of 10 mA 
at 2 ms pulse width. Limitations to bipolar pacing, including anodal 
capture, and the limitations to pacing with a minimal fixed output, 
including generation of a virtual electrode that captures more tis-
sue with higher stimulus strength, need to be recognized (S8.4.15). 
Pacing at stimulus strengths only slightly greater than threshold is 
desirable to avoid capture over a large area, which can reduce accu-
racy; however, checking the threshold at each mapping point is time 
consuming and might not be practical. 
 Smaller interelectrode spacing, smaller electrode size, and un-
ipolar pacing could increase the accuracy of pace mapping (see 
Section  8.1 ) (S8.4.16). 
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 8.5  |  Sinus rhythm substrate mapping 
 8.5.1  |  Substrate mapping in sinus rhythm 
 Recommendations for substrate mapping in sinus rhythm 
 COR  LOE  Recommendations  References 
 I  B- NR  1. In patients with scar- related VT, substrate- guided ablation is useful for prevention of arrhyth-
mia recurrences.  
 S8.5.2.1–S8.5.2.11 
 IIa  B- NR  2. High- density multielectrode mapping to obtain a more comprehensive characterization of the 
arrhythmogenic tissue during catheter ablation of scar- related VT can be useful.  
 S8.5.2.12–S8.5.2.14 
 IIa  B- NR  3. In patients with no or minimal endocardial bipolar electrogram abnormalities, reduced unipolar 
voltage can be useful for detection of epicardial or intramural scar.  
 S8.5.2.15–S8.5.2.19 
 Recommendation- specific supportive text 
 1 Substrate-guided mapping and ablation during sinus rhythm are 
intended to overcome the limitations of conventional mapping 
and ablation. They allow ablation of multiple VT morphologies 
irrespective of inducibility or hemodynamic tolerance. Multiple 
studies have shown that substrate-guided ablation is effec-
tive for prevention of arrhythmia recurrences in scar-related 
unmappable VT (S8.5.2.1–S8.5.2.11). 
 2 Multielectrode mapping has been shown to increase mapping 
density and to shorten mapping and RF delivery time (S8.5.2.12–
S8.5.2.14). Although in retrospective studies the use of multielec-
trode mapping has been associated with better outcome, no effect 
on acute and long-term outcome has yet been prospectively dem-
onstrated (S8.5.2.12, S8.5.2.14). 
 3 Bipolar electrograms have a limited field of view to detect epicar-
dially or intramurally located scar. Unipolar voltage mapping can 
be used to extend field of view of endocardial mapping, and low 
unipolar voltages can indicate regions of epicardial or intramural 
involvement in patients with no or minimal endocardial abnormali-
ties evident on bipolar electrogram analysis; however, there is sub-
stantial overlap of unipolar low voltage between scar zones and 
regions without scar (S8.5.2.15–S8.5.2.19). 
 8.5.2  |  Summary 
 The majority of patients with SHD presenting for catheter abla-
tion have hemodynamically unstable VTs that prevent accurate 
delineation of the critical part of the reentrant circuit with activa-
tion or entrainment mapping (S8.5.2.20). Substrate mapping is an 
approach to characterize areas likely to support reentry based on 
electrophysiological characteristics that can be determined during 
stable sinus or paced rhythm. It allows for elimination of VT, irre-
spective of inducibility or hemodynamic tolerance. Even for hemo-
dynamically stable VTs, substrate mapping is often used to limit 
activation mapping or entrainment to a region of interest (S8.5.2.7, 
S8.5.2.10, S8.5.2.11). 
 The concept of substrate mapping has developed from the suc-
cess of surgical subendocardial resection for postinfarction VT, 
which has established the physical link between the VT circuit and 
the infarction scar (S8.5.2.21). Current criteria to define the ab-
normal arrhythmogenic substrate rely on a combination of lower 
bipolar or unipolar voltage and abnormal electrogram characteris-
tics (eg, fragmented, split, and late electrograms). These abnormal 
electrogram features can represent slow or delayed activation that 
constitute surrogate markers for potential VT circuits (S8.5.2.22, 
S8.5.2.23). 
 Voltage criteria for scar identification 
 Scar tissue can be identified based on bipolar electrogram ampli-
tude. Using a 4- mm tip mapping catheter and 1- mm ring intere-
lectrode spacing with a 2- mm ring filtered at 10- 400 Hz, 95% of 
normal LV endocardial electrograms have a peak- to- peak amplitude 
>1.55 mV (S8.5.2.24). Conversely, bipolar voltage <0.5 mV has been 
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designated as “dense scar,” but it is important to recognize that these 
regions can still contain viable myocytes (S8.5.2.25) that can be cap-
tured by pacing. Use of cutoff values has important limitations as 
shown by recent work integrating voltage mapping and full human 
heart histology (S8.5.2.26). This is particularly relevant in patients 
with NICM with patchy scar, in whom larger bundles of surviving 
myocytes are mixed with fibrotic tissue. Bipolar voltage and elec-
trogram characteristics can be further affected by different elec-
trode size and/or interelectrode distance of the mapping catheter 
(S8.5.2.13), direction of activation wavefront (S8.5.2.27), and wall 
thickness (S8.5.2.26). 
 Bipolar voltage mapping can have a limited field of view to de-
tect epicardially or intramurally located scar, typically observed in 
patients with NICM. Under these circumstances, unipolar voltage 
mapping can be used to extend the field of view of endocardial 
mapping (S8.5.2.15, S8.5.2.16, S8.5.2.19). Endocardial low uni-
polar voltages could indicate regions of epicardial or intramural 
involvement in patients with no or minimal endocardial abnormal-
ities evident on bipolar electrogram analysis. Although various 
studies have reported different cutoff values to identify deeper 
scar tissue, validation studies with CMR- defined scar have demon-
strated that there is a substantial overlap of unipolar low voltage 
between scar zones and regions without scar. CMR- defined scar 
remains the gold standard for precise demarcation of scar and 
is preferable over unipolar voltage mapping for defining scar. 
Furthermore, cutoff values are impacted by electrode size, wall 
thickness, surrounding anatomical structures, and ventricular hy-
pertrophy, or are region specific (S8.5.2.16, S8.5.2.18, S8.5.2.26, 
S8.5.2.28). 
 Other electrogram characteristics as ablation targets 
 Low- voltage areas in patients with SHD are often large, and not all 
are related to VT. To limit the extent of ablation, several other elec-
trogram features obtained during spontaneous rhythm or elicited 
by pacing maneuvers have been studied to identify areas within the 
scar potentially related to VT. In the seminal study of de Bakker et al 
(S8.5.2.22), the authors have demonstrated the presence of inhomo-
geneous “zig- zag” conduction within the infarcted area, which was 
related to the presence of poor cell- to- cell coupling of surviving my-
ocyte bundles interspersed among fibrous tissue. In these regions, 
abnormal fractioned and LPs were recorded. Although fragmented 
electrograms can be typically recorded throughout the whole scar, 
isolated and LPs have been demonstrated to be a more specific 
marker of the VT circuit (S8.5.2.29–S8.5.2.33). However, clinical 
studies have adopted heterogeneous definitions of abnormal elec-
trograms, with nonuniform use of terms such as “fragmented,” “split,” 
and “late,” and the relationship between these surrogate markers and 
the VT circuits remains to be thoroughly explored (S8.5.2.34). In this 
respect, LAVA has been proposed as a global term that incorporates 
all abnormal ventricular signals that represent near- field signals from 
poorly coupled fibers within scar, representing potential VT isthmus 
sites (S8.5.2.35). 
 Importantly, the lines of block delimiting the channels responsible 
for arrhythmias can be both fixed and functional (S8.5.2.34), and the 
participation of functional barriers in VT circuits challenges the iden-
tification of potential VT circuits during substrate mapping. Abnormal 
local electrograms can be hidden in far- field signals, preventing their 
recognition during sinus rhythm or RV pacing. Identification of such 
electrograms might require pacing maneuvers to demonstrate their 
poorly coupled nature (S8.5.2.35–S8.5.2.37). This could be relevant 
in the presence of smaller, nontransmural scars, in which subepicardial 
viable myocardium can overlay the subendocardial scar, creating far- 
field obscuration of the local signal (S8.5.2.38). 
 Some abnormal electrograms can be disclosed only by catheters 
with small electrodes and shorter interelectrode distance, which 
allow for higher near- field resolution (S8.5.2.39) (see Section  8.1 ). 
 Most of the studies concerning substrate mapping were per-
formed on patients after MI, and significant differences exist with 
respect to the arrhythmogenic substrate characteristics between 
patients with ICM and NICM (see Section  9 ). 
 There is currently no standardized approach for substrate- guided 
ablation. A number of substrate- based ablation approaches have been 
developed, with the main purpose of targeting and eliminating areas 
of slow conduction within the abnormal substrate defined during 
sinus rhythm (S8.5.2.24, S8.5.2.29, S8.5.2.30, S8.5.2.35, S8.5.2.40–
S8.5.2.44) or evoked by pacing (S8.5.2.36–S8.5.2.38) (see Section  9.5 ). 
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 8.6  |  Intraprocedural imaging: Intracardiac echocardiography, fluoroscopy, cardiac magnetic resonance imaging 
 8.6.1  |  Intraprocedural imaging during catheter ablation of ventricular arrhythmias 
 Recommendations for intraprocedural imaging during catheter ablation of VAs 
 COR  LOE  Recommendations  References 
 I  B- NR  1. Coronary angiography or ICE is recommended to localize the ostia of the coronary 
arteries prior to ablation within the SV.  
 S8.6.2.1–S8.6.2.4 
 I  B- NR  2. Coronary angiography is recommended to identify the course of the coronary arteries 
when ablation is performed in the coronary venous system or in the epicardium.  
 S8.6.2.5–S8.6.2.8 
 I  B- NR  3. ICE is beneficial to identify and target the papillary muscles with ablation and to assess 
for catheter stability.  
 S8.6.2.9–S8.6.2.20 
 I  B- NR  4. ICE or transthoracic echocardiography is useful to assess for pericardial effusion in case 
of hemodynamic deterioration of the patient.  
 S8.6.2.21–S8.6.2.23 
 I  C- LD  5. ICE is useful for early recognition of complications, including pericardial effusion.   S8.6.2.21–S8.6.2.23 
 IIb  B- NR  6. ICE may be useful as an adjuvant technique to identify wall segments with wall thin-
ning, wall motion abnormalities, and segments with increased echogenicity, and also to 
identify intracardiac thrombi.  
 S8.6.2.24, S8.6.2.25 
 Recommendation- specific supportive text 
 1 For the coronary ostia, a distance of ≥1 cm of the cathe-
ter tip from a coronary ostium is considered a safe distance 
(S8.6.2.3), although ablations have been reported to be as 
close as 7.3 mm (S8.6.2.1) and 7.5 mm (S8.6.2.4) from the 
coronary ostium, without resulting complications. 
 2 In the epicardial space, coronary angiography should be consid-
ered prior to ablation to ensure that there is no coronary artery 
in the proximity of the ablation catheter (S8.6.2.7, S8.6.2.8); a 
minimal distance of >5 mm from the ablation catheter tip to an 
epicardial coronary artery has been considered safe (S8.6.2.7). 
 3 No randomized studies have shown improved outcomes if ICE 
is used to target papillary muscle arrhythmias. Several case 
series, however, have demonstrated that ICE is useful for tar-
geting papillary muscle arrhythmias with real-time localization 
of the papillary muscle apparatus and the ablation catheter tip 
(S8.6.2.9–S8.6.2.20). Catheter stability on the papillary mus-
cles or other parts of the myocardium can be assessed with ICE. 
 4 ICE further can help to identify complications such as pericardial 
effusions, allowing for early intervention (S8.6.2.21–S8.6.2.23). 
It also can be used to assess intracardiac structures, including 
wall thickness, wall motion abnormalities, increased echogenic-
ity to identify scarring, and intracardiac thrombi (S8.6.2.24–
S8.6.2.26). Furthermore, ICE is beneficial in monitoring catheter 
contact during ablation for arrhythmias not related to papillary 
muscles and could be useful to assess for tissue changes preced-
ing steam pops (S8.6.2.27). 
 8.6.2  |  Summary 
 For intraprocedural imaging during catheter ablation of VAs, several 
technologies have been used: fluoroscopy (including coronary angiog-
raphy), echocardiography (intracardiac, transthoracic, or transesoph-
ageal), and real- time CMR. Although no randomized studies have 
demonstrated the benefit of intraprocedural imaging, there are data 
supporting the use of coronary angiography or ICE to enhance pro-
cedural safety for selected cases, allowing for real- time imaging while 
mapping and ablation are performed (S8.6.2.1–S8.6.2.20). 
 Fluoroscopy is routinely used for catheter placement and cath-
eter manipulations during mapping and ablation procedures. With 
the development and improvement of EAM systems, the need for 
fluoroscopy can be minimized (S8.6.2.28, S8.6.2.29). 
 Integration of fluoroscopic cine loops into electroanatom-
ical maps has further helped to shorten fluoroscopy times 
(S8.6.2.30–S8.6.2.32). 
 With respect to the coronary arteries, the use of coronary angi-
ography or ICE to localize the ostia of the coronary arteries has been 
found useful when ablation is directed toward the SV (S8.6.2.1–
S8.6.2.3). Although data are limited, a minimal distance of ≥10 mm 
from the coronary ostia has been considered to be safe for RF abla-
tion (S8.6.2.9). The coronary ostia can also be identified by ICE and 
can be marked in the electroanatomical map. This could obviate the 
need for coronary angiography. Coronary angiography is the preferred 
technique to identify the course of the coronary arteries when abla-
tion is performed in the coronary venous system or the epicardium. A 
distance of >5 mm of the ablation catheter to an epicardial coronary 
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artery is considered safe (S8.6.2.3). A coronary angiogram is often re-
peated at the conclusion of the procedure to document patency of the 
coronary arteries. 
 ICE is beneficial to identify and target VAs originating from the 
papillary muscles (S8.6.2.10–S8.6.2.21). No randomized studies, how-
ever, have shown improved outcomes when ICE was used. Several 
case series, however, have demonstrated that ICE is useful for tar-
geting papillary muscle arrhythmias. The main benefit is the real- time 
localization of the papillary muscle apparatus in conjunction with the 
ablation catheter tip being visualized in the EAM system. Integration 
of ICE images into the EAM system together with the mapping or 
ablation catheter is particularly helpful (S8.6.2.16). ICE helps to de-
fine the level of the pulmonary valve when arrhythmias are targeted 
in the RVOT or in the pulmonary artery. This is of importance when 
ablation needs to be performed in the pulmonary artery, which can 
be in close proximity to the coronary arteries. Furthermore, ICE can 
be used as an adjuvant technique to identify scarring by identifying 
wall segments with wall thinning, wall motion abnormalities, exces-
sive trabeculations (S8.6.2.23), segments with increased echogenic-
ity (S8.6.2.24, S8.6.2.26), and also to identify intracardiac thrombi 
(S8.6.2.25). Furthermore, predictors for steam pops can be identified 
with ICE (S8.6.2.27), which might help to prevent complications. 
 ICE further can help to identify complications such as pericar-
dial effusions, allowing for early intervention (S8.6.2.21–S8.6.2.23). 
Transthoracic echocardiography, as well as ICE, can be useful to 
assess for pericardial effusion in case of intraprocedural hemody-
namic deterioration of the patient (S8.6.2.33). 
 Real- time CMR can enable visualization of lesion formation. It 
has the advantage of avoiding ionizing radiation and of imaging the 
whole heart in real time, and it has been used to target typical atrial 
flutter (S8.6.2.34, S8.6.2.35). However, real- time imaging during 
VT ablation in humans has not yet been reported and has thus far 
been limited to postablation image acquisition (S8.6.2.36). A labo-
ratory with real- time CMR capabilities requires a major financial in-
vestment, adaptation, and commitment to a work flow that is very 
different from that of a standard electrophysiology laboratory. At 
this time, real- time CMR is used only in a few centers on an inves-
tigational basis. Other investigational imaging techniques include 
the use of endoscopy in the epicardial space for visualization of 
catheters, epicardial structures, and ablation lesions (S8.6.2.37). 
 References 
 S8.6.2.1.   OuyangF,Fotuhi P,HoSY, et al.Repetitivemonomorphic ven-
tricular tachycardia originating fromthe aortic sinus cusp: 
electrocardiographic characterization for guiding catheter 
ablation.  J Am Coll Cardiol. 2002;39:500–8. 
 S8.6.2.2.   Hoffmayer KS, Dewland TA, Hsia HH, et al. Safety of radiofre-
quency catheter ablation without coronary angiography in aortic 
cusp ventricular arrhythmias.  Heart Rhythm. 2014;11:1117–21. 
 S8.6.2.3.   Hachiya H, Aonuma K, Yamauchi Y, IgawaM, Nogami A, Iesaka 
Y. How to diagnose, locate, and ablate coronary cusp ventric-
ular tachycardia.  J Cardiovasc Electrophysiol. 2002;13:551–6. 
 S8.6.2.4.   Yamada T,McElderry HT, Doppalapudi H, et al. Idiopathic 
ventricular arrhythmias originating from the aortic root 
prevalence, electrocardiographic and electrophysiologic 
characteristics, and results of radiofrequency catheter abla-
tion.  J Am Coll Cardiol. 2008;52:139–47. 
 S8.6.2.5.   Baman TS, Ilg KJ, Gupta SK, et al. Mapping and ablation of epi-
cardial idiopathic ventricular arrhythmias from within the coro-
nary venous system.  Circ Arrhythm Electrophysiol. 2010;3:274–9. 
 S8.6.2.6.   Yokokawa M, Latchamsetty R, Good E, et al. Ablation of 
epicardial ventricular arrhythmias from nonepicardial sites. 
 Heart Rhythm. 2011; 8:1525–9. 
 S8.6.2.7.   D ' Avila A, Gutierrez P, Scanavacca M, et al. Effects of radiof-
requency pulses delivered in the vicinity of the coronary ar-
teries: implications for nonsurgical transthoracic epicardial 
catheter ablation to treat ventricular tachycardia.  Pacing Clin 
Electrophysiol. 2002;25:1488–95. 
 S8.6.2.8.   Sacher F, Roberts- Thomson K, Maury P, et al. Epicardial ven-
tricular tachycardia ablation a multicenter safety study.  J Am 
Coll Cardiol. 2010; 55:2366–72. 
 S8.6.2.9.   Good E, Desjardins B, Jongnarangsin K, et al. Ventricular ar-
rhythmias originating from a papillary muscle in patients with-
out prior infarction: a comparison with fascicular arrhythmias. 
 Heart Rhythm. 2008; 5:1530–7. 
 S8.6.2.10.   Yokokawa M, Good E, Desjardins B, et al. Predictors of suc-
cessful catheter ablation of ventricular arrhythmias arising 
from the papillary muscles.  Heart Rhythm. 2010;7:1654–9. 
 S8.6.2.11.   Yamada T, McElderry HT, Okada T, et al. Idiopathic focal ventric-
ular arrhythmias originating from the anterior papillary muscle in 
the left ventricle.  J Cardiovasc Electrophysiol. 2009;20:866–72. 
 S8.6.2.12.   Yamada T, Doppalapudi H, McElderry HT, et al. 
Electrocardiographic and electrophysiological characteris-
tics in idiopathic ventricular arrhythmias originating from the 
papillary muscles in the left ventricle: relevance for catheter 
ablation.  Circ Arrhythm Electrophysiol. 2010; 3:324–31. 
 S8.6.2.13.   Yamada T, Doppalapudi H, McElderry HT, et al. Idiopathic 
ventricular arrhythmias originating from the papillary mus-
cles in the left ventricle: prevalence, electrocardiographic 
and electrophysiological characteristics, and results of the 
radiofrequency catheter ablation.  J Cardiovasc Electrophysiol. 
2010;21:62–9. 
 S8.6.2.14.   Bassil G, Liu CF, Markowitz SM, et al. Comparison of robotic 
magnetic navigation- guided and manual catheter ablation of 
ventricular arrhythmias arising from the papillary muscles. 
 Europace. 2018;20:ii5–ii10. 
 S8.6.2.15.   Ban JE, Lee HS, Lee DI, et al. Electrophysiological character-
istics related to outcome after catheter ablation of idiopathic 
ventricular arrhythmia originating from the papillary muscle 
in the left ventricle.  Korean Circ J. 2013;43:811–8. 
 S8.6.2.16.   Crawford T,Mueller G, Good E, et al. Ventricular arrhythmias 
originating from papillary muscles in the right ventricle.  Heart 
Rhythm. 2010;7:725–30. 
 S8.6.2.17.   Rivera S, Ricapito Mde L, Tomas L, et al. Results of cryoen-
ergy and radiofrequency- based catheter ablation for 
treating ventricular arrhythmias arising from the papil-
lary muscles of the left ventricle, guided by intracardiac 
echocardiography and image integration.  Circ Arrhythm 
Electrophysiol. 2016;9:e003874. 
 S8.6.2.18.   Proietti R, Rivera S, Dussault C, et al. Intracardiac echo- 
facilitated 3D electroanatomical mapping of ventricular ar-
rhythmias from the papillary muscles: assessing the ‘fourth 
dimension’ during ablation.  Europace. 2017;19:21–8. 
 S8.6.2.19.   Peichl P, Baran J, Wichterle D, et al. The tip of the muscle is a 
dominant location of ventricular ectopy originating from pap-
illary muscles in the left ventricle.  J Cardiovasc Electrophysiol. 
2018;29:64–70. 
 S8.6.2.20.  Lee A, Hamilton- Craig C, Denman R, Haqqani HM. Catheter 
ablation of papillary muscle arrhythmias: implications of 
400  |     CRONIN  ET AL .
mitral valve prolapse and systolic dysfunction.  Pacing Clin 
Electrophysiol. 2018;41:750–8. 
 S8.6.2.21.   Ren JF, Marchlinski FE. Early detection of iatrogenic pericar-
dial effusion: importance of intracardiac echocardiography. 
 JACC Cardiovasc Interv . 2010;3:127. 
 S8.6.2.22.  Filgueiras- Rama D, de Torres- Alba F, Castrejón- Castrejón S, 
et al. Utility of intracardiac echocardiography for catheter 
ablation of complex cardiac arrhythmias in a medium- volume 
training center.  Echocardiography . 2015;32:660–70. 
 S8.6.2.23.  Weintraub AR, Schwartz SL, Smith J, Hsu TL, Pandian NG. 
Intracardiac two- dimensional echocardiography in patients 
with pericardial effusion and cardiac tamponade.  J Am Soc 
Echocardiogr . 1991;4:571–6. 
 S8.6.2.24.   Bala R, Ren JF, Hutchinson MD, et al. Assessing epicardial 
substrate using intracardiac echocardiography during VT ab-
lation.  Circ Arrhythm Electrophysiol. 2011;4:667–73. 
 S8.6.2.25.  Peichl P, Wichterle D, Cihak R, Aldhoon B, Kautzner J. 
Catheter ablation of ventricular tachycardia in the presence 
of an old endocavitary thrombus guided by intracardiac echo-
cardiography.  Pacing Clin Electrophysiol. 2016;39:581–7. 
 S8.6.2.26.   Callans DJ, Ren JF, Michele J, Marchlinski FE, Dillon SM. 
Electroanatomic left ventricular mapping in the porcine 
model of healed anterior myocardial infarction: correlation 
with intracardiac echocardiography and pathological analysis. 
 Circulation. 1999;100:1744–50. 
 S8.6.2.27.   Nguyen DT, Zipse M, Borne RT, Zheng L, Tzou WS, Sauer 
WH. Use of tissue electric and ultrasound characteristics to 
predict and prevent steamgenerated cavitation during high- 
power radiofrequency ablation.  JACC Clin Electrophysiol. 
2018;4:491–500. 
 S8.6.2.28.   Von Bergen NH, Bansal S, Gingerich J, Law IH. Nonfluoroscopic 
and radiation- limited ablation of ventricular arrhythmias in 
children and young adults: a case series.  Pediatric Cardiology . 
2011;32:743–47. 
 S8.6.2.29.   Tuzcu V. Significant reduction of fluoroscopy in pediatric 
catheter ablation procedures: long- term experience from a 
single center.  Pacing Clin Electrophysiol. 2012;35:1067–73. 
 S8.6.2.30.  Cano O, Alonso P, Osca J, et al. Initial experience with a new 
image integration module designed for reducing radiation 
exposure during electrophysiological ablation procedures.  J 
Cardiovasc Electrophysiol. 2015; 26:662–70. 
 S8.6.2.31.   Reents T, Buiatti A, Ammar S, et al. Catheter ablation of ven-
tricular arrhythmias using a fluoroscopy image integration 
module.  Pacing Clin Electrophysiol. 2015;38:700–5. 
 S8.6.2.32.   Cano O, Andres A, Osca J, et al. Safety and feasibility of a min-
imally fluoroscopic approach for ventricular tachycardia abla-
tion in patients with structural heart disease: influence of the 
ventricular tachycardia substrate.  Circ Arrhythm Electrophysiol. 
2016;9:e003706. 
 S8.6.2.33.   Cheitlin MD, Alpert JS, Armstrong WF, et al. ACC/AHA guidelines 
for the clinical application of echocardiography: executive sum-
mary. A report of the American College of Cardiology/American 
Heart Association Task Force on practice guidelines (Committee 
on Clinical Application of Echocardiography).  J Am Coll Cardiol. 
1997;29:862–79. 
 S8.6.2.34.  Eitel C, Piorkowski C, Hindricks G, Gutberlet M. 
Electrophysiology study guided by real- time magnetic reso-
nance imaging.  Eur Heart J. 2012;33:1975. 
 S8.6.2.35.   Piorkowski C, Grothoff M, Gaspar T, et al. Cavotricuspid isth-
mus ablation guided by real- time magnetic resonance imag-
ing.  Circ Arrhythm Electrophysiol. 2013;6:e7–e10. 
 S8.6.2.36.  Grant EK, Berul CI, Cross RR, et al. Acute cardiac MRI as-
sessment of radiofrequency ablation lesions for pediatric 
ventricular arrhythmia: feasibility and clinical correlation.  J 
Cardiovasc Electrophysiol. 2017; 28:517–22. 
 S8.6.2.37.   Nazarian S, Kantsevoy SV, Zviman MM, et al. Feasibility of 
endoscopic guidance for nonsurgical transthoracic atrial and 
ventricular epicardial ablation.  Heart Rhythm. 2008;5:1115–9. 
 8.7  |  Electroanatomical mapping systems and robotic navigation 
 Recommendations for the use of EAM systems and remote navigation in ablation procedures for VAs 
 COR  LOE  Recommendations  References 
 I  B- NR  1. In patients with VA due to SHD undergoing an ablation procedure, EAM is useful.   S8.7.1–S8.7.9 
 IIa  B- NR  2. In patients with idiopathic VA undergoing an ablation procedure, EAM can be useful.   S8.7.4, S8.7.6 
 IIa  B- NR  3. In patients undergoing an ablation procedure for VA, magnetic catheter navigation can be 
useful to reduce fluoroscopy use.  
 S8.7.10–S8.7.14 
 Recommendation- specific supportive text 
 EAM systems combine cardiac electrical information obtained from 
catheter- mounted electrodes and 3D spatial location information 
to reconstruct an image that represents the targeted cardiac cham-
ber (S8.7.15). Several EAM systems are commonly used in clinical 
practice. The CARTO mapping system (current version CARTO 3, 
Biosense- Webster, Diamond Bar, CA) makes use of magnetic field 
differences for accurate localization of proprietary mapping and 
ablation catheters. This system also uses an impedance- based al-
gorithm to visualize the electrodes and shafts of various diagnostic 
catheters. A proprietary intracardiac ultrasound cathe   ter can in-
terface with the mapping system to further define cardiac geom-
etry within the mapping field (S8.7.1). The EnSite Precision system 
(Abbott Laboratories, Abbott Park, IL; formerly EnSite Velocity and 
EnSite NavX, St. Jude Medical, St. Paul, MN) uses voltage and imped-
ance measurements to localize diagnostic and ablation catheters. 
With the use of proprietary catheters, the EnSite Precision system 
can now also provide magnetic- based navigation. The Rhythmia HDx 
mapping system (Boston Scientific, Marlborough, MA) uses both 
magnetic- and impedance- based methods for catheter tracking. A 
prominent feature of this system is the proprietary 64- pole mini 
basket catheter with closely spaced electrodes. The Topera mapping 
system (Abbott Laboratories, Abbott Park, IL) combines unipolar 
electrogram data from an intracavitary basket catheter with pro-
prietary electrogram analysis software algorithms to identify focal 
and rotational activity during cardiac fibrillation. Though it is mar-
keted for atrial mapping, it has been used in cases of idiopathic VF 
(S8.7.16). Access to EAM systems worldwide is limited, largely due 
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to the high cost of systems, necessary peripherals, and proprietary 
catheters. 
 Regardless of the type of EAM available, knowledge of the first 
principles of cardiac electrophysiology remains essential to create 
maps that accurately represent the physiology and anatomy. Maps 
created using EAM systems are subject to considerable variability 
depending on a number of factors, including (but not limited to) 
accurate annotation of electrogram qualities, consistent catheter 
contact with tissue, distributed sampling of the entire structure 
of interest, density of location “points” in the map, type of rhythm 
being mapped, direction of activation wavefront propagation, and 
the size and spacing of the electrodes used to acquire the data. 
Numerous technologies have been developed or are in development 
to improve mapping quality and user experience. These include au-
tomated chamber segmentation, imported scar delineation from 
alternative cardiac imaging, such as CMR, CT, and echocardiogra-
phy, and automated electrogram analysis tools. Ultra high- density 
mapping catheters have significantly changed the resolution of scar 
features and, as a result, our understanding of VT circuit physiology. 
 EAM has proven to be a versatile technology to guide treatment 
of a wide range of arrhythmias. Prospective randomized trials with 
and without EAM in patients with SVT demonstrate similar acute 
procedural success rates and substantial reduction in fluoroscopy 
use (S8.7.2, S8.7.3). No such randomized trials with and without 
EAM exist for VAs, and no prospective trial has demonstrated su-
perior outcomes with the use of EAM. It is generally accepted that 
the use of EAM can reduce fluoroscopy time and allow for more pre-
cise mapping, with comparative analyses of nearby locations during 
VA ablation procedures. Particularly for more complex strategies of 
mapping ventricular scar, EAM enables the user to perform the nec-
essary mapping to achieve a successful result, which would other-
wise be impossible without EAM (S8.7.4). 
 In patients with SHD undergoing catheter ablation for VA, EAM 
is particularly helpful. EAM is especially versatile in this setting, of-
fering the operator the possibility of using various mapping strat-
egies, including activation maps, entrainment maps, pace maps, 
electrogram amplitude (voltage) maps, and tagging location of spe-
cific electrograms of interest. A prospective multicenter trial for VA 
ablation in patients with IHD has used EAM (S8.7.6). Several retro-
spective reports have used EAM for a wide range of SHDs and loca-
tions within the heart (S8.7.7, S8.7.8, S8.7.17–S8.7.25). 
 In patients with idiopathic VA undergoing catheter ablation, EAM 
can be useful. It is technically feasible to perform successful ablation 
for idiopathic VA without EAM, using 12- lead ECG, fluoroscopy, and 
careful analysis of intracardiac electrograms. Common examples in-
clude ablation of BBRVT and idiopathic VT originating from RVOT 
or LV fascicular system locations. For most centers, when EAM is 
available, it has become a mainstay in the procedure workflow for 
VA ablation procedures. EAM systems allow activation mapping of 
idiopathic VA to support catheter ablation in the RV, LV, aortic si-
nuses, and coronary venous system (S8.7.4, S8.7.5, S8.7.26). Reasons 
to not choose EAM for ablation of idiopathic VA include increased 
cost and limited access. 
 Catheter- based ablation of VA requires significant demands on the 
skill and experience of the operator. The concept of remote or robotic 
catheter navigation is appealing to reduce the physical demands of 
the procedure while developing more advanced abilities to achieve 
stable and precise catheter location than traditional catheters can 
afford. Several technologies have been developed to achieve these 
goals. The Niobe magnetic navigation system (Stereotaxis, St. Louis, 
MO) remotely controls the tip of a proprietary ablation catheter using 
changes in magnetic field direction from large rotating earth magnets 
(S8.7.27). This system can be combined with robotic catheter manipu-
lation components (Vdrive system) to control various diagnostic cathe-
ters remotely as well. Previous technologies include a second magnetic 
navigation system, the Catheter Guidance Control and Imaging system 
(Magnetecs, Inglewood, CA), which used 8 electromagnets to guide a 
proprietary magnetically tipped catheter. The Sensei robotic system 
(Hansen Medical, Mountain View, CA) robotically steered a deflectable 
sheath. A stand- alone robotic catheter manipulation system (Amigo, 
Catheter Precision, Ledgewood, NJ), interacted with a wide range of 
diagnostic and ablation catheter handles via a handheld remote con-
trol. Use of such technologies is a matter of operator preference: the 
potential advantages are offset by additional costs for the navigation 
systems, disposables, and maintenance contracts. 
 For patients undergoing ablation for VA, the use of an approved 
magnetic navigation system can be useful to reduce fluoroscopy ex-
posure. One small prospective randomized trial comparing magnetic 
navigation to manual ablation demonstrated reduced use of fluoros-
copy without clear differences in procedure outcome (S8.7.13). A 
retrospective case series supported similar conclusions, with a low 
rate for procedural complication (S8.7.28). A multicenter, single- arm 
study using remote navigation for patients with ischemic VT has 
demonstrated favorable procedural outcomes of VT noninducibility 
and longer- term VT freedom rates that are comparable to published 
results for manual catheter ablation (S8.7.29). Several retrospective 
comparison studies and single- arm series in patients with SHD con-
sistently support reduced fluoroscopy times during the procedure 
and low rates of procedural complication (S8.7.14, S8.7.30–S8.7.36). 
None of the remote navigation systems are specifically indicated to 
facilitate the catheter ablation procedure for VAs, though a prospec-
tive clinical trial using the Niobe remote magnetic navigation system 
is underway (S8.7.37). 
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 9    |   MAPPING AND ABL ATION 
 9.1  |  Ablation power sources and techniques  
 9.1.1  |  Introduction 
 Successful ablation requires the creation of durable lesions of 
adequate size (S9.1.9.1). When successful ablation cannot be 
achieved from the endocardium, percutaneous access of the peri-
cardial space (discussed in Section  6.3 ) that permits contact map-
ping and ablation of the arrhythmogenic substrate, which is close 
to the epicardial surface, can be effective but is limited when 
there are pericardial adhesions, overlying fat (S9.1.9.2), or criti-
cal structures nearby (S9.1.9.3, S9.1.9.4), or when the substrate 
is located deeper within the myocardium (S9.1.9.5). Innovative 
techniques intended to reach deeper arrhythmogenic substrates 
have been developed. 
 9.1.2  |  Unipolar radiofrequency catheter ablation 
 Unipolar RF energy has been the mainstay of catheter ablation tech-
nologies since the early 1990s. This technology was refined with the 
addition of temperature sensing and larger tip catheters and further 
with catheter tip cooling. Lesion depth is limited by the amount of 
power that can be safely delivered: too much power will result in 
overheating at the tip- tissue interface and consequent protein de-
naturation with thrombus formation (S9.1.9.6, S9.1.9.7). Irrigation of 
the ablation electrode reduces temperature at this interface and al-
lows greater power delivery and thus the creation of larger lesions 
(S9.1.9.8–S9.1.9.10). Several catheter tip designs and irrigation rates 
have been made available, each of which generates similar myocar-
dial lesion depth and volume (S9.1.9.11). Some degree of surface 
sparing is observed with irrigation, more so at higher flow rates and 
with tip designs that direct more irrigant at the surface (S9.1.9.11, 
S9.1.9.12). Power delivery, however, remains limited by the risk of 
deep tissue overheating and steam pops (S9.1.9.9). Catheter tip de-
signs with greater irrigant dispersion might permit lower irrigation 
flow rates and less volume load for patients with reduced ventricular 
function. Ablation lesion size increases with the duration of current 
application (S9.1.9.13), and although short duration applications are 
sufficient for ablation in thin structures, 60- 90 seconds or longer 
applications are usually employed for VT. The optimal duration has 
not yet been defined. 
 Steam pops can occur when excessive heating of myocardial tis-
sue occurs and can occasionally result in harmful tissue disruption 
(S9.1.9.14). However, the methods for avoiding steam pops are lim-
ited. Catheter tip irrigation partially attenuates the correlation be-
tween tip temperature and tissue temperature. Steam pops can still 
occur when tip temperatures rise excessively, although higher flow 
catheters with more irrigation ports could reduce the incidence of 
steam pops (S9.1.9.15). Monitoring the impedance could be useful 
in preventing steam pops, most of which occur when the impedance 
decreases more than 18 ohms from baseline or when greater power 
is delivered for longer durations (S9.1.9.16). A typical initial power 
setting for ablation with an open irrigated catheter in the LV is 30 
watts and can be adjusted up to 50 watts to achieve an impedance 
drop of 10 Ω. 
 9.1.3  |  Contact force sensing 
 Lesion size is critically dependent on the contact of the ablating elec-
trode with the tissue (S9.1.9.17). Catheters with contact force sen-
sors have become common and can help to ensure lesion creation 
at intended sites (S9.1.9.18). Although a clear improvement in clini-
cal outcomes for catheter ablation for VA is difficult to demonstrate 
(S9.1.9.19), RF applications with a mean contact force >10 g are more 
likely to result in electrical unexcitability in scar areas (S9.1.9.20), and 
contact force sensing has become an integral part of RF catheter 
ablation (S9.1.9.21). 
 Key Points 
 •  An impedance drop ≥10 Ω or a contact force ≥10 g is 
commonly used as a target for RF energy delivery. 
 •  The use of half normal saline generates larger ablation 
lesions but can result in steam pops. 
 •  Simultaneous bipolar or unipolar ablation can result in 
larger ablation lesions. 
 •  Cryoablation can be beneficial for achieving more stable 
contact on the papillary muscles. 
 •  Ethanol ablation can generate lesions in areas where the 
arrhythmogenic substrate cannot be otherwise reached, 
provided that suitable target vessels are present. 
 •  Stereotactic radiotherapy is an emerging alternative to 
ablation, requiring identification of a region of interest 
that can be targeted prior to the radiation treatment. 
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 9.1.4  |  Hypotonic external irrigation 
 Most ablation catheter tips are 3.5–4 mm in length and are typically 
irrigated with 0.9% sodium chloride solution. The efficiency of deliv-
ering current to myocardial tissue can be increased by using smaller 
electrode tip sizes (S9.1.9.22) and less conductive irrigant, such as 
0.45% sodium chloride (S9.1.9.23, S9.1.9.24). These techniques de-
liver greater current to myocardial tissue for any given applied power 
but remain limited by the potential for tissue steam pops. The ef-
fectiveness and safety of using a higher impedance irrigant has been 
supported by a multicenter, prospective, observational human study; 
however, direct clinical comparisons are still pending (S9.1.9.25). The 
use of hypotonic saline irrigant can have the additional advantage 
of a reduced salt load for patients with compromised ventricular 
function. 
 9.1.5  |  Simultaneous unipolar or simultaneous 
bipolar radiofrequency delivery 
 Conventional unipolar RF catheter ablation delivers current be-
tween the catheter tip and a dispersive skin electrode. Two 
catheters placed on either side of the target tissue, delivering si-
multaneous unipolar RF energy (using two RF generators), have 
been employed to reach deeper myocardial substrates, which 
could create larger lesions than sequential ablations at each of 
these sites by raising the temperature of tissue deep to either abla-
tion site, limiting its heat sink effect, and increasing the conduc-
tive heating zone (S9.1.9.26). This method provides independent 
control and monitoring of RF delivery from each ablating catheter 
but can pose technical challenges with device interactions. The 
efficacy and risks of this procedure have not been completely 
characterized. 
 Bipolar ablation is performed by replacing the dispersive skin 
electrode with a second catheter that is closely apposed to tissue 
with culprit substrate between the catheters. This technique con-
centrates current density between the catheters. Lesion creation 
extends from both catheters, and lesions are larger and more likely 
to be confluent than those achieved with sequential unipolar en-
ergy delivery (S9.1.9.27). The efficacy of this technique has been 
demonstrated in both preclinical models (S9.1.9.28, S9.1.9.29) and 
in humans (S9.1.9.30, S9.1.9.31). Bipolar ablation can be delivered 
between catheters that are positioned across the interventricular 
septum from one another, on either side of a papillary muscle, or with 
catheters in the endocardial and epicardial spaces. Bipolar ablation is 
limited by the requirement for custom cabling and the technical chal-
lenges of visualizing and placing two catheters sufficiently close with 
target tissue between them. The catheter tip temperature cannot be 
monitored simultaneously for both catheters, and impedance will be 
influenced by both tip- tissue interfaces. Optimal power and current 
settings have not yet been defined, and the risk of coagulation has 
not yet been fully characterized. An investigational system is under 
evaluation. 
 9.1.6  |  Needle ablation 
 Infusion needle ablation has been reported as a means to achieve 
intramural ablation lesions. A catheter with an extendable/retract-
able needle at the tip can function as an intramural electrode for 
the temperature- controlled delivery of RF energy (S9.1.9.32), which 
can create large, deep lesions during saline irrigation (S9.1.9.33, 
S9.1.9.34). This approach has been demonstrated to be effective 
for select patients with treatment- refractory VA in small series 
(S9.1.9.35). The efficacy and procedural risks of this technique have 
not been fully characterized. Investigational systems are under eval-
uation (S9.1.9.36). 
 9.1.7  |  Cryoablation 
 Catheter cryoablation has been infrequently employed for treating VA. 
Compared with RF ablation, focal cryoablation lesions are smaller and 
take longer to develop. Larger lesions can be created with larger tip 
cryoablation catheters (S9.1.9.37), but the clinical effectiveness and 
recurrence rates are less favorable than those achieved with RF ab-
lation (S9.1.9.38, S9.1.9.39), likely because of the smaller lesion size. 
Cryoablation catheters become adherent to the tissue during lesion 
creation, which enhances catheter stability and can provide additional 
utility in the catheter ablation for VA arising from highly mobile papil-
lary muscles, which can be difficult to ablate using RF ablation cath-
eters (S9.1.9.40). Although surgical cryoablation for VA has been used 
for decades (S9.1.9.41, S9.1.9.42), currently available technology will 
likely be limited to specialized circumstances unless further innova-
tion enables larger cryoablation lesion delivery from catheter platforms 
(S9.1.9.43). 
 9.1.8  |  Transvascular ethanol ablation 
 Creating an arterial occlusion and controlled infarction has long 
been used to create ventricular ablation lesions (S9.1.9.44). Early 
experiences had moderate success but with a higher risk of 
complications (S9.1.9.45). The refinement of mapping strategies 
and percutaneous coronary interventional technology encour-
aged further development, and several series have reported on 
treatment- refractory patients who underwent transcoronary 
ethanol ablation (S9.1.9.46, S9.1.9.47). Larger series have demon-
strated that this technique ' s efficacy can be limited by the avail-
ability of suitable target vessels, its procedural risk, and the risk 
of collateral injury (S9.1.9.2). Heart block is a frequent risk when a 
septal substrate is targeted (S9.1.9.48). 
 Although experience is limited, ventricular ablation can be per-
formed by injecting alcohol in a retrograde manner into the coronary 
venous system, which can lead to a lower risk than in the coronary 
arterial system. Reports from small series have been promising, al-
though collateral myocardial injury and recurrence are still a con-
cern (S9.1.9.49–S9.1.9.51). Further study could help to refine the 
technique. 
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 9.1.9  |  Stereotactic radiotherapy 
 The use of stereotactic motion- gated external beam radiation for abla-
tion has been explored in animal models (S9.1.9.52), and its feasibility 
has been demonstrated in humans (S9.1.9.53–S9.1.9.56). Tissue injury 
is likely the result of a combination of cell nuclear damage and vascu-
lar damage, the results of which can manifest within days or weeks 
(S9.1.9.53). This method requires the accurate preprocedure identifica-
tion of the culprit arrhythmogenic substrate, using either intracardiac 
mapping, imaging, or noninvasive ECGI (S9.1.9.53). Limiting the radiation 
to the target is complicated by cardiac and respiratory motion. Further 
study is required to quantify the risk of injury to nontarget myocardial 
and adjacent structures and to further define the methods and efficacy. 
 References 
 S9.1.9.1.   Tokuda M, Kojodjojo P, Tung S, et al. Characteristics of clinical 
and induced ventricular tachycardia throughout multiple ab-
lation procedures.  J Cardiovasc Electrophysiol. 2016;27:88–94. 
 S9.1.9.2.   Kumar S, Barbhaiya CR, Sobieszczyk P, et al. Role of alter-
native interventional procedures when endo- and epicardial 
catheter ablation attempts for ventricular arrhythmias fail. 
 Circ Arrhythm Electrophysiol. 2015;8:606–15. 
 S9.1.9.3.   Soejima K, Couper G, Cooper JM, Sapp JL, Epstein LM, 
Stevenson WG. Subxiphoid surgical approach for epicardial 
catheter- based mapping and ablation in patients with prior 
cardiac surgery or difficult pericardial access.  Circulation. 
2004;110:1197–201. 
 S9.1.9.4.   Tokuda M, Kojodjojo P, Tung S, et al. Acute failure of cath-
eter ablation for ventricular tachycardia due to structural 
heart disease: causes and significance.  J Am Heart Assoc. 
2013;2:e000072. 
 S9.1.9.5.   Dinov B, Fiedler L, Schonbauer R, et al. Outcomes in cathe-
ter ablation of ventricular tachycardia in dilated nonischemic 
cardiomyopathy compared with ischemic cardiomyopathy: 
results from the Prospective Heart Centre of Leipzig VT 
(HELP- VT) Study.  Circulation. 2014;129:728–36. 
 S9.1.9.6.   Demolin JM, Eick OJ, Munch K, Koullick E, Nakagawa H, 
Wittkampf FH. Soft thrombus formation in radiofrequency 
catheter ablation.  Pacing Clin Electrophysiol. 2002;25:1219–22. 
 S9.1.9.7.   Matsudaira K, Nakagawa H, Wittkampf FH, et al. High inci-
dence of thrombus formation without impedance rise during 
radiofrequency ablation using electrode temperature control. 
 Pacing Clin Electrophysiol. 2003;26:1227–37. 
 S9.1.9.8.   Nakagawa H, Yamanashi WS, Pitha JV, et al. Comparison of 
in vivo tissue temperature profile and lesion geometry for 
radiofrequency ablation with a saline- irrigated electrode ver-
sus temperature control in a canine thigh muscle preparation. 
 Circulation. 1995;91:2264–73. 
 S9.1.9.9.   Weiss C, Antz M, Eick O, Eshagzaiy K, Meinertz T, Willems 
S. Radiofrequency catheter ablation using cooled electrodes: 
impact of irrigation flow rate and catheter contact pressure on 
lesion dimensions.  Pacing Clin Electrophysiol. 2002;25:463–9. 
 S9.1.9.10.   Yokoyama K, Nakagawa H, Wittkampf FH, Pitha JV, Lazzara 
R, Jackman WM. Comparison of electrode cooling between 
internal and open irrigation in radiofrequency ablation lesion 
depth and incidence of thrombus and steam pop.  Circulation. 
2006;113:11–19. 
 S9.1.9.11.   Guerra JM, Jorge E, Raga S, et al. Effects of open- irrigated 
radiofrequency ablation catheter design on lesion formation 
and complications: in vitro comparison of 6 different devices. 
 J Cardiovasc Electrophysiol. 2013;24:1157–62. 
 S9.1.9.12.   Gonzalez- Suarez A, Berjano E, Guerra JM, Gerardo- Giorda L. 
Computational modeling of open- irrigated electrodes for ra-
diofrequency cardiac ablation including blood motion- saline 
flow interaction.  PLoS One . 2016;11:e0150356. 
 S9.1.9.13.   Skrumeda LL, Mehra R. Comparison of standard and irrigated 
radiofrequency ablation in the canine ventricle.  J Cardiovasc 
Electrophysiol. 1998;9:1196–205. 
 S9.1.9.14.   Matsumoto N, Kishi R, Kasugai H, et al. Experimental 
study on the effectiveness and safety of radiofrequency 
catheter ablation with the cooled ablation system.  Circ J . 
2003;67:154–8. 
 S9.1.9.15.   Cooper JM, Sapp JL, Tedrow U, et al. Ablation with an inter-
nally irrigated radiofrequency catheter: learning how to avoid 
steam pops.  Heart Rhythm. 2004;1:329–33. 
 S9.1.9.16.   Seiler J, Roberts- Thomson KC, Raymond JM, Vest J, 
Delacretaz E, StevensonWG. Steam pops during irrigated ra-
diofrequency ablation: feasibility of impedance monitoring 
for prevention.  Heart Rhythm. 2008;5:1411–6. 
 S9.1.9.17.   Ikeda A, Nakagawa H, Lambert H, et al. Relationship between 
catheter contact force and radiofrequency lesion size and in-
cidence of steam pop in the beating canine heart: electrogram 
amplitude, impedance, and electrode temperature are poor 
predictors of electrode- tissue contact force and lesion size. 
 Circ Arrhythm Electrophysiol. 2014;7:1174–80. 
 S9.1.9.18.   Sacher F, Wright M, Derval N, et al. Endocardial versus 
epicardial ventricular radiofrequency ablation: utility of in 
vivo contact force assessment.  Circ Arrhythm Electrophysiol. 
2013;6:144–50. 
 S9.1.9.19.   Hendriks AA, Akca F, Dabiri Abkenari L, et al. Safety and 
clinical outcome of catheter ablation of ventricular arrhyth-
mias using contact force sensing: consecutive case series.  J 
Cardiovasc Electrophysiol. 2015;26:1224–9. 
 S9.1.9.20.   Elsokkari I, Sapp JL, Doucette S, et al. Role of contact force 
in ischemic scar- related ventricular tachycardia ablation; opti-
mal force required and impact of left ventricular access route. 
 J Interv Card Electrophysiol. 2018;53:323–31. 
 S9.1.9.21.   Ariyarathna N, Kumar S, Thomas SP, Stevenson WG,Michaud 
GF. Role of contact force sensing in catheter ablation of car-
diac arrhythmias: evolution or history repeating itself?  JACC 
Clin Electrophysiol. 2018;4:707–23. 
 S9.1.9.22.   Nakagawa H, Wittkampf FH, Yamanashi WS, et al. Inverse 
relationship between electrode size and lesion size during 
radiofrequency ablation with active electrode cooling. 
 Circulation. 1998;98:458–65. 
 S9.1.9.23.   Nguyen DT, Gerstenfeld EP, Tzou WS, et al. Radiofrequency 
ablation using an open irrigated electrode cooled with half- 
normal saline.  JACC Clin Electrophysiol. 2017;3:1103–10. 
 S9.1.9.24.   Nguyen DT, Olson M, Zheng L, BarhamW,Moss JD, Sauer WH. 
Effect of irrigant characteristics on lesion formation after ra-
diofrequency energy delivery using ablation catheters with ac-
tively cooled tips.  J Cardiovasc Electrophysiol. 2015;26:792–8. 
 S9.1.9.25.   Nguyen DT, Tzou WS, Sandhu A, et al. Prospective 
multicenter experience with cooled radiofrequency 
ablation using high impedance irrigant to target deep myo-
cardial substrate refractory to standard ablation.  JACC Clin 
Electrophysiol. 2018;4:1176–85. 
 S9.1.9.26.   Yamada T, Maddox WR, McElderry HT, Doppalapudi H, 
Plumb VJ, Kay GN. Radiofrequency catheter ablation of id-
iopathic ventricular arrhythmias originating from intramural 
foci in the left ventricular outflow tract: efficacy of sequential 
versus simultaneous unipolar catheter ablation.  Circ Arrhythm 
Electrophysiol. 2015;8:344–52. 
 S9.1.9.27.   Sivagangabalan G, Barry MA, Huang K, et al. Bipolar ablation 
of the interventricular septum is more efficient at creating a 
406  |     CRONIN  ET AL .
transmural line than sequential unipolar ablation.  Pacing Clin 
Electrophysiol. 2010;33:16–26. 
 S9.1.9.28.   Ring ME, Huang SK, Graham AR, Gorman G, Bharati S, LevM. 
Catheter ablation of the ventricular septum with radiofre-
quency energy.  Am Heart J. 1989;117:1233–40. 
 S9.1.9.29   Piers SR, Dyrda K, Tao Q, Zeppenfeld K. Bipolar ablation of 
ventricular tachycardia in a patient after atrial switch op-
eration for dextro- transposition of the great arteries.  Circ 
Arrhythm Electrophysiol. 2012;5:e38–e40. 
 S9.1.9.30.   Koruth JS, Dukkipati S, Miller MA, Neuzil P, d ' Avila A, Reddy 
VY. Bipolar irrigated radiofrequency ablation: a therapeutic 
option for refractory intramural atrial and ventricular tachy-
cardia circuits.  Heart Rhythm. 2012;9:1932–41. 
 S9.1.9.31.   Nguyen DT, Tzou WS, Brunnquell M, et al. Clinical and bio-
physical evaluation of variable bipolar configurations during 
radiofrequency ablation for treatment of ventricular arrhyth-
mias.  Heart Rhythm. 2016;13:2161–71. 
 S9.1.9.32.   Sapp JL, Cooper JM, Soejima K, et al. Deep myocardial abla-
tion lesions can be created with a retractable needle- tipped 
catheter.  Pacing Clin Electrophysiol. 2004;27:594–99. 
 S9.1.9.33.   Sapp JL, Cooper JM, Zei P, Stevenson WG. Large radiof-
requency ablation lesions can be created with a retract-
able infusion- needle catheter.  J Cardiovasc Electrophysiol. 
2006;17:657–61. 
 S9.1.9.34.   Berte B, Cochet H, Magat J, et al. Irrigated needle ablation 
creates larger and more transmural ventricular lesions com-
pared with standard unipolar ablation in an ovine model.  Circ 
Arrhythm Electrophysiol. 2015;8:1498–506. 
 S9.1.9.35.   Sapp JL, Beeckler C, Pike R, et al. Initial human feasibility of 
infusion needle catheter ablation for refractory ventricular 
tachycardia.  Circulation. 2013;128:2289–95. 
 S9.1.9.36.   John RM, Connell J, Termin P, et al. Characterization of warm 
salineenhanced radiofrequency ablation lesions in the infarcted 
porcine ventricular myocardium.  J Cardiovasc Electrophysiol. 
2014;25:309–16. 
 S9.1.9.37.   Khairy P, Rivard L, Guerra PG, et al. Morphometric ab-
lation lesion characteristics comparing 4, 6, and 8 mm 
electrode- tip cryocatheters.  J Cardiovasc Electrophysiol. 
2008;19:1203–7. 
 S9.1.9.38.   Deisenhofer I, Zrenner B, Yin YH, et al. Cryoablation versus ra-
diofrequency energy for the ablation of atrioventricular nodal 
reentrant tachycardia (the CYRANO Study): results from a 
large multicenter prospective randomized trial.  Circulation. 
2010;122:2239–45. 
 S9.1.9.39.   Opel A, Murray S, Kamath N, et al. Cryoablation versus ra-
diofrequency ablation for treatment of atrioventricular nodal 
reentrant tachycardia: cryoablation with 6- mm- tip catheters is 
still less effective than radiofrequency ablation.  Heart Rhythm. 
2010;7:340–3. 
 S9.1.9.40.   Gordon JP, Liang JJ, Pathak RK, et al. Percutaneous cryoabla-
tion for papillary muscle ventricular arrhythmias after failed 
radiofrequency catheter ablation.  J Cardiovasc Electrophysiol. 
2018;29:1654–63. 
 S9.1.9.41.   Guiraudon GM, Thakur RK, Klein GJ, Yee R, Guiraudon CM, 
Sharma A. Encircling endocardial cryoablation for ventricular 
tachycardia after myocardial infarction: experience with 33 
patients.  Am Heart J. 1994;128:982–9. 
 S9.1.9.42.   Frapier JM, Hubaut JJ, Pasquie JL, Chaptal PA. Large encir-
cling cryoablation without mapping for ventricular tachycar-
dia after anterior myocardial infarction: long- term outcome.  J 
Thorac Cardiovasc Surg. 1998;116:578–83. 
 S9.1.9.43.   Baust JM, Robilotto A, Guerra P, et al. Assessment of a 
novel cryoablation device for the endovascular treatment 
of cardiac tachyarrhythmias.  SAGE Open Med . 2018;6:
2050312118769797. 
 S9.1.9.44.   Brugada P, de Swart H, Smeets JL, Bar FW, Wellens HJ. 
Termination of tachycardias by interrupting blood flow to the 
arrhythmogenic area.  Am J Cardiol. 1988;62:387–92. 
 S9.1.9.45.   Kay GN, Epstein AE, Bubien RS, Anderson PG, Dailey SM, 
Plumb VJ. Intracoronary ethanol ablation for the treatment 
of recurrent sustained ventricular tachycardia.  J Am Coll 
Cardiol. 1992;19:159–68. 
 S9.1.9.46.   Segal OR, Wong T, Chow AW, et al. Intra- coronary guide-
wire mapping- a novel technique to guide ablation of human 
ventricular tachycardia.  J Interv Card Electrophysiol. 2007;18:
143–54. 
 S9.1.9.47.   Sacher F, Sobieszczyk P, Tedrow U, et al. Transcoronary eth-
anol ventricular tachycardia ablation in the modern electro-
physiology era.  Heart Rhythm. 2008;5:62–8. 
 S9.1.9.48.   Tokuda M, Sobieszczyk P, Eisenhauer AC, et al. Transcoronary 
ethanol ablation for recurrent ventricular tachycardia 
after failed catheter ablation: an update.  Circ Arrhythm 
Electrophysiol. 2011;4:889–96. 
 S9.1.9.49.   Kreidieh B, Rodriguez- Manero M, Schurmann P, Ibarra- 
Cortez SH, Dave AS, Valderrabano M. Retrograde coronary 
venous ethanol infusion for ablation of refractory ventricular 
tachycardia.  Circ Arrhythm Electrophysiol. 2016;9:e004352. 
 S9.1.9.50.   Baher A, Shah DJ, Valderrabano M. Coronary venous ethanol 
infusion for the treatment of refractory ventricular tachycar-
dia.  Heart Rhythm. 2012; 9:1637–9. 
 S9.1.9.51.   Kato K, Tanaka A, Hasegawa S, Kametani R. Successful eth-
anol injection into the anterior interventricular cardiac vein 
for ventricular premature contractions arising from the left 
ventricular summit.  Heart Rhythm Case Rep . 2018;4:310–13. 
 S9.1.9.52.   Sharma A, Wong D, Weidlich G, et al. Noninvasive stereotac-
tic radiosurgery (CyberHeart) for creation of ablation lesions 
in the atrium.  Heart Rhythm. 2010;7:802–10. 
 S9.1.9.53.   Cuculich PS, Schill MR, Kashani R, et al. Noninvasive cardiac 
radiation for ablation of ventricular tachycardia.  N Engl J Med. 
2017;377:2325–36. 
 S9.1.9.54.   Loo BWJr, Soltys SG, Wang L, et al. Stereotactic ablative ra-
diotherapy for the treatment of refractory cardiac ventricular 
arrhythmia.  Circ Arrhythm Electrophysiol. 2015;8:748–50. 
 S9.1.9.55.   Lehmann HI, Graeff C, Simoniello P, et al. Feasibility study 
on cardiac arrhythmia ablation using high- energy heavy ion 
beams.  Sci Rep . 2016;6:38895. 
 S9.1.9.56.   Lehmann HI, Deisher AJ, Takami M, et al. External arrhyth-
mia ablation using photon beams: ablation of the atrioven-
tricular junction in an intact animal model.  Circ Arrhythm 
Electrophysiol. 2017;10:e004304. 
 9.2  |  Idiopathic outflow tract ventricular arrhythmia 
 
 Key Points 
 •  The RVOT, pulmonary arteries, SVs, LV epicardium and en-
docardium contain most of the OT arrhythmias. 
 •  Activation mapping and pace mapping can be used to guide 
ablation in the RVOT. 
 •  Imaging of coronary artery ostia is essential before ablation 
in the aortic SVs. 
 •  The LV summit is a challenging SOO, often requiring map-
ping and/or ablation from the RVOT, LVOT, SVs, coronary 
venous system, and sometimes the epicardial space. 
 •  Deep intraseptal VA origins can be challenging to reach. 
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 9.2.1  |  Introduction 
 Approximately two- thirds of idiopathic VAs originate from the ven-
tricular OTs, accounting for 10% of all patients referred for VA abla-
tion (S9.2.7.1). OT VAs comprise a wide spectrum of VAs, ranging 
from premature ventricular beats to sustained monomorphic VT. 
Approximately three- quarters originate from the RVOT, with the 
remaining from the LVOT and adjacent structures, including the 
pulmonary artery, the area surrounding the His bundle, the aor-
tic SVs, the epicardium and GCV region, LV summit, AMC, and the 
superior mitral and tricuspid valve annuli (S9.2.7.1–S9.2.7.11). OT 
VAs usually exhibit either an RBBB or LBBB morphology with an 
inferior axis. OTs and adjacent areas have a broad and complex 3D 
anatomical structure, accounting for some of the unique challenges 
in arrhythmia localization and ablation (S9.2.7.2, S9.2.7.4–S9.2.7.6). 
 Most idiopathic OT VAs have a focal origin and are thought to 
be due to adenosine- sensitive, cAMP- mediated triggered activity 
(S9.2.7.12, S9.2.7.13). 
 9.2.2  |  General approach 
 The success of ablation depends largely on the presence of VA 
at the time of the procedure. All AADs should be discontinued 
for at least 5 half- lives before the procedure. Sedation with long- 
acting sedatives can decrease spontaneous or inducible VA and 
should be avoided if possible. If spontaneous VA is absent, limited 
physical activities, including hand grip and leg- rising exercises, 
programmed stimulation, burst pacing, and the administration of 
isoproterenol, epinephrine, or phenylephrine, can be helpful in 
eliciting the arrhythmia (Section  7 ). 
 Ablation is based on activation mapping and pace mapping 
(S9.2.7.4, S9.2.7.14), the latter of which is helpful when the VA is in-
frequent. Activation mapping is, however, more accurate (S9.2.7.15), 
given a similar paced QRS morphology can be observed over a rela-
tively large area (S9.2.7.14) and can be misleading in the SV (S9.2.7.14, 
S9.2.7.16). 
 The most frequent SOO remains the RVOT (S9.2.7.1), but failure 
of catheter ablation at the earliest RVOT site should raise concerns 
that the RVOT breakthrough is not sufficiently close to the focus, 
warranting further mapping, including adjacent structures. A step-
wise approach to the detailed and careful mapping of the region of 
interest, avoiding futile ablation at inappropriate sites, shortens the 
procedure and enhances success (S9.2.7.4, S9.2.7.17). 
 Detailed knowledge of OT anatomy is required, and the use of 
fluoroscopy alone is often sufficient for guiding catheter position. 
However, preprocedure CT or CMR can help to exclude myocar-
dial disease and define the anatomy that can be registered in the 
mapping system. ICE can help to precisely determine the catheter 
location in relation to the valves and the adjacent coronary arter-
ies at risk of injury from ablation in the SV or pulmonary artery. 
 For VA with LBBB morphology, mapping should start at the 
RVOT and pulmonary artery. When mapping indicates a focus out-
side the RVOT and pulmonary artery, mapping of the GCV via the 
CS provides useful information prior to left heart catheterization. 
Mapping can then include the AIV and its septal branches followed 
by the SV and endocardial LVOT. 
 9.2.3  |  Right ventricular outflow tract and 
pulmonary artery 
 VAs ablated at the RVOT typically display LBBB morphology 
and transition at or >V3, without broad initial r waves in the right 
precordial leads. Most VAs arise from the septal anterior aspect of 
the RVOT. ECG algorithms can help to suggest the specific region 
(S9.2.7.18) and identify those with this morphology that can arise 
outside the RVOT or in the pulmonary artery (S9.2.7.17, S9.2.7.19, 
S9.2.7.20). Given that the posterior RVOT abuts the RSV, mapping 
of this structure is useful when ablation in the RVOT fails (S9.2.7.5). 
Some RVOT VAs originate from a conus papillary muscle that can be 
identified by ICE (S9.2.7.21). 
 Myocardial fibers extend along the pulmonary artery and can 
give rise to VAs that can be ablated from within the pulmonary ar-
tery. ECG and electrophysiological characteristics of pulmonary 
artery VAs are not well delineated (S9.2.7.3). Mapping at the pulmo-
nary artery should be considered while performing catheter ablation 
at the RVOT. ICE or angiography is required to know with certainty 
whether the catheter is above or below the valve. 
 Acute procedural success is in the range of 90% (S9.2.7.14, 
S9.2.7.22, S9.2.7.23), with more than 80% free of recurrent VA 
during follow- up. Serious complications occur in approximately 1% 
of patients and are usually related to cardiac perforation (S9.2.7.14). 
The left main coronary artery is directly posterior to the distal RVOT 
and is at risk of injury when ablating in the distal posterior RVOT 
(S9.2.7.24) or the pulmonary artery. The left anterior descending ar-
tery can be damaged when ablation is performed at the insertion of 
the anterior free wall to the septum of the RVOT, especially when 
high power (>30 W) is used for ablation. 
 9.2.4  |  Aortic sinuses of valsalva 
 The aortic root lies posterior and rightward of the RVOT and is com-
prised of the SVs and commissures. Both the RSV and the anterior 
part of the LSV are connected to the adjacent LVOT, while both the 
posterior LSV and the NCSV are in fibrous continuity with the mitral 
annulus at the AMC (S9.2.7.5, S9.2.7.6, S9.2.7.25). Although this is 
a fibrous structure, rare VAs can arise from this region. Myocardial 
sleeves can cross the aortic valve plane and extend a few millimeters 
above the basal valvular attachment, most commonly adjacent to the 
RSV and sometimes at the LSV. Myocardial sleeves are rarely ob-
served adjacent to the NCSV (S9.2.7.5, S9.2.7.6, S9.2.7.25). 
 The ECG characteristics of VAs from the SV vary, but relatively 
common features that are not usually encountered in RVOT VAs 
include a QRS transition <V3, prominent tall or broad R waves in 
V1 or V2 (S9.2.7.4, S9.2.7.8, S9.2.7.25–S9.2.7.28), qrS or notched 
complexes in V1–V2 (S9.2.7.29, S9.2.7.30), and a large R wave in 
lead I (S9.2.7.31). A single focus can result in VAs with different QRS 
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morphologies (RBBB and LBBB), suggesting a fiber with multiple OT 
connections (S9.2.7.32). 
 Initial mapping should include the LVOT and SVs (S9.2.7.33). 
ICE is useful for confirming the catheter position and the relation 
to adjacent structures. Local electrograms are helpful indications of 
catheter location: in NCSV, the atrial electrograms are larger than 
the ventricular electrogram, whereas the ventricular electrogram is 
larger in the other SVs, particularly in the RSV (S9.2.7.5, S9.2.7.25, 
S9.2.7.34, S9.2.7.35). SV foci are typically characterized by a small 
pre- QRS fragmented electrogram that precedes a large far- field 
ventricular electrogram during the VA and follows the QRS and far- 
field ventricular potential during sinus rhythm (S9.2.7.5, S9.2.7.25, 
S9.2.7.30). 
 Prior to ablation, ICE imaging or coronary angiography is re-
quired to ensure that the distance between the ablation catheter 
and the nearest coronary ostia exceeds 10 mm (S9.2.7.25, S9.2.7.26, 
S9.2.7.36). Coronary angiography can be repeated after the ablation 
to confirm the absence of injury or spasm. Injury to the aortic valve 
is theoretically possible. An RF power of 25- 35 W and a duration of 
30- 60 seconds for each RF energy application are commonly em-
ployed for irrigated or nonirrigated RF ablation catheters (S9.2.7.25). 
 The compact AV node and His bundle are potentially at risk 
during ablation from the NCSV or commissure between the NCSV 
and RSV and can be identified by the presence of a His potential 
(S9.2.7.6, S9.2.7.25). AV conduction should be monitored during 
ablation, which might necessitate the delivery of RF energy during 
sinus rhythm rather than during tachycardia, as well as gradually in-
creasing power (S9.2.7.25). 
 Ablation for VAs at the aortic root is usually successful (S9.2.7.8, 
S9.2.7.15, S9.2.7.35). In rare cases, earliest activation is identified at 
a coronary artery ostium or even within the proximal coronary ar-
tery, precluding ablation directly on the focus (S9.2.7.26, S9.2.7.35). 
Potential complications include aortic valve injury, coronary artery 
injury and thromboemboli; with appropriate precautions, however, 
these complications appear to be rare. 
 9.2.5  |  Left ventricular outflow tract and left 
ventricular summit 
 Endocardial left OT VAs can originate from the superior basal re-
gions of the interventricular septum or the LV free wall, near the 
aortic annulus, including the area adjacent to the His- bundle region 
where ablation carries a risk of AV block. The QRS typically has an 
LBBB inferior axis configuration, with R waves in V1, V2 and domi-
nant R waves in these leads for those originating in the more left-
ward aspect of the LVOT near the AMC. 
 The epicardial area bounded by the left anterior descending 
and circumflex coronary arteries has been termed the LV summit 
(Figure  7 ) (S9.2.7.4). Ablation for VAs in this region can be challeng-
ing and less successful than other OT VAs. The GCV divides the LV 
summit into two parts: the inferior part can be accessible to epicar-
dial catheter ablation, while the superior one—the triangle of Brocq 
and Mouchet (S9.2.7.37)—is inaccessible due to the close proximity 
of the coronary arteries and overlying epicardial fat (S9.2.7.38). One 
group has reported success in mapping and identifying origins of VA 
from the summit region within communicating veins between the 
aortic cusp and the pulmonary artery in half of the patients allowing 
for anatomic targeting of these VAs (S9.2.7.39). Ablation in the ad-
jacent endocardium is occasionally successful even when activation 
is later than 10 ms prior to the QRS onset at that site (S9.2.7.40–
S9.2.7.42). VAs originating from the apical summit are rightward of 
those in the basal part and tend to have a longer QRS duration, more 
rightward axis, and more often an RBBB configuration compared 
with those from the basal part of the summit (S9.2.7.41). Ablation 
from within the GCV or epicardium can be successful for VAs arising 
from the inferior part of the summit. 
 Epicardial VAs often cluster at perivascular sites, with the major-
ity at the junction of the GCV/AIV or at the proximal AIV (S9.2.7.26, 
S9.2.7.28, S9.2.7.43, S9.2.7.44). ECG characteristics can be similar to 
those of VAs originating from the SVs. Mapping within the GCV/AIV 
can be performed using standard RF catheters or small- diameter (2- 
Fr) multipolar electrode catheters (S9.2.7.26, S9.2.7.28). RF ablation 
in the coronary veins has a risk of perforation or injury to adjacent 
coronary arteries, or, in some patients, injury to the left phrenic nerve. 
Some physicians perform ablation in the GCV only after failure of RF 
energy application at the adjacent LVOT endocardium and SV, even if 
activation at these sites occurs later. Coronary angiography prior to 
ablation in the vein is essential, and a distance of 5 mm from the adja-
cent artery is recommended for ablation to be considered (S9.2.7.26, 
S9.2.7.44). An irrigated catheter is needed due to the low flow in the 
vein, and the impedance cutoff is usually disabled given that imped-
ance in the vein might exceed the set parameters. Some physicians 
limit the maximum power to 20 W, the maximum temperature to 
43°C, and the RF duration to 60 seconds (S9.2.7.26). Cryoablation has 
been considered when the target site is very close to the artery, but ar-
terial injury is also possible with cryoablation (S9.2.7.26, S9.2.7.42). To 
avoid phrenic nerve injury, ablation should not be attempted if there is 
diaphragmatic capture while pacing at the site at 20 mA. 
 In some cases, VAs in the apical portion of the LV summit are 
sufficiently leftward to be accessible from the pericardial space 
(S9.2.7.26, S9.2.7.38, S9.2.7.41). Proximity to major coronary ar-
teries and overlying epicardial fat can limit ablation (S9.2.7.38). 
When proximity to the epicardial coronary artery precludes 
catheter ablation, a direct surgical approach can be an option 
(S9.2.7.45–S9.2.7.47). 
 9.2.6  |  Para- Hisian ventricular arrhythmias 
 The His bundle is located at the most proximal and rightward 
part of the RVOT in the region of the perimembranous septum. 
VAs originating from this area often have distinctive ECG char-
acteristics, including a QS in V1- V2, relatively narrow QRS, and 
tall R waves in the lateral leads (S9.2.7.10). Ablation risks include 
damage to the His bundle or RBB and the possibility of complete 
AV block. When earliest activation is recorded near the His bun-
dle, mapping at the RSV and NCSV should be performed, given 
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that earlier activation can be identified at these sites (S9.2.7.34, 
S9.2.7.35, S9.2.7.48). Ablation with careful monitoring of AV con-
duction can be successful. Cryoablation can be an option to avoid 
AV block (S9.2.7.49). 
 9.2.7  |  Deep intraseptal sites 
 Often, idiopathic OT VAs can arise from deep intraseptal sites and 
share LBBB morphology with inferior axis (S9.2.7.50); however, no 
specific ECG pattern has been described indicating an intramural ori-
gin. Identification of the SOO is often only possible in retrospect after 
several structures (including the RVOT, LVOT, cusps, and coronary ve-
nous system) have been carefully mapped, and timing has been found 
to be equally early in several anatomical structures without match-
ing pace maps. Activation mapping from within a vascular perforator 
branch within the interventricular septum can be helpful in identify-
ing the SOO that can be targeted from an adjacent endocardial site 
(S9.2.7.50). Temporary suppression of VAs by cold saline infused into 
the distal coronary venous system and perforator veins can also sug-
gest an intramural septal focus (S9.2.7.51). Body surface mapping and 
multisite pacing have been found to help in indicating a deep septal 
origin (S9.2.7.52, S9.2.7.53). Ablation is attempted by RF application 
at the earliest endocardial breakthrough sites or as close as possible 
to the site identified by intraseptal mapping. If this is ineffective, si-
multaneous unipolar (S9.2.7.54) or simultaneous bipolar RF ablation 
(investigational) between two RF catheters positioned at both break-
through sites (S9.2.7.26), or between RVOT and SV (S9.2.7.55), or RF 
ablation directly within a septal perforator vein (S9.2.7.50) have been 
reported. Intracoronary ethanol infusion (S9.2.7.4) and the use of an 
investigation needle ablation catheter have been reported (S9.2.7.56). 
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 9.3  |  Idiopathic nonoutflow tract 
ventricular arrhythmia 
 
 9.3.1  |  Ventricular arrhythmias from the 
tricuspid and mitral annuli 
 Arrhythmias arising from the mitral annulus occur in approximately 
5% of patients presenting for ablation for idiopathic VAs and can 
arise from anywhere around the mitral annulus, with a slight pre-
dilection for the superior aspect (S9.3.1.1–S9.3.1.3). In the surface 
ECG, VAs from the mitral annulus have an RBBB morphology, with 
dominant R waves from V1 to V5, and can have an S wave in V6 
(S9.3.1.2–S9.3.1.4). Successful ablation has been reported in 80%- 
100% of cases (S9.3.1.1–S9.3.1.3). Some cases have an epicardial 
origin and can be approached from the CS or GCV, in which case the 
use of coronary angiography to verify a sufficient distance from the 
adjacent coronary arteries is warranted. 
 VAs from the tricuspid annulus are encountered in 8%–10% 
(S9.3.1.5) of patients with idiopathic VA referred for abla-
tion (S9.3.1.6). VAs from the tricuspid annulus have an LBBB 
morphology, positive polarity in leads I, V5, and V6, and a QS 
or rS pattern in aVR. Compared with RVOT arrhythmias, lead I 
has a taller R wave. A precordial R wave transition >V3 favors a 
free wall location, and a QS pattern in V1 favors a septal location 
(S9.3.1.5, S9.3.1.6). 
 Outcomes from ablation for VAs from the free wall of the tri-
cuspid annulus are favorable, with success rates of approximately 
90% (S9.3.1.5, S9.3.1.6). Ablation for VAs from the septal side of 
the tricuspid annulus are more challenging due to difficult cathe-
ter contact, proximity to the conduction system, and a possible in-
tramural origin for the arrhythmias (S9.3.1.6). Use of a deflectable 
sheath can help to improve catheter contact, and exploration of 
the LV or SV and the coronary venous system should be consid-
ered when ablation at the RV septum is unsuccessful (S9.3.1.7). The 
risk of AV block should be considered, and careful mapping of the 
conduction system prior to ablation at the septal tricuspid annulus 
is warranted. 
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 9.3.2  |  Mapping and ablation of ventricular 
arrhythmia from the papillary muscles 
 Ablation of papillary muscle arrhythmias presents unique anatomical 
challenges that can result in long procedural, fluoroscopy, and RF times 
(S9.3.2.1). Idiopathic VAs from the papillary muscles comprise up to 5% 
of patients presenting for PVC ablation (S9.3.2.1), typically have a focal 
origin consistent with triggered activity or abnormal automaticity as 
the mechanism, and are more likely to be provoked by catecholamine 
administration than by programmed stimulation (S9.3.2.2–S9.3.2.4). 
 Key Points 
 •  VAs originating from the papillary muscles can be challeng-
ing due to multiple morphologies of the VA and the diffi-
culty in achieving and maintaining sufficient contact during 
ablation. 
 •  VAs originate in LV papillary muscles more often than in 
RV papillary muscles; they more often originate from the 
posteromedial than the anterolateral papillary muscle and 
occur more often at the tip than at the base. 
 •  Pace mapping is less accurate than in other focal VAs. 
 •  ICE is particularly useful for assessing contact and stability. 
 •  Cryoablation can also aid in catheter stability during lesion 
delivery. 
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Postinfarction VAs from the papillary muscle can arise from an area of 
scar tissue and can have a reentrant mechanism (S9.3.2.5). Preprocedural 
imaging including CMR is helpful for identifying areas of scar tissue or 
fibrosis that are potential sources of arrhythmia. 
 Although most idiopathic PVCs from the papillary muscles are 
benign, they have the potential to cause cardiomyopathy (S9.3.2.6, 
S9.3.2.7), and rarely they are triggers for VF (S9.3.2.8). Patients with 
frequent papillary muscle arrhythmias are also more likely to have mi-
tral valve prolapse (S9.3.2.7, S9.3.2.9). While the large majority of these 
patients have benign outcomes, sudden death can occasionally occur, 
and this condition has been associated with the female sex, bileaflet 
prolapse, complex VAs, inverted or biphasic T waves in the inferior ECG 
leads of sinus beats, and LGE- CMR, typically in the inferior LV (S9.3.2.10, 
S9.3.2.11). Further studies on risk stratification are therefore needed. 
 Papillary muscle arrhythmias can arise from either ventricle, but 
the LV is the most common origin, with the posteromedial papillary 
muscle being the most frequent (S9.3.2.12). Papillary muscle ar-
rhythmias originate more frequently toward the tip of the muscle, 
in its distal third (S9.3.2.13). QRS morphology can suggest the origin, 
but variable papillary muscle anatomy and exit sites into the myo-
cardium limit ECG accuracy. PVCs from the posteromedial papillary 
muscles have RBBB QRS morphology with a superior axis and a tran-
sition in leads V3- V5. PVCs from the anterolateral papillary muscles 
have RBBB QRS morphology, a rightward axis, and inferior leads, 
demonstrating an inferior or discordant axis (S9.3.2.4, S9.3.2.14). A 
small initial q wave in V1 is common. Papillary muscle PVCs have a 
longer QRS duration compared with fascicular PVCs (153 ± 27 ms 
vs 127 ± 25 ms,  P < 0.05) (S9.3.2.14), and fascicular PVCs frequently 
exhibit an rsRʹ morphology in V 1 , which is more consistent with a 
typical RBBB morphology. 
 Papillary muscle VAs in the same patient often exhibit variability 
in QRS morphology, which can be due to variable exits from the same 
origin (S9.3.2.15). Pacing can produce the same QRS over a relatively 
large area on the papillary muscle, and ablation at a site with a pace 
map identical to the VA might not eliminate the arrhythmia, leading 
to ablation over larger areas (S9.3.2.15). In some patients, the VA can 
originate in a deep intramural location, and the electrograms with 
the earliest activation time can have a far- field appearance or be dif-
ficult to define. In these patients, ablation at sites with a matching 
pace map and prolonged S- QRS might be successful, although longer 
and higher- powered RF application might be necessary (S9.3.2.16). 
 Defining the anatomy and maintaining consistent catheter con-
tact and stability during ablation delivery are significant challenges. 
The use of ICE integrated with EAM systems can help to identify 
papillary muscle surfaces within the ventricle and provide real- time 
visualization of catheter contact on the papillary muscle during ab-
lation (Figure  8 ) (S9.3.2.4, S9.3.2.12, S9.3.2.17). Catheter instability 
often induces PVCs that complicate mapping. Steerable sheaths can 
be useful when a transseptal approach is employed, although there 
is a lack of comparative data. Cryoablation has the advantage of 
achieving stable contact with the papillary muscle during freezing 
and can be effective; however, data are limited (S9.3.2.18). 
 Lower success rates and higher recurrence rates have been re-
ported for the catheter ablation of papillary muscle arrhythmias, 
compared with other idiopathic VAs, with one study citing a 60% 
long- term success rate for ablation in patients with idiopathic papil-
lary muscle PVCs (S9.3.2.1). Although worsening mitral regurgitation 
following ablation of the papillary muscles has been reported, this is 
a rare occurrence, and complications from ablation of papillary mus-
cle arrhythmias are generally not significantly different from abla-
tion at other LV locations (S9.3.2.4, S9.3.2.19, S9.3.2.20). 
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 9.4  |  Bundle branch reentrant ventricular 
tachycardia and fascicular ventricular tachycardia 
 
 9.4.1  |  Introduction 
 There are 4 distinct groups of Purkinje- related monomorphic VTs: 
(a) BBR including interfascicular reentry VTs; (b) idiopathic fascicular 
reentrant VT; (c) fascicular reentrant VT post infarction; and (d) focal 
nonreentrant fascicular VT. The mechanism of focal nonreentrant 
fascicular VT is abnormal automaticity from the distal Purkinje sys-
tem, and the ablation target is the earliest Purkinje activation during 
the VT. The other VTs are caused by macroreentry and usually occur 
in specific locations with specific QRS morphologies. 
 9.4.2  |  Bundle branch reentrant ventricular 
tachycardia 
 Recognition 
 BBRVT is a unique, typically fast (200- 300 bpm), monomorphic 
tachycardia, which is usually associated with hemodynamic col-
lapse, syncope, and/or cardiac arrest (S9.4.2.4.1). BBRVT is 
caused by a macroreentry circuit involving the RBB and LBB, and 
septal ventricular muscle (S9.4.2.4.1–S9.4.2.4.5). BBR is often as-
sociated with advanced heart disease and has been observed in 
DCM (S9.4.2.4.3), coronary artery disease (S9.4.2.4.3), valvular 
 Key Points 
 •  BBR can occur in a variety of patients in whom the conduc-
tion system can be affected, including patients with DCM, 
valvular heart disease, MI, myotonic dystrophy, Brugada 
syndrome, and ARVC, among others. 
 •  Ablation of either the RBB or LBB eliminates BBRVT but 
does not eliminate other arrhythmic substrates. 
 •  A correct diagnosis of BBRVT is crucial and should employ 
established criteria prior to ablation of either of the bundle 
branches. 
 •  Ablation of the AV node does not cure BBRVT. 
 •  Ablation of either bundle branch does not cure interfascicular 
VT. 
 •  For posterior fascicular VTs, the P1 potential is targeted 
during VT; if P1 cannot be identified or VT is not tolerated, 
an anatomical approach can be used. 
 •  Purkinje fibers can extend to the papillary muscles, and 
these can be part of the VT circuit. 
 •  For anterior fascicular VTs, the P1 potential is targeted with 
ablation. 
 •  Focal nonreentrant fascicular VT is infrequent and can 
occur in patients with IHD; however, it cannot be induced 
with programmed stimulation, and the target is the earliest 
Purkinje potential during VT. 
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heart disease (S9.4.2.4.3, S9.4.2.4.6, S9.4.2.4.7), muscular dys-
trophy (S9.4.2.4.8–S9.4.2.4.10), CHD (S9.4.2.4.11), LV noncom-
paction (LVNC) (S9.4.2.4.12), ARVC (S9.4.2.4.13), and Brugada 
syndrome (S9.4.2.4.14). BBRVT can also occur in association with 
His- Purkinje system disease in the absence of SHD (S9.4.2.4.15–
S9.4.2.4.17). Although classically associated with DCM, BBRVT 
can also occur in the setting of isolated, unexplained conduction 
system disease (S9.4.2.4.15, S9.4.2.4.18, S9.4.2.4.19). Recently, 6 
cases of idiopathic BBRVT were identified in patients with nor-
mal biventricular size and function. All patients were noted to 
have His- Purkinje system disease, with prolonged HV at base-
line (mean 69.2 ms), and underwent successful ablation targeting 
the RBB. Mutations were identified in 3 of the 6 patients: 2 in 
the  SCN5A gene and 1 in the  LMNA gene (S9.4.2.4.19). Idiopathic 
BBRVT can be a genetic conduction disease, manifested by 
isolated conduction system disease and curable with catheter 
ablation. 
 The reported incidence of BBRVT is 3.5%, representing 6% of 
VTs in separate series and 20% in a series of patients with NICM 
alone undergoing evaluation for ablation (S9.4.2.4.20–S9.4.2.4.22). 
The incidence of BBRVT is likely underestimated. 
 BBRVT can have a typical LBBB (S9.4.2.4.23) or RBBB pattern, 
depending on which bundle forms the anterograde limb (Table  5 ); 
however, both morphologies can occur in the same patient 
(S9.4.2.4.24). Tchou and Mehdirad (S9.4.2.4.25) described three 
categories of BBRVT (Table  5 ). Type A and type C are the clas-
sic counterclockwise and clockwise BBRVT circuits, respectively. 
Type B is reentry within the LBB fascicles (interfascicular reentry). 
Counterclockwise BBR (type A) accounts for 98% of BBRVTs and 
has a typical LBBB pattern with an R- wave transition between 
leads V 4 and V 5 (S9.4.2.4.26). Alternatively, activation can pro-
ceed in an anterograde manner via the LBB and then through the 
septum, with retrograde activation via the RBB, creating an RBBB 
morphology (“clockwise” reentry, type C) (S9.4.2.4.20, S9.4.2.4.27). 
Interfascicular reentry tachycardia often has an RBBB and left he-
miblock QRS pattern. 
 Patients with BBR generally have a prolonged PR interval, QRS 
duration, and H- V interval. LBBB, or less commonly RBBB, on the 
sinus rhythm ECG, is due to conduction slowing in the bundle rather 
than complete block. 
 Single BBR beats can occur in patients who have apparently 
normal His- Purkinje conduction during sinus rhythm but who have 
functional conduction impairment (S9.4.2.4.28). This condition is ob-
served as a normal response to premature ventricular extrastimuli 
in patients undergoing PES and has been called a V3 phenomenon 
(S9.4.2.4.2, S9.4.2.4.29). 
 In the electrophysiology laboratory, ventricular extrastimuli 
delivered with short–long–short coupling intervals (pacing train of 
400 ms with a delay of 600 or 800 ms before the short- coupled 
premature coupling intervals are introduced) tend to cause unidirec-
tional block in the bundle branches facilitating the initiation of BBR 
(S9.4.2.4.30). Atrial pacing and/or isoproterenol might be required 
(S9.4.2.4.18). 
 Specific considerations 
 Several criteria help in diagnosing BBRVT:
 1 The typical 12-lead ECG morphology during tachycardia is LBBB 
or RBBB. 
 2 A critical delay in His-Purkinje system conduction is needed to 
initiate tachycardia. 
 3 Although AV dissociation can be present, there is usually per-
sistent 1:1 His-bundle or QRS activation, with the H-V interval 
during the tachycardia equal to or longer than the H-V interval in 
sinus rhythm (and no H-V dissociation) (S9.4.2.4.31). 
 4 Tachycardia stops and cannot be reinitiated if conduction in one 
of the bundle branches is interrupted. 
 5 During BBR, the His-bundle, RBB, and LBB activation sequences 
during an LBBB morphology tachycardia (or the His-bundle, LBB, 
and RBB activation sequences during an RBBB morphology tach-
ycardia) remain stable. 
 6 If the CL fluctuates, then the H-H interval oscillations precede the 
V-V interval oscillations. The H-V timing remains constant. 
 7  Entrainment with constant fusion (manifest entrainment) is pre-
sent during pacing from the RV apex (S9.4.2.4.32). However, it 
results in a PPI within 30 ms of the tachycardia cycle (S9.4.2.4.33). 
 8  Entrainment with concealed fusion is present during atrial pacing 
faster than the tachycardia, provided that AV nodal conduction 
allows 1:1 conduction. 
 In type A and C BBRVTs, the onset of ventricular depolarization is 
preceded by His- bundle, RBB, or LBB potentials with an appropriate 
sequence of His- bundle>RBB>LBB activation. Spontaneous variations 
in V- V intervals are preceded by similar changes in H- H/RBB- RBB/
LBB- LBB intervals. Recording from both sides of the septum can help 
to identify the BBR mechanism. 
 Interfascicular tachycardia is an uncommon type (S9.4.2.4.3, 
S9.4.2.4.18, S9.4.2.4.34–S9.4.2.4.37) in which one of the fascicles 
  Type A 
 Type B (Interfascicular 
tachycardia)  Type C 
 ECG morphology  LBBB pattern  RBBB pattern  RBBB pattern 
 Anterograde limb  RBB  LAF or LPF  LBB 
 Retrograde limb  LBB  LPF or LAF  RBB 
 Abbreviations: LAF, left anterior fascicle; LBB, left bundle branch; LBBB, left bundle branch block; 
LPF, left posterior fascicle; RBB, right bundle branch; RBBB, right bundle branch block. 
 TA B L E  5     Types of bundle branch 
reentrant tachycardia 
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serves as the anterograde limb while the other serves as the retro-
grade circuit. The distal link between fascicles occurs through the 
ventricular myocardium. The LAF is usually the anterograde limb 
and the LPF is the retrograde limb (S9.4.2.4.16, S9.4.2.4.37). BBRVT 
and interfascicular tachycardia can be present in the same patient 
(S9.4.2.4.2, S9.4.2.4.34, S9.4.2.4.38). In contrast to BBR, the H- V 
interval during interfascicular tachycardia is usually shorter by more 
than 40 ms than that recorded in sinus rhythm (S9.4.2.4.39). This 
condition occurs because the upper turnaround point of the circuit 
(the LBB point) is relatively far from the His bundle activated in the 
retrograde direction. 
 It is important to recognize BBRVT and interfascicular tachycar-
dia because they can be cured with catheter ablation. The differen-
tial diagnosis for BBR includes (a) VT due to myocardial reentry, (b) 
idiopathic left intrafascicular VT, (c) SVT with aberrant conduction, 
and (d) atriofascicular reentry. 
 With myocardial reentry, the His potential usually does not 
precede the QRS complex, and variations in the H- H interval fol-
low changes in the V- V interval because there is retrograde passive 
activation of the His- Purkinje system. The PPI after entrainment of 
tachycardia from the RV apex will usually be long, unless the myo-
cardial reentrant VT involves the apex (S9.4.2.4.3, S9.4.2.4.33). 
 The possibilities of other Purkinje- related VTs (S9.4.2.4.40), 
such as idiopathic fascicular VT (S9.4.2.4.41), fascicular VT post- MI 
(S9.4.2.4.42–S9.4.2.4.44), automatic His- Purkinje VT, focal Purkinje 
VT (S9.4.2.4.45, S9.4.2.4.46), and AV node/His- Purkinje reentry 
(S9.4.2.4.47), should also be considered (see below). 
 Catheter ablation 
 Pharmacological antiarrhythmic therapy is usually ineffective; how-
ever, RF catheter ablation of a bundle branch can cure BBRVTs and 
is currently regarded as first- line therapy (S9.4.2.4.3, S9.4.2.4.20, 
S9.4.2.4.48). Given that significant underlying structural disease is 
usually present, concomitant placement of an ICD should be strongly 
considered. 
 The technique of choice is ablation of the RBB (S9.4.2.4.3, 
S9.4.2.4.38, S9.4.2.4.49). BBRVT can be prevented by ablating the 
right or left main bundle branch (S9.4.2.4.16, S9.4.2.4.25). Although 
most patients demonstrate conduction system disease in the LBB, 
the RBB is typically the target for ablation because of the technical 
ease and desire to avoid complete LBBB. In patients with a com-
plete LBBB pattern during sinus rhythm, anterograde ventricular 
activation occurs solely via the RBB due to slow anterograde con-
duction over the LBB, potentially with retrograde LBB activation 
due to transseptal concealed conduction (S9.4.2.4.16, S9.4.2.4.50). 
Complete AV block can develop with RBB ablation, and the LBB may 
be targeted in such patients (S9.4.2.4.16, S9.4.2.4.50). 
 Complete RBB or LBB develops with successful ablation, al-
though QRS changes can be subtle in patients with preexisting con-
duction abnormalities. Elimination of retrograde V- H conduction has 
been used as a marker of successful ablation. 
 In interfascicular reentry, RBB ablation will not cure the tachy-
cardia because the RBB is a bystander. Similarly, ablation of the main 
LBB would not be expected to terminate the tachycardia because 
the circuit is distal to this point. Catheter ablation of the LAF or LPF 
will result in termination of the tachycardia (S9.4.2.4.35, S9.4.2.4.37, 
S9.4.2.4.38). A change of electrical axis might be the only manifesta-
tion during sinus rhythm after fascicular ablation. 
 Outcomes and risks 
 In the 2 largest reported series, acute success rates for BBRVT and 
interfascicular reentry were 100% (S9.4.2.4.3, S9.4.2.4.51). After 
ablation, BBRVT recurrence is uncommon but has not been thor-
oughly assessed with follow- up testing (S9.4.2.4.3, S9.4.2.4.37, 
S9.4.2.4.51). 
 The reported incidence of clinically significant conduction 
system impairment requiring implantation of a permanent pace-
maker varies from 0% to 30% (S9.4.2.4.3, S9.4.2.4.6, S9.4.2.4.8, 
S9.4.2.4.29–S9.4.2.4.31, S9.4.2.4.39). 
 Despite the success of BBRVT ablation, patients with cardiomyopa-
thy and heart failure continue to have a high mortality rate. Despite the 
impressive success of ablation for BBRVT, progressive heart failure is a 
common cause of death (S9.4.2.4.3, S9.4.2.4.6, S9.4.2.4.20, S9.4.2.4.26, 
S9.4.2.4.28, S9.4.2.4.38, S9.4.2.4.48, S9.4.2.4.49). Therefore, a CRT 
defibrillator should be considered after ablation based on the status of 
the residual conduction system and the severity of the underlying SHD. 
Furthermore, VT of myocardial origin can be induced in 36% to 60% 
of patients after successful ablation for BBR (S9.4.2.4.26, S9.4.2.4.37). 
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 9.4.3  |  Idiopathic fascicular reentrant ventricular 
tachycardia 
 Recognition 
 Verapamil- sensitive fascicular reentrant VT is the most common form 
of idiopathic left- sided VT and was first recognized as an electrocar-
diographic entity in 1979 by Zipes et al. (S9.4.4.3.1), who identified the 
following characteristic diagnostic triad: (a) induction with atrial pac-
ing, (b) RBBB and left- axis configuration, and (c) manifestation in pa-
tients without SHD. In 1981, Belhassen et al (S9.4.4.3.2) were the first 
to demonstrate the verapamil sensitivity of the tachycardia, a fourth 
identifying feature. In 1988, Ohe et al (S9.4.4.3.3) reported another 
type of this tachycardia, with RBBB and a right- axis configuration. 
Nogami (S9.4.4.3.4) and Talib et al (S9.4.4.3.5) subsequently reported 
on upper septal fascicular tachycardia. According to the QRS morphol-
ogy, verapamil- sensitive left fascicular reentrant VT can be divided 
into 3 subgroups (S9.4.4.3.4): (a) left posterior fascicular reentrant 
VT, in which the QRS morphology exhibits a RBBB configuration and 
a superior axis; (b) left anterior fascicular reentrant VT, in which the 
QRS morphology exhibits an RBBB configuration and inferior axis; 
and (c) upper septal fascicular VT, in which the QRS morphology ex-
hibits a narrow QRS configuration and normal or right- axis deviation 
(S9.4.4.3.4–S9.4.4.3.6). The left posterior type is most common, the 
left anterior type is uncommon, and left upper fascicular VT is very 
rare but sometimes occurs after catheter ablation of other fascicular 
reentrant VTs. 
 The reentrant circuit of verapamil- sensitive fascicular reen-
trant VT can involve the Purkinje network around the papillary 
muscles (S9.4.4.3.7). In addition to the current classification with 
3 subtypes, papillary muscle fascicular VT is another identifiable 
verapamil- sensitive fascicular reentrant VT. Finally, verapamil- 
sensitive left fascicular reentrant VT can be classified into 5 
subgroups (Table  6 ). Papillary muscle VTs originating from the 
Purkinje fiber system and VT originating from myocardial tissue of 
the papillary muscle appear to be different entities, although there 
can be some overlap. 
 Specific considerations 
 The anatomical basis of this tachycardia has provoked considerable 
interest, with data suggesting that the tachycardia can originate 
from a false tendon or fibromuscular band in the LV (S9.4.4.3.8–
S9.4.4.3.11). Using ICE and 3D mapping systems, the successful 
ablation site appears to be at the connection of a false tendon and 
ventricular wall in some cases. The Purkinje networks in these small 
anatomical structures can be important parts of the circuit. In papil-
lary muscle fascicular VTs, fibromuscular bands near papillary mus-
cles can potentially be the substrate of the circuit. 
 During tachycardia, two distinct groups of potentials, P1 and 
P2, are typically recorded from a catheter lying along the midsep-
tum (S9.4.4.3.12–S9.4.4.3.14). The mid- diastolic potentials (P1) 
show proximal to distal activation along the septum, and the fused 
presystolic Purkinje potential (P2) shows distal to proximal acti-
vation. During sinus rhythm, the P2 potentials are later than the 
 TA B L E  6     Fascicular ventricular tachycardias 
 I. Verapamil- sensitive fascicular reentrant VT 
 1. Left posterior type 
 i. Left posterior septal fascicular reentrant VT 
 ii. Left posterior papillary muscle fascicular reentrant VT 
 2. Left anterior type 
 i. Left anterior septal fascicular reentrant VT 
 ii. Left anterior papillary muscle fascicular reentrant VT 
 3. Upper septal type 
 II. Nonreentrant fascicular VT 
 Abbreviations: VT, ventricular tachycardia. 
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His- bundle potential and earlier than the onset of the QRS, which 
is consistent with an origin in the LPF. P1 represents the activation 
from tissue that has decremental properties and verapamil sensi-
tivity that constitutes the anterograde limb of the circuit in VT. P2 
represents the activation of the LPF or a Purkinje fiber near the 
LPF and is a bystander during VT. The LV septal muscle is likely the 
retrograde limb. 
 Catheter ablation 
 VT can be initiated with atrial extrastimuli or burst pacing, or ventric-
ular extrastimuli or burst pacing, facilitated by an isoproterenol infu-
sion, if necessary. When evaluating these tachycardias, a multipolar 
catheter placed along the left septum can be helpful in delineating 
parts of the reentry circuits (S9.4.4.3.12–S9.4.4.3.14). 
 Left posterior septal fascicular reentrant VT mapping along the 
LV septum identifies 2 distinct groups of potentials (P1 and P2) 
during the VT (S9.4.4.3.4, S9.4.4.3.12). The apical third of the septum 
with a P1 potential is usually targeted to avoid creating LBBB or AV 
block. If the VT or ventricular echo beats are not inducible, an empir-
ical anatomical approach can be effective (S9.4.4.3.14). First, the VT 
exit site is determined by pace mapping during sinus rhythm, and RF 
energy is delivered to that site. Second, a linear lesion is placed at the 
midseptum, perpendicular to the long axis of the LV, approximately 
10- 15 mm proximal to the VT exit. This anatomical approach is also 
useful in patients in whom diastolic Purkinje potentials cannot be 
recorded during VT. 
 Reported cases of left posterior papillary muscle fascicular VT pre-
sented an RBBB configuration and right- axis deviation QRS configu-
ration. A diastolic Purkinje potential (P1) is recorded at the papillary 
muscle with the location confirmed by ICE imaging. Ablation at this 
site is highly effective for suppressing this VT (S9.4.4.3.7). 
 Left anterior septal fascicular VT exhibits an RBBB QRS mor-
phology with Rs pattern in V5–V6. A Purkinje potential is recorded 
in the diastolic phase during the VT at the midanterior LV septum 
(S9.4.4.3.13). In this circuit, P1 potentials represent activation in the 
proximal portion of the specialized Purkinje tissue, which has dec-
remental conduction properties. During VT, the anterograde limb is 
the Purkinje tissue exhibiting P1, and the retrograde limb is the LV 
muscle. The circuits of the left anterior and posterior fascicular reen-
trant VTs are mirror images. 
 Left anterior papillary muscle fascicular VTs have RBBB with 
deep S waves in V5- V6. LV endocardial mapping during left anterior 
fascicular reentrant VT identifies the earliest ventricular activation 
in the anterolateral wall of the LV, where ablation suppresses VT 
(S9.4.4.3.7, S9.4.4.3.13). 
 Upper septal fascicular VT has a narrow QRS and inferiorly di-
rected frontal plane axis. P1 represents the activation potential of the 
specialized Purkinje tissue at the LV septum (S9.4.4.3.5). P2 represents 
the activation of the left anterior and posterior fascicles. Both the left 
anterior and posterior fascicles are the anterograde limbs of the reen-
trant circuit in VT, producing the narrow QRS configuration and infe-
rior axis. This VT is successfully ablated at the LV midseptum. 
 Outcomes and risks 
 In the largest series of reentrant fascicular VTs, which included 160 
patients with left posterior septal fascicular VT, 30 patients with left 
anterior septal fascicular VT, and 8 patients with left upper septal 
fascicular VT (S9.4.4.3.15), the success and recurrence rates were 
97% and 4%, respectively, for left posterior septal fascicular VT; 90% 
and 11%, respectively, for left anterior septal fascicular VT; and 100% 
and 2.5%, respectively, for left upper septal fascicular VT. Recurrence 
of papillary muscle fascicular VT after ablation was high (S9.4.4.3.7), 
with 3 of 8 patients (38%) with posterior papillary muscle fascicular 
VT and 1 of 5 patients (20%) with anterior papillary muscle fascicular 
VT requiring a second ablation session for VT recurrences. 
 Aside from the complications that can result from any LV elec-
trophysiological procedure, the only complications specifically as-
sociated with catheter ablation of idiopathic left fascicular VT have 
been LBBB and AV block. Tsuchiya et al (S9.4.4.3.16) have reported 
that two patients in their series of 16 patients (12.5%) had transient 
LBBB after ablation. The authors targeted the left basal septum, and 
the LBBB disappeared within 10 minutes without VT recurrence. In a 
larger series (S9.4.4.3.15), 1 (0.5%) of 198 patients had a transient AV 
block. This patient presented with left posterior fascicular VT, and 
the diastolic potential (P1) at the midseptum was targeted for abla-
tion. Before the ablation, the patient had catheter- induced RBBB. 
The AV block disappeared immediately after discontinuing the RF 
energy delivery. 
 9.4.4  |  Focal nonreentrant fascicular ventricular 
tachycardia and premature ventricular complex 
 Recognition 
 Focal nonreentrant fascicular VT is classified as propranolol- sensitive 
automatic VT (S9.4.4.3.17, S9.4.4.3.18) and is usually observed in pa-
tients with IHD (S9.4.4.3.19), although it has been observed in pa-
tients with structurally normal hearts (S9.4.4.3.20, S9.4.4.3.21). VT 
can be induced by exercise and catecholamines (eg, isoproterenol 
and phenylephrine); however, it cannot be induced or terminated 
by PES (S9.4.4.3.17). VT is transiently suppressed by adenosine and 
with overdrive pacing. Although this VT is responsive to lidocaine 
and beta blockers, it is usually not responsive to verapamil. These 
features can be employed to distinguish it from reentrant fascicu-
lar VT. The clinical and electrophysiological characteristics of this 
VT have not yet been well defined. Gonzalez et al (S9.4.4.3.20) have 
reported the electrophysiological spectrum of Purkinje- related 
monomorphic VT in 8 patients and have shown the mechanism to be 
consistent with abnormal automaticity or triggered activity in five 
patients. Talib et al (S9.4.4.3.17) have reported on 11 patients (2.8%) 
with idiopathic nonreentrant fascicular VT among 530 patients with 
idiopathic VT without SHD. All patients had monomorphic VT with 
a relatively narrow QRS (123 ± 12 ms) and did not respond to vera-
pamil. The VT exhibited RBBB and superior- axis configuration in 11 
patients (73%), inferior axis in 3 (20%), and LBBB and superior- axis 
configuration in 1 (7%). The VT could not be entrained. 
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 Catheter ablation 
 The ablation target of nonreentrant fascicular VT is the earliest 
Purkinje activation during VT. If the VT was not induced by ventricu-
lar stimulation and catecholamines, isolated PVCs with a similar QRS 
morphology to that observed during the VT can be targeted. At the 
earliest Purkinje activation during VT/PVC, a Purkinje potential is 
also recorded during sinus rhythm (S9.4.4.3.17). 
 Outcomes and risks 
 Although VT and PVC had been suppressed by catheter ablation in 
one series, the acute success rate is unclear because this VT is dif-
ficult to induce (S9.4.4.3.17). VT recurrence was observed in four 
patients (27%), 3 of whom underwent pace map–guided ablation 
during the first session. A second ablation with activation mapping 
guidance eliminated the VT during the 88 ± 8–month follow- up. 
Catheter ablation guided by activation mapping appears effective, 
whereas the pace map–guided approach is less efficacious. 
 LBBB and AV block have been associated with catheter ablation of 
nonreentrant fascicular VT. In verapamil- sensitive reentrant fascicular VTs, 
the creation of LBBB or AV block is rare because the ablation target is the 
diastolic abnormal Purkinje potential (P1) during VT, and the abolition of 
the normal Purkinje or fascicle potential (P2) is not needed to suppress 
the VT. By contrast, abolition of a portion of the Purkinje network is usu-
ally necessary to suppress the nonreentrant fascicular VT. After successful 
ablation, the amplitude of the local myocardium is diminished, and the 
Purkinje potential appears after the myocardial potential. When the ab-
lation site is located at the distal portion of the left fascicle, there is no 
change in the surface QRS morphology or H- V interval after ablation. If 
the VT arises from a more proximal portion of the fascicle, there is a po-
tential risk for causing LBBB or AV block by the ablation. Rodriguez et al. 
(S9.4.4.3.21) have reported cases of nonreentrant fascicular VT with an 
RBBB configuration and right- axis deviation in patients who presented 
left anterior fascicular block after the ablation. Lopera et al (S9.4.4.3.19) 
have reported on two patients with nonreentrant fascicular VT and IHD in 
whom complete AV block occurred after successful ablation for VT. 
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 9.5  |  Postinfarction ventricular tachycardia 
 
 9.5.1  |  General considerations 
 The mechanism for most VTs after MI is macroreentry involving 
ventricular scar areas, and initial events commonly occur several 
years after the acute MI (S9.5.5.1–S9.5.5.4). Focal nonreentrant 
mechanisms have been described in up to 9% of cases (S9.5.5.5). The 
chronic scar pattern observed after coronary occlusion has been 
most widely described as compact in architecture, extending from 
the subendocardium to the epicardium, with increasing ischemia 
duration, typically sparing the endocardial rim close to the cavity. 
Along the border of the scar, viable myocardium is interspersed with 
fibrous tissue, providing the substrate for slow conduction (S9.5.5.1, 
S9.5.5.2, S9.5.5.6, S9.5.5.7). Although most reentry circuits appear 
to involve the subendocardium, intraoperative mapping studies have 
demonstrated that a substantial number of VT circuits involve or are 
confined to the subepicardial layer (S9.5.5.3). 
 Early reperfusion therapy, which has been increasingly ad-
opted for effective management of acute MI, has not only resulted 
in myocardial salvage but also less LV aneurysm formation, scar 
transmurality, and wall thinning. Less confluent histological and 
electroanatomical scars (S9.5.5.8) are associated with the induction 
of faster VTs (S9.5.5.8, S9.5.5.9) and pose additional challenges for 
mapping and ablation for post- MI VT. 
 9.5.2  |  Clinical, unknown clinical, and nonclinical 
ventricular tachycardia 
 The first goal of VT ablation is to abolish the clinical VT, which can 
be accomplished in 90%–100% of patients inducible at baseline 
(S9.5.5.10–S9.5.5.13). However, determining which VT is clinical 
can often be challenging. Although a 12- lead VT ECG is not avail-
able for most patients, the stored ICD electrograms, if available, 
can act as an accurate surrogate for the 12- lead ECG (S9.5.5.14). 
CL of both spontaneous and induced VTs can vary, and CL alone is 
often insufficient for recognizing clinical VT (S9.5.5.14). Adding to 
the challenge of determining the area of interest and the endpoint 
for ablation is the lack of up- front inducibility of any VT in 7%–24% 
of patients (S9.5.5.12, S9.5.5.15, S9.5.5.16) and specifically that of 
clinical VT in 13%–30% of patients (S9.5.5.12, S9.5.5.14, S9.5.5.17). 
It is important to note that most patients are inducible for multiple 
previously undocumented VTs, with separate circuits and variable 
exit sites from the scar (S9.5.5.12, S9.5.5.18–S9.5.5.20). The clinical 
relevance of VTs induced in the electrophysiology laboratory with-
out prior documentation is unclear; numerous laboratories have only 
targeted induced VTs with CL equal to or longer than that of clini-
cally observed VT(s) but not those with comparatively shorter CLs 
(S9.5.5.18, S9.5.5.20). In these multicenter trials, the VT rate could 
be markedly reduced in a substantial number of patients; however, 
approximately 50% of patients experienced VT recurrence within 
6 months (S9.5.5.18–S9.5.5.20). 
 The association between noninducibility following ablation for 
any VT, including nonclinical VTs and the subsequent greater free-
dom from VT recurrence, supports the clinical relevance of non-
clinical VTs. However, as many as 41% of the patients who remain 
inducible for nonclinical VT do not present with recurrence during 
short- term follow- up (see Section  9.17 ) (S9.5.5.12, S9.5.5.21). A po-
tentially useful electrophysiological characteristic in distinguishing 
relevant from nonrelevant induced VTs is the similarity between 
VT CL and the baseline ventricular refractory period, given that 
VTs with a CL within 30 ms of the ventricular refractory period CL 
(fast VT based on the individual ventricular refractory period) rarely 
occur spontaneously (S9.5.5.22). The presence of only the latter VTs 
has been associated with low VT recurrence, comparable to that of 
patients who were rendered noninducible by ablation (S9.5.5.22). 
 9.5.3  |  Mapping and ablation strategy 
 Mapping and ablation strategies are determined by the type of VT 
and substrate. After MI, a minority of patients have only mappable 
VTs (hemodynamically tolerated, reproducibly inducible, with stable 
morphology) that allow for extended activation and entrainment 
mapping (S9.5.5.12, S9.5.5.18, S9.5.5.20). Hence, for most patients, 
additional mapping methods need to be employed in conjunction 
with entrainment mapping to identify critical components of the 
reentry circuit. Although there is no single gold standard approach, a 
reasonable workflow is presented in Figure  9 . 
 Voltage mapping facilitated by 3D EAM systems (Section  8 ) is con-
sidered the standard for invasive identification of scar tissue during sinus 
rhythm and has been validated by histology in postinfarct animal models 
(S9.5.5.23–S9.5.5.26). For electroanatomically confluent and dense scars 
typical of nonreperfused infarcts (S9.5.5.8), VT- related sites are often 
but not exclusively located in low- voltage areas (S9.5.5.27, S9.5.5.28). To 
provide additional guidance in identifying putative isthmus sites in low- 
voltage areas, especially for unmappable VTs, several additional strate-
gies have been suggested focusing on electrogram characteristics (split, 
late, fractionated potentials) and pace mapping (S9.5.5.18, S9.5.5.20, 
 Key Points 
 •  In cases of multiple inducible VTs, the clinical VT should be 
preferentially targeted. 
 •  Elimination of all inducible VTs reduces VT recurrence and 
is associated with prolonged arrhythmia-free survival. 
 •  For tolerated VTs, entrainment mapping allows for focal ab-
lation of the critical isthmus. 
 •  For nontolerated VTs, various ablation strategies have been 
described, including targeting abnormal potentials, match-
ing pace mapping sites, areas of slow conduction, linear le-
sions, and scar homogenization. 
 •  Imaging can be beneficial in identifying the arrhythmogenic 
substrate. 
 •  Epicardial ablation is infrequently required, but epicardial 
substrate is an important reason for VT recurrence after VT 
ablation in patients with prior infarcts. 
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S9.5.5.23, S9.5.5.24, S9.5.5.29, S9.5.5.30). Mapping within regions of low 
voltage while pacing with extrastimuli at sites remote from low- voltage 
regions has also been demonstrated to be useful for exposing abnormal 
conduction regions that can be critical for VT (S9.5.5.31–S9.5.5.34). 
 Various RF lesion delivery strategies have been described, rang-
ing from focal ablations guided by entrainment mapping to ablation 
of the entire scar (S9.5.5.13, S9.5.5.18). Suggested strategies include 
short linear lesions from the putative VT exit sites toward the center 
of the substrate, across the presumed critical isthmus and/or along the 
scar border zone (S9.5.5.23, S9.5.5.24, S9.5.5.30). However, the end-
point for these short linear lesions is often arbitrary. Circumferential 
isolation of the identified scar (bipolar voltage <1.5 mV) (S9.5.5.35) 
or the “core” containing potential VT isthmus elements (regions with 
bipolar voltage <0.5- 1 mV and potentially important sites identified by 
entrainment, activation, and pace mapping) (S9.5.5.36), confirmed by 
demonstrating exit block from the core, has been suggested as an in-
crementally useful ablation endpoint beyond VT noninducibility. Other 
methods incorporate the goal of demonstrating functional entrance 
block into regions of scar tissue, as demonstrated by the elimination 
of all previously identified LPs or local abnormal ventricular activities, 
either by targeting channels of conduction or by direct ablation at all 
abnormal sites (S9.5.5.13, S9.5.5.37–S9.5.5.39). These approaches 
often involve more comprehensive substrate modification than the 
initial strategy of transecting potential circuits with linear lesion sets. 
 Although substrate- based ablation for clinical and induced VTs 
remains a probabilistic approach to VT ablation, the technique has 
been successfully performed after a presumed first VT episode 
and in patients with recurrent VT despite AAD therapy (S9.5.5.18, 
S9.5.5.29, S9.5.5.30, S9.5.5.40). 
 After substrate modification guided by clinical and induced non-
clinical VT, a significant number of patients experience recurrence of 
symptomatic VT, including 30% of patients who have been rendered 
noninducible after ablation (S9.5.5.21). The number of induced VTs is 
a potential surrogate for a larger and complex substrate (S9.5.5.12, 
S9.5.5.18), and larger scars have been associated with VT recurrence 
(S9.5.5.12). Recurrent VT can be due to lesion recovery or incomplete 
lesions with local modification of the substrate (S9.5.5.16, S9.5.5.41). 
Although some of these VTs originate from a previously targeted area, 
they can have a different morphology based on 12- lead ECGs or ICD 
electrograms (S9.5.5.16, S9.5.5.41). However, recurrent VT can also 
originate from unmapped areas or from those areas not considered 
relevant during the index ablation (S9.5.5.41). 
 9.5.4  |  Substrate- based ablation strategies without 
upfront ventricular tachycardia induction 
 Substrate- based approaches that target some or all abnormal elec-
trograms, irrespective of clinical and/or induced VTs, have been 
suggested (Table  7 ), which can also be performed if VT is not in-
ducible or if VT induction is not desired because of safety concerns 
(S9.5.5.13, S9.5.5.15, S9.5.5.31, S9.5.5.37). These strategies have 
targeted sites with abnormal electrograms, either of the entire scar 
in the endocardium and epicardium (S9.5.5.13) or, more selectively, 
target sites with LPs (S9.5.5.15) anywhere within the scar or sites 
with fractionated potentials predominantly located in the border 
zone, which are markers for conducting channels (S9.5.5.37), or that 
have targeted sites with abnormal potentials that are poorly coupled 
to the myocardium (ie, LAVA) (S9.5.5.31). These techniques have 
been demonstrated to be superior to those employed in the control 
groups in the previously cited studies. There is, however, no gener-
ally accepted control group, and it is therefore difficult to compare 
the benefit of the various approaches with each other. 
 There is currently no standardized approach for substrate- 
guided ablation, and definitive comparisons between different tech-
niques and endpoints are not available. The procedural outcomes 
(eg, noninducibility, elimination of LPs or LAVA, substrate or core 
isolation, scar dechanneling) are acute endpoints that cannot be eas-
ily randomized and/or applied to all patients with VT. The associa-
tion between a procedure ' s endpoint and favorable VT- free survival 
might simply reflect a less complex substrate in patients for whom 
the desired endpoint can be achieved. However, success with more 
comprehensive ablation strategies has been consistently observed 
(S9.5.5.42). 
 It is important to note that studies have suggested various defi-
nitions for abnormal electrograms as surrogates for the VT substrate 
targeted by ablation (S9.5.5.15, S9.5.5.16, S9.5.5.31–S9.5.5.34, 
S9.5.5.38, S9.5.5.39, S9.5.5.43, S9.5.5.44). Validation is challenging 
and usually limited to mappable VTs (S9.5.5.38). The specificity and 
sensitivity of these abnormal electrograms for identifying the VT 
substrate throughout the range of observed post- MI scars recorded 
 F I G U R E  9     Overview of the workflow for catheter ablation of 
 VT in patients with  IHD . Not all of these steps might be required, 
and steps can be performed in a different sequence. For instance, 
repeat  VT induction can be deferred in patients with hemodynamic 
instability. In addition, the operator might have to adapt to events 
that arise during the case, for instance, to take advantage of 
spontaneous initiation of stable  VT during substrate mapping 
and switch to activation mapping.  IHD = ischemic heart disease; 
 PES = programmed electrical stimulation;  SR = sinus rhythm; 
 VT = ventricular tachycardia 
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with different catheters, electrode sizes, and interelectrode spac-
ings remain to be determined. 
 High- resolution mapping of post- MI reentrant VT in an animal 
model of reperfused MI indicates that functional conduction block 
during VT can play an important role (S9.5.5.45), and these areas 
might not be detectable during sinus rhythm or pacing at slow rates. 
Targeting sites that show delayed conduction after delivering ex-
trastimuli has been shown to be beneficial, with a smaller target 
area and lower VT recurrence than when other sites were targeted 
(S9.5.5.33, S9.5.5.34). 
 This result might be particularly relevant for patients with small, 
less confluent or nontransmural scars after MI, in whom parts of the 
VT substrate might be functional, and a systematic application of an 
RV short- coupled extrastimuli can be useful for identifying hidden 
substrate components. 
 High- density multielectrode mapping with smaller electrode 
sizes and spacings can be helpful in obtaining more complete and 
rapid characterization of the arrhythmogenic substrate (Section  8 ), 
allowing for superior characterization of low- amplitude local elec-
trograms from thin endocardial myocardium, which can be ob-
scured by large far- field potentials from adjacent myocardium if 
catheters with large electrodes with distant interelectrode spac-
ing are used (S9.5.5.46–S9.5.5.49). Further studies are required 
to assess the effect of these mapping techniques on ablation 
outcomes. 
 Finally, imaging is of major importance for identifying scars and 
the critical arrhythmogenic substrate within the scar. The use of var-
ious imaging modalities has been detailed in Section  5 . Numerous 
studies have demonstrated a good correlation between CMR- 
defined scars and EAM- defined scars. The same is true for CT in 
which the wall thickness has been employed to identify scars in 
patients post infarction. Increased tissue heterogeneity within the 
scar demonstrated by CMR has helped to identify critical sites that 
can be selectively targeted (S9.5.5.50), resulting in decreased VT re-
currences. Likewise, CT- defined scar topography helps to identify 
critical VT target sites (S9.5.5.51). Critical areas are often located in 
myocardial ridges that are separated by areas of thinning (S9.5.5.51). 
 9.5.5  |  Epicardial mapping and ablation 
 The role of postinfarction epicardial mapping and ablation is not 
clearly defined. 
 Despite a predominant subendocardial substrate in most pa-
tients, reentry circuits can be confined to the subepicardial layer 
(S9.5.5.3). The current incidence of epicardial substrate in patients 
referred for catheter ablation is unknown. ECG features are not 
reliable for predicting epicardial LV- VT exit in postinfarction VT 
(S9.5.5.52). Epicardial circuits might also be interrupted from the en-
docardium, particularly in areas with wall thinning, and evidence of 
this phenomenon is more frequently observed in post- MI patients 
than in patients with DCM (S9.5.5.53). Some 42%- 57% of all post- MI 
patients included in multicenter studies (S9.5.5.18, S9.5.5.29, 
S9.5.5.40, S9.5.5.54) and 23%- 41% of patients from single- center 
series (S9.5.5.12, S9.5.5.15, S9.5.5.16) had previously undergone car-
diac surgery. In most patients, the presence of substantial pericardial 
adhesions from surgery or postinfarct pericarditis requires the cre-
ation of a surgical window in the electrophysiology lab or operating 
room to access the pericardial space. Even after epicardial access has 
been achieved, mapping can be particularly limited over the anterior 
wall (S9.5.5.55, S9.5.5.56). Continued oral anticoagulation and dual 
antiplatelet therapy raise the concern for bleeding risks associated 
with pericardial puncture (S9.5.5.16). 
 In experienced referral centers, percutaneous or surgical epicar-
dial access has been considered appropriate in 9%- 29% of patients 
(S9.5.5.12, S9.5.5.15, S9.5.5.16, S9.5.5.55). At least 6% of post- MI pa-
tients referred for VT ablation benefit from an epicardial procedure 
(S9.5.5.55). A previously failed endocardial ablation preceded most 
of the epicardial procedures. Caution is advised, however, given the 
often associated comorbidities and the large proportion of patients 
with insufficient target structures that can be safely ablated in the 
epicardium (S9.5.5.55). Furthermore, procedural failure can be re-
lated to reasons other than an epicardial VT origin. 
 Based on the available data, the relative contribution of first- line 
epicardial ablation to a patient ' s outcome remains unclear. For a large 
number of patients, accessible epicardial ablation target sites cannot 
be identified, and these patients are exposed to additional proce-
dural risks and discomfort. Considering the higher risk for procedural 
complications with an epicardial approach (S9.5.5.57), careful pa-
tient selection is warranted. Further study is required to determine 
whether preprocedural imaging can help to identify post- MI patients 
who will benefit from an epicardial approach (S9.5.5.58, S9.5.5.59). 
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 9.6  |  Dilated cardiomyopathy 
 
 In nonischemic DCM, ablation may be considered for sustained 
monomorphic VT, recurrent polymorphic VT, or VF initiated by trigger-
ing PVCs (see Section  9.9 ), and for frequent nonsustained VT and PVCs 
that are suspected of contributing to ventricular systolic dysfunction 
or interfering with effective delivery of cardiac resynchronization pac-
ing (see Section  4.3 ). 
 The prevalence of DCM is estimated to be in the range of 37 cases 
per 100 000 population (S9.6.1). Although the etiology is often clin-
ically obscure, approximately 40% of patients have a genetic cause 
 Key Points 
 •  Identifying the location and extent of scarring on CMR is 
beneficial in procedural planning and has improved the out-
comes of ablation in patients with DCM. 
 •  The ablation strategy is similar to postinfarction VT. 
 •  An intramural substrate is more frequently encountered in 
DCM than in postinfarction patients and requires a differ-
ent ablation strategy than for patients with either epicardial 
or endocardial scarring. 
 •  Epicardial ablation is beneficial if the scar is located in the 
epicardium of the LV free wall. 
 •  For intramural circuits involving the septum, epicardial ab-
lation is not beneficial. 
 •  In the absence of CMR, unipolar voltage mapping has been 
described as a method to indicate a deeper-seated scar. 
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(S9.6.1). Although uncommon, sustained monomorphic VT occurs at 
an annual rate of approximately 3%- 4% in patients with an ICD, a LVEF 
≤0.35, nonsustained VT, and no prior history of sustained VAs (S9.6.2). 
In the DANISH trial, fewer than 3% of the patients with class II or III 
heart failure symptoms and an LVEF ≤0.35 had sustained VT during a 
median follow- up of 5.6 years (S9.6.3). In a series of 158 patients with 
DCM, a mean LVEF of 0.31, and no history of sustained VT, 13% of 
the patients were found to have inducible sustained monomorphic VT 
(S9.6.4). VT due to DCM is occasionally encountered in patients with 
atherosclerotic coronary artery disease and is suggested by the pres-
ence of multiple basal origin VTs and scar regions extending beyond 
the distribution expected from an infarct (S9.6.5). 
 Three VT mechanisms have been identified in patients un-
dergoing ablation (S9.6.6–S9.6.8), the most common of which is 
scar- related reentry, accounting for more than 80% of sustained 
monomorphic VTs. Reentry involving the bundle branches or fas-
cicles (see Section  9.4 ) is encountered in up to 19% of patients, 
whereas focal VT mechanisms occur less frequently. 
 CMR with gadolinium contrast identifies areas of delayed hype-
renhancement consistent with myocardial fibrosis in 30%–50% of 
patients with DCM, and the presence of this scarring is associated 
with an increased risk of sudden death and VT (S9.6.9–S9.6.11). In 
patients with monomorphic VT, CMR also identifies scar areas that 
are a valuable guide to potential ablation target regions, given that 
the reentry circuit sites are usually associated with >25% scar trans-
murality (S9.6.12–S9.6.18). CMR is therefore particularly helpful 
in planning and performing ablation procedures in these patients. 
Knowledge of the scar location has improved ablation outcomes in 
patients with DCM (S9.6.19). 
 The approaches to mapping and ablation for scar- related VTs in 
DCM are similar to those for postinfarction VTs; however, intramural 
substrates that are not easily identifiable or accessible for ablation 
are more common than in the postinfarct population and contrib-
ute to procedure failures and recurrences (S9.6.8, S9.6.12, S9.6.20, 
S9.6.21). The relevant scar area is identified from imaging and/or 
substrate mapping. When VT can be induced and is sustained and 
hemodynamically tolerated, a combination of activation mapping 
and entrainment mapping can be used to select the ablation region 
in or near the scar area (S9.6.20, S9.6.22). When VT is not mappable 
and an area of low voltage (bipolar voltage <1.5 mV) can be identi-
fied that is consistent in location with the VT QRS morphology, a 
substrate type of approach can be used in the endocardium and/
or epicardium (S9.6.23–S9.6.26). Although isolated LPs and fraction-
ated potentials are encountered less frequently than in postinfarct 
VT scars, these electrogram targets can still be used to guide abla-
tion (S9.6.26, S9.6.27). Pace mapping can suggest the VT exit region; 
however, as with other scar- related VTs, critical parts of the reentry 
circuit where ablation may also be successful can be several centi-
meters distant from the exit region. One study found that when a 
low- voltage area is present, extensive ablation over the region (both 
endocardially and epicardially) was associated with a lower risk of 
VT recurrence compared with targeting only inducible VTs (S9.6.28). 
Absence of inducible VT after ablation is associated with a lower 
risk of VT recurrence (S9.6.29–S9.6.31). Another study found that 
the presence of only rapid VTs after ablation (CL <30 ms plus the RV 
effective refractory period measured at a pacing CL of 400 ms) was 
not associated with a greater risk of recurrence (S9.6.32). 
 Scar- related VTs tend to originate from scar regions along the mi-
tral annulus or within the interventricular septum (S9.6.12, S9.6.20, 
S9.6.22, S9.6.33). Multiple morphologies of inducible VT and poorly 
tolerated VTs are common. The VT circuit can involve the endocar-
dial, epicardial, or intramural regions of the LV. The ECG morphology 
of the VT is a useful guide to the likely target region and can inform 
the initial approach. The risk, outcomes, and approach to ablation 
also vary with the substrate location. 
 VTs that originate from an LV scar in the free wall along the mitral 
annulus typically have an RBBB configuration and dominant R waves 
in the midprecordial leads (V3, V4), with an axis directed inferiorly 
(if the VT exit is superior) or superiorly (if the VT exit is inferiorly 
located) (S9.6.12, S9.6.20). A qS or QS configuration in lead I often 
indicates an epicardial exit, consistent with initial forces directed 
from the epicardium to the endocardium. The QRS morphology can 
be misleading, however, particularly for fast VTs (S9.6.14, S9.6.34). 
Epicardial ablation is often helpful, although some of these VTs can 
be successfully ablated from the endocardium. With LV free wall 
VTs, some laboratories start with mapping in the epicardium, obtain-
ing epicardial access before anticoagulation is administered. Other 
laboratories always start on the endocardium to avoid the risks of 
epicardial access and obtain this if the endocardial approach fails. In 
reported series from experienced centers, epicardial mapping is per-
formed in 29%- 74% of patients (S9.6.12, S9.6.22, S9.6.35, S9.6.36). 
The approach to epicardial ablation is reviewed in Section  6.3 . 
Recognizing that low voltage can be recorded over epicardial fat and 
avoiding the left phrenic nerve and coronary artery injury are im-
portant considerations (S9.6.37). 
 VTs that originate from the anteroseptal region typically have a 
dominant S wave in V1, with an inferior axis and prominent R waves 
by V3 to V4 (S9.6.12, S9.6.20). The frontal plane axis can be inferiorly 
or superiorly directed. If the scar extends leftward along the aortic 
root and toward the AMC region, the VT can have a dominant R wave 
in V1 with an inferior axis. If the scar extends inferiorly in the septum, 
VTs with a superiorly directed axis can be present. Ablation for VTs 
that originate in scars at the anteroseptum has a lower success rate 
compared with those from the inferolateral basal LV in a number of 
studies (S9.6.12, S9.6.20). Access from the epicardial aspect is limited 
by the overlying RVOT, the epicardial fat pad, and the left coronary 
arteries. In the septum, ablation can be limited by proximity to the 
AV conduction system. Determining the risk of heart block and man-
aging its consequences are important considerations. Implementation 
of pacing for CRT might be warranted if ablation results in AV block. 
 Intramural VTs can occur in any location but are common 
in the periaortic region and septum (S9.6.12, S9.6.20, S9.6.33). 
Preprocedural CMR is the gold standard for identifying scarring 
and is particularly helpful in identifying intramural scars (Section  5 ). 
Identification of intramural scars is best accomplished by a pre-
procedural CMR. In the absence of CMR data, intramural scarring 
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is suspected when the endocardial bipolar voltage is >1.5 mV (with 
3.5- mm electrode mapping catheters) over the endocardial region 
that is closest to the VT. If located at the LV free wall, an epicardial 
origin can be excluded when epicardial mapping fails to identify a 
VT substrate in the overlying epicardium. The unipolar endocardial 
voltage can be helpful for identifying deeper seated scar tissue. An 
LV unipolar voltage <8.3 mV over an area with an endocardial bipo-
lar voltage >1.5 mV is consistent with intramural or epicardial scars; 
however, electrogram amplitude is also dependent on wall thick-
ness, and there is substantial variability (S9.6.33, S9.6.38–S9.6.40). 
As indicated in Section  8.5.2 , different voltage cutoff values have 
been reported, and validation studies with CMR- defined scars have 
demonstrated that there is a substantial overlap of unipolar low 
voltage between scar zones and regions without scars. These cut-
off values should therefore be used with caution in the absence of 
available CMR data. Septal intramural scars are suggested by a con-
duction time of >40 ms when pacing is performed on the RV side of 
the septum, and recording from the adjacent LV septum (S9.6.41). 
Use of intracardiac ultrasound has also been suggested for detecting 
scars, but data are limited (S9.6.42). The optimal approach to abla-
tion for these VTs is not defined; however, ablation targeting the 
closest overlying endocardial and epicardial sites is effective in some 
patients. 
 Overall outcomes are largely from case series published by expe-
rienced centers, a number of which have included results from mul-
tiple procedures (S9.6.12, S9.6.20–S9.6.24, S9.6.26, S9.6.28, S9.6.31, 
S9.6.36, S9.6.43). Ablation abolishes at least one inducible VT in 
60%- 74% of patients and all inducible VTs in 43%–72% of patients. 
Programmed stimulation is not performed after ablation in 10%- 15% 
of patients, largely due to hemodynamic concerns. Persistent induc-
ibility of sustained monomorphic VT is associated with increased 
recurrences (S9.6.29–S9.6.31). During median/mean follow- ups 
ranging from 15 to 48 months, 31%- 61% of patients experience at 
least 1 VT recurrence. Approximately half of those with recurrent 
VT experience fewer VT episodes than prior to ablation (S9.6.12, 
S9.6.22). When directly compared in the same center, recurrent 
VT is more frequent after ablation for DCM VT than for postin-
farction VT (S9.6.21). Transplant- free survival ranges from 76% to 
89%. Patients with large scar areas associated with larger areas of 
low voltage and VTs that have LV apical exits, often associated with 
scar extending from base to near the apex, have increased mortality 
during follow- up (S9.6.43, S9.6.44). 
 Complications, including vascular access bleeding, tamponade, 
and volume overload, are reported in 4%- 11% of patients (S9.6.22, 
S9.6.23, S9.6.31). Serious complications, including tamponade re-
quiring surgery, phrenic nerve injury, and coronary artery injury, are 
more frequent when percutaneous epicardial access is performed 
(S9.6.22, S9.6.35). Thromboembolic complications appear to be rare, 
but pulmonary embolism can occur. In- hospital mortality is as high 
as 3% and has been reported due to uncontrollable VT, refractory 
heart failure, and tamponade sequelae (S9.6.23). When LV systolic 
function is severely depressed, the option of cardiac transplantation 
or an LVAD is an important consideration if the arrhythmia cannot 
be controlled or if the procedure is complicated by hemodynamic 
deterioration. Mechanical support has also been employed during 
ablation procedures to prevent hemodynamic deterioration and to 
facilitate mapping (Section  6 ). Ablation that results in LBBB or AV 
block can lead to hemodynamic deterioration due to cardiac dys-
synchrony that can warrant implementation of biventricular pacing. 
Extensive ablation of areas of normal myocardium has the potential 
to further impair ventricular function, although this risk has not been 
clearly defined. It seems prudent to avoid empiric ablation over large 
regions that are not known to contain scars. 
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 9.7  |  Ventricular tachycardia ablation in 
hypertrophic cardiomyopathy 
 
 Malignant VA contributes to sudden death in patients with HCM. 
ICDs are therefore the mainstay of prevention. The substrate for VAs 
in HCM is complex. The combination of myofibrillar disarray and fi-
brosis likely generates heterogeneous conduction properties and, 
together with the vulnerability of the hypertrophied myocardium to 
supply- demand ischemia, creates a potentially arrhythmogenic milieu 
(S9.7.1–S9.7.3). Interstitial- type fibrosis (compared with replacement 
fibrosis), postmyectomy scars, alcohol ablation, and the presence of 
an apical aneurysm can also influence arrhythmogenesis (S9.7.4). The 
fibrotic areas visualized on CMR that characterize HCM can result in a 
similar substrate to scars from ischemic disease, in which case similar 
techniques can be applied during VT ablation (S9.7.5–S9.7.8). However, 
increased myocardial thickness and intramyocardial or epicardial sites 
of fibrosis limit the reach of classical mapping and ablation methods. 
The varying mechanisms (eg, reentrant vs triggered) and morphology 
(monomorphic vs polymorphic) of VAs encountered in HCM represent 
further challenges. ICD records indicate that polymorphic VT degener-
ating to VF is the most common event (S9.7.9–S9.7.11). 
 Ablation is generally performed for monomorphic VT that recurs 
despite antiarrhythmic therapy, particularly with ICD shocks. These 
VAs are only a small proportion of VAs in HCM, and the ablation ex-
perience is limited to case reports and small case series of highly se-
lected patients. In a series of 10 patients with preserved LVEF (LVEF 
of 57 ± 13%), programmed stimulation induced clinical VT in 7 patients 
(S9.7.12). A mean of 2 VTs per patient (including nonclinical VTs) were 
induced. VTs were sometimes stable and permitted activation and 
entrainment mapping. Voltage mapping identified a combination of 
epicardial and endocardial scars in most patients. Isolated endocardial 
or epicardial scarring rarely occurred. The ablation strategy entailed 
targeting late or fractionated electrograms and pace mapping and/or 
substrate modification targeting low bipolar voltage (≤1.5 mV) regions. 
It is worth noting that epicardial ablation was required in most patients. 
During a 3- year follow- up, 30% of the patients underwent recurrent 
shocks, with repeat procedures required for two patients. 
 A similar approach was used in another series of 22 patients with 
more advanced disease (mean LVEF of 35%) (S9.7.13). Scar- related 
VTs occurred most often (60%) from the LV- RV junctions, either at 
the basal (42%) or apical (18%) LV segment level (coinciding with the 
anatomical regions frequently associated with fibrosis). Epicardial 
ablation was required in almost two- thirds of the patients, and 73% 
remained arrhythmia- free at 20 months. In another report of five pa-
tients with the dilated phase of HCM (LVEF of approximately 35%), 
VT circuits were predominantly distributed in the basal septum and 
the basal anterior to anterolateral LV. In addition to the endocardial 
ablation, intracoronary ethanol ablation and surgical cryoablation 
were required in a number of patients (S9.7.14). 
 Patients with HCM and an LV apical aneurysm have a greater 
risk of sudden death, embolic stroke, and progressive heart failure 
than the general population with HCM and warrant special consid-
eration (S9.7.15). The thin- walled dyskinetic or akinetic segment 
can be composed of dense scars with channels of viable myocar-
dium (resembling ischemic substrate). Both sustained monomor-
phic VTs and VTs with an RBBB or LBBB pattern in lead V1 can 
occur, the latter consistent with an exit from the septal aspect of 
the aneurysm. Careful imaging is important for defining the aneu-
rysm and ruling out thrombi prior to the procedure. Transthoracic 
contrast echocardiography, left ventriculography, and real- time 
visualization with ICE can be helpful. Anticoagulation therapy is 
a reasonable postprocedure treatment. Ablation strategies can in-
clude those techniques used for ICM (S9.7.16). In a recent series, 
endocardial ablation was successful in most patients, and epicar-
dial ablation was required in only 1 patient (S9.7.17). In a number 
of cases, however, the aneurysm does not have low- voltage endo-
cardial or epicardial scars. When ablation is not possible or is inef-
fective, surgical approaches could be successful (S9.7.18, S9.7.19). 
 Common themes emerge from these reports on ablation for mono-
morphic VT in HCM. ECG characteristics might not be helpful for locating 
epicardial or intramural circuits (S9.7.16). Preprocedural imaging is rec-
ommended when deciding on the endocardial vs combined endocardial- 
epicardial approach, as in other VT substrates (see Section  5 ). If unavailable, 
epicardial access can be obtained at the beginning of the case in anticipa-
tion of the need for combined endocardial- epicardial ablation (S9.7.12). 
Intramural reentry might be difficult to target because the myocardium 
is thick. Mapping methods can include a combination of voltage- based 
substrate mapping (using conventional voltage ranges) and activation, 
entrainment, and late or fractionated potential mapping. VTs associated 
with apical aneurysms are often ablated endocardially. Although the ar-
rhythmia mechanisms for monomorphic VTs in HCM appear to be mostly 
 Key Points 
 •  Polymorphic VT and VF are the most common VAs in HCM; 
monomorphic VT is less common. 
 •  The arrhythmogenic substrate in HCM often involves the 
septum but can extend to the epicardium, often necessitat-
ing combined endocardial and epicardial ablation procedures 
to eliminate the VT. 
 •  VT associated with apical aneurysms is often ablated 
endocardially. 
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scar- related reentry, reports have also mentioned ablation of BBR, focal 
RVOT (S9.7.12, S9.7.16), papillary muscle VTs, and left posterior fascicular 
VT (S9.7.20). Reports have not suggested an increased incidence of major 
complications compared with VT ablation in other populations, although 
cardiac tamponade can be more of a concern in patients with apical an-
eurysms. The results of ablation are encouraging, acutely eliminating VT 
in 80% of patients, with more than two- thirds of patients free of VT in 
the long- term follow- up. If catheter ablation is ineffective, other methods, 
including transcoronary alchohol and surgical resection and ablation, may 
be considered. Methods enhancing lesion size in order to reach the deep 
arrhythmia substrate will likely facilitate treatment. 
 References 
 S9.7.1.   Maron BJ, Anan TJ, Roberts WC. Quantitative analysis of the 
distribution of cardiac muscle cell disorganization in the left 
ventricular wall of patients with hypertrophic cardiomyopa-
thy.  Circulation. 1981;63:882–94. 
 S9.7.2.   Maron BJ. Contemporary insights and strategies for risk strat-
ification and prevention of sudden death in hypertrophic car-
diomyopathy.  Circulation. 2010;121:445–56. 
 S9.7.3.   Basso C, Thiene G, Corrado D, Buja G, Melacini P, Nava A. 
Hypertrophic cardiomyopathy and sudden death in the young: 
pathologic evidence of myocardial ischemia.  Hum Pathol . 
2000;31:988–98. 
 S9.7.4.   Almaas VM, Haugaa KH, Strom EH, et al. Increased amount of 
interstitial fibrosis predicts ventricular arrhythmias, and is as-
sociated with reduced myocardial septal function in patients 
with obstructive hypertrophic cardiomyopathy.  Europace. 
2013;15:1319–27. 
 S9.7.5.   Rudolph A, Abdel- Aty H, Bohl S, et al. Noninvasive detection 
of fibrosis applying contrast- enhanced cardiac magnetic reso-
nance in different forms of left ventricular hypertrophy rela-
tion to remodeling.  J Am Coll Cardiol. 2009;53:284–91. 
 S9.7.6.   Satoh H, Matoh F, Shiraki K, et al. Delayed enhancement on 
cardiac magnetic resonance and clinical, morphological, and 
electrocardiographical features in hypertrophic cardiomyop-
athy.  J Card Fail . 2009;15:419–27. 
 S9.7.7.   Rickers C, Wilke NM, Jerosch- Herold M, et al. Utility of car-
diac magnetic resonance imaging in the diagnosis of hypertro-
phic cardiomyopathy.  Circulation. 2005;112:855–61. 
 S9.7.8.   Leonardi S, Raineri C, De Ferrari GM, et al. Usefulness of car-
diac magnetic resonance in assessing the risk of ventricular 
arrhythmias and sudden death in patients with hypertrophic 
cardiomyopathy.  Eur Heart J. 2009; 30:2003–10. 
 S9.7.9.   Maron BJ, Spirito P, Shen WK, et al. Implantable cardioverter- 
defibrillators and prevention of sudden cardiac death in hy-
pertrophic cardiomyopathy.  JAMA . 2007;298:405–12. 
 S9.7.10.   Cha YM, Gersh BJ, Maron BJ, et al. Electrophysiologic mani-
festations of ventricular tachyarrhythmias provoking appro-
priate defibrillator interventions in high- risk patients with 
hypertrophic cardiomyopathy.  J Cardiovasc Electrophysiol. 
2007;18:483–7. 
 S9.7.11.   Fananapazir L, Chang AC, Epstein SE, McAreavey D. Prognostic 
determinants in hypertrophic cardiomyopathy. Prospective 
evaluation of a therapeutic strategy based on clinical, holter, 
hemodynamic, and electrophysiological findings.  Circulation. 
1992;86:730–40. 
 S9.7.12.   Dukkipati SR, d ' Avila A, Soejima K, et al. Long- term outcomes 
of combined epicardial and endocardial ablation of monomor-
phic ventricular tachycardia related to hypertrophic cardio-
myopathy.  Circ Arrhythm Electrophysiol. 2011;4:185–94. 
 S9.7.13.   Santangeli P, Di Biase L, Lakkireddy D, et al. Radiofrequency 
catheter ablation of ventricular arrhythmias in patients with 
hypertrophic cardiomyopathy: Safety and feasibility.  Heart 
Rhythm. 2010;7:1036–42. 
 S9.7.14.   Ueda A, Fukamizu S, Soejima K, et al. Clinical and elec-
trophysiological characteristics in patients with sustained 
monomorphic reentrant ventricular tachycardia associated 
with dilated- phase hypertrophic cardiomyopathy.  Europace. 
2012;14:734–40. 
 S9.7.15.   Maron MS, Finley JJ, Bos JM, et al. Prevalence, clinical sig-
nificance, and natural history of left ventricular apical 
aneurysms in hypertrophic cardiomyopathy.  Circulation. 
2008;118:1541–9. 
 S9.7.16.   Inada K, Seiler J, Roberts- Thomson KC, et al. Substrate 
characterization and catheter ablation for monomorphic 
ventricular tachycardia in patients with apical hypertrophic 
cardiomyopathy.  J Cardiovasc Electrophysiol. 2011;22:41–8. 
 S9.7.17.   Igarashi M, Nogami A, Kurosaki K, et al. Radiofrequency catheter 
ablation of ventricular tachycardia in patients with hypertrophic 
cardiomyopathy and apical aneurysm.  JACC Clin Electrophysiol. 
2018;4:339–50. 
 S9.7.18.   Kobayashi K, Ohata T, Ueda H, Miyamoto K. Recurrent sus-
tained ventricular tachycardia, hypertrophic cardiomyopathy, 
and apical aneurysm: electroanatomic map- guided surgical ab-
lation and left ventricular restoration.  J Thorac Cardiovasc Surg. 
2013;146:983–5. 
 S9.7.19.   Shimahara Y, Kobayashi J, Fujita T, Sato S. Transapical my-
ectomy and surgical cryoablation for refractory ventricular 
tachycardia due to hypertrophic cardiomyopathy with apical 
aneurysm.  Eur J Cardiothorac Surg . 2015;48:334–5. 
 S9.7.20.   Ergul Y, Ozyilmaz I, Bilici M, Ozturk E, Haydin S, Guzeltas A. 
Radiofrequency ablation of fast ventricular tachycardia caus-
ing an ICD storm in an infant with hypertrophic cardiomyopa-
thy.  Pacing Clin Electrophysiol. 2018;41:425–8. 
 9.8  |  Brugada syndrome 
 
 9.8.1  |  Introduction 
 Catheter ablation for VA in Brugada syndrome may be considered 
for VF, polymorphic VT, sustained monomorphic VT or PVCs trig-
gering VF or polymorphic VT. Ablation strategies have evolved 
from initially only targeting the PVC triggers for VA storms to the 
current complete elimination of the arrhythmogenic substrate that 
is usually located on the epicardial aspect of the RVOT (S9.8.6.1, 
S9.8.6.2). 
 Key Points 
 •  PVC-triggered VF or polymorphic VT are the most preva-
lent VAs that motivate device therapy in patients with 
Brugada syndrome. 
 •  Monomorphic VT is less frequent but can be caused by 
BBRVT in patients with Brugada syndrome. 
 •  The arrhythmogenic substrate is located in the RV epicar-
dium and can be demonstrated by sodium channel blockers. 
 •  Ablation targets include fractionated prolonged electro-
grams on the epicardial aspect of the RV. 
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 Although quinidine can be effective for VA suppression in 
Brugada syndrome, its use is complicated by its limited availability, 
its difficult pharmacokinetics, and its adverse effects in two- thirds 
of patients, leading to discontinuation in a quarter of patients in a re-
cent randomized double- blind trial (S9.8.6.3). The clinical indications 
for catheter ablation in Brugada syndrome are detailed in Section  4 . 
 The worldwide prevalence of Brugada syndrome ranges from 0.5 
to 35.5 per 1000 inhabitants (S9.8.6.4). Brugada syndrome was first 
systematically described in 1992 in a series of 8 patients with VF ar-
rest. Brugada syndrome is an inherited arrhythmogenic condition de-
fined on the basis of its characteristic ECG phenotype (S9.8.6.5). An 
RBBB- like pattern with ≥2 mm coved ST segment elevation in the right 
precordial leads constitutes the so- called type I Brugada pattern nec-
essary for diagnosis (S9.8.6.6). This pattern is dynamic and can fluc-
tuate according to variations in autonomic tone, body temperature, 
diurnal influences, electrolyte levels, and drug exposure, especially 
drugs with sodium channel blocking properties (S9.8.6.7–S9.8.6.9). 
Additionally, the ECG pattern can be concealed unless V1 and V2 are 
recorded at the higher second and third intercostal spaces (S9.8.6.10, 
S9.8.6.11). Multiple conditions can present as a Brugada phenocopy 
and need to be ruled out before a diagnosis of Brugada syndrome can 
be reached (S9.8.6.12). The inheritance pattern for Brugada syndrome 
is usually autosomal dominant. Although its genetic basis was initially 
identified as a loss- of- function mutation in the  SCN5A gene encoding 
the α- subunit of the cardiac sodium channel  Na  V  1.5 , numerous ge-
netic culprits have since been recognized (S9.8.6.13). 
 The mechanism generating the Brugada syndrome phenotype 
has been the focus of significant research, and considerable recent 
evidence has implicated depolarization abnormalities in the patho-
genesis of Brugada syndrome (S9.8.6.14). However, repolarization 
abnormalities have also been described, with disproportionate 
shortening of the epicardial action potential leading to the poten-
tial for phase 2 reentry and the induction of polymorphic VT or VF 
(S9.8.6.15, S9.8.6.16). Subtle but significant cardiac ultrastructural 
alterations, especially on the epicardial aspect of the RVOT, have also 
been found in numerous patients (S9.8.6.17). Electrophysiological 
and electroanatomical abnormalities have also been described in 
this location, present both spontaneously and upon provocation 
with sodium channel blockers or the pericardial instillation of warm 
water (S9.8.6.18–S9.8.6.20). High- frequency, low- amplitude, long- 
duration fractionated electrograms are routinely recorded from this 
region and are the target of substrate- based ablation procedures 
(S9.8.6.18). Complete elimination of all spontaneous and provoked 
epicardial fractionation is associated with normalization of the 
Brugada ECG phenotype and with elimination of inducible and spon-
taneous VAs in most patients at the short- term follow- up (S9.8.6.18, 
S9.8.6.20–S9.8.6.23). 
 9.8.2  |  Approach to triggering premature 
ventricular complexes 
 For patients with recurrent PVC- triggered VF or polymorphic VT 
with ongoing spontaneous PVCs, localization of these focal triggers 
by activation mapping or pace mapping has been the dominant pro-
cedural strategy (S9.8.6.1). Patients with Brugada syndrome, how-
ever, generally have little ambient ectopy in between phases of 
arrhythmic instability, and ablation targeting VF triggers is rarely 
reported. Moreover, isoproterenol administration can suppress VF 
storms and prevent VF inducibility and is not likely to be useful for 
provoking triggering PVCs during an ablation procedure (S9.8.6.24, 
S9.8.6.25). In most reported cases, foci have been mapped to endo-
cardial sites in the RVOT (S9.8.6.26, S9.8.6.27). 
 9.8.3  |  Approach to sustained monomorphic 
ventricular tachycardia 
 Sustained monomorphic VT can occur but is unusual in Brugada 
syndrome. Rodriguez- Manero et al. (S9.8.6.28) observed Brugada 
syndrome in 4.2% of patients with appropriate ICD interventions, 
with approximately half of these patients able to be pace terminated. 
Most of these tachycardias were mapped to and ablated in the 
RVOT, although BBR was observed in 2 of the 8 patients who under-
went ablation. Sustained monomorphic VT ablation is approached 
similarly to other conditions with reentrant VTs, and CMR imaging 
is beneficial for assessing scarring that might be due to another dis-
ease process. The effectiveness of empiric targeting of the epicardial 
RVOT substrate when sustained monomorphic VT is not inducible is 
not known. 
 9.8.4  |  Approach to polymorphic ventricular 
tachycardia/ventricular fibrillation 
 Polymorphic VT and VF causing recurrent ICD shocks or electrical 
storms are the most pressing arrhythmic indications for catheter ab-
lation in Brugada syndrome. In the absence of a triggering PVC, the 
arrhythmogenic substrate in the RVOT is the only possible ablation 
target. The preponderance of experience finds this substrate located 
on the epicardial aspect of the RVOT, with only 10% of patients hav-
ing some potential abnormal substrate identified from endocardial 
mapping (S9.8.6.29). For this reason, catheter ablation for Brugada 
syndrome should be performed at centers with experience in the 
specialized techniques of percutaneous pericardial access and epi-
cardial mapping (see Section  6 ). 
 Percutaneous epicardial access can be obtained in accordance 
with the operator ' s usual technique. The anterior pericardial access 
approach provides direct access to the epicardial RVOT, and the best 
access to this region via a posterior pericardial access approach can 
be achieved with the catheter passing through the transverse sinus. 
Double- wiring the initial access sheath allows for a second pericardial 
sheath to be placed, through which a multipolar mapping catheter can 
be introduced. The ablation catheter is usually deployed through a de-
flectable sheath to aid in obtaining optimal tissue contact. 
 Once the appropriate catheter set has been deployed, the rel-
evant anatomy should be defined. Integration of a preacquired CT 
into the EAM, particularly with the assistance of ICE, is an efficient 
means for defining anatomy (Figure  10 A). Virtual epicardial (and/or 
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endocardial RV) chamber geometry in the EAM system can also be 
acquired directly with a roving catheter. 
 Mapping efforts are then concentrated on the region of interest in 
the epicardial aspect of the RVOT. Multielectrode catheters with small 
electrodes can provide better definition of high- frequency fraction-
ation than ablation catheters. Although mapping can commence in the 
basal state if the Brugada syndrome ECG pattern is present at base-
line, several studies have shown an increase in the area of arrhyth-
mogenic substrate after administration of a sodium channel blocker 
(S9.8.6.21, S9.8.6.22, S9.8.6.30). A similar effect has been observed 
with the pericardial instillation of warm water (S9.8.6.20). 
 All high- frequency, long- duration, multicomponent, low- 
amplitude fractionated or isolated late electrograms are tagged on 
the substrate map (Figure  10 A). Given the potential presence of 
significant epicardial fat, low voltage in isolation is not indicative of 
underlying substrate. Caudal extension of the substrate has been as-
sociated with the presence of concomitant inferolateral J waves and 
early repolarization syndrome (S9.8.6.31, S9.8.6.32). 
 After a complete map has defined the region and extent of the 
arrhythmogenic Brugada syndrome substrate, an ablation strategy 
can be devised. The most important factor in this regard is the rela-
tionship of the surrounding at- risk structures. Although the phrenic 
nerve is not usually a consideration, the proximal large subdivisions 
of the right coronary artery are potentially at risk, particularly the 
conus branch and the RV marginal arteries (S9.8.6.32). Ablation- 
induced acute occlusion of the former could potentially result in 
VF, and injury to the latter risks infarction of an otherwise normally 
contractile RV. Coronary angiography prior to lesion delivery is 
therefore strongly recommended. Coronary angiography of the left 
coronary arteries should also be performed because the disease pro-
cess can also involve the LV epicardium. 
 An irrigated RF ablation catheter is used for epicardial lesion de-
livery, targeting the previously defined fractionated electrograms. 
Contact force sensing helps to confirm an optimal catheter contact 
vector toward the epicardium rather than outward toward the pari-
etal pericardium. Characteristic accentuation of Brugada syndrome- 
type ST elevation in the right precordial leads is generally observed 
with RF application (Figure  10 B) and usually resolves after RF delivery 
ceases. However, acute occlusion of an RV marginal coronary artery 
needs to be ruled out if it persists. Ablation continues until all electro-
gram fractionation in the arrhythmogenic substrate region has been 
eliminated, both at rest and with repeat provocation with sodium 
channel blockers. When this has been achieved, the Brugada syn-
drome ECG phenotype has usually normalized (both in the standard 
 F I G U R E  1 0     Epicardial substrate ablation in a patient with Brugada syndrome and appropriate  ICD shocks for  VF . Image integration 
of a preacquired  CT with the electroanatomical epicardial substrate map is shown in (A). Purple represents bipolar voltage >1.5 mV. 
Fractionated potentials (arrows) are tagged with black dots, and a representative example is displayed. Widespread fractionated potentials 
were recorded from the epicardial aspect of the  RVOT extending down into the basal  RV body. Ablation lesions are tagged with red dots. 
Some fractionated potentials could not be ablated due to the proximity of the acute marginal branches of the right coronary artery. Panel 
(B) shows the significant transient accentuation of the Brugada  ECG pattern during the application of radiofrequency energy at one of 
these sites.  CT = computed tomography;  ECG = electrocardiogram;  ICD = implantable cardioverter defibrillator;  PA = pulmonary artery; 
 RA = right atrium;  RCA = right coronary artery;  RFA = radiofrequency ablation;  RV = right ventricle;  RVOT = right ventricular outflow tract; 
 VF = ventricular fibrillation 
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and higher interspace recordings), and polymorphic VAs are no longer 
inducible. 
 9.8.5  |  Outcomes 
 There have been no randomized trials of catheter ablation in 
Brugada syndrome, and all reported clinical outcomes are from 
short- term follow- ups of largely single- center observational stud-
ies. These initial data are encouraging, with most investigators 
reporting 73%- 100% freedom from recurrent VT/VF during fol-
low- up (S9.8.6.18, S9.8.6.22, S9.8.6.30, S9.8.6.33). A systematic 
review of all published cases to 2018 found an overall 96.7% free-
dom from recurrent VT/VF (S9.8.6.29). However, given that recur-
rent VF was observed in several patients despite an apparently 
successful procedure, catheter ablation cannot be recommended 
as a replacement for ICD insertion to mitigate the risk of sudden 
death in symptomatic Brugada syndrome. Additionally, most of 
the reported patients had undergone ablation for symptomatic 
VA, and there are no controlled outcome data to support a role 
for catheter ablation in asymptomatic individuals with the Brugada 
syndrome ECG phenotype. 
 9.8.6  |  Risks 
 Catheter ablation for Brugada syndrome is an invasive and complex 
procedure with significant potential for acute and delayed compli-
cations. These events include those related to epicardial access and 
epicardial ablation and the general risks related to invasive cath-
eter ablation, which are detailed elsewhere in this document (see 
Sections  6.3 and  10.2 ). The most frequent reported complications are 
isolated pericardial effusions and pericarditis (S9.8.6.18, S9.8.6.22, 
S9.8.6.30, S9.8.6.33). No procedural deaths, strokes, MIs, or tampon-
ades have been reported to date, but the early published worldwide 
experience includes only approximately 200 cases. It should be noted 
that these reports are from high- volume centers, and complication 
rates with more widespread deployment could be higher. 
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 9.9  |  Polymorphic ventricular tachycardia/
ventricular fibrillation triggers 
 
 Although relatively rare, polymorphic VT and VF can be triggered by 
PVCs in patients with or without structural and/or electrical heart dis-
ease (long QT syndrome, catecholaminergic polymorphic VT, Brugada 
syndrome) (S9.9.1–S9.9.9). When this occurs, the clinical presentation 
is often a polymorphic VT/VF storm (S9.9.4, S9.9.5, S9.9.7–S9.9.9). 
The syndrome is recognized when short- coupled, unifocal PVCs (typ-
ically from the RVOT or Purkinje fiber system, including the RV and 
LV papillary muscles) (S9.9.1, S9.9.2, S9.9.7) trigger polymorphic VT 
or VF episodes. Ruling out acute myocardial ischemia as the cause is 
important. Several considerations have emerged from a number of 
small studies on catheter ablation in patients with polymorphic VT or 
VF refractory to antiarrhythmic therapy (S9.9.1–S9.9.9): (a) mapping 
and ablation is facilitated when the index PVCs are frequent; proce-
dural planning includes withdrawal of AADs where feasible and min-
imal sedation; (b) ablation sites are often associated with presystolic 
Purkinje activation; in some instances, there can be slight variation in 
PVC morphology and Purkinje potential to local ventricular activation 
time, suggesting different exits from the same source (S9.9.1); (c) in 
the setting of MI, successful ablation sites are related to Purkinje ac-
tivation in the infarct border zone (S9.9.4–S9.9.6, S9.9.8); (d) multiple 
ablation lesions are typically delivered, given the relative imprecision 
of mapping and the serious consequences of failed ablation; and (e) 
although acute procedural success in experienced centers is high, 
late recurrence of PVC- triggered polymorphic VT/VF is observed in 
5%- 15% of patients, emphasizing the need for defibrillator therapy. 
Multipolar mapping and ICE imaging, especially for PVCs originating 
from papillary muscles, is helpful. 
 As discussed in Section  4.3 , catheter ablation is indicated 
for patients with drug- refractory, recurrent, monomorphic PVCs 
triggering polymorphic VT/VF in the absence of SHD and for pa-
tients with remote MI. In the acute phase of MI or in the early 
phase following coronary revascularization, PVC- triggered poly-
morphic VT/VF is initially best treated conservatively, given that 
these arrhythmias often resolve spontaneously in a relatively 
short period. 
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 Key Points 
 •  Recurrent PVC-induced VF is most often triggered by PVCs 
originating from Purkinje fibers, located in the RVOT, the 
moderator band, or the LV. 
 •  Patients with a single triggering PVC are better ablation 
candidates; however, there are often multiple triggers. 
 •  Patients with healed MI often require extensive ablation of 
the Purkinje fiber system within or at the scar border. 
 •  Ischemia should be ruled out as a trigger for VF prior to 
ablation. 
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 9.10  |  Arrhythmogenic right ventricular 
cardiomyopathy 
 
 9.10.1  |  Introduction to the specific disease 
substrate characteristics 
 ARVC is a genetically determined myocardial disease characterized by 
progressive RV fibrofatty replacement, VAs, heart failure, and sudden 
cardiac death. Fibrofatty replacement starts at the epicardium or mid-
myocardium and extends until becoming transmural (S9.10.4.1). The 
scar distribution predominantly affects the subtricuspid and OT regions 
and, less frequently, the apex (S9.10.4.2–S9.10.4.4). LV involvement 
is present in more than half of all cases and is more frequent in ad-
vanced stages (S9.10.4.5), affecting the posterolateral subepicardium 
(S9.10.4.5, S9.10.4.6). ARVC is typically diagnosed through the estab-
lished Task Force Criteria, although there is increasing evidence sup-
porting a role for invasive EAM to diagnose the early stages of ARVC 
when Task Force Criteria are inconclusive (S9.10.4.7–S9.10.4.9). In the 
early stages of the disease, VT reentry circuits are located nearly exclu-
sively in the epicardium (S9.10.4.4, S9.10.4.5, S9.10.4.10, S9.10.4.11). 
In more advanced disease, the VT substrate reaches the endocardium, 
and areas in the epicardium can be fibrotic and lack reentry circuits 
(S9.10.4.4, S9.10.4.5, S9.10.4.10, S9.10.4.11). 
 9.10.2  |  General management 
 ICDs are recommended to prevent death in patients with ARVC and 
VAs and can also be considered in those with recognized risk factors 
who have not yet had VT (S9.10.4.12). Neither AADs nor catheter abla-
tion provides sufficient protection against sudden cardiac death. AADs 
(sotalol and amiodarone) are frequently used to improve symptoms and 
to prevent recurrent VT episodes, but have limited efficacy. Sotalol has 
been shown to reduce VT inducibility in an electrophysiology study 
(S9.10.4.13); however, data on its long- term efficacy are limited. Limited 
evidence suggests that amiodarone is the most effective drug for pre-
venting VAs (S9.10.4.14). Flecainide combined with metoprolol or sotalol 
has also been used to suppress arrhythmias (S9.10.4.15). Catheter abla-
tion is commonly used to reduce the frequency of arrhythmia episodes. 
 9.10.3  |  General approach for ablation 
 Given that ARVC affects the epicardium first, endocardial VT ablation 
alone is often insufficient (S9.10.4.10, S9.10.4.16–S9.10.4.19) and can re-
sult in VT recurrence. A combined endoepicardial approach as first- line 
therapy (S9.10.4.4, S9.10.4.5, S9.10.4.20, S9.10.4.21) or adjuvant epicar-
dial ablation after unsuccessful endocardial ablation or after VT recur-
rence results in improved acute and long- term outcomes (S9.10.4.11, 
S9.10.4.22). After combined or adjuvant epicardial ablation, VT reoc-
curs in 16%- 29% of patients after approximately 3 years of follow- up, 
with varying proportions of patients in these studies taking AADs 
(S9.10.4.5, S9.10.4.11, S9.10.4.20–S9.10.4.22). Predominant LV involve-
ment is an independent predictor of recurrence after ablation (S9.10.4.5). 
 Given the variable endocardium- to- epicardium disease involve-
ment, the benefit of epicardial ablation likely varies among patients. 
The presence of an epicardial arrhythmic substrate in patients with 
limited or no endocardial VT substrate can be identified by endo-
cardial unipolar voltage mapping (S9.10.4.23). Areas of endocardial 
unipolar voltage <5.5 mV are associated with epicardial low- voltage 
scar regions. Isolated epicardial involvement with a completely 
normal endocardial bipolar map has been observed in 26%- 40% of 
patients (S9.10.4.4, S9.10.4.5, S9.10.4.11, S9.10.4.18), and these pa-
tients might require epicardial ablation. The low- voltage areas are 
typically adjacent to the tricuspid valve annulus and in the free wall 
of the RVOT. In contrast, patients with advanced stage ARVC have 
more extensive involvement of the RV endocardium (wider areas of 
low voltage in the bipolar map) and can have less arrhythmic sub-
strate in the epicardium, which is likely due to the progressive fibro-
fatty replacement of the subepicardial myocardium, such that the 
surviving myocardium supporting reentry is closer to the endocar-
dium (S9.10.4.5). These patients constituted approximately 20% of 
patients with ARVC in a recent multicenter study and can be recog-
nized by an endocardial bipolar vs unipolar low- voltage area ratio of 
≥0.23 (Figure  11 ) (S9.10.4.5). 
 One strategy for guiding the selective use of epicardial map-
ping and ablation in ARVC is based on initial endocardial mapping. 
Epicardial access is obtained for patients whose endocardial voltage 
map shows limited or no endocardial substrate [eg, a bipolar vs uni-
polar low- voltage endocardial area ratio of <0.23 (S9.10.4.5)], which 
is characteristic of early disease. Initial endocardial ablation is per-
formed for patients with more extensive endocardial low- voltage 
substrate characteristic of advanced disease, followed by epicardial 
access for epicardial ablation if the VTs that are considered clinically 
relevant are still inducible. Alternatively, Santangeli et al (S9.10.4.22) 
found that a strategy of epicardial mapping and ablation only when 
VTs are still inducible or recur after endocardial ablation achieved 
good long- term outcomes. 
 Conventional mapping and ablation techniques used for other 
scar- related VT substrates are also employed in ARVC. Ablation can 
be performed during sinus rhythm, targeting the substrate based on 
electrogram characteristics and pace mapping (see Section  8 ) and/or 
during mappable monomorphic VTs. These ablation strategies have not 
been directly compared in patients with ARVC and are complementary 
 Key Points 
 •  The arrhythmogenic substrate in ARVC is located in the epi-
cardium and can involve the endocardium in advanced stages. 
 •  The most commonly affected areas are the subtricuspid and 
RV outflow regions. 
 •  LV involvement is not uncommon. 
 •  Endocardial-epicardial ablation is often required and results 
in higher acute success and lower recurrence rates com-
pared with endocardial ablation alone. 
 •  Conventional mapping and ablation techniques, including 
entrainment mapping of tolerated VT, pace mapping, and 
substrate ablation, are used. 
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and often combined. The procedure can be started during sinus rhythm 
with the hope of reducing radiation exposure and the need for elec-
trical cardioversion (S9.10.4.24). Complete elimination of all substrate 
characterized by electrograms with delayed components by targeting 
the conducting channel entrances has been shown to be a feasible and 
efficient strategy, needing only a small amount of RF delivery in some 
patients (S9.10.4.4, S9.10.4.5, S9.10.4.20). Complete substrate elimina-
tion and noninducibility of any sustained monomorphic VT as proce-
dural endpoints are associated with good long- term results. 
 Some VTs are catecholamine induced. A recent study found that 
high- dose isoproterenol infusions could induce PVCs that had the 
same morphology as sustained VTs, and focal ablation of the PVCs 
eliminated these catecholamine- mediated VTs (S9.10.4.25). 
 9.10.4  |  Risks 
 The additional benefit in arrhythmia control obtained with epicardial 
mapping and ablation in ARVC should be carefully weighed against 
the risks associated with obtaining epicardial access. The risk of in-
advertent RV puncture with pericardial bleeding can be increased 
with RV enlargement or advanced stage disease (S9.10.4.5). The in-
cidence of major complications related to epicardial access has 
been reported to be as high as 8% (see Section  6.3 ) (S9.10.4.11, 
S9.10.4.20–S9.10.4.22, S9.10.4.26, S9.10.4.27). Although the risk of 
coronary injury from epicardial ablation appears to be low, MI from 
an injury to an anomalous RV coronary branch has been reported 
(S9.10.4.28). 
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 9.11  |  Mapping and ablation in congenital 
heart disease 
 
 Key Points 
 •  Patients with a VT substrate after congenital heart defect 
surgery include those with repaired tetralogy of Fallot, re-
paired VSD, and repaired d-transposition of the great ar-
teries (D-TGA), as well as Ebstein ' s anomaly among other 
disease processes. 
 •  VT isthmuses are often located between anatomical barri-
ers and surgical incisions or patch material. 
 •  An AI can be identified and targeted during sinus rhythm. 
 •  For tolerated VTs, entrainment mapping is the method of 
choice for identifying critical components of the reentry 
circuit. 
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 9.11.1  |  Introduction 
 As the population of patients with repaired CHD continues to grow, 
management of recurrent VT in this population becomes increas-
ingly important (Figure  2 ). Monomorphic sustained VT approach-
able by catheter or surgical ablation typically occurs in patients with 
ventricular incisions, surgical scars, and patch materials. Accordingly, 
for patients with CHD included in mapping and ablation stud-
ies, repair of tetralogy of Fallot is the most commonly performed 
procedure, followed by VSD closure and complex D- TGA repair 
(S9.11.3.1–S9.11.3.7). As in other patients with SHD who present 
with VT, a complete evaluation of factors that promote arrhythmias 
is necessary. Cardiac imaging to identify residual or new lesions is 
also important. Hemodynamic abnormalities resulting in increased 
wall stress and ischemia can serve as important triggers for VAs 
(S9.11.3.8). In particular, significant pulmonary regurgitation after 
prior transannular patching with subsequent RV enlargement is a 
common finding in repaired tetralogy of Fallot (S9.11.3.9) and might 
require surgery or transcutaneous valve replacement. Treatment 
of the underlying hemodynamic abnormalities can reduce the in-
cidence of recurrent VAs by eliminating the triggers; however, the 
underlying substrate for monomorphic VT in repaired tetralogy of 
Fallot remains (S9.11.3.10). Accordingly, concomitant intraopera-
tive cryoablation with (S9.11.3.9, S9.11.3.11, S9.11.3.12) or without 
(S9.11.3.13, S9.11.3.14) intraoperative mapping has been success-
fully performed in select patients with tetralogy of Fallot, VT, and an 
indication for reoperation. 
 9.11.2  |  Mapping and ablation 
 Most spontaneous and induced monomorphic VTs in patients with 
CHD referred for ablation are due to macroreentry, with a critical isth-
mus defined by anatomical barriers, bordered by unexcitable tissue 
(S9.11.3.1–S9.11.3.4, S9.11.3.6, S9.11.3.7); however, focal mecha-
nisms are occasionally encountered (S9.11.3.3, S9.11.3.4, S9.11.3.6). 
The boundaries of AIs are the valve annuli and (unlike most other 
acquired heart diseases) patch material and surgical incisions. Four 
VT- related AIs in tetralogy of Fallot have been identified: isthmus 1, 
bordered by the tricuspid annulus and the scar or patch in the an-
terior RVOT; isthmus 2, between the pulmonary annulus and the RV 
free wall incision or RVOT patch, sparing the pulmonary valve annu-
lus; isthmus 3, between the pulmonary annulus and the VSD patch 
or septal scar; and isthmus 4 (which is rarely encountered), between 
the VSD patch or septal scar and the tricuspid annulus in case of an 
inferior muscular rim (S9.11.3.2) (Figure  12 ). Additional AIs bordered 
by surgical scars and valve annuli have been described after surgery 
for other CHDs, including complex D- TGA, VSD closure, and surgery 
for Ebstein ' s anomaly (S9.11.3.4, S9.11.3.6, S9.11.3.15). Substrate for-
mation might depend on the coincidence of pathological myocardial 
remodeling and anatomical boundaries determined by the type and 
timing of prior corrective surgery. Changes in surgical approaches over 
the past decades (eg, a combined transatrial- transpulmonary approach 
avoiding ventriculotomies in tetralogy of Fallot) are likely to affect the 
incidence and the potential substrate for arrhythmias (S9.11.3.16). 
Therefore, knowledge of the malformation and careful review of all 
operation records before ablation is important. 
 AIs can be reconstructed during sinus rhythm by noncon-
tact mapping (S9.11.3.3) or by electroanatomical bipolar voltage 
mapping combined with high- output pacing (10 mA, 2 ms) at low- 
voltage sites (<1.5 mV) to identify unexcitable tissue (S9.11.3.2, 
S9.11.3.4). Noncapture despite good catheter contact is indicative 
of patch material or surgical scars. VT induction and activation 
mapping for hemodynamically tolerated VT or pace mapping within 
anatomically defined isthmuses can be performed to confirm that 
the AI is critical for sustaining VT (S9.11.3.2, S9.11.3.4, S9.11.3.6). 
Transection of the AI by connecting the adjoining anatomical 
boundaries by linear RF lesions can be performed during sinus 
rhythm (S9.11.3.2, S9.11.3.4, S9.11.3.6, S9.11.3.7). Demonstration 
of conduction block after transection of the VT isthmus provides 
a defined procedural endpoint similar to that for achieving block in 
the cavotricuspid isthmus for atrial flutter and is a valuable acute 
procedural endpoint combined with noninducibility (see below) 
(S9.11.3.2, S9.11.3.4, S9.11.3.6). 
 Isthmus dimension and conduction properties likely determine 
the susceptibility to arrhythmias. In a study that included 24 patients 
with tetralogy of Fallot, electroanatomical voltage mapping com-
bined with activation mapping during sinus rhythm demonstrated 
that relatively narrow and slowly conducting AIs (calculated conduc-
tion velocity <0.5 m/s) were the substrate for all 37 documented and 
induced VTs in patients with preserved cardiac function (S9.11.3.17). 
These slowly conducting isthmuses can be identified and ablated 
during sinus rhythm; inducibility of the clinical arrhythmia and he-
modynamic tolerance is no longer a prerequisite for successful abla-
tion in patients with AI- dependent macroreentrant VT (S9.11.3.17). 
Isthmus 3 between the pulmonary annulus and the VSD patch or 
septal scar is the most common cause of VT and occasionally re-
quires ablation from both the RV and LV sides of the septum or SV 
for transection (S9.11.3.18). 
 9.11.3  |  Outcome after ablation 
 Four recent series have reported on ablation outcomes, combining 
activation mapping with a substrate- based ablation approach and 
including a total of 99 patients with CHD (82 of 99 had tetral-
ogy of Fallot) (S9.11.3.3, S9.11.3.4, S9.11.3.6, S9.11.3.7). VTs were 
typically fast, with a median CL of 295- 300 ms, requiring a map-
ping and ablation approach during the underlying baseline rhythm. 
The definition of complete acute success (noninducibility with or 
without isthmus block) differed among the studies or changed 
during the study period (S9.11.3.7) but was achieved in 73%- 82% 
of the patients. During a mean follow- up ranging from 33 months 
to 9.5 years, VT recurred in 12%- 32% of the patients after a sin-
gle procedure and in 5%- 11% after repeat ablation (S9.11.3.6, 
S9.11.3.7). 
 In two series of adults with CHD (most with tetralogy of Fallot), 
successful AI ablation (combined endpoint noninducibility and 
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isthmus block) was achieved in 25 of 34 patients (S9.11.3.4) and in 8 
of 14 patients (S9.11.3.6), respectively. No patients with confirmed 
conduction block had a recurrence of monomorphic VT during 
follow- ups of 46 ± 29 (S9.11.3.4) and 33 ± 7 months (S9.11.3.6), 
respectively. Accordingly, noninducibility with conduction block 
across the targeted isthmus is a useful ablation procedure endpoint 
(S9.11.3.2–S9.11.3.4, S9.11.3.6, S9.11.3.7). 
 Serious procedure- related complications are rare (S9.11.3.4, 
S9.11.3.6, S9.11.3.7); however, high- risk ablation target sites, in-
cluding the para- Hisian region with a risk of AV block, need to be 
considered (S9.11.3.5, S9.11.3.17). Ablation failure can result from 
withholding ablation due to proximity to the conduction system 
and coronary arteries, myocardial hypertrophy, and the protec-
tion of portions of the AIs by patch material (S9.11.3.3, S9.11.3.5, 
S9.11.3.6, S9.11.3.18). In particular, a pulmonary homograft can 
cover parts of the infundibular septum in patients with tetralogy 
of Fallot, preventing isthmus transection from an RV approach 
(S9.11.3.18). Although a septal AI can be successfully approached 
from the LV or aorta after right- sided ablation failure, proximity 
to the coronary arteries and potential damage to the aortic valve 
can increase the procedural risk (S9.11.3.18). Accordingly, sur-
gical ablation concomitant with repair of residual hemodynamic 
 F I G U R E  1 2     Anatomical isthmuses ( AI ) in repaired tetralogy of Fallot according to the surgical approach and variation of the 
malformation.  RV = right ventricle;  TA = tricuspid annulus;  VSD = ventricular septal defect 
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abnormalities should be considered in these patients with spon-
taneous VT, especially if new patch material will prevent postsur-
gical access to the substrate. For these patients, a preoperative 
electrophysiology study and EAM can be helpful in guiding sur-
gical ablation (S9.11.3.17). The use of empirical intraoperative lin-
ear cryoablation without preoperative or intraoperative mapping, 
transecting AI III and AI I, has been reported in patients with and 
without clinical VT, with mixed results (S9.11.3.13). However, em-
piric linear lesions might not be sufficient. After intraoperative 
isthmus ablation was performed in 31 patients who were induc-
ible for VA prior to pulmonary valve replacement, 47% remained 
inducible after surgery (S9.11.3.14). Similar to catheter ablation, 
preoperative mapping, tailored cryoablation, and intraoperative 
confirmation of bidirectional conduction block across linear le-
sions can improve outcomes. 
 The strong link between a slowly conducting AI and sustained 
VT (S9.11.3.17, S9.11.3.18) in tetralogy of Fallot is intriguing, and 
preventive ablation of these potential isthmus areas with a demon-
stration of conduction block may be considered, especially if future 
surgical procedures might affect the accessibility of these potential 
VT isthmus areas. Whether this would be beneficial for patients 
with tetralogy of Fallot remains to be determined and will need to be 
demonstrated by randomized studies. 
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 9.12  |  Sarcoidosis 
 
 Cardiac sarcoidosis is a dynamic infiltrative noncaseating granu-
lomatous disease with periods of inflammation that often culminate 
in fibrosis (S9.12.1–S9.12.4). Patients with cardiac symptoms and 
low LVEF fare the poorest among patients with cardiac sarcoidosis 
in terms of prognosis and mortality. In contrast, patients with asymp-
tomatic cardiac sarcoidosis and normal LVEF have a 10- year survival 
rate of 89%- 100%. Although only approximately 5% of patients with 
systemic sarcoidosis have symptomatic cardiac involvement, autopsy 
and imaging studies suggest that asymptomatic cardiac involvement 
occurs in 25%–92% of patients (S9.12.4–S9.12.6). Isolated cardiac in-
volvement has been increasingly recognized; a longitudinal study in 
 Key Points 
 •  The arrhythmogenic substrate in cardiac sarcoidosis is 
often intramurally located but can include the endocardium 
and epicardium. 
 •  A CMR is beneficial in planning an ablation procedure in 
cardiac sarcoidosis. 
 •  The arrhythmogenic substrate can be complex and can in-
clude areas of active inflammation and chronic scarring. 
 •  The VT recurrence rate after ablation is high. 
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Finland found that nearly two- thirds of 110 patients with histologi-
cally confirmed cardiac sarcoidosis had isolated cardiac involvement. 
The initial presentation was associated with AV block in 48% of cases 
and with VT or VF in 38% (S9.12.5). The 5- year survival probability for 
patients with cardiac sarcoidosis treated with immunosuppression has 
been reported to be as high as 95%, with the greatest benefits seem-
ingly gained by those without severe LV systolic dysfunction (S9.12.1, 
S9.12.5–S9.12.7). For patients with cardiac symptoms and low LVEF, 
the 10- year survival rate is 19%–27% and the cause of death is often 
heart failure or arrhythmia (S9.12.4–S9.12.6). These findings suggest 
that early recognition and treatment could be of value, although there 
are no randomized trials on this issue. For patients presenting with 
VT, consideration of cardiac sarcoidosis is important, given the differ-
ences in both acute and long- term management, specifically regard-
ing therapy with immunosuppressive drugs (S9.12.4). A CMR can be 
particularly helpful in raising the suspicion of an infiltrative disease 
process such as cardiac sarcoidosis (S9.12.8), and obtaining this imag-
ing is recommended in current heart failure guidelines (COR IIa, LOE 
B) (S9.12.9). Importantly, cardiac sarcoidosis can mimic ARVC, and its 
involvement can be localized to the RV (S9.12.4, S9.12.10–S9.12.15). 
There is substantial overlap in the clinical diagnostic criteria for ARVC 
and cardiac sarcoidosis, including imaging characteristics, identifica-
tion of epsilon waves, surface ECG characteristics, including signal- 
averaged ECG, scar distribution, VT morphologies, and other substrate 
characteristics identified in intracardiac mapping (S9.12.4, S9.12.10–
S9.12.15). There are a number of clinically useful findings that can help 
to differentiate the two conditions. In contrast to cardiac sarcoidosis, 
ARVC rarely involves the septum, and therefore the conduction sys-
tem is rarely involved in ARVC (S9.12.13). The disease process in ARVC 
also originates in the epicardium, whereas the granulomas in the in-
flammatory process of sarcoidosis are located within the myocardium 
and reach the endocardium/epicardium by extension of the intramural 
lesions (S9.12.16). Reaching a cardiac tissue diagnosis is often diffi-
cult because granulomatous infiltration can be patchy, and the yield 
of blind endomyocardial biopsy is <25% (S9.12.4). Endomyocardial bi-
opsy targeting areas of abnormal bipolar or unipolar voltage has shown 
promise for providing greater diagnostic yield (S9.12.4, S9.12.17). 
 The mechanisms of VT in patients with cardiac sarcoidosis in-
clude abnormal automaticity and triggered activity during the in-
flammatory phase and predominantly scar- related reentry in the 
chronic phase. Multiple VT mechanisms can be encountered in the 
same patient (S9.12.15, S9.12.18–S9.12.27). 
 When PET scanning identifies active inflammation at the time the 
VT presents, acute treatment with immunosuppressive agents and 
AADs may be considered over ablation (S9.12.1, S9.12.4, S9.12.13, 
S9.12.22, S9.12.26). There are limited data supporting the use of 
steroids or immunosuppressive therapy alone for managing cardiac 
sarcoidosis- related VT (S9.12.12, S9.12.24, S9.12.26). Regimens 
have included corticosteroids (prednisolone 1 mg/kg/d or equiv-
alent), along with steroid- sparing agents (including methotrexate, 
cyclophosphamide, cyclosporine, mycophenolate, and infliximab), 
for a minimum of 3 months, after which the medication may be ta-
pered based on treatment response (S9.12.7, S9.12.26). A number of  TA
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studies have suggested that immunosuppression reduces the burden 
of VAs (S9.12.13, S9.12.19, S9.12.24, S9.12.26), whereas others have 
either failed to show a benefit or have demonstrated a worsening 
of VAs (S9.12.28–S9.12.30). Data suggest that immunosuppression 
could be more beneficial for VAs in early disease with preserved LVEF 
(S9.12.4). Nevertheless, the current expert consensus recommen-
dation is to consider assessing the patients for active inflammation 
using PET scanning and administering therapy with immunosuppres-
sants and AADs if active inflammation is present (S9.12.4). 
 Medical therapy, including immunosuppression therapy, has 
failed for most patients in reports on VT ablation in cardiac sar-
coidosis (Table  8 ) (S9.12.12, S9.12.15, S9.12.26). If urgent imaging 
is unavailable or the VT persists despite empiric medical treatment, 
ablation may also be considered (S9.12.4). 
 The ablation approach to scar- related macroreentrant VT in car-
diac sarcoidosis is similar to that employed in other scar- related VTs 
(see Sections  8 and  9 ) and is largely based on identifying the abnormal 
substrate during sinus rhythm. Activation and/or entrainment mapping 
during VT is often limited due to hemodynamic instability, multiple 
VT morphologies, or noninducibility (S9.12.12, S9.12.15, S9.12.23–
S9.12.26). Substrate- based ablation targets areas with abnormal 
electrograms (see Section  8 ) and favorable pace maps (see Section  8 ) 
(S9.12.12, S9.12.15, S9.12.23–S9.12.27). A feature common to other 
nonischemic VT substrates is the predilection for involvement of the 
epicardium (22%- 26%) (S9.12.15, S9.12.25–S9.12.27) and midmyo-
cardium, the latter of which can be difficult to define in the absence 
of a CMR or with standard mapping techniques. Granulomatous infil-
tration can affect any part of the myocardium; cardiac imaging studies 
with CMR, nuclear perfusion scanning, and PET scanning can there-
fore be helpful for locating and assessing the burden of the complex 
substrate (S9.12.4, S9.12.11, S9.12.13, S9.12.25, S9.12.27). The fre-
quent involvement of the basal septum results in a high prevalence of 
right septal VTs or VTs involving the Purkinje fiber system (S9.12.24), 
and the predominance of a basal substrate gives rise to peritricus-
pid and perimitral VTs (S9.12.15, S9.12.24). Nonstandard and inves-
tigational adjunctive ablation techniques (see Section  9.1 ) designed 
to create larger and deeper lesions have been used to attempt the 
ablation of intramural substrate when standard ablation fails, includ-
ing bipolar ablation, needle- facilitated ablation, the use of half normal 
saline RF electrode irrigation, and transcoronary arterial or venous 
ethanol ablation (S9.12.28–S9.12.31). 
 A number of observational studies have investigated the util-
ity of catheter ablation in patients with cardiac sarcoidosis (Table  8 ). 
Outcomes have varied widely, as have the differences in patient char-
acteristics, the concomitant use of immunosuppression, and follow- up 
times (S9.12.12, S9.12.15, S9.12.24–S9.12.27, S9.12.32). In general, 
freedom from any recurrent VT is achieved in 45.8% of cases for up 
to 2 years of follow- up, with multiple procedures required in 12.5%- 
43% of patients (S9.12.15, S9.12.24–S9.12.27, S9.12.32); however, 
the overall VT burden has been reduced by 88% (S9.12.32). Major 
procedural complications have been observed in up to 5% of cases 
(S9.12.25, S9.12.27, S9.12.32). 
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 9.13  |  Chagas disease 
 
 9.13.1  |  Chagas disease 
 ChD is a chronic parasitosis affecting the heart and other organs and 
is caused by the protozoan  Trypanosoma cruzi . ChD is transmitted to 
humans mainly through parasite- laden feces from a hematophagous 
insect vector found only in the Americas, where the disease in con-
sidered endemic. The World Health Organization estimates a preva-
lence of ChD ranging from 1%- 6% in endemic areas, with 10 million 
people infected worldwide (mostly in Latin American countries), 100 
million at risk of infection, and 300 000 new cases reported each 
year. The World Health Organization estimates that 50 000 CCM- 
related deaths occur annually, with 60%, 25%, and 15% related to 
sudden cardiac death, progressive heart failure, and stroke, respec-
tively (S9.13.3.1, S9.13.3.2). 
 Cardiac involvement is the most frequent and serious manifesta-
tion of chronic ChD. Although the pathogenesis of cardiac damage is 
complex and not completely understood, at least 4 possible mecha-
nisms have been suggested: cardiac parasympathetic neuronal de-
population, immune- mediated myocardial injury, parasite persistence 
in cardiac tissue with secondary antigenic stimulation, and coronary 
microvascular abnormalities causing myocardial ischemia. Diffuse 
arteriolar dilatation found in CCM can result in a coronary steal phe-
nomenon of blood flow from epicardial coronary arteries to dilated 
arterioles, producing low perfusion pressure in the distal microvas-
culature supplying susceptible areas distal to the coronary branches. 
The watershed areas between main coronary artery branches would 
be the most susceptible to this steal phenomenon, causing low per-
fusion pressure, secondary ischemia, microinfarctions, and reparative 
fibrosis. The most frequently observed areas of myocardial scarring 
in CCM are the posterolateral LV and the LV apex in the watershed 
zones between the right coronary and circumflex arteries, and the 
anterior descending and posterior descending coronary arteries, 
respectively. VT is typically related to an inferolateral LV aneurysm 
(S9.13.3.2). 
 9.13.2  |  Ventricular tachycardia in chagas 
cardiomyopathy 
 Sustained VT is usually due to reentry, associated with an inferolat-
eral LV scar in over 70% of patients. Occasionally, endocardial ra-
diofrequency ablation can result in transmural injury, effectively 
treating all portions of the myocardium involved in the arrhythmia 
circuit. However, scars commonly exist intramyocardially and/or 
subepicardially in an area with an associated thick layer of subendo-
cardial myocardium. Mapping and ablation from the epicardial sur-
face is performed in up to 40% of patients (S9.13.3.3, S9.13.3.4). A 
myocardial isthmus of surviving tissue between the inferolateral LV 
scar and the mitral valve annulus can be involved in a macroreen-
trant submitral circuit, as has been described for postinfarction VTs 
(S9.13.3.5). BBR can occur but is unusual (S9.13.3.6). 
 In CCM that presents with VT storms, cardiac sympathetic de-
nervation (CSD) can reduce VT episodes and is a potentially valuable 
treatment option (S9.13.3.7). 
 Key Points 
 •  The pathogenesis of ChD is poorly understood but often 
results in an inferolateral LV aneurysm. 
 •  The arrhythmogenic substrate is located intramurally and 
on the epicardial surface, often necessitating an epicardial 
ablation procedure. 
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 9.13.3  |  Epicardial ablation of sustained ventricular 
tachycardia in chagas heart disease 
 The prevalence of epicardial VT origins in patients with CCM is high 
(approximately 37%). Electrograms obtained during epicardial mapping 
from the areas giving rise to VT are similar to those observed for other 
scar- related VTs, including delayed potentials, mid- diastolic potentials, 
and continuous electrical activity during VT. The critical isthmus of the 
reentrant circuit can be confirmed by entrainment maneuvers or in-
terruption of VT with RF ablation. With the progressive nature of the 
disease, VT recurrences are common (S9.13.3.4, S9.13.3.8). 
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 9.14  |  Miscellaneous diseases and clinical scenarios 
with ventricular tachycardia 
 
 9.14.1  |  Lamin cardiomyopathy 
 The cardiac phenotype associated with mutations in the  LMNA 
gene includes a familial form of DCM with autosomal dominant 
inheritance and a variety of clinical manifestations ranging from 
progressive heart failure, AV block to supraventricular block, and 
VAs (S9.14.4.1–S9.14.4.3). Malignant VAs are particularly prevalent 
in these patients and can precede the development of overt DCM 
(S9.14.4.4). Risk factors for developing VAs include the presence 
of AV conduction abnormalities, the male sex, and the presence of 
nonmissense mutations in the  LMNA gene (S9.14.4.4–S9.14.4.6). LV 
dysfunction has also been reported as a risk factor for developing 
VAs, although malignant VAs can occur in up to one- third of cases 
despite the presence of normal LV function (S9.14.4.4). Longitudinal 
studies assessing the natural history of patients with  LMNA DCM 
have consistently described a poor long- term prognosis regardless 
of the initial clinical presentation, with most patients eventually 
progressing to end- stage heart failure and the need for advanced 
therapies including heart transplantation (S9.14.4.1, S9.14.4.4). 
 The management of recurrent VAs in patients with  LMNA DCM 
is challenging owing to the progressive nature of the disease, the 
variable response to AAD therapy, and the predominant anterosep-
tal location of the underlying arrhythmogenic substrates, with a high 
prevalence of intramural substrates. The role of catheter ablation in 
managing recurrent VT in patients with  LMNA cardiomyopathy has 
been recently evaluated in a multicenter registry (S9.14.4.7). Of the 25 
patients included in the registry, an anteroseptal substrate was found 
in 82%, with all patients having multiple inducible VT morphologies. 
Ablation was challenging, with most patients having residual VT induc-
ible at the end of the ablation procedure. Over a relatively short- term 
follow- up (median of 7 months), the mortality rate was 26%, 44% of 
patients were considered for mechanical circulatory support or heart 
transplantation, and the cumulative recurrence rate was 91%. Of note, 
a procedure- related complication occurred in 25% of cases, including 
anticipated complete heart block (in the process of ablating septal 
substrate), asystole, cardiogenic shock, and thromboembolic events. 
Given the overall poor success in achieving lasting VT control, the high 
risk of procedural complications, and the rapid progressive nature of 
the disease, catheter ablation has only a palliative role for patients 
with  LMNA cardiomyopathy and recurrent drug- refractory VAs. 
 9.14.2  |  Left ventricular noncompaction 
 LVNC is a rare primary cardiomyopathy likely caused by an arrest of 
the normal embryogenesis of the endocardium and mesocardium, 
leading to the formation of prominent trabeculations and deep in-
tertrabecular recesses within the LV wall communicating with the 
cavity (S9.14.4.8, S9.14.4.9). The inferior and lateral walls of the LV 
from the mid- cavity to the apex are the most commonly involved 
regions. The clinical presentation of LVNC is highly variable, ranging 
from completely asymptomatic to end- stage heart failure, and is fre-
quently associated with VAs and thromboembolic events (S9.14.4.8, 
S9.14.4.10). The substrate underlying VAs in these patients is 
 Key Points 
 •  Lamin cardiomyopathy often has a poor prognosis, pro-
gressing to end-stage heart failure. 
 •  VT ablation is challenging due to intramural substrates. 
 •  VT recurrence rate is high after ablations. 
 •  VT in patients with noncompaction tends to originate from 
regions of noncompacted myocardium where scar can be 
identified in the midapical LV. 
 •  VT ablation in patients with LVAD can be challenging due 
to the limitation of preprocedural imaging, and the electro-
magnetic noise generated by the LVAD. 
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complex and involves pathological myocardial changes consisting 
of fibrosis, disruption of cellular architecture, and noncompacted 
myocardium. Reentrant VAs tend to colocalize with the regions of 
noncompacted myocardium in the midapical LV cavity, and patients 
can have a unique substrate distribution compared with other forms 
of NICM, with isolated involvement of the mid to apical LV seg-
ments and sparing the perivalvular regions (S9.14.4.11). However, 
significant heterogeneity in the VA substrates has been described, 
and VAs can also arise from regions remote from the noncompacted 
myocardial segments (S9.14.4.11, S9.14.4.12). Small observational 
studies and isolated reports of patients with drug- refractory VA 
have shown that catheter ablation can be performed safely and can 
achieve long- term arrhythmia control (S9.14.4.11–S9.14.4.16). Owing 
to the high thromboembolic risk associated with LVNC, long- term 
oral anticoagulation is usually warranted, and it is important that 
patients undergo a careful preprocedural imaging evaluation to rule 
out the presence of intracavitary thrombi, which can be challenging 
to identify due to the presence of dense trabeculations. Catheter 
ablation can be performed on uninterrupted oral anticoagulation or 
with efforts to minimize the time off of oral anticoagulation using 
periprocedural bridging with heparin (S9.14.4.11). 
 9.14.3  |  Congenital left ventricular aneurysms 
 Congenital LV aneurysms and diverticula are rare and believed to be 
the result of the disrupted embryogenesis of portions of the ventric-
ular myocardium (S9.14.4.17, S9.14.4.18). The diagnosis of congenital 
ventricular aneurysms and diverticula is typically reached through 
noninvasive imaging studies after ruling out secondary aneurysmal 
evolution from myocardial insults such as coronary artery disease, 
inflammatory cardiomyopathies, and trauma. Congenital ventricular 
aneurysms and diverticula can be asymptomatic or can present with 
thromboembolic complications, heart failure, myocardial rupture, 
or malignant VAs and sudden cardiac death (S9.14.4.17–S9.14.4.19). 
Monomorphic reentrant VTs can originate from congenital ventricu-
lar aneurysms or diverticula (S9.14.4.20–S9.14.4.22), and isolated 
reports have demonstrated that catheter ablation can achieve ar-
rhythmia control (S9.14.4.20, S9.14.4.23, S9.14.4.24). 
 9.14.4  |  Left ventricular assist devices 
 Patients with permanent LVADs have a high incidence of recur-
rent VT, with an estimated incidence of 22%- 53%, with the high-
est incidence in patients with a history of sustained VT prior to 
LVAD placement (S9.14.4.25–S9.14.4.27). Recurrent sustained 
VT has been associated with increased mortality in a select num-
ber of studies (S9.14.4.27–S9.14.4.29). Sustained VT has nega-
tive hemodynamic consequences in some patients, possibly due 
to the deterioration of RV function. Whenever a patient with an 
LVAD presents with new- onset VA, it is important to rule out 
mechanical triggers such as mechanical interaction between the 
inflow cannula and the adjacent apical- septal myocardium, “suc-
tion events,” and mechanical pump failure resulting in worsening 
heart failure (S9.14.4.30, S9.14.4.31). These issues can typically 
be ruled out with a transthoracic echocardiogram, LVAD interro-
gation, and blood tests for hemolysis, which can be a marker of 
pump thrombosis. However, most patients presenting with repeti-
tive sustained VAs, particularly those with a history of VAs before 
the LVAD implantation (S9.14.4.29, S9.14.4.32), have no identifi-
able mechanical trigger and usually require therapy to achieve VA 
suppression. Although antiarrhythmic therapies have not been 
well studied, an observational study by Raasch et al (S9.14.4.32) 
of 61 patients undergoing LVAD implantation reported that 9 of 
15 (60%) patients in whom amiodarone was initiated after the 
occurrence of VAs remained free of recurrent arrhythmias; how-
ever, the follow- up duration in this subgroup was not specified. 
In the patients experiencing recurrent VAs despite therapy with 
amiodarone, the authors reported no convincing benefits for ad-
juvant therapy with other antiarrhythmic agents, including sotalol, 
lidocaine, mexiletine, and procainamide. In particular, mexiletine 
was added to amiodarone in 4 patients but was effective in only 1. 
 For recurrent VAs despite AAD therapy, catheter ablation should 
be considered. Multiple observational studies and a large multicenter 
registry have shown that catheter ablation can be performed safely 
and effectively in patients with LVADs (S9.14.4.33, S9.14.4.34), al-
though there are several important considerations. The preprocedural 
definition of the substrate can be challenging due to significant im-
aging artifacts from ICD devices and the LVAD cannula. LVADs that 
have a magnetically levitated impeller introduce substantial electro-
magnetic noise that can render the QRS morphology of VT from the 
body surface ECG uninterpretable. The aortic valve often has minimal 
or no motion in patients with LVADs, cusp fusion can develop, and, 
in some instances, the aortic valve is surgically oversewn to abolish 
aortic insufficiency. The SVs can be sources of thrombi. A transseptal 
approach to access the LV is usually preferred, and is the only option 
in some cases (S9.14.4.33–S9.14.4.35), although the resulting atrial 
septal communication can potentially cause clinically significant right 
to left shunting, with systemic oxygen desaturation in some patients 
who have concomitant RV failure and increased right atrial pressure. 
 Sacher et al (S9.14.4.33) have reported on a multicenter study of 
catheter ablation in 34 patients with LVADs who underwent 39 proce-
dures (25 with a transseptal and 14 with a retrograde aortic approach). 
Of note, the targeted VT was related to the LVAD cannula in only 9% of 
the cases, whereas the remaining VAs were associated with the under-
lying disease substrate. After a mean follow- up of 25 ± 15 months, 7 
patients underwent heart transplantation, 10 died, and 13 (76%) of the 
remaining 17 patients remained free from recurrent VT. These results 
are in line with other single- center observational series (S9.14.4.34–
S9.14.4.39) and support the benefits of catheter ablation as an import-
ant treatment option for patients with LVADs and recurrent VT. 
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 9.15  |  Surgical therapy 
 
 In some patients, standard endocardial approaches combined with 
percutaneous epicardial catheter ablation remain ineffective in provid-
ing VA control due to deep intramural circuits (S9.15.1). Percutaneous 
epicardial access might not be feasible for patients with prior pericarditis 
or cardiac surgery, and epicardial VTs might not be easily targeted using 
standard ablation approaches (S9.15.2). Alternative treatment methods 
need to be considered for patients with failed endocardial and epicar-
dial ablation procedures (S9.15.3). The threshold for a surgical approach 
might be lower if a concomitant surgical procedure is indicated. For 
patients with an inaccessible epicardial space, percutaneous catheter 
ablation in the electrophysiology laboratory can be facilitated by a surgi-
cally created epicardial window allowing entry into the pericardial space 
(S9.15.4). This approach is most straightforward in patients with an 
apical or inferior VA substrate, because the area of the heart closest to 
the window is most easily accessed, and pericardial adhesions can limit 
extensive mapping. Surgical cryoablation can also be conducted in the 
operating room utilizing a lateral thoracotomy or sternotomy (S9.15.5, 
S9.15.6). Thoracotomy is the preferred approach to lateral and posterior 
substrates, whereas sternotomy is often needed for anterior substrates. 
Portable EAM can be utilized to help to localize the substrate, and VT 
can be inducible when the patient is off the cardiopulmonary bypass. 
When possible, preprocedural planning should include CT imaging of 
grafts for patients with prior bypass surgery to prevent injury to these 
structures. The use of surgical VT ablation has also been described in pa-
tients undergoing percutaneous LVAD implantation (S9.15.7, S9.15.8). 
Recently, there has been growing concern regarding the increased rates 
of LVAD thrombosis among patients who undergo both endocardial 
and epicardial surgical cryoablation at the time of LVAD implantation 
(S9.15.9). In highly selected patients with epicardial LVOT VAs refractory 
to standard techniques due to overlying epicardial fat and/or proximity 
to coronary arteries, open (S9.15.10) or minimally invasive (S9.15.11, 
S9.15.12) approaches have been used. The full characterization of the 
efficacy and safety of these approaches is pending. 
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 9.16  |  Sympathetic modulation 
 
 The autonomic nervous system (ANS) has a central role in regulat-
ing heart rate and cardiac function and contributes to the pathogenesis 
 Key Points 
 •  Surgery-facilitated access to the epicardium via a limited 
subxiphoid incision can be helpful in the case of adhesions. 
 •  Cryoablation via thoracotomy is possible for posterolateral 
substrates and via sternotomy for anterior substrates. 
 Key Points 
 •  Sympathetic modulation targeting the stellate ganglia by 
video-assisted thoracoscopy may be considered for failed 
VT ablation procedures or VF storms. 
 •  A temporary effect can be obtained with the percutaneous 
injection or infusion of local anesthetics. 
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of VA in structurally normal hearts, abnormal hearts, and channelopa-
thies (S9.16.1). The ANS includes the parasympathetic component me-
diated by the vagus nerve and a sympathetic component mediated by 
cervicothoracic paravertebral sympathetic ganglia. The ANS undergoes 
remodeling and becomes dysfunctional in SHD (S9.16.1). In most situ-
ations, ANS imbalances contribute to the onset and/or maintenance of 
VAs, especially through the activation of efferent sympathetic pathways. 
Interventions that decrease sympathetic tone are often beneficial. 
 Sympathetic activation and vagal withdrawal are associated 
with diminished respiratory sinus arrhythmia and heart rate vari-
ability. Iodine- 123 metaiodobenzylguanidine and 11C- meta- 
hydroxyepinephrine imaging provide an indication of sympathetic nerve 
distribution and local noradrenaline reuptake that reflects sympathetic 
activity (S9.16.1). Although iodine- 123 metaiodobenzylguanidine and 
11C- meta- hydroxyepinephrine (S9.16.2) imaging findings are associ-
ated with VA in various settings, the clinical utility of using these findings 
for risk stratification and to guide therapy has yet to be proven (S9.16.1). 
 Beta blockers are a first- line therapy for VA sensitive to ANS 
influences. Beta blockers often decrease idiopathic RVOT PVCs in 
healthy individuals (S9.16.3) and reduce the rate of sudden cardiac 
death after MI (S9.16.4, S9.16.5). Conversely, in electrical storms due 
to Brugada syndrome or idiopathic VF, beta- adrenergic stimulation 
by isoproterenol infusion can abolish recurrent arrhythmia (S9.16.6, 
S9.16.7). 
 Transient CSD achieved by high thoracic epidural anesthesia with 
bupivacaine administered at the T1- T2 or T2- T3 level into the epidural 
space can be employed as a bridge to more definitive therapy (S9.16.8). 
An 80% reduction in VA episodes was observed in 6 of 8 patients un-
dergoing thoracic epidural anesthesia, with infusion durations ranging 
from 48 to 96 hours (S9.16.8). Partial denervation can be achieved 
by percutaneous stellate ganglion block and can also quiet post- MI 
electrical storms (S9.16.5). A recent meta- analysis of nonrandomized 
studies found that temporary percutaneous stellate ganglion block 
was associated with a major acute reduction in the burden and sup-
ports its potential use as a bridge to more definitive therapy (S9.16.9). 
 Persistent CSD is achieved at open surgery (or by video- assisted 
thoracoscopy) by resecting the lower third to half of the stellate ganglia 
and the T2- T4 or T5 thoracic ganglia, as well as transecting the nerve of 
Kuntz when present (S9.16.10). Potential complications include Horner 
syndrome, Harlequin syndrome, dyshydrosis, and regional temperature 
changes (S9.16.11, S9.16.12). In a series of heterogeneous patients 
with drug- refractory VA storms undergoing unilateral or bilateral surgi-
cal CSD, ICD shocks were reduced by 90% in 90% of the patients, with 
left CSD less efficient (50% shock free) than bilateral CSD (S9.16.10, 
S9.16.13, S9.16.14). CSD has also been shown to be effective in CCM 
(S9.16.15). However, denervation through stellate ganglion ablation sur-
gery is not always complete, and VA can recur. Nonetheless, in patients 
with VA storms for whom beta blockers, antiarrhythmic medications, 
and catheter ablation are ineffective or not tolerated, CSD can be con-
sidered a reasonable option, provided the treating physicians have ex-
pertise with these techniques (S9.16.4, S9.16.13, S9.16.15). 
 Surgical CSD can be considered for high- risk patients with con-
traindications for beta blockers, for patients with symptomatic long 
QT syndrome when beta blockers are not effective, or when ICD 
therapy is contraindicated or declined (S9.16.11, S9.16.12, S9.16.16–
S9.16.18). CSD is associated with a significant reduction of events in 
patients with high- risk long QT syndrome, with a reported 50%–80% 
long- term success rate (S9.16.17–S9.16.21). A significant decrease in 
QTc duration is usually observed after CSD (S9.16.11, S9.16.17). 
 CSD can also be considered for patients with catecholaminergic 
polymorphic VT and recurrent symptomatic VA (syncope or ICD shocks) 
while undergoing optimal drug therapy with beta blockers and flecain-
ide and for patients with a contraindication for beta blockers (S9.16.12, 
S9.16.22, S9.16.23). In catecholaminergic polymorphic VT with recur-
rent VA despite optimal therapy, CSD achieved 80% event- free survival 
at 2 years and has been advocated as an alternative to an ICD (S9.16.21). 
 Spinal cord stimulation of T1- T5 with an external stimulator ap-
pears to modulate autonomic activity, possibly via both sympathetic 
inhibition and an increase in vagal activity (S9.16.2). Spinal cord 
stimulation reduced VA episodes 75%- 100% in a small number of pa-
tients with cardiomyopathy and high VA burden (S9.16.17). The spi-
nal cord stimulation mechanism is not completely understood, and 
the long- term clinical effects and safety have not been studied in hu-
mans. Low- level stimulation of the cervical vagosympathetic trunks 
or carotid body can antagonize proarrhythmic sympathetic surges 
and decrease VAs in animal models, but there is no experience for 
this with humans (S9.16.2). 
 Renal denervation decreases both central sympathetic activity and 
systemic catecholamine excretion, possibly mediated through either 
afferent or efferent renal sympathetic nerves and independent of the 
effect on blood pressure (S9.16.2, S9.16.24). In small series or isolated 
cases with various cardiomyopathies and refractory VA, catheter- 
based percutaneous renal denervation was observed to reduce VAs 
and appeared safe (S9.16.25–S9.16.28). Techniques and acute pro-
cedural endpoints need further evaluation, and randomized trials are 
needed to assess the efficacy and safety. 
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 9.17  |  Endpoints of catheter ablation of ventricular 
tachycardia 
 
 9.17.1  |  Historical perspective 
 In the early days of electrophysiology testing to study arrhyth-
mias, PES was recognized as a tool for evaluating the efficacy of 
treatments (at that time, drugs and surgical ablation). For both 
supraventricular arrhythmia and VA, elimination of inducible sus-
tained tachycardia following drug or surgical intervention, when 
the arrhythmia had been reproducibly induced with PES prior to 
intervention, correlated with successful treatment at least by the 
short- term follow- up (S9.17.4.1, S9.17.4.2). PES was known to be 
a somewhat unreliable assessment tool in that (a) it did not per-
fectly predict outcomes (sensitivity or specificity) and )b) significant 
day- to- day variability in the results was demonstrable in the ab-
sence of an intervention (S9.17.4.3). In addition, varying definitions 
of “noninducibility” have been used, including noninducible VA of 
any type using up to triple extrastimuli from 2 RV sites and 2 drive 
CLs; initiation of only “nonclinical” VTs that had morphologies and/
or CLs that had not been previously observed spontaneously; and 
rendering a previously easily inducible VT no longer inducible at 
that step of the PES protocol but without performing the complete 
 Key Points 
 •  Noninducibility of VT by PES after ablation is a reasonable 
endpoint and predictor for VT recurrence after VT ablation 
in patients with SHD. 
 •  Due to the limitations of programmed stimulation, end-
points other than noninducibility have been described, 
including elimination of excitability, elimination of LPs or 
LAVA, dechanneling, substrate homogenization, core iso-
lation, image-guided ablation, and anatomically fixed sub-
strate ablation. 
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PES protocol. Despite these shortcomings, VA noninducibility was 
regarded for over two decades as the standard means for assessing 
the efficacy of therapeutic interventions, including catheter abla-
tion (S9.17.4.4, S9.17.4.5). 
 9.17.2  |  Programmed electrical stimulation 
 PES at the end of the ablation procedure is still employed and remains 
a reasonable predictor of VT recurrence. In particular, patients in whom 
relatively slow VTs (CL >300 ms) remain inducible at the end of the pro-
cedure are more likely to experience recurrence than those in whom no 
VT (or only rapid, unmappable VT) is inducible (S9.17.4.6). In a recent 
study, inducible nonclinical VT that has a CL longer than the RV effec-
tive refractory period plus 30 ms was associated with recurrent VTs, 
whereas faster inducible nonclinical VTs were not associated with recur-
rence (S9.17.4.7). A meta- analysis of post- MI VT ablation studies found 
that the absence of inducible VT was associated with a substantially 
lower risk of recurrent VT compared with the inducibility of nonclinical 
VT (odds ratio [OR] 0.49) and clinical VT (OR 0.10) (S9.17.4.5). 
 The predictive capacity of immediate postablation PES was re-
cently challenged by Frankel et al (S9.17.4.8), who have shown that 
NIPS using the patient ' s ICD a few days after the ablation procedure 
yielded a more accurate picture of the likelihood of VT recurrence 
after ablation than the acute end- of- procedure stimulation protocol. 
In this study, 18% of patients without inducible VT at the end of 
the ablation procedure had inducible clinical VT using subsequent 
NIPS, and another 37% had inducible nonclinical VT. Each group had 
shorter recurrence- free survival than those without inducible VT at 
delayed NIPS. Similar results were recently reported by Oloriz et al 
(S9.17.4.9). Numerous potential causes of postablation recurrent VT 
episodes have been proposed, including ablation lesion healing, de-
velopment of new circuits, withdrawal of AADs that had suppressed 
some VTs, and emergence of VTs at the periphery of ablation zones 
(S9.17.4.10). The optimal management of patients found to have in-
ducible VT has not yet been defined. 
 9.17.3  |  Current ablation strategies and 
assessment of results 
 For focal arrhythmias (such as nonsustained or sustained VT or 
PVCs, typically observed in individuals without SHD), activation 
and/or pace mapping are generally adequate guides for ablation 
(assuming the arrhythmia was present spontaneously or inducible 
prior to ablation). Assessment of efficacy is termination of VT, or 
elimination of PVCs, and subsequent noninducibility of VT or PVCs 
by catecholamine infusion or electrical stimulation that had reliably 
provoked episodes prior to ablation. 
 For patients with SHD in whom reentry is the primary VT mecha-
nism, the effectiveness of ablation has usually been assessed by PES 
(typically through triple ventricular extrastimuli at 1 or 2 RV sites 
and 1- 2 drive CLs), with or without an adjunctive catecholamine in-
fusion. In addition to these mapping tools, a variety of substrate- 
based strategies are currently in use for ablation for VA, each with 
their own procedural endpoints (almost all combined with end- of- 
procedure PES). A short description of these strategies is provided 
below (S9.17.4.11, S9.17.4.12). In many of these studies, substrate 
ablation was combined with ablation guided by activation and en-
trainment mapping when a hemodynamically tolerated VT was in-
ducible. For all of these approaches, data are largely limited to small 
series from single centers or groups of investigators. 
 1 Elimination of electrical excitability (S9.17.4.13): Targeting VT 
isthmuses between areas of electrically unexcitable scar and 
ablation to the extent that isthmus tissue cannot be stimulated 
with unipolar pacing output of 10 mA (the endpoint of this 
strategy) has been shown to result in fewer VT recurrences in 
follow-up. This approach has the drawbacks of contact depen-
dency and time expense, especially in cases with more extensive 
areas of ablation in which repeated cycles of stimulation and 
ablation can be tedious and time-consuming. 
 2  Elimination of LPs (S9.17.4.14): Elimination of all recordable LPs 
(high-frequency electrogram components inscribed after the 
end of the surface QRS complex that reflect slowed conduc-
tion or block) has been shown to improve freedom from recur-
rent VT compared with cases in which LPs were not eliminated 
(S9.17.4.15). This approach is limited by sampling density and the 
time required for remapping to assess the absence of LPs. 
 3 Elimination of LAVAs (S9.17.4.16): LAVAs are defined as electro-
grams with 2 or more distinct components that might be evident 
in the resting rhythm or can be revealed by a stimulation wave-
front arriving from a different direction. LAVAs thus include 
standard LPs but also the split potentials (those with an isoelec-
tric interval between components of at least 30 ms) that are not 
late and even some normal-appearing electrograms for which 
stimulation might reveal previously unobserved abnormalities. 
Whereas elimination of LPs has generally been performed on the 
endocardium, LAVA mapping and ablation requires endocardial 
and (when possible) epicardial mapping and ablation. Elimination 
of all LAVAs (the endpoint of this strategy) has been correlated 
with high rates of freedom from spontaneous recurrence of VT. 
Problems with this approach include the lack of standard pro-
grammed stimulation methods to detect LAVA at sites without 
these potentials during sinus rhythm, the extent of ablation 
needed to treat all LAVAs (endocardial and epicardial ablation, 
the latter might not always be feasible), and the inability to know 
when all LAVAs had been ablated successfully (sampling bias). 
Additionally, the mapping catheter used can affect LAVA detec-
tion, with small, closely spaced electrodes detecting LAVA and 
LP more readily than standard ablation electrodes. However, this 
might necessitate double access to the chamber in question or 
repeated catheter exchanges. 
 4 Dechanneling: Using this method, EAM is used to identify sites 
with high-frequency delayed (not necessarily “late”) potentials in-
scribed after a far-field component in sinus rhythm and targets 
those with relatively short intervals from potential entry sites into 
channels within scars that can participate in reentry. Endpoints of 
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this “dechanneling” approach are the elimination of delayed po-
tentials or reversal of the activation sequence of delayed poten-
tials when recorded with multipolar catheters. VT-free outcomes 
were better when complete dechanneling could be affected 
(S9.17.4.17). 
 5 Substrate homogenization (S9.17.4.18): This strategy is similar 
in principle to LP and LAVA ablation but more broadly targets 
the entire region in which low-amplitude (<1.5 mV bipolar) ab-
normal electrograms are observed with very extensive abla-
tion on both the endocardium and epicardium when abnormal 
epicardial substrate is identified. The endpoint is electrogram 
elimination (amplitude reduction to the background noise level 
or below) and noninducibility of VT. In a small randomized trial 
of patients with prior MI and a nonrandomized series of pa-
tients with post-MI and NICM, VT recurrence was less likely 
with extensive substrate ablation than with ablation guided by 
activation and entrainment mapping targeting only the clinical 
VT (S9.17.4.18, S9.17.4.19). However, it is not known whether 
this technique would be superior to the targeting of clinical 
VT(s) plus more limited substrate ablation using the other de-
scribed techniques. This approach necessarily requires exten-
sive ablation (with more fluid volume administered if irrigated 
ablation is employed) and potentially longer procedural times. 
The technique is not applicable to diseases that do not have 
identifiable low-voltage scar regions. 
 6 Core isolation (S9.17.4.20, S9.17.4.21): The principle underlying 
this strategy is that endocardial VT circuits can be somewhat 
“compartmentalized” by layers of midmyocardial scar tissue, such 
that conduction is largely spread on the endocardial surface. The 
encircling of the region with abnormal electrograms that contain 
the VT circuits need only reach the midmyocardial barrier to iso-
late the area (ie, damage need not be transmural). In the study 
by Tzou et al (S9.17.4.21), core isolation was usually achievable 
and was associated with improved freedom from VT recurrence 
compared with a nonrandomized reference group. This approach 
is not always feasible and requires extensive ablation in some pa-
tients. The extent to which these core elements reconnect with 
healing of the ablation lesions and resolution of the edema is 
unknown. 
 7 Imaging-guided lesion assessment: Estimating the acute extent (par-
ticularly depth) of ablation-related damage, particularly in normal 
ventricular tissue, has been shown to be feasible with intracardiac 
ultrasound (S9.17.4.22), CMR (S9.17.4.23), near-infrared spec-
troscopy (S9.17.4.24), and by elevations in the pacing threshold 
(S9.17.4.25), as well as with other methods. Lesion size assessment 
has promise for future applications as an indicator of the adequacy of 
ablation but has not been studied in detail as a procedural endpoint. 
 8 Identification of a largely anatomically fixed substrate during 
baseline rhythm by pace mapping (S9.17.4.26) and by locating 
isolated potentials (S9.17.4.14) has been beneficial in identify-
ing a critical isthmus. Targeting the arrhythmogenic substrate by 
combining pace mapping and electrogram mapping has further 
demonstrated a reduction in VT recurrence in patients post in-
farction (S9.17.4.27). 
 As noted, most strategies also use PES to assess for VT inducibility at 
the end of the procedure. It is important to note that the assessment 
of efficacy of these ablation strategies is predicated on the assumption 
that ablation lesions have permanent effects, which cannot be known. 
 9.17.4  |  Summary 
 The preponderance of experience for assessing the results of VT abla-
tion is with PES, despite its inherent limitations. Multiple methods of 
substrate ablation have been described, each with its own procedural 
endpoint (but almost always with PES assessment at the end of the 
procedure). Several observations can be made based on available data: 
 1 Some method of assessing success (prespecified endpoints) should 
be employed at the end of any ablation procedure for treating 
VA, insofar as possible (constrained by patient safety consider-
ations). Scar-based reentrant VT usually incorporates PES using 3 
extrastimuli at 2 drive CLs from 1 or more RV stimulation sites 
or at least as vigorous a stimulation protocol as was required to 
initiate arrhythmia prior to ablation, as well as achieving endpoints 
particular to whichever substrate-based ablation strategy is used. 
 2 If a “clinical” (spontaneously occurring) VT remains inducible at the 
end of the procedure, the likelihood of postprocedure recurrence is 
high. 
 3 Nonclinical VTs induced at the end of an ablation procedure have 
a recurrence rate during follow-up lower than persistently induc-
ible clinical VTs but higher than if no VT is induced at the end of 
the ablation procedure. Clinicians should carefully consider the 
risks and benefits of targeting these nonclinical VTs, which entail 
longer procedure time and potential risk. 
 4 It is reasonable to consider using NIPS 2-3 days after ablation to 
refine the prognosis (see Section  10.4 ). If clinical VT can be initi-
ated at that time, repeat ablation may be considered, although 
the risks and benefits of this approach have not been defined. 
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 10   |   POSTPROCEDUR AL C ARE 
 10.1  |  Postprocedural care: Access, anticoagulation, disposition 
 10.1.1  |  Postprocedural care: Access 
 Recommendations for management of venous access sites after catheter ablation of VA 
 COR  LOE  Recommendations  References 
 I  A  1. Manual compression is effective in achieving hemostasis after 
venous access for VT ablation. 
 S10.1.2.1–S10.1.2.3 
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 COR  LOE  Recommendations  References 
 IIa  B- R  2. Venous access closure using temporary purse- string or figure- 
of- 8 suture techniques can be useful in achieving faster hemostasis 
and earlier ambulation and reducing pain or discomfort associated 
with hemostasis compared to manual compression. 
 S10.1.2.1, S10.1.2.2 
 Recommendation- specific supportive text 
 1  Although little has been written on postprocedural management of 
access sites specifically after catheter VT ablation, practices have 
been adapted by extrapolating results from other procedures requir-
ing femoral venous or arterial access. Manual compression has been 
the standard of care for achievement of hemostasis after venous 
sheath removal. In randomized studies of other electrophysiology 
procedures comparing manual compression with temporary suture 
closures or a vascular closure device, comparable high rates of 
hemostasis had been achieved (S10.1.2.1–S10.1.2.3). Extrapolating 
these results to ventricular ablation procedures, manual compression 
is effective in achieving hemostasis, though time to hemostasis 
can be expected to be shorter with temporary suture techniques 
compared with manual compression (S10.1.2.1–S10.1.2.3). 
 2  The use of a temporary purse-string or figure-of-8 suture that can 
be removed after achieving hemostasis has been studied after ve-
nous access in other ablation procedures, such as for AF, in which 
procedures are routinely performed on uninterrupted antico-
agulation and/or with large-bore catheters (S10.1.2.4–S10.1.2.8). 
Compared with manual compression, temporary suture techniques 
can yield faster hemostasis and ambulation times and reduce the 
pain or discomfort associated with hemostasis. Two randomized 
studies have shown shorter times to hemostasis and ambulation, 
with one reporting reduced rates of access complications com-
pared with manual compression (S10.1.2.1, S10.1.2.2). 
 3  Vascular closure device-based methods for venous closure have 
not been specifically studied for electrophysiology procedures 
(S10.1.2.9–S10.1.2.11). One randomized study compared manual 
compression to an extravascular closure system that delivers re-
sorbable polyethylene glycol sealant external to the vessel at the 
sheath access point in 208 patients with a 5, 6, or 7 Fr sheath in the 
common femoral vein (S10.1.2.3). There were no vascular compli-
cations in either arm. Time to hemostasis was significantly shorter 
in the device arm (0.12 ± 0.89 vs 7.6 ± 5.7 minutes;  P < 0.001). 
 4  When the writing committee was surveyed regarding venous ac-
cess hemostasis, all the respondents used manual compression, 
approximately half (53%) used temporary figure-of-8 or purse-
string sutures some of the time, and only 1 (6%) had used a vas-
cular closure device. 
 5  Given that venous access complications are driven primarily by 
insertion difficulties or concomitant arterial access, reduction in 
venous access complication outcomes might be best achieved 
with methods such as use of ultrasound at insertion, rather than 
by device- or suture-based methods. 
 Recommendation for management of arterial access sites after catheter ablation of VA 
 COR  LOE  Recommendation  References 
 I  A  1. Achieving arterial access site hemostasis using either manual 
compression or a vascular closure device is recommended. 
 S10.1.2.12, S10.1.2.13 
 Recommendation- specific supportive text 
 1  Arterial access after VT ablation is typically closed by manual 
compression or use of vascular closure devices, with com-
parably high success rates in achieving hemostasis. Though 
not specifically studied for VT ablation access closure, man-
ual compression and vascular closure device use have been 
extensively studied for coronary or structural intervention 
procedures. Several systematic reviews and randomized trials 
have demonstrated shorter time to hemostasis, with little need 
for compression, shorter time to mobilization, and lower he-
matoma rates with use of vascular closure devices for arterial 
closure compared with manual compression, with no differ-
ences in vascular injury, thrombosis, or infection (S10.1.2.12, 
S10.1.2.13). Extrapolating these results to arterial closure after 
VT ablation, vascular closure device use could reduce the 
time to hemostasis and ambulation and reduce the risk of 
hematoma, compared with manual compression. Vascular injury 
rates for pseudoaneurysm, dissection, or arteriovenous fistula 
might be more reflective of insertion difficulties rather than 
of closure methods. 
 2  Use of vascular closure devices is generally avoided if the arte-
riotomy site is at or distal to the common femoral bifurcation, if 
contamination of the sheath is suspected, or if the posterior wall 
of the artery is suspected to have been punctured. 
 3  When the writing committee was surveyed regarding arterial ac-
cess hemostasis, 42% of the respondents had used manual com-
pression 100% of the time, 29% had used temporary figure-of-8 
or purse-string sutures 1%-25% of the time, and 67% had used a 
vascular closure device at least some of the time (24% had used a 
vascular closure device over half the time). 
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 Recommendations for management of epicardial access sites after catheter ablation of VA 
 COR  LOE  Recommendations  References 
 I  C- EO  1. If pericardial bleeding or cardiac tamponade has occurred during epicardial VT abla-
tion, a pericardial drain should be left in place until bleeding has resolved. 
 
 IIa  B- NR  2. The instillation of intrapericardial corticosteroids can be effective in reducing 
pericarditic chest pain after epicardial VT mapping or ablation. 
 S10.1.2.14, S10.1.2.15 
 IIa  B- NR  3. To reduce pericardial pain after epicardial VT ablation, unless pericardial bleeding 
or cardiac tamponade has occurred, it is reasonable to remove all pericardial access 
sheaths at the end of the procedure. 
 S10.1.2.14, S10.1.2.15 
 IIb  C- EO  4. Leaving a pericardial drain in place might be reasonable in patients at high risk 
for late bleeding or cardiac tamponade after epicardial VT ablation. 
 
 Recommendation- specific supportive text 
 1. If pericardial bleeding or cardiac tamponade has occurred during 
the procedure, the pericardial drain should ideally be left in place 
until there is minimal drainage output. This often requires obser-
vation in an intensive care unit and follow- up echocardiograms to 
assess for residual or loculation of fluid. 
 2. Epicardial access for VT ablation can be associated with postpro-
cedure pericarditic pain and acute pericarditis. The use of steroids 
can reduce the incidence of postprocedure pericardial chest pain. 
In an animal model, triamcinolone 2 mg/kg significantly attenuated 
inflammation and postprocedure inflammatory adhesion forma-
tion after epicardial mapping and ablation (S10.1.2.16). Della Bella 
et al (S10.1.2.14) compiled the epicardial VT ablation experience 
of 6 European high- volume VT ablation centers. Of 218 patients, 
postprocedural precordial pain occurred in 21% and was consid-
ered severe in half of these. Oral steroids were used by 1 center 
routinely after 2007; 1 center routinely used intrapericardial ste-
roids; and 4 centers did not use steroids. Dyrda et al (S10.1.2.15) 
retrospectively evaluated the use of 3 therapeutic approaches on 
the incidence of pericarditis and AF after epicardial mapping and 
ablation for VT in 85 cases. The approach evolved over time from 
no steroids to systemic oral or intravenous steroids (1 mg/kg/d for 
3 days) to intrapericardial steroids (triamcinolone acetate 2 mg/kg, 
injected into the pericardial space via a pigtail catheter and left in 
place by capping of the pigtail). Compared with no steroids, the 
incidence of pericarditic chest pain was lower with intrapericardial 
steroids (21.1% vs 58.8%;  P = 0.006), but not with intravenous or 
oral steroids (43.4% vs 58.8%,  P = 0.31). No difference was found in 
the occurrence of ECG findings for pericarditis with steroid therapy 
(36.8%, 30.0%, and 41.2% for intrapericardial steroids, intravenous 
or oral steroids, or no steroids, respectively), and a nonsignificant 
reduced incidence of chest pain with ECG changes was found with 
steroid use (13.2%, 10.0%, and 29.4% for intrapericardial steroids, 
intravenous or oral steroids, or no steroids, respectively). 
 Among the writing committee members, 75% reported instilling 
steroids in the pericardial space after epicardial mapping/ablation, 
with 2 reporting this practice only after extensive epicardial abla-
tion. Methylprednisolone, triamcinolone, or triamcinolone acetate 
were used by 40%- 50%, and 9% had used dexamethasone. Only 
8% instilled lidocaine into the pericardial space after ablation. In the 
absence of bleeding or tamponade, 38% leave a pericardial drain 
in place after epicardial ablation, usually for 8- 24 hours (89%) or 
>24 hours (11%). 
 3. Whether or not to leave a pericardial drain in place after epi-
cardial ablation can be a difficult decision and is based on con-
cerns for late cardiac tamponade. However, Della Bella et al. 
(S10.1.2.14) noted that precordial pain could be due to the pigtail 
left in the pericardium for continuous drainage. In the Dyrda et al 
(S10.1.2.15) study the pigtail catheter was left in place <3 hours in 
8% and ≥24 hours in 44%. More chest pain occurred if the pigtail 
was left in place ≥24 hours (51% vs 25%;  P = 0.012); however, 
ECG changes were noted less frequently (19% vs 48%;  P = 0.006). 
 4. In deciding whether to remove the pericardial drain, leaving a guide-
wire in the pericardial space after pericardial sheath removal and 
observing several minutes with intracardiac or transthoracic echo 
might be useful. This can exclude a “through and through” punc-
ture of the RV, which will present with early significant hemorrhage 
after sheath removal. A pericardial drain may be left in place after 
epicardial ablation based on concerns for late cardiac tamponade. 
Della Bella et al (S10.1.2.14) noted that 4 of 8 patients with cardiac 
tamponade occurred late, which provided the rationale for leaving 
a pericardial drain in place. In the study by Dyrda et al (S10.1.2.15), 
postprocedure pericardial effusion or tamponade occurred in 13 
patients, observed 18 ± 14 hours after the procedure. There were 
4 cases of severe pericardial bleeding, occurring acutely in 2 and 
delayed in 2. The delayed cases were given low- molecular- weight 
heparin or heparin plus dual antiplatelet therapy. If the drain is left 
in place, longer duration can be associated with pericarditic chest 
pain (see above), and removal of the drain within 24 hours might 
reduce the incidence of pericarditic chest pain. 
 10.1.2  |  Atrial fibrillation after epicardial ventricular 
arrhythmia ablation 
 The use of amiodarone might be reasonable to lower the risk of new- onset 
AF after epicardial VT ablation in patients with evidence of acute pericar-
ditis. AF is reported to occur in 4.1%- 19.5% (S10.1.2.16–S10.1.2.18) of 
patients after epicardial VT ablation and tends to occur more commonly 
in those with signs of pericarditis. In the study by Dyrda et al (S10.1.2.15), 
AF occurred in 8.3% of patients with no prior history of it. Median time 
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to new- onset AF was 36 hours. Patients with pericarditic ECGs tended 
to be at greater risk of AF (16.7 vs 3.6%;  P = 0.091). Mahapatra et al. 
(S10.1.2.18) reported a new AF incidence of 19.5%, and all had clini-
cal symptoms of pericarditis. New AF was associated with younger 
age, longer epicardial ablation time (424 ± 169 vs 867 ± 450 seconds; 
 P < 0.001), longer epicardial mapping time (103 ± 28 vs 135 ± 51 min-
utes;  P = 0.02), RV puncture (9.1% vs 50.0%;  P = 0.02), and pericarditis 
pain score at 24 hours (1.58 ± 0.79 vs 2.25 ± 0.16;  P = 0.03). Prolonged 
drainage >24 hours was not associated with AF incidence ( P = 0.28). The 
occurrence of pericarditis renders anticoagulation decisions challenging; 
however, the use of steroids was not associated with a lower incidence of 
AF after epicardial VT ablation in these studies (S10.1.2.16, S10.1.2.18). 
In contrast, the use of amiodarone was associated with lower rates of AF 
in this population (87.9% vs 12.5%;  P < 0.001 in the study by Mahapatra 
et al) (S10.1.2.16, S10.1.2.18). New- onset AF tends to be paroxysmal and 
self- limited after epicardial VT ablation. Amiodarone was used by only 1 
writing committee member (4%) for AF prophylaxis after epicardial abla-
tion. The writing committee did not feel there was sufficient evidence to 
make a recommendation about amiodarone use in this setting. 
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 10.1.3  |  Postprocedural care: Anticoagulation 
 Recommendations for anticoagulation after VA ablation procedures 
 COR  LOE  Recommendations  References 
 IIa  C- LD  1. After less extensive endocardial VT ablation, treatment with an antiplatelet agent for a 
limited period of time is reasonable.  
 S10.1.4.1, S10.1.4.2 
 IIa  C- LD  2. Heparin reversal with protamine for sheath removal after ablation is reasonable.   S10.1.4.3, S10.1.4.4 
 IIb  C- LD  3. After extensive endocardial VT ablation, treatment with an oral anticoagulant for a 
limited period of time might be reasonable.  
 S10.1.4.1, S10.1.4.2 
 IIb  C- EO  4. The use of heparin bridging after endocardial VT ablation may be considered but can be 
associated with an increased risk of periprocedural bleeding.  
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 Recommendation- specific supportive text 
 1 Antiplatelet therapy for less extensive endocardial VT ablation 
appears to be safe, with no significant bleeding nor thromboem-
bolism risks. The Multicenter Thermocool Ventricular Tachycardia 
Ablation Trial has recommended antiplatelet therapy with aspirin 
325 mg/d or anticoagulation with warfarin for 3 months after 
ablation, if ablation has been performed over an area with >3 cm 
between ablation sites (S10.1.4.1). No procedure-related thrombo-
embolic complication or stroke had been detected by neurological 
examination. In the study by Siontis et al (S10.1.4.2), in patients 
with less extensive ablation, antiplatelet agents with full-dose 
aspirin or clopidogrel plus aspirin were used at the physician ' s 
discretion instead of therapeutic anticoagulation. Among 24 pa-
tients discharged on only antiplatelet agents (4 low-dose aspirin, 
9 full-dose aspirin, 1 clopidogrel, 10 combination of aspirin and 
clopidogrel), no definite or possible thromboembolic events and no 
bleeding events were documented in the first 3 months. Among 
the writing committee, over 90% prescribe either antiplatelets or 
anticoagulants after endocardial VA ablation, with various criteria 
used to decide which. When antiplatelets were used (almost 
exclusively aspirin), the most common duration was 4-6 weeks. 
 2 Anticoagulation during left-sided VT ablation procedures is gener-
ally reversed for sheath removal, typically with protamine. In a ret-
rospective cohort study of 158 patients undergoing RF catheter 
ablation, including 11 for VAs, 116 received protamine and 42 did 
not (S10.1.4.3). No significant difference in thrombotic events was 
observed between groups (one pulmonary embolism in the prota-
mine group and 0 thrombotic events in the control group). Among 
150 patients undergoing AF ablation, a randomized trial reported 
that compared to control, protamine reversal of heparin led to 
a trend toward shorter duration of manual compression (20 ± 9 
vs 24 ± 16 minutes;  P = 0.06) and a shorter time to ambulation 
(316 ± 80 vs 480 ± 92 minutes;  P < 0.001), with no differences in 
vascular access complications or thromboembolic events (S10.1.4.4). 
 3 After extensive endocardial VT ablation, use of anticoagula-
tion for a period of time has frequently been included as part 
of postprocedural practice, although there are no comparison 
studies. In the Multicenter Thermocool Ventricular Tachycardia 
Ablation Trial, antiplatelet therapy with aspirin 325 mg/d or 
anticoagulation with warfarin was administered for 3 months 
after ablation if ablation was performed over an area with 
>3 cm between ablation sites (S10.1.4.1). No procedure-related 
thromboembolic complication or stroke was detected. The an-
ticoagulation regimens used in other major prospective clinical 
trials are described in Table  9 . Siontis et al. (S10.1.4.2) evalu-
ated an anticoagulation protocol after VT ablation of large LV 
endocardial ablation areas (>3 cm between ablation sites) in 217 
patients with infarct-related VT without evidence of procedure-
related pericardial effusion. Starting 8 hours after access site 
hemostasis, an infusion of low-dose, slowly escalating unfrac-
tionated heparin 600-900 U/h was administered for 6 hours, 
along with initiation of warfarin. This was followed by 3 months 
of anticoagulation, or longer if another indication was present. 
If a direct oral anticoagulant had been administered prior to the 
procedure, it was resumed as early as 48 hours after sheath re-
moval if there was no bleeding. With this regimen, in-hospital 
bleeding occurred in 6% and an arterial thromboembolic event 
occurred in 1 (0.6%) patient who had received bridging antico-
agulation. Among the 214 patients discharged, 89% were pre-
scribed systemic anticoagulation, and no definite or possible 
thromboembolic events were documented in the first 3 months; 
1 patient had a major bleeding event. Of the writing commit-
tee members, approximately two-thirds initiate anticoagulation 
after LV endocardial ablation in some patients, generally after 
more extensive lesions. The postprocedural anticoagulation 
protocols in the major prospective studies of VT catheter abla-
tion are outlined in Table  9 . 
 4 Heparin bridging to oral anticoagulation or ambulation has been 
practiced but can be associated with a small risk of periprocedural 
bleeding after VT ablation. Among patients bridged with low-mo-
lecular-weight heparin to oral anticoagulation after VT ablation, 
Siontis et al (S10.1.4.2) reported in-hospital bleeding in 6% of the 
patients. Of the two-thirds of writing committee members who 
initiate anticoagulation after endocardial LV ablation, 60% initiate 
heparin until this has been established, and a further 20% if start-
ing warfarin until the international normalized ratio is >2, but not if 
starting a direct oral anticoagulant. See Section  5.5 for further dis-
cussion of this topic, including the writing committee ' s practices. 
 10.1.4  |  Postprocedural care: Disposition 
 After completion of VT ablation, patients are generally monitored 
on telemetry in the hospital for at least 1 day, and often longer for 
VT ablation in cases of SHD or heart failure. Patients who are hemo-
dynamically unstable, who require hemodynamic or ventilator sup-
port, or who have had pericardial bleeding, cardiac tamponade, or a 
pericardial drain left in place are usually monitored and stabilized in 
an intensive care unit prior to transfer to a regular telemetry floor. 
Selected right- sided ablation patients may be discharged the same 
day, if stable, but patients with significant comorbidities, any insta-
bility, or left- sided VA ablation are typically monitored >24 hours. 
Transtelephonic or CIED remote monitoring is often used to facili-
tate follow- up (see Section  10.4 ). Outpatient follow- up generally oc-
curs by 1- 4 months after the procedure. 
 A survey of the writing committee showed that 42% routinely 
have patients monitored in an intensive care unit after ventricular 
ablation. Stable patients are kept in the hospital for 1 day (overnight) 
by 35%, 2 days by 52%, 3 days by 9%, and >3 days by 4% of the writ-
ing committee members. 
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 10.2  |  Incidence and management of complications 
 10.2.1  |  Introduction 
 Ablation of VAs is an invasive procedure that can be performed in 
patients with or without SHD. Despite new technologies and pro-
gress in techniques in recent years, complications are expected, es-
pecially in patients with more severe disease. In fact, the incidence 
of complications related to VT ablation is higher in patients with 
SHD than in idiopathic VT (S10.2.9.1–S10.2.9.3). 
 For the purpose of this document, major complications are 
defined as those that result in prolongation of hospital stay or 
another hospitalization, those that require additional interven-
tion for treatment, and/or those that result in significant injury or 
death. All other complications, such as small hematomas not re-
quiring intervention, are defined as minor. A recent meta- analysis 
reported major complication rates of 8%- 10% after VT ablations 
(S10.2.9.4). Slightly higher complication rates have been reported 
in administrative and registry real- world studies compared with 
clinical trials (9.39% vs 7.97%) (S10.2.9.4). The most common 
complication reported is vascular damage, followed by pericar-
dial complications (cardiac tamponade, hemopericardium, peri-
carditis). Although new technologies and techniques have been 
incorporated for VT ablations, the rate of complications has not 
decreased, perhaps because more patients at high risk have been 
scheduled for ablation (S10.2.9.2). It is also notable that in one re-
cent study, the complication rates were independently related to 
operators and to timing of the procedure, with significantly higher 
complication rates when the ablation was begun after 2  PM (10% vs 
5%;  P < 0.0001) (S10.2.9.5). 
 10.2.2  |  Mortality 
 Interpretation of mortality in the setting of VT ablations in patients 
with SHD is difficult, given mortality can be a consequence of 
procedure- related complications but can also be related to proce-
dural failure (incessant or recurrent VT). Table  10 shows the inci-
dence of in- hospital or early mortality in patients who underwent 
VT ablation. Some clinical trials have shown no mortality, whereas 
other studies have reported rates of in- hospital or early mortality as 
high as 3% (S10.2.9.1, S10.2.9.2, S10.2.9.6–S10.2.9.10). Some of the 
following predictors of in- hospital or early mortality have been re-
ported: smoking, hypothyroidism, fluid and electrolyte disturbances, 
chronic renal failure, peripheral vascular disease, lower LVEF, history 
of AF, ICM, and multiple slow VTs (S10.2.9.1, S10.2.9.6, S10.2.9.7). It 
is also important to note that VT ablation in low- or medium- volume 
centers has been shown to be an independent predictor of mortality 
in these complex ablations (S10.2.9.1). 
 10.2.3  |  Acute periprocedural hemodynamic 
decompensation and cardiogenic shock 
 Periprocedural AHD, defined as sustained systolic hypotension de-
spite optimized doses of vasopressors or requiring mechanical HS 
and procedure discontinuation, can occur in up to 11% of VT abla-
tions in patients with SHD (S10.2.9.10). The occurrence of AHD is 
associated with increased in- hospital and long- term mortality, higher 
recurrence of VT, and procedure failure (S10.2.9.10, S10.2.9.12–
S10.2.9.14). Some of the following predictors of AHD have been 
reported, although they were tested only in a univariate analysis: 
older age, diabetes mellitus, ICM, NYHA class III/IV, VT storm, lower 
EF, prolonged procedure duration, and general anesthesia. Ablation 
should be carefully planned in these patients (S10.2.9.10). A score 
was developed to identify higher- risk patients, who might benefit 
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from periprocedural HS. The PAAINESD score is further discussed 
in Section  5.1 . 
 Some measures can help to prevent these complications: close 
monitoring of fluid balance and diuresis, careful attention to he-
modynamic status, optimization of medical status before ablation, 
avoidance of VT induction in higher- risk patients, preferring sub-
strate mapping ablation, and avoidance of general anesthesia and 
certain drugs that can result in myocardial depression, including 
propofol. Use of a pLVAD, as discussed in Section  6.4 , might be help-
ful in specific cases (S10.2.9.11–S10.2.9.14). 
 The pLVAD has been used in two scenarios: prophylactic, when 
higher- risk patients are identified, and for rescue during an acute 
complication. When used prophylactically, the pLVAD has been 
shown to prevent AHD and has a lower 30- day mortality (4.2% vs 
58%). Mathuria et al (S10.2.9.15) showed a similar 30- day mortality 
among patients with prophylactic use compared to the non- pLVAD 
group (4.2% vs 3.1%), although the first group showed a higher 
PAAINESD score (16.5 vs 13.5;  P =  0.02). Other studies have failed 
to demonstrate the benefit of pLVAD, although the fact that these 
devices are selected for patients with more severe disease is a bias 
that is not possible to rule out (S10.2.9.11, S10.2.9.13–S10.2.9.16). 
Furthermore, few randomized, prospective, controlled trials exist 
to identify the appropriate utility of this device in the setting of VA 
ablation. 
 10.2.4  |  Neurological complications 
 Neurological complication is a rare but devastating event due to 
cerebral emboli or intracerebral hemorrhage that can occur with VA 
ablation, with a reported incidence of 0%- 2.7% (S10.2.9.1, S10.2.9.6–
S10.2.9.9). It can occur during or shortly after the ablation procedure, 
usually in the first 24 hours, although in the two subsequent weeks 
following the procedure the risk is still present. Possible mechanisms 
for thromboembolic complications include thrombus formation on 
the catheter or on the tissue, air embolism, plaque disruption in 
the aortic arch, displacement of endocardial thrombus adhered to 
LV prior to ablation, char formation and/or tissue disruption during 
ablation, or generation of calcific emboli while passing a catheter 
through a heavily calcified aortic valve. Optimal anticoagulation dur-
ing the procedure targeting ACT >300 seconds and adequate control 
of RF energy delivery parameters are important practices that could 
help to prevent thrombus formation during ablation. Given that air 
embolism can also occur, careful attention to sheath management is 
crucial. In the presence of specific neurological symptoms suggest-
ing stroke or transient ischemic attack after ablation, brain MRI, CT, 
or cerebral angiography should be performed. If stroke is confirmed, 
thrombolytic therapy or endovascular mechanical or pharmacologi-
cal therapy might be useful. 
 A possible neurological complication is asymptomatic microem-
bolism that results from thrombus formation, gas, tissue and/or fat 
dislodgement, and/or air embolism (S10.2.9.17). The long- term con-
sequences of this phenomenon are unknown. 
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 10.2.5  |  Pericardial complications: Cardiac 
tamponade, hemopericardium, and pericarditis 
 Pericardial complication is the second most common reported compli-
cation of VT ablation in patients with SHD, being reported in 0%- 4.5% 
of procedures, although it can be higher in the subgroup of procedures 
in which pLVAD is used (S10.2.9.1, S10.2.9.6, S10.2.9.8, S10.2.9.9, 
S10.2.9.15, S10.2.9.16). In one study by Turagam et al. (S10.2.9.13), 
however, the incidence of cardiac tamponade was 5% vs 1.8% when 
HS was used in VT ablation procedures. A greater incidence of peri-
cardial effusion is expected in epicardial compared with endocardial 
approaches (S10.2.9.18). Possible mechanisms of this complication are 
cardiac perforation due to overheating, direct trauma due to catheter 
manipulation, transseptal accident when this approach is chosen, or 
accident when using a pericardial approach. The level of anticoagula-
tion can also influence the possibility of hemopericardium, facilitating 
the perpetuation of bleeding. Cardiac tamponade must be suspected 
if there is a drop in blood pressure; thus, an arterial line for continu-
ous blood pressure monitoring is important, and previous recordings 
of cardiac silhouette in the left anterior oblique view can be helpful. 
ICE can help to prevent or quickly detect this complication, allowing 
earlier initiation of appropriate treatment that might prevent more 
serious and irreversible consequences. The use of ICE in this setting 
is discussed in Section  8.6 . When pericardial drainage is needed, an-
ticoagulation therapy should be reevaluated, and reversing heparin 
effects with protamine might be necessary. Percutaneous pericar-
diocentesis and placement of a pericardial drain are frequently man-
datory in cardiac tamponade. The aspirated pericardial blood can be 
returned to the central vein when the cardiac tamponade is diagnosed 
during the procedure, although this approach has not been systemati-
cally evaluated. The ablation procedure is usually interrupted unless 
bleeding stops shortly after drainage. In some cases, surgical repair 
might be necessary if the bleeding is not controlled. After drainage 
and clinical stability, a pericardial drain should be maintained during 
the first 24 hours, and echocardiography should be used for further 
evaluation and decisions regarding the timing of removing the peri-
cardial drain. It is also important to carefully evaluate the appropriate 
timing of reintroducing anticoagulation therapy as needed. 
 Another pericardial complication that can be found after VT ab-
lation is pericarditis. It can be the sole complication or it might follow 
pericardial drainage due to cardiac tamponade. Symptoms of chest 
pain and low- grade fever, leukocytosis, and elevated C- reactive 
protein levels are commonly observed; diagnosis can be confirmed 
with ECG or echocardiogram. Pericarditis is also typically more fre-
quent when an epicardial approach is used. Steroid administration 
in the pericardial space might be useful to prevent pericarditis (see 
Section  10.1 ). Treatment with nonsteroidal anti- inflammatory drugs, 
colchicine, and/or steroids is useful. 
 10.2.6  |  Vascular injury 
 The incidence of vascular injury after VT ablation ranges from 0% to 
8.6% and is the most common major complication reported after VT 
ablation procedures (S10.2.9.4). Vascular complications after VT ab-
lation are typically related to vascular access and include hematoma, 
retroperitoneal hematoma, pseudoaneurysm, arteriovenous fistula, 
and dissection or occlusion of the artery accessed. Prior to sheath 
deployment, confirmation that the guide wire used for arterial ac-
cess is indeed in the lumen and not in the arterial wall is important 
to avoid retrograde dissection of the iliac artery and aorta. This can 
be accomplished with techniques such as ultrasound or angiography. 
Furthermore, longer sheaths are preferable in the setting of tortu-
ous peripheral vessels to avoid damage of the vessel wall with the 
catheter tip. Imaging of the aortic arch (with transesophageal echo-
cardiography or CT) prior to ablation using a retrograde approach 
could help to identify patients at risk for thromboembolic events in 
the presence of mobile atheromas or thick plaque material. ICE can 
also be beneficial to identify plaque material in the ascending aorta 
prior to a planned retrograde approach. Many electrophysiologists 
curve the ablation catheter to a “J” shape in the descending aorta 
to minimize trauma to the aortic valve when mapping the LV with 
a retrograde approach. The catheter is then prolapsed into the LV. 
 In higher- risk patients, such as those with high body mass index, 
body surface area <1.6 m 2 , hypertension, age >70 years, baseline 
anemia, and known peripheral vascular disease, ultrasound- guided 
percutaneous access and careful management of anticoagulation 
status should be strongly considered (S10.2.9.19). Reversal of hepa-
rin with protamine before sheath removal can also be useful to pre-
vent groin hematoma. There are no conclusive data demonstrating 
that the use of vascular closure devices decreases this complication 
compared with manual compression (S10.2.9.20). 
 Large hematomas after sheath removal are the most common 
complication and are usually self- limited, but they can be large 
enough to result in blood transfusion. When femoral arterial pseu-
doaneurysm and arteriovenous fistulas are suspected, ultrasound 
Doppler or CT scan are useful imaging tools for diagnosis. A CT scan 
can also be useful in patients with back pain and acute anemia after 
ablation to evaluate for retroperitoneal hematoma. Percutaneous 
thrombin injection, surgical repair of pseudoaneurysm and arterio-
venous fistula, and surgical evacuation of large hematomas are pos-
sible interventions for these vascular complications. 
 10.2.7  |  Myocardial ischemia, coronary 
artery damage 
 Myocardial ischemia can occur during VT ablation due to hypoten-
sion after VT induction or other causes. MI was reported in 1.7% in a 
large retrospective database study (S10.2.9.1). Caution is crucial es-
pecially in patients with known nontreatable ischemia, possibly with 
avoidance of VT induction. Coronary artery damage can also cause 
myocardial ischemia. Although injury to coronary arteries is rare, 
it can occur while crossing the aortic root with the catheter when 
using the retrograde aortic approach, with ablation in the coronary 
cusps, or with dislodgement of the ablation catheter in the LVOT. 
ICE, as discussed in Section  8.6 , can be useful for continuous visu-
alization of the ablation catheter and the coronary artery ostium. 
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Coronary angiography and continuous protection using a coronary 
angioplasty wire can be useful when the ablation site is close to a 
coronary ostium (S10.2.9.21). 
 10.2.8  |  Valve injury 
 Valve injury is a rare but potentially fatal complication of VT ablation 
(Table  10 ). The incidence of valve injury is reported in up to 0.7% of 
cases (S10.2.9.6–S10.2.9.9); when using the retrograde aortic ap-
proach, it can occur while crossing the aortic valve with the ablation 
catheter. Entrapment of the ablation catheter in the mitral or tricuspid 
valve can also occur using transseptal or retrograde approaches. Energy 
delivery direct to the valve apparatus can lead to valve injury. Ablation 
of the papillary muscle could result in this complication, and it can occur 
with both RF energy and cryoablation (S10.2.9.22, S10.2.9.23). 
 Clinical presentations of this complication include acute cardio-
vascular collapse, new murmurs, and symptoms of worsening con-
gestive heart failure. It is important to note that this complication 
can occur immediately after the ablation when resulting from en-
trapment or mechanical damage, but when resulting from direct en-
ergy delivery to the papillary muscle, symptoms can appear weeks 
after the ablation procedure. 
 To prevent valve damage, one should be careful whenever ma-
nipulating the catheter when crossing the aortic valve and mapping 
near the mitral valve. ICE is useful to continuously visualize catheter 
position and its relationship with the valve apparatus and papillary 
muscle (see details of ICE in Section  8.6 ). Surgical intervention might 
be needed for removal of an entangled catheter or for repair of a dam-
aged valve. Given the acute damage of the valve, repair instead of 
valve replacement is always preferable whenever possible. 
 10.2.9  |  Atrioventricular block 
 AV block is reported in up to 1.4% of the VT ablations (S10.2.9.1, 
S10.2.9.6–S10.2.9.9), and it can occur when ablation is performed in the 
septal region near the conduction system. It can be anticipated in pa-
tients with a known diseased conduction system, especially in patients 
with previous complete bundle branch block (either right or left) and en-
ergy delivered to the basal septum (either left or right sided). If the abla-
tion is performed during VT, monitoring of AV conduction is not possible, 
and ablation during sinus rhythm might be preferable. Although many VT 
ablations are performed in patients with a CIED, the need for RV pacing 
could worsen LVEF, and upgrade to CRT might be required. 
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 10.3  |  Hemodynamic deterioration and proarrhythmia 
 Recommendation for echocardiography after VA ablation 
 COR  LOE  Recommendation  Reference 
 I  C- LD  Echocardiography should be performed in case of hemodynamic deterioration 
post- VT ablation to assess for pericardial effusion and cardiac tamponade.  
 S10.3.1 
 Recommendation- specific supportive text 
 1  Cardiac tamponade is a serious and potentially reversible cause 
of hemodynamic deterioration after VA ablation. It can present 
intraprocedure, postprocedure, or late. When suspected, immediate 
transthoracic, transesophageal, or ICE should be performed to as-
sess for the presence of a pericardial effusion or thrombus (S10.3.1). 
 Synopsis 
 Extensive ablation in viable myocardium and repeated VT epi-
sodes with hypotension that can cause myocardial ischemia can 
lead to worsening of heart failure or cardiogenic shock in pa-
tients with impaired ventricular function. In patients with scar- 
related VT, particularly after MI, heart failure accounts for more 
than one- third of mortality during follow- up late after ablation 
and exceeds 10% per year in some studies (S10.3.2–S10.3.10). 
In the Multicenter Thermocool Ventricular Tachycardia Ablation 
Trial, 35% of 1- year mortality was due to heart failure (S10.3.3). 
In another study, despite the lack of a difference in the EF for the 
entire group, 14 of 62 (22.5%) patients did have a decline in EF 
when a repeat echocardiogram was performed within 7 days of 
the ablation (S10.3.10). However, some observations suggest that 
VT ablation might not be the sole nor major cause of the heart 
failure, given several studies that assessed pre- and postablation 
LV function did not report adverse effects on LVEF before and 
after ablation (S10.3.11, S10.3.12). Clinical pre- and intraproce-
dural variables indicating poorer clinical status, such as low LVEF, 
chronic kidney disease, VT storm, and unmappable VTs can pre-
dict mortality after VT ablation. The International VT Ablation 
Center Collaborative Group Study reported that patients with 
more severe illness who have multiple comorbidities who received 
HS during ablation had higher mortality (S10.3.13). Therefore, the 
reported heart failure mortality could be in line with expecta-
tions for these patients. Of 100 early mortality cases, 48 (48%) 
patients had early recurrent VT preceding death, although the 
time course from time of first VT recurrence to death was highly 
variable. Refractory VT was the cause of death in 22% of cases, 
with another 39% dying of other cardiac causes (most commonly 
advanced heart failure) (S10.3.14). 
 Nevertheless, hemodynamic deterioration and early mortality 
from heart failure after ablation remain concerns, especially in pa-
tients with fragile hemodynamic status, patients with evident hemo-
dynamic deterioration, or patients who required extensive ablation 
in areas of normal ventricular myocardium or near coronary arteries. 
Close monitoring of LV function and potential need for continued 
hemodynamic monitoring and/or support might be necessary after 
such ventricular ablation procedures. 
 Nontransmural and incomplete lesions can form a new or modi-
fied substrate, promoting arrhythmia after ablation; indeed, the ma-
jority of VTs recurring after ablation of postinfarction VT are new 
VTs, as determined by analysis of ICD electrograms and repeat abla-
tion procedures (S10.3.15). 
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 10.4  |  Follow- up of patients post catheter ablation of ventricular tachycardia 
 Recommendation for NIPS after catheter ablation of VT 
 COR  LOE  Recommendation  References 
 IIa  B- NR  NIPS can be useful in the several days following VT catheter ablation to inform 
further management, including ICD programming, predicting the risk of VT recur-
rence, and/or considering a repeat VT catheter ablation. 
 S10.4.1, S10.4.2 
 Recommendation- specific supportive text 
 1 Some advocate for routine PES, largely NIPS, shortly after VT 
catheter ablation and before discharging patients. However, there 
are no data from RCTs on the clinical usefulness of such a 
practice. Data on NIPS after VT catheter ablation were gener-
ated by two observational studies. In one such study, 132 patients 
with SHD underwent NIPS an average of 3 days after VT catheter 
ablation; 59 (44.7%) patients had no inducible VT, 49 (37.1%) 
had inducible nonclinical VT, and 24 (18.2%) had inducible clinical 
VT. At 1 year, patients with inducible clinical VT had a signifi-
cantly lower VT-free survival than patients with no inducible VT 
(<30% vs >80%;  P < 0.001). The authors concluded that when 
patients with VT and SHD have no VT or have only inducible 
nonclinical VT at the end of ablation or if they are too unstable 
to undergo final programmed stimulation during ablation, NIPS 
can be useful in the subsequent several days to further define 
the risk of VT recurrence, and if clinical VT is inducible during 
NIPS, to consider repeating VT catheter ablation due to the 
high risk of recurrence during follow-up (S10.4.1). In another 
study, 218 PESs (186 noninvasive and 32 invasive) were per-
formed an average of 6 days after ablation on beta-blocker 
therapy in 210 consecutive patients. The positive and negative 
predictive values of PES for VT recurrence over 1 year of follow-
up were 53% and 88%, respectively, and the negative predictive 
value was highest among patients with IHD and those with an 
LVEF >35% (S10.4.2). However, these studies were single-center, 
retrospective studies that did not include a large number of 
patients and that did not subject all patients undergoing VT 
catheter ablation to PES (S10.4.1, S10.4.2). As such, the routine 
performance of NIPS is currently not standard of care, and deci-
sions regarding NIPS should be individualized until more data 
from prospective studies, preferably RCTs, emerge on the clinical 
usefulness of NIPS post-VT catheter ablation. 
 Summary 
 Close follow- up of patients after VT catheter ablation is critically 
important because complications can be detected and addressed 
during this period, and decisions regarding postprocedure manage-
ment are made. These decisions relate to whether to perform NIPS, 
whether to maintain the patient on an AAD, and how to best pro-
gram and follow ICDs in patients with such devices. 
 Another important decision after VT catheter ablation is whether 
to maintain a patient on an AAD, and if so, what medication to choose 
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and for what duration. No RCTs have specifically addressed these is-
sues, and RCTs of VT catheter ablation implemented different pro-
tocols related to postprocedure use of AADs (Table  9 ). In 3 clinical 
trials of VT catheter ablation, preablation AADs (mostly amiodarone) 
were continued either for 3- 6 months or for an unspecified period 
of time (S10.4.3–S10.4.6). In 3 other clinical trials of VT ablation, the 
use of AADs post- VT catheter ablation was either discouraged or left 
to the discretion of the treating physician (S10.4.7–S10.4.9). In the 
SMASH- VT trial, no patient received an AAD (other than beta block-
ers) before the primary endpoint was reached (S10.4.10). Given this 
variability in the use of AADs post- VT ablation in prior RCTs, there is 
no standard of care for their use in this scenario; as such, decisions in 
this regard should be individualized based on patient characteristics 
and findings of the PES at the end of the VT catheter ablation (or 
later), keeping in mind the toxicities of these medications and their 
potential detrimental effects on survival (S10.4.11). In particular, 
given its toxicities, many favor discontinuing amiodarone after abla-
tion. In fact, amiodarone use had decreased in several prospective 
cohort studies of VT ablation (S10.4.4, S10.4.6, S10.4.9), and dose 
reduction or discontinuation had been feasible in patients who were 
not inducible post ablation in 1 single- center experience (S10.4.12). 
 Data on the best programming parameters of ICDs post- VT 
catheter ablation are scarce, given that studies of optimal ICD 
programming were conducted largely in patients with no prior VT 
(S10.4.13–S10.4.15). In a few clinical trials of VT catheter abla-
tion, information on ICD programming was not provided (S10.4.3, 
S10.4.4, S10.4.10). In the clinical trials that provided information on 
ICD programming, programming instructions to the sites were vari-
able (Table  9 ). However, based on current practice, ICDs may be pro-
grammed with a 10- 20 bpm margin if the patient has slower VT and, 
where appropriate, with ATP and prolonged arrhythmia detection 
durations and higher detection rates for VF. Although not specific 
to post- VT catheter ablation programming, the HRS document on 
optimal programming of ICDs can be a useful resource (S10.4.15). 
Given the risk of VT recurrence after VT ablation, it is imperative to 
follow ICDs closely, preferably with remote monitoring that allows 
earlier detection and treatment of VT recurrences (S10.4.16). 
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 10.5  |  Assessing the outcomes of catheter ablation 
 10.5.1  |  Introduction 
 Important outcomes of clinical trials for VA catheter ablation include 
procedure- related complications and mortality, recurrent VA, long- 
term mortality, and quality of life. It is also important to recognize 
that outcomes are also impacted by the many factors following 
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ablation that have the potential to influence the frequency and na-
ture of arrhythmia recurrences (Figure  13 ). 
 10.5.2  |  Recurrent arrhythmias 
 Recurrence of any sustained VT is an important endpoint for patients 
who have ICDs. In patients with SHD and ICDs, the QRS morphology 
of recurrent VT compared with preablation VT is frequently difficult 
to assess and is not usually reported in clinical trials. The ECG mor-
phology of spontaneous VTs terminated by ICDs is often unknown, 
and the QRS morphology of VTs can be altered by changes in the ar-
rhythmia substrate and AAD therapy after ablation. Any spontaneous 
sustained VT might be of clinical significance, whether it was observed 
previously or not. Clinical trials assessing the effect of catheter abla-
tion on recurrent sustained VT have reported the time from the abla-
tion procedure to the first recurrence of VT in Kaplan–Meier curves 
(S10.5.7.1–S10.5.7.4). These curves provide important information 
and are widely understood. They fail, however, to capture other po-
tential benefits of the procedure, including reduction in VT burden, 
prevention of VT storm, conversion of symptomatic episodes causing 
ICD shocks to asymptomatic episodes terminated by ATP, and reduc-
tions in medications. 
 For patients with nonsustained VAs and PVCs, outcome as-
sessment is determined by ambulatory monitoring of a duration 
sufficient to detect recurrences, based on the frequency of the ar-
rhythmia prior to treatment, and considering the goals of therapy. 
 10.5.3  |  Arrhythmia burden 
 Several studies have reported arrhythmia burden using the patient as 
their own reference during a specified time prior to ablation and com-
paring the arrhythmia frequency after ablation in patients who have 
ICDs (S10.5.7.5–S10.5.7.7). This type of analysis can be challenging. 
The number of VT episodes before and after ablation can be influ-
enced by programmed ICD detection criteria and AAD management. 
It is also difficult to know how to assign a “frequency” to preabla-
tion incessant VT or VT storm for comparison with single VT recur-
rences post ablation. Prior ICD interrogations are not always available 
to confirm the arrhythmia burden. The VT burden that has clinical 
relevance has not been defined and likely would vary depending on 
other patient factors. Further work on methods by which arrhythmia 
burden can best be assessed and compared in patients undergoing 
VT ablation is needed. 
 10.5.4  |  Ventricular tachycardia storm 
 VT storm has been defined as 3 or more separate episodes of sus-
tained VT in a 24- hour period, and it has been associated with poorer 
outcomes (S10.5.7.8). Prevention of VT storm is an important goal. 
Again, ICD programming has an important influence on detection 
and counting of these events. 
 10.5.5  |  Hospitalizations 
 Hospitalizations for cardiovascular disease and recurrent VA are 
also potentially important outcomes. Recurrent arrhythmias can be 
precipitated by intercurrent illness. Whether a patient requires hos-
pitalization for a recurrence is sometimes a subjective assessment. 
 10.5.6  |  Patient- reported outcomes 
 Assessing the impact of therapies on quality of life and measur-
ing patient- reported outcomes is endorsed by the AHA and the 
European Society of Cardiology (S10.5.7.9, S10.5.7.10). In the United 
 F I G U R E  1 3     Factors influencing 
outcomes post  VA ablation. 
 ICD = implantable cardioverter 
defibrillator;  LVAD = left ventricular assist 
device;  VA = ventricular arrhythmia; 
 VT = ventricular tachycardia 
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States, the Food and Drug Administration has also recently imple-
mented the Medical Device Development Tools program in which 
patient- reported outcome tools can be submitted for evaluation and 
potential certification allowing their use for clinical outcome assess-
ment in trials of medical devices (S10.5.7.11). 
 Assessment of the impact of ablation on quality of life is likely to 
reflect not only the outcome of ablation therapy, but also the severity 
of the arrhythmia ' s impact on the patient prior to ablation. For exam-
ple, a recent trial of left ventricular assist devices (LVADs) found that 
LVADs improved health status in patients with heart failure who had 
low self- reported quality of life, but not in those with acceptable qual-
ity of life at the time of LVAD implantation (S10.5.7.12). The measure 
of quality of life prior to ablation is potentially useful information for 
defining who benefits from ablation. 
 Although a number of validated tools are available, the inter-
pretation of findings can also be challenging. The VANISH trial as-
sessed quality of life using 4 validated instruments (Short Form 36 
Health Survey, the Implantable Cardioverter Defibrillator Concerns 
Questionnaire, the Hospital Anxiety and Depression Scale, and the 
EuroQol five dimensions questionnaire) (S10.5.7.13). Among 16 dif-
ferent measures of quality of life at 6 months and 1 year that were 
compared with baseline, persistent improvements were observed in 
some (energy and fatigue), transient improvements that were no lon-
ger present at 1 year in others (eg, social functioning), and no improve-
ment was found in yet others (eg, general health perceptions scale). 
How to integrate multiple measures to assess net benefit of the proce-
dure could be a challenge. 
 10.5.7  |  Mortality 
 Assessing mortality after ablation is important. Although mortality is 
relatively high in many VA ablation populations, and VA recurrence 
has been associated with increased mortality, no trial has yet shown 
a mortality benefit from catheter ablation. Efforts to enroll a suf-
ficient number of patients will be key to conclusively establishing 
the impact of ablation on mortality in a randomized trial (S10.5.7.4, 
S10.5.7.14). Recently, risk scores for predicting mortality in patients 
with SHD undergoing VT ablation have been developed, and await 
further validation (S10.5.7.15, S10.5.7.16). 
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 11   |   TR AINING AND INSTITUTIONAL REQUIREMENTS AND COMPETENCIES 
 11.1  |  Training requirements and competencies for catheter ablation of ventricular arrhythmias 
 Recommendation for training requirements and competencies for catheter ablation of VA 
 COR  LOE  Recommendation 
 I  C- EO  For clinical cardiac electrophysiologists who perform catheter ablation of VAs, appropriate advanced 
training and continued lifelong learning is recommended.  
 Recommendation- specific supportive text 
 1 Catheter ablation of VAs requires advanced skills in clinical 
cardiac electrophysiology. Physicians performing these procedures 
should be trained at electrophysiology programs with expertise 
in complex VA ablations and should meet the general and ad-
vanced training requirements for clinical cardiac electrophysiolo-
gists during training or with an experienced mentor if novel pro-
cedures and approaches have developed after training. 
 11.1.1  |  Training requirements 
 For adult electrophysiologists in the United States, these training compe-
tencies are outlined in the  2015 ACC COCATS 4: Task Force 11: Training in 
Arrhythmia Diagnosis and Management, Cardiac Pacing, and Electrophysiology 
report , the  2015 ACC/AHA/HRS Advanced Training Statement on Clinical 
Cardiology Electrophysiology , and the  2009 EHRA/HRS Expert Consensus 
on Catheter Ablation of Ventricular Arrhythmias (S11.1.8.1–S11.1.8.3). For 
pediatric electrophysiologists in the United States, these training com-
petencies are outlined in the  2015 SPCTD/ACC/AAP/AHA Task Force 4: 
Pediatric Cardiology Fellowship Training in Electrophysiology and the  2013 
Recommendations for Advanced Fellowship Training in Clinical Pediatric and 
Congenital Electrophysiology: A Report from the Training and Credentialing 
Committee of the Pediatric and Congenital Electrophysiology Society (S11.1.8.4, 
S11.1.8.5). Although these requirements mainly reflect fellowship training in 
the United States, other countries have requirements that are similar, includ-
ing the Working Group of Pacing, Electrophysiology of the French Society 
of Cardiology (S11.1.8.6). Training requirements vary from country to coun-
try, but irrespective of local differences, appropriate advanced training and 
continued lifelong learning are strongly recommended for all clinical cardiac 
electrophysiologists who perform catheter ablation for VAs. 
 As the field of catheter ablation for VAs continues to evolve 
with introduction of new approaches, technology, and application in 
higher- risk and more complex patients (ie, adults with VADs and CHD), 
trainees and practicing operators specializing in these ablations are 
expected to continue to maintain their core and specialized compe-
tencies as outlined in the  2017 ACC/HRS Lifelong Learning Statement 
of Clinical Cardiac Electrophysiology Specialists (S11.1.8.7). These proce-
dures should be performed by select qualified cardiac electrophysiolo-
gists with a practice focus on VAs at programs with expertise. 
 Physicians performing catheter ablation for VAs should achieve 
proficiency in 6 core competency domains promulgated by the 
Accreditation Council of Graduate Medical Education and American 
Board of Medical Specialties. These 6 core competency domains include 
Medical Knowledge, Patient Care and Procedural Skills, Systems- Based 
Practices, Practice- Based Learning and Improvement, Professionalism, 
and Interpersonal and Communications Skills (S11.1.8.8). 
 11.1.2  |  Medical knowledge 
 A detailed understanding of cardiac anatomy is required, including the 
conduction system, the coronary arterial and venous systems, and 
anatomical variations due to underlying heart disease. Knowledge 
is necessary of the mechanisms and pathophysiology of VAs, with a 
particular focus on the relationship between these arrhythmias and 
acquired, inherited, or SHD; sympathetic and parasympathetic tone; 
and drugs. This understanding, along with proficiency in electrocar-
diographic interpretation, helps guide appropriate mapping and ab-
lation approaches. In addition, knowledge of patient- specific factors 
such as disease type, severity, and comorbidities; procedural risks; 
and alternative therapies such as AADs, surgery, or device therapy 
should be used to guide appropriate patient selection. 
 11.1.3  |  Patient care and procedural skills 
 A comprehensive and structured approach to the clinical evaluation 
and management of patients with VAs undergoing catheter ablation 
is necessary across all settings (inpatient and outpatient) and time 
points (preprocedural planning, periprocedural and intraprocedural 
care, and postprocedural follow- up). Trainees should demonstrate 
and maintain these proficiencies as pertains to their practice area of 
focus. A clear understanding of the various approaches and systems 
used (mapping, ablation, and imaging) and proficient demonstra-
tion of the skills to perform VA ablations are required. Additional 
advanced technical skills are needed for those seeking to perform 
epicardial ablations or ablations in CHD. Given patients undergoing 
complex VA ablations often have underlying medical conditions and 
comorbidities, recognition of the potential need for a multidiscipli-
nary approach and coordination with other specialists (anesthesi-
ologists, surgeons, interventional cardiologists, cardiologists, heart 
failure specialists, and/or intensivists) will ensure optimal procedural 
outcomes. 
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 11.1.4  |  Systems- based practice 
 Complications can occur in catheter ablation procedures for VAs that 
can range from minimal to fatal. These can include vascular injury, 
thromboembolic events, cardiac tamponade, malignant VA including 
electrical storm, acute MI, and hemodynamic instability or collapse. A 
careful understanding of the potential procedural complications that 
might arise from either the patient ' s underlying medical conditions or 
the electrophysiology procedure itself is necessary. When appropriate, 
the use of a multidisciplinary team for the management of high- risk 
patients should be in place for prevention, prompt detection, timely 
intervention, and optimal management of complications. Functional 
systems should be in place to promptly care for patients in case of 
unanticipated complications. 
 11.1.5  |  Practice- based learning and improvement 
 All trainees should continue to participate in lifelong learning to 
maintain and enhance skills and knowledge through self- assessment, 
regular literature review, updated practice guidelines, consensus 
document and appropriate use criteria, and attending appropriate 
scholarly meetings with a focus on VAs. 
 11.1.6  |  Professionalism 
 On the basis of personal expertise and technical skills, practicing 
clinical cardiac electrophysiologists and trainees should practice 
within their scope as pertains to the specialized field of catheter ab-
lation for VAs. 
 11.1.7  |  Interpersonal and communications skills 
 Catheter ablation for VAs can be challenging due to increased proce-
dural risk and complexity necessitating additional technical expertise. 
Practicing clinical cardiac electrophysiologists and trainees should 
engage patients, families, and interprofessional teams in a shared 
decision- making approach. These physicians must develop the skills 
to communicate and counsel effectively regarding the diagnosis, risks, 
and benefits of catheter ablation, and alternative management options. 
 11.1.8  |  Ionizing radiation 
 Awareness is rising of the detrimental effects on patients, the 
electrophysiology staff, and the operator of ionizing radiation 
during imaging. The use of low- frame rate fluoroscopy equip-
ment, pre- and intraprocedural imaging with ICE, as well as 3D 
EAM, all contribute to reduce radiation exposure. Appropriate 
education of all personnel involved in the procedure on the 
risks and benefits of radiation is key for safer imaging. Societal 
recommendations have emphasized the importance of awareness 
of the principles of radiation safety and their implementation 
on a day- by- day basis while using radiation for medical imaging 
(S11.1.8.9, S11.1.8.10). 
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 11.2  |  Institutional requirements for catheter ablation of ventricular tachycardia 
 Recommendations for institutional requirements for catheter ablation of VT 
 COR  LOE  Recommendations 
 I  C- EO  1. Patients with certain underlying medical conditions and comorbidities undergoing complex VA ablations who 
are deemed to have increased procedural risk should undergo procedures in a hospital- based electrophysiology 
laboratory.  
 I  C- EO  2. Onsite interventional cardiology expertise is recommended for electrophysiology procedures requiring coronary 
imaging to delineate coronary anatomy for epicardial ablation, aortography to delineate coronary ostia for SV VT 
ablation, and need for placement of HS devices.  
 I  C- EO  3. Onsite cardiothoracic surgical backup is recommended for electrophysiology procedures requiring pericardial 
access due to the potential need for emergent sternotomy and cardiopulmonary bypass.  
 I  C- EO  4. Availability of anesthesia personnel is recommended for all patients undergoing catheter ablation of VAs.  
 Recommendation- specific supportive text 
 1 High-risk patients include those with advanced heart failure, severe 
ventricular dysfunction, severe valvular dysfunction, prosthetic 
heart valves, CHD, inherited arrhythmia disorders, recent MI, re-
cent stroke, chronic kidney disease, severe obstructive pulmonary 
disease, pulmonary hypertension, severe/morbid obesity, active 
oral anticoagulation, and advanced or pediatric age groups. Due 
to the potential risks associated with catheter ablation in close 
proximity to the coronary arteries and epicardial ablation, these 
procedures should be performed in a hospital-based electrophys-
iology lab with immediate availability of interventional cardiology 
or cardiothoracic surgical support (S11.2.1). 
 2 Interventional procedures, including coronary angiography, aor-
tography, and deployment of percutaneous HS devices (pLVAD, 
IABP), requires advanced skills and should be performed by ap-
propriately trained personnel. 
 3  Epicardial ablation and mapping requires pericardial access 
that carries the risk of ventricular laceration or perforation. 
Inadvertent injury to the ventricle can result in life-threatening 
tamponade and hemodynamic collapse, which might require 
emergent surgical intervention via sternotomy. Immediate sur-
gical intervention is critical and dependent on designated surgi-
cal backup (in-room or onsite with a clear notification protocol 
in place) and immediate access to an emergency surgical tray 
(S11.2.1). 
 4  Due to procedural complexities and patient factors, including un-
derlying medical conditions and comorbidities, the use of anes-
thesia services (anesthesiologist, nurse anesthetist, or equivalent 
trained personnel) provides optimal periprocedural patient care 
and additional expertise in the setting of life-threatening complica-
tions (S11.2.1). 
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 11.3  |  Ventricular tachycardia network and 
ventricular tachycardia unit 
 VT ablation is a domain of specialized centers with high operational ex-
pertise. Within these centers, logistics for optimizing patient flow and 
referral are crucial. Therefore, many tertiary referral centers for VT 
ablation have established their network of regional referring centers 
to improve patient admission and early VT ablation. Few studies have 
documented their experience with this concept (S11.3.1, S11.3.2). 
 Conceptionally, “VT networks” centralize around highly expe-
rienced centers capable of all techniques associated with VT and 
electrical storm ablation, including epicardial ablation and HS. 
Discussion with a multidisciplinary team and immediate transfer 
should be possible. Electrophysiology staff should be available 
on a 24/7 basis. Although acute ablation, defined as ablation for 
rhythm stabilization within 8 hours after onset, is rare, there is 
a potential need for catheter ablation on a 24/7 basis (S11.3.1–
S11.3.3). However, very few electrophysiology labs worldwide 
have this capacity. 
 Dedicated VT units have been established in some tertiary 
referral centers to expedite the transfer and management of 
patients with VT in a specialized intensive care unit. The op-
timal technical set- up of a dedicated VT unit has not been de-
fined, but 12- lead ECG monitoring, online device telemetry, 
and intensive care unit facilities are helpful. The organization 
of VT units and networks would likely vary substantially across 
different countries according to the local health care deliv-
ery organization and resources. The ability to provide 24/7 
catheter ablation might be useful for effective early rhythm 
stabilization, specifically in unstable patients with recurrent 
VA; however, comparisons with standards of care, including 
pharmacological suppression, HS, and neuromodulation, have 
not been made (S11.3.1, S11.3.2). Less than half of the writ-
ing committee members’ institutions have a formal capacity 
to perform VA ablations outside of regular working hours (ne-
cessitating personnel to be called into the hospital overnight 
or on weekends), although two- thirds had performed such a 
procedure after hours in exceptional circumstances, almost 
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all between <1 and 5 times per year. Opinions were divided 
about whether a formal on- call schedule for VA ablation was 
necessary. 
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 12   |   FUTURE DIREC TIONS 
 12.1  |  Clinical trials of catheter ablation of 
ventricular tachycardia 
 12.1.1  |  Introduction 
 The development of high- quality randomized trial evidence to es-
tablish an optimal therapy for VT has been challenging, despite 
the clinical importance of the question. Relatively few RCTs have 
been published comparing catheter ablation with noninterven-
tional therapies. Recent consensus and guideline documents have 
consistently stressed the importance of further research in the 
field (S12.1.4.1–S12.1.4.3), particularly the need for prospective 
randomized trials. Important clinical questions remain regard-
ing optimal techniques for catheter ablation, its optimal role and 
timing in ischemic and nonischemic cardiomyopathies, as well as 
the relative merits of catheter ablation in comparison with anti-
arrhythmic or other pharmacological therapy. Published rand-
omized trials completed thus far have included patients with ICM. 
Three trials compared catheter ablation to standard care in the 
setting of initial presentations with VAs (S12.1.4.4), with presen-
tations with tolerated VT (S12.1.4.5), and with nontolerated VT 
(S12.1.4.6). One trial compared ablation to more aggressive AAD 
therapy for patients with VT despite first- line AAD treatment 
(S12.1.4.7). At least 8 trials of catheter ablation for VT have been 
initiated but were terminated because of insufficient enrollment 
(STAR- VT, NCT02130765; VeTAMed, NCT01798277; INTERVENE, 
NCT02301390; AVATAR, NCT02114528; ASPIRE, NCT01557842; 
CEASE- VT, NCT01097330; BERLIN- VT, NCT01045668; 
CALYPSO, NCT01576042), of which only CALYPSO has published 
results available. Trials comparing various methods of VT ablation 
or treatment have been reported [VISTA (S12.1.4.8); Ultra High 
Density mapping, NCT02083016 (S12.1.4.9)] or are listed as on-
going on trial registry sites [MAGNETIC VT (S12.1.4.10); Impress, 
NCT03531502; ZFOVA zero fluoro trial, NCT03041519; Ripple 
Mapping, NCT02216760]. Barriers to completion of research in 
this area are significant, and include patient and provider biases 
and preferences (particularly for randomized trials of procedures 
compared to pharmacotherapy), challenges to standardization of 
procedural techniques and endpoints, as well as trial funding and 
reimbursement (S12.1.4.11). 
 12.1.2  |  Ongoing randomized controlled trials 
 Several randomized trials comparing catheter ablation with medical 
therapy are ongoing. The PARTITA trial (NCT01547208) is enroll-
ing and following 586 patients with ICD implantation, and randomly 
allocating 176 who present with first ICD shocks to early cath-
eter ablation vs withholding ablation until electrical storm occurs, 
with a primary composite endpoint of heart failure hospitalization 
and death from any cause. The PAUSE- SCD trial (NCT02848781) 
is enrolling 120 patients with ICM or NICM and randomly allocat-
ing them to ICD implant followed by catheter ablation or medical 
therapy with a composite endpoint of recurrent VT, cardiovascu-
lar re- hospitalization, and all- cause mortality. The IMPRESS TRIAL 
(NCT03531502) is enrolling 75 patients with cardiomyopathy who 
experienced a first ICD shock and is performing a NIPS procedure 
with a noninvasive mapping system (Cardioinsight, Medtronic). If the 
NIPS procedure is positive, then patients will be randomized to cath-
eter ablation guided by noninvasive mapping or standard medical 
therapy with a primary endpoint of ICD shocks. The PREVENTIVE 
VT Trial (NCT03421834) is a randomized trial of 60 patients with 
a subset of ICM (chronic total occlusion of infarct- related area). 
Patients will be randomized to ICD alone or ICD plus catheter ab-
lation, with an endpoint of time to first ICD therapy or VT- related 
hospitalization. The VANISH2 trial (NCT02830360) is enrolling 366 
patients with prior MI who present with sustained monomorphic VT 
and is randomizing them to receive either catheter ablation or AAD 
therapy, with a primary composite endpoint of death, appropriate 
shock, or VT storm. 
 12.1.3  |  Endpoints for prospective clinical trials of 
ventricular tachycardia ablation 
 Although observational studies have demonstrated an association 
between recurrent VAs and mortality (S12.1.4.12–S12.1.4.15), no 
prospective study thus far has demonstrated a significant beneficial 
effect of VT ablation on survival. Successful completion of a pro-
spective trial of VT ablation with a primary outcome of mortality is 
challenging due to competing mortality risks in patients with VT. In 
the VANISH trial, there was no clear effect of ablation on mortality 
in comparison with escalated AAD therapy (S12.1.4.7, S12.1.4.16), 
likely because arrhythmia was an infrequent cause of death in the 
trial, and because additional interventions were undertaken when 
patients experienced clinical deterioration or recurrent arrhythmia. 
For randomized trials enrolling patients with low- frequency VT 
events, the use of time- to- event endpoints (rather than measures 
of arrhythmia burden) has traditionally been preferred, given cli-
nicians and patients might not tolerate large burdens of recurrent 
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arrhythmia events without considering treatment alternatives to as-
signed therapy. For randomized trials specifically enrolling patients 
with high VT burden, the use of reduction in VT burden provides 
a meaningful endpoint for both patient satisfaction and scientific 
inquiry. 
 12.1.4  |  Future clinical studies 
 Further research is required to identify optimal methods for arrhyth-
mia suppression and to understand the influences of each method 
on arrhythmia outcomes, as well as on cardiac function, symptoms, 
quality of life (S12.1.4.17), cost- effectiveness (S12.1.4.18, S12.1.4.19), 
and long- term outcomes. The best first- line therapy for VT, beyond 
the use of ICDs, remains undetermined, as does the most appropri-
ate time to intervene. Ablation outcomes in nonischemic cardiomyo-
pathies, specific disease states, and patient subgroups also require 
further study. Developing, funding, and executing patient- centered, 
prospective, and randomized trials are strongly encouraged to move 
the field of VT ablation forward in ways that promote patient health 
and minimize confounding biases. 
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 12.2  |  Future directions in the treatment of patients 
with ventricular arrhythmias 
 12.2.1  |  Introduction 
 Awareness of the importance of VAs as a frequent and poten-
tially modifiable cause of death has led to increased development 
of novel methods to improve VT mapping (both inside and out-
side the body), VT treatment (inside and outside the body), and 
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identification of an individual patient ' s status, along the spectrum 
of cardiac illness. 
 12.2.2  |  Advances in mapping 
 Cardiac mapping has made an important advance with the develop-
ment of tools that employ multiple small, closely spaced electrodes. 
These tools provide higher resolution mapping during sustained VT 
and sinus rhythm (see Section  8.1 ). 
 Outside of catheter mapping, tools have been created to take 
advantage of coronary vasculature access to intramyocardial struc-
tures. The most common example involves mapping the perforator 
veins (S12.2.4.1) facilitated by the use of electrically protected wires 
into septal perforating branches (S12.2.4.2), the use of cold saline 
(S12.2.4.3), and the use of dual site pace mapping (S12.2.4.4) to iden-
tify intramural VA origins. 
 Advances in cardiac imaging are enabling a more comprehen-
sive understanding of the 3D nature of cardiac scarring and the 
dynamic nature of ventricular electrophysiology. Preprocedural 
imaging with CMR and CT is increasingly being used to identify 
abnormal myocardium, but its value as a stand- alone ablation 
guide has not yet been proven. Studies are underway to address 
this possibility. 
 The synthesis of cardiac imaging with detailed cardiac mapping 
is furthering the understanding of the relationship between the VT 
circuit and myocardial scarring. Important observations have been 
made from mapping several surfaces of the heart simultaneously 
(S12.2.4.5). Additional observations can be made by comparing 
maps and electrograms in sinus rhythm, RV pacing, LV pacing and 
sustained VT (S12.2.4.6). However, these detailed maps are time- 
consuming to create, potentially exposing patients to additional 
procedural risk. The translation of these observations into tangible 
value for the operator or for improved patient outcomes remains to 
be proven and is an area of active investigation. 
 Entirely noninvasive electrophysiological mapping has been 
developed with ECGI. This technology combines body surface uni-
polar electrograms obtained from a vest of electrodes with patient- 
specific heart- torso geometry. Local ECGs are reconstructed on the 
surface of the heart geometry, requiring a single beat of arrhyth-
mia. ECGI has been shown to localize the site of VT origin (S12.2.4.7, 
S12.2.4.8), ventricular scar locations (S12.2.4.9), and risk assessment 
for future VT events in a small cohort of patients with IHD and 
ICDs (S12.2.4.10). Compared with catheter- based mapping, nonin-
vasive ECGI mapping of VT does not provide similar local bipolar 
electrogram detail and ECGI does not image during ventricular di-
astole. Unipolar ECG reconstructions on the ventricular surface can 
infer activation patterns from deeper structures, such as septum or 
papillary muscles, but further refinement is needed to reliably map 
these structures. Advantages include the ability to map both ventri-
cles simultaneously in a single beat, obtaining an immediate sense 
of VT entrance and exit locations, as well as mapping unstable VT/
VF. Outside of the electrophysiology lab, ECGI offers possibilities 
for clinical VT risk stratification, such as was recently demonstrated 
with Brugada syndrome (S12.2.4.11), long QT syndrome (S12.2.4.12), 
and early repolarization syndrome (S12.2.4.13). 
 12.2.3  |  Advances in ablation 
 A better understanding of biophysical properties of RF energy to 
create ablative heat in both normal and abnormal ventricular myo-
cardium has driven important innovations. A change in the catheter 
irrigant to half normal saline alters the local ionic content, which cre-
ates a larger ablation lesion (S12.2.4.14). In prospective clinical use, 
this approach has translated into high rates of successful ablations in 
patients who failed traditional ablation (S12.2.4.15), although direct 
comparisons with conventional irrigant are lacking. Caution should 
be exercised, given the authors reported a 12% rate of steam pop 
with this technique. 
 Alternate forms of delivering RF energy have been developed. 
The most prominent of such technologies is a catheter with a 
needle that can be deployed into ventricular myocardium to both 
map and ablate (S12.2.4.16). Clinical trials in patients with VA are 
underway (NCT01791543; NCT03204981). Advantages include 
more precise intramyocardial mapping, injection of dye to assess 
location of potential ablation using fluoroscopy, and deeper ab-
lation lesions than standard catheter ablation. Disadvantages in-
clude the difficulty ensuring safe use and unpredictable energy 
distribution. A warm saline- infused needle ablation catheter, ca-
pable of creating large lesions, is currently being studied in pa-
tients with ICM and VT (NCT02994446) (S12.2.4.17). Alternative 
methods for RF delivery to larger areas are under development, 
including expandable catheter tips that form spheres or round lat-
tice structures. 
 Beyond RF energy to create thermal ablation, alternative en-
ergies have been studied to control VT. These alternatives include 
localized intracoronary alcohol injection, locally applied pulsed field 
direct current electroporation, and noninvasive focused stereotac-
tic radiation. Coronary ethanol infusion has been performed in both 
an antegrade (S12.2.4.18) and retrograde fashion (S12.2.4.19) on 
patients for the treatment of refractory VT. Electroporation using 
localized direct current is a technology in rapid development with 
significant advantages of speed (seconds) and a tissue- selective ab-
lation effect in preclinical models. Its safety and efficacy in humans 
has yet to be established. Stereotactic radioablation is a noninvasive 
and rapid (minutes) method for delivery of photons (X- rays), pro-
tons, or heavy ions (carbon) into selected cardiac tissue. The use of 
noninvasive photon ablation in humans was first reported in 2015 
(S12.2.4.20). The development of an entirely noninvasive process 
for mapping and ablating VT, combining ECGI, cardiac imaging, and 
stereotactic cardiac ablation, represents a promising new option in 
the field (S12.2.4.21). 
 Outside of a direct ablative effect on the diseased myocardium, 
modulation of the nervous system can alter the likelihood that VT will 
occur. Neuromodulation is largely designed to decrease sympathetic 
tone and enhance parasympathetic tone. There are many locations 
at which to manipulate the nervous system, including cervical vagal 
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stimulation, transcutaneous auricular vagal stimulation, barorecep-
tor activation therapy, spinal cord stimulation, ganglionated plexus 
ablation, renal sympathetic denervation, and left CSD. 
 12.2.4  |  Advances in patient evaluation 
 As we progress into a future where artificial intelligence becomes in-
creasingly used for predictive analytics, the field of VT ablation is ripe 
for such advances. In silico multiscale cardiac modeling of patients 
with ICM has provided an exciting possibility for the development of 
a patient- specific a priori ablation strategy (S12.2.4.22). Beyond this 
approach, the use of predictive tools can further help physicians to 
identify the right patients, the proper timing of the procedure, and 
the expected outcomes with various forms of ablation techniques to 
ultimately offer the right patient the right ablation at the right cardiac 
location at the right time in the course of the disease. 
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